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Abstract
Ultrasound (US) imaging has made significant progress over the past 20 years in 
relation to its role in inflammatory  arthritis, and in particular, Rheumatoid Arthritis. 
Modern US machines provide crisp, detailed images of superficial anatomical 
structures which has facilitated the uptake of US imaging as an important 
assessment tool within the Rheumatology  department. Diagnostic and prognostic 
information can now assist clinicians decisions with the goal of improving patient 
treatment and subsequent outcome. In addition, 3D US imaging has recently  been 
suggested as an additional imaging modality  with potential benefits in the 
assessment of inflammatory  arthritis. Recent work has focused on providing a 
reliable, responsive US joint count which can be assimilated into routine care as well 
as providing a platform for clinical research. Thus, my  first aim was to show  that a 
defined limited US data set, including 2D and 3D imaging, shows acceptable 
reliability. I demonstrate that both imaging modalities are reliable in terms of reading 
and image acquisition when restricted to a limited US data set. My second aim, was 
to demonstrate that a limited US data set is responsive. Using both a physiological 
and pharmacological trigger, I demonstrate that both 2D and 3D imaging are 
responsive and that combining US endpoints with DAS28 (Disease Activity Score - 
28) increased the effect size and identifies treatment effects early. 
Despite notable advances in musculoskeletal US research, there is still need for 
better understanding of the pathophysiological correlates of ultrasound imaging. 
Therefore my  final aim was to examine the relationship  of Power Doppler Signal 
(PDS) and gray-scale synovial thickening with histological features of synovitis at a 
single joint level and with an extended joint US data set. I firstly  show that the 
harvesting of synovial tissue, using a minimally  invasive US-guided biopsy  technique, 
is safe and well tolerated by  patients and that the quality  of tissue and RNA extracted 
is good. Using this tissue collection method, I demonstrate a good correlation of US 
and histological parameters of synovitis (specifically  CD68+ sub-lining macrophages) 
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at  a single joint level, in both an early  and established RA cohort. This relationship is 
maintained if the US assessment is extended to a discrete US joint data set. 
Furthermore, within the knee joint I demonstrated that PDS correlates well with 
synovial tissue expression of inflammatory mediators of neoangiogenesis and 
histological assessment of synovial vascular area. 
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TGF-β - Transforming Growth Factor - β
Th -T helper cell
Tie - Angiopoietin receptor Tyrosine kinase
TNFa - Tumour necrosis factor α
TLS - Tertiary lymphoid structures
TUI - Topographical ultrasound imaging
UK- United Kingdom
US - Ultrasound
USA- United States of America
VAS - Visual Analogue Scale
VASCi - Vascular index
VGEF -vascular growth endothelial factor
VEGF-R - vascular growth endothelial factor - receptor
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1. Introduction
Rheumatoid arthritis (RA) is one of the most important chronic inflammatory 
disorders in the UK. The diagnosis of RA leads to considerable morbidity  and an 
increased mortality1 2. According to the National Audit Office (2009 - http://
www.nao.org.uk/) there are 26,000 new cases of RA each year with 582,000 
prevalent cases in England. 45% of these people are of working age and within 1 
year of diagnosis 30% are unemployed. RA is characterized by  a symmetrical, 
erosive polyarthritis, resulting from chronic synovitis, and the presence of circulating 
autoantibodies such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide 
(ACPA), strongly suggesting an autoimmune pathogenesis3.
One of the first recorded descriptions of inflammatory arthritis was noted in the Ebers 
Papyrus, an Egyptian medial text, dated approximately 1500 BC4. Post-mortem 
examinations of Egyptian mummies has also shown evidence of an erosive 
polyarthritis. This was extensively  reported by Sir Grafton Elliot Smith FRCS FRCP, 
who was the first chair holder of anatomy at the Cairo School of Medicine from 
1900-19095. Other societies have made similar description of an RA-like disorder 
with Charak Samhita from Indian in around 300 – 200 BC describing a condition 
involving joint pain, swelling with subsequent loss of joint mobility and function. 
Hippocrates also made some insightful observations regarding different forms of 
arthritis including gout, osteoarthritis and RA around 400 B.C. It wasn’t until the 1st 
centuary  AD that Celsus, the Roman encyclopedist, documented the classic 
manifestations of joint inflammation (tumor - swelling, rubor - redness, calor - warmth 
and dolor - pain).  It is Galen however, who is attributed to adding a fifth tenant of 
inflammation, functio laesa - loss of function.  Treatment of joint pain, swelling and 
warmth in inflammatory  arthritis has been our aim as physicians for many  centuries. 
The long term consequences of joint damage and loss of function relating to poorly 
controlled RA are obvious. Despite this clear relationship  for many  years the classic 
pyramidal therapeutic approach to treatment escalation was the norm. Following a 
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number of seminal publications, a systematic approach to early  intervention with 
frequent monitoring and escalation of therapy  has become widely  accepted6-11. The 
consequence of this has been the recognition of an important population of patients 
with early  inflammatory  arthritis. In parallel, more focus has been given to the 
assessment and charcterisation of inflammation in these subjects. A focus on 
disease pathogenesis has resulted in a better understanding of the pathological 
processes causing joint inflammation with the consequence of targeted therapeutic 
discoveries, such as anti-TNF12. The technological advancements in this time frame 
have also heralded ultrasound and MRI imaging as potential novel imaging 
modalities which may contribute to disease activity  assessment in addition to 
already  validated tools such as the Disease Activity Score (DAS). This thesis focuses 
on the role of ultrasound imaging in the assessment of synovitis. I examine its 
relationship with clinical and histological parameters of Rheumatoid arthritis as well 
as its responsiveness to physiological and pharmacological induced changes. The 
over arching aim is to build upon the current existing evidence base for ultrasound 
imaging and suggest further areas for research and development, with a particular 
focus on patients with early inflammatory arthritis.
1.1 Early Inflammatory Arthritis
Over the past decade there has been a focus on early Rheumatoid arthritis (RA) 
which has lead to the formation of Early Arthritis Clinics (EAC) within Rheumatology 
departments.  The development of such clinics is a direct consequence of the proven 
benefit of early  initiation of disease-modifying anti-rheumatic drug (DMARD) 
therapy13-15. Previously, therapeutic intervention in RA was guided by a ‘pyramid 
approach’, delaying aggressive therapy until either the patients symptoms warranted 
escalation or following evidence of joint destruction. We are now aware that patients 
with inflammatory  arthritis, who have early  initiation of therapy, do better in terms of 
function and disease progression than patients with a delayed start 16-18. 
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There is a wide spectrum of patients who potentially  may  attend an Early 
Inflammatory  Arthritis Clinic. These will range from true ‘undifferentiated arthritis’, 
early  RA, Spondyloarthropathies, Connective Tissue Disease (CTD) and 
sarcoidosis19. The table below  gives a reflection of the relative proportion of patients 
attending such a clinic.
Table 1-1: Diagnostic categories seen in an early arthritis clinic
The approximate percentage of diﬀerent diagnostic categories presenting to an 
Early Arthritis Clinic over a 2 year period (modified from Visser et.al.19)
Diagnosis Percentage
Rheumatoid Arthritis 30
Undifferentiated Arthritis 26
Crystal arthropathy 11
Osteoarthritis 6
Psoriatic Arthritis 5
Sarcoid arthritis 5
Reactive arthritis 3
Connective tissue disorders 3
Spondylarthropathy 4
Other 7
1.1.1 Prognostic algorithms
1.1.2 Clinical variables
There have been a number of studies reporting the basic demographics of patients 
with early inflammatory  arthritis8-10. Unfortunately, the definition of early  inflammatory 
arthritis, period of follow up and patient inclusion criteria are inconsistent, thus 
limiting any  conclusions which may be drawn. Earlier studies have tended to include 
only  those patients fulfilling the ACR diagnostic criteria (1987) which provides 
suitable information pertaining to this specific sub-group of inflammatory arthritis 
patients but omits a substantial population of undifferentiated inflammatory  arthritis 
suffers. Fulfilling the ACR diagnostic criteria at inception is a marker of poor 
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prognosis, which makes the analysis of its individual components impossible in such 
a prospective study20. Prospective studies using more general inclusion criteria, such 
as one or two swollen joints, Rheumatoid factor (RF) positivity  and inflammatory 
symptoms, are more representative of the case load seen by  clinicians in their early 
arthritis clinics. This approach has facilitated the development of prognostic 
algorithms and predictive frameworks which attempted to clarify  the risk of 
radiological and functional deterioration from the initial clinical presentation19 21. 
Early  arthritis studies recruiting undifferentiated arthritis, have shown that a number 
of patients have a self-limiting course for their arthritis (15-50%) and this tends to be 
associated with younger age of onset (18-25 years), a short duration of symptoms 
before presentation and not fulfilling the ACR diagnostic criteria22-26. Although the 
follow up period of these studies varied from 1 to 5 years, those patients who were 
eventually  diagnosed as having a self-limiting disease tended to show  improvement 
much earlier. Tunn et. al. reported 50% of patients in their EAC having a self-limiting 
disease process, however limiting the inclusion criteria to 6 months of symptom 
duration22. This clearly  skews the population of patients with a greater likely hood of 
having a self-limiting course rather than persistence of symptoms. Perhaps a more 
useful conclusions drawn from these prospective studies are the Positive and 
Negative predictive value of the selected variables (PPV / NPV). The Norfolk Arthritis 
Register showed a Positive predictive value for the above variables in predicting a 
self-limiting disease course is approximately  63% whilst poor prognostic factors could 
only  provide a 60% and 63%  PPV for radiographic progression and functional 
deterioration (as measured by  Health assessment questionnaire – HAQ)27. This has 
been reflected in a number of other similar studies but this degree of accuracy  is 
insufficient to allow these variables to be used to direct therapeutic intervention which 
is of paramount importance with respects to improving disease outcomes in early 
Rheumatoid and undifferentiated arthritis28-30.
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1.1.3 Serology
The predictive value of serological markers for RA has also been explored separately 
from clinical variables in early  arthritis populations. The frequency  of positive RF or 
Anti-CCP antibodies has been commented on by  a number of studies. RF positivity 
varies from 20 - 45% in early  arthritis populations with Anti-αnti-CCP antibodies being 
found in 15-38% of patients31-34.
Ates et al. assessed the diagnostic value of anti-CCPantibodies in patients with early 
arthritis. Sixty-four adult patients with early  arthritis and disease duration of less than 
4 months were followed up for 9 months. The combination of anti-CCP and IgM-RF 
positivity  had a very  high specificity  and positive predictive value (100%) but a rather 
low  sensitivity  (33.3%) with respects to an eventual diagnosis of RA35. Overall 
performance of the anti-CCP test alone for the early  RA was better than IgM-RF and 
similar to the combination of anti-CCP and IgM-RF.
Jansen et.al. assessed the predictive value of anti-cyclic citrullinated peptide (anti-
CCP) antibodies above conventional variables for progressive erosive in a cohort of 
patients with early  inflammatory  oligo- and polyarthritis36. Symptom duration was 
limited to less than 2 years and patients with bacterial, psoriatic, crystal-induced 
arthritis or spondyloarthropathy  excluded. Two hundred and eight-two patients were 
included with thirty-two percent of the patient’s positive for anti-CCP at baseline. Anti-
CCP correlated significantly (p < 0.001) with a progressive erosive disease after 2 
years, but not with a low functional capacity. The positive predictive value (PPV) for 
radiographic progressive disease was 63%, whilst the negative predictive value 
(NPV) was 90%. Raza et. al. have also investigated the use of Anti-CCP and 
rheumatoid factor (RF), alone and in combination, in patients with very  early  synovitis 
(symptom duration less than 3 months) and followed up for nearly  18 months37. One 
hundred twenty-four patients were assessed at base line with ninety-six patients 
followed up longitudinally. The specificity, PPV and sensitivity  of this antibody 
combination for the development of persistent disease-fulfilling classification criteria 
for RA were 97%, 86%, and 63% respectively. 
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1.1.4 Composite frameworks
A seminal paper was published by  Visser et. al, who followed a similar approach to 
other prospective early  arthritis databases. However, his predefined outcome 
measures differed significantly19. His rational is based upon the premise that making 
a diagnosis of RA is merely  a surrogate marker for what the clinician and patients are 
really  concerned with at presentation. Rheumatoid Arthritis is a heterogeneous 
disease process with a spectrum of possible clinical outcomes in terms of functional 
ability  and radiographic erosions. Whether a patient will have a persistent, erosive 
arthritis is a much more pertinent question with the potential, if answered, to guide 
therapeutic intervention rather than predicting whether their arthritis will ever satisfy  a 
set of classification criteria. In most studies, either the physician’s clinical diagnosis 
or the disease classification according to the 1987 American College of 
Rheumatology (ACR) classification criteria has been used as the gold standard38-42. 
As a consequence, assessing the same diagnostic tests used in the diagnostic 
criteria (e.g. early morning stiffness, symmetrical synovitis etc) against this physician 
defined gold standard leads to circularity  and overestimation of the diagnostic 
properties of such tests. The ideal algorithm would allow patients with predicted poor 
outcome to be treated more aggressively  whilst those with a relatively  a benign 
prognosis could be spared the potential complications of such aggressive therapy. 
Five hundred and twenty-four, newly referred patients with early  inflammatory arthritis 
were evaluated and potentially  diagnostic determinants obtained at the first visit. The 
Arthritis outcome was recorded at 2 years’ follow up (persistent vs self-limiting, 
erosive vs non-erosive). Variables from the patient’s history, physical examination, 
blood and imaging were processed by logistic regression analysis. The discriminative 
ability  of the model was expressed as a receiver operating characteristic (ROC) area 
under the curve (AUC). The predictive variables are shown in table 1 with their odds 
ratio and score. 
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Table 1-2: Predictive model of persistent and erosive arthritis
Adapted from Visser et.al. Arthritis and Rheumatism 46,2: 357-36519. A prediction 
model for Persistent and erosive arthritis.
Criterion
Persistent vs Self-limiting 
arthritis
Erosive vs Non-erosive 
arthritis given persistence
Odds Ratio Score Odds Ratio Score
 Symptom duration
     > 6 weeks but < 6 months
     > 6 months
2.49
5.49
2
3
0.96
1.44
0
0
 Morning Stiﬀness > 1hr 1.96 1 1.96 1
 Arthritis in 3 or more joint groups 1.73 1 1.73 1
 Bilateral MTP compression 1.65 1 3.78 2
 IgM-RF 2.99 2 2.99 2
 Anti-CCP 4.58 3 4.58 3
 Erosions on radiographs 2.75 2 Infinite Infinite
A score of 8, 9 or 10 provides a probability  of persistence of 0.87, 0.92 and 0.95 
respectively  and a score of 7, 8 and 9 provides a probability  of erosive disease of 
0.86, 0.92 and 0.95 respectively. This model fares reasonably  well and the 
discriminating ability  for erosive versus non-erosive arthritis model was 0.90. The 
discriminating ability  for persistent versus self-limiting arthritis was lower at 0.82 
which is insufficient to allow for accurate management decisions to be made with 
confidence. However, a small proportion of patients will have a high score which 
would still confer a high probability  of erosive disease and thus should precipitate the 
initiation of aggressive disease modifying therapy at an early stage.
Recently, Van der Helm-Vanmil et. al. attempted a similar exercise on a large cohort 
of undifferentiated arthritis (570) followup for 1 year28. A prediction rule was 
developed using data from the Leiden Early Arthritis Clinic. The prediction rule 
consisted of 9 clinical variables: sex, age, localization of symptoms, morning 
stiffness, the tender joint count, the swollen joint count, the C-reactive protein level, 
RF positivity, and the presence of anti-cyclic citrullinated peptide antibodies. The 
clinical end point for this study  was the development of Rheumatoid Arthritis which as 
previously  discussed introduces circularity  in attempting to evaluate variables which 
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themselves are required to confirm the clinical endpoint. Despite this one useful 
aspect to the model developed was that its negative predictive value was 0.97. Given 
the significant proportion of patients who will ultimately  have a self-limiting arthritis 
this could be a useful model for identifying such patients. Unfortunately this model 
only  attempts to discriminate between Rheumatoid Arthritis and Non-Rheumatoid 
Arthritis patients. The Non-RA patients do not necessarily  all have a benign course 
and so further work is required to produce a definitive predictive frame work for both 
self-limiting disease and aggressive persistent erosive disease which can be easily 
introduced to daily clinical practice.
1.2 Assessment tools in Rheumatoid Arthritis
1.2.1 Disease activity score (DAS)
The DAS score was developed initially  form a large prospective cohort of patients. A 
comprehensive list of variables was identified as relevant factors used by  clinicians in 
making decisions about patients disease activity  and treatment. Factor analysis and 
regression analysis produced a weighted 4 factor score with weighting of individual 
components. The subsequent development of the EULRA response criteria  was 
based on a large cohort of patients receiving treatment with DMARDS. High and low 
disease activity  were determined by  clinical decisions and the DAS assessed in this 
light (figure 1-1). High disease activity  was deemed to be the commencement of 
DMARDS or lack of DMARD effect. A low disease activity  state was declared if the 
DMARD was stopped because of remission, no change DMARD therapy  or not 
starting  DMARDs for at least 1 year. Compared to the ILAR / ACR response criteria 
the EULRA response criteria showed reproducibility and discriminate ability43 44. 
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Figure 1-1: Depiction of DAS score mapped to clinical decision of high and low disease 
activity.
Mapping of the DAS score to low and high disease activity state as indicated by 
expert clinical decision. Reproduced from van Gestel, et. al.  Arthritis and 
Rheumatism vol. 39; 1 p34 - 4045
The graph above may be considered dated with the current use of DAS28 as a 
measure of RA disease activity  however it illustrates the significant variation seen in 
DAS and clinicians interpretation of the patients disease activity. While at a cohort 
level, a distinction can be made between low and high disease activity  based on 
DAS, there is significant spread of results. A new theme in the literature is clinical and 
imaging remission in patients with RA. We are aware that some patients with a low 
DAS28 score may continue to have develop progressive erosive disease. It has been 
suggested that imaging may help to identify  these ‘progressors’. From the graph 
above it is clear that even with a low DAS, a significant number of patients were still 
deemed sufficiently  active  and required change in therapy. It may  be that imaging is 
helping us to identify  those patients with sub-clinical disease activity  (by  DAS 
standards). It remains unclear weather the escalation of these treatment for these 
patients makes a difference in erosive disease progression.
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The EULAR response criteria were subsequently  developed using the DAS score 
providing a further dimension to patients assessment to include change as well as an 
absolute measure of disease activity45. Construct validity  was assumed based on the 
prediction of erosive progression on x-rays and close correlation with the HAQ score. 
The mean error of the DAS score was 0.6 which underlies the 1.2 change in DAS (2 
x error) which is still used to day in assessing response to therapy. The EULAR 
response criteria developed from this work seems to fair well when compared to the 
ACR improvement criteria. 
Table 1-3: EULAR response criteria for DAS28
EULAR response criteria for DAS28
DAS 28 at endpoint Improvement of DAS28 from baseline
≤ 1.2 >0.6  and ≤ 1.2 ≤ 0.6
≤ 3.2 Good
>3.2 and ≤ 5.1 Moderate
> 5.1 None
Subsequently, the DAS28 was proposed and a modified but valid clinical assessment 
tool. The DAS28 was developed in a similar fashion to the DAS44 but with a reduced 
joint count and different weights to the individual factors46. The prospective cohort 
used to develop the DAS28 was again based on a set of early  rheumatoid arthritis 
patients. Long term follow  up of these patients provided the construct validity  in terms 
of erosive disease and HAQ47. Since their development the DAS28 has been 
extensively  validated and is currently  used in routine care, as well as clinical trials, as 
an effective tool for measuring disease activity  and monitoring response to 
therapy48-50.
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1.2.2 Health Assessment Questionnaire (HAQ)
The HAQ was first published in 1980 by  Stanford Arthritis center51. It was the result of 
work to encapsulate patient reported outcomes in Rheumatoid Arthritis. The original 
HAQ had a number of dimensions (death, disability, discomfort, iatrogenic, economic) 
with further subdivision of these categories into subdomains, and further still into 
components.  The disability  dimension however has come to be used in isolation as 
the HAQ-DI.
The HAQ-DI is usually  self-αdministered, but may  also be given face-to-face. The 
Disability  Index consists of eight categories 1) dressing and grooming, 2) arising, 3) 
eating, 4) walking, 5) hygiene, 6) reach, 7) grip, and 8) common daily  activities. For 
each of these categories, patients report the amount of difficulty  they  have in 
performing two or three specific activities. HAQ  Disability  Index is entirely self-
explanatory and easily performed in clinic. 
The HAQ-DI has been validated extensively  including as a self reported outcome 
when posted making it a very flexible assessment tool. Construct and criterion 
validity  have been demonstrated as well as responsiveness and reliability52-56. It has 
been correlated with many  other self-reported outcome measures including AIMS57, 
EuroQuol58, Depression scales59 60, Nottingham Health Profile61, WOMAC score62 
and importantly  radiographic progression63 64. It is also often included in models of 
health economics particularly  productivity, morbidity, health care utilization due to its 
correlation with work capacity, occupation and the ability  to maintain an independent 
life within the community65-67.
The HAQ  is also integral to current drug approval processes within the UK. The 
National Institute for Clinical Excellence (NICE) accepts submissions from the 
pharmaceutical industry  and a decision is made as to the cost of the improvement in 
quality  of life generated. The HAQ plays an important role in assessing the quality  of 
life in a number of models used for submissions68.
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1.2.3 Radiographic assessment
The use of radiographs to examine the damage to joints from synovial inflammation 
has been a constant feature of clinical practice and therapeutic trials for many  years. 
It has many  advantages such as relatively  inexpensive, easily  performed and images 
of many joints of both hands and feet can be assessed in one sitting. Two major 
scoring systems have been used over the past two decades - Larsen score69 and 
Sharp score70. Lately, most clinical trials use the modified Sharp  score as proposed 
by  van der Heijde71. This particular score includes the hands and feet:  16 joints of 
the hands and wrists / 15 joints of the feet scored for erosions, 15 joints of the hands 
and wrists / 6 joints of the feet scored for loss of joint space. This provides a maximal 
score of 280 for erosions and 168 for joint space narrowing. The large number of 
joints scored provides plenty of opportunity to detect change over time.
Scoring of radiographs can be performed in time order or blinded to time order. 
Whilst chronological reading improves the signal detection of this scoring system it is 
not usually  performed in the setting of clinical trials72. Two readers are used in trials 
with a third reader  present as an adjudicator. The averaged score is used between 
both readers, reducing measurement error although a likely  consequence is the 
concurrent reduction in signal although this is thought to be small in experts73. An 
interesting debate surrounding the relevance of negative radiographic scores is 
underway. The possibility  of ‘healing’ erosions with negative radiographic scores 
being seen in the context of clinical trials. Due to the inherent margins of error in the 
scoring system a small negative result may  not be clinically  relevant however there is 
on going work to better understand the relevance at both the cohort and individual 
level74 75.
There is good evidence that the radiographic damage correlates with inflammatory 
activity. Time integrated values for DAS and CRP have been shown to correlate with 
erosive progression on radiographs76-78. In addition, a number of studies have 
confirmed the relationship between radiological damage scores and function as 
determined by  the HAQ  in cross-sectional populations78-81. Longitudinal data is 
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available which suggests that erosive disease is not a linear concept but patients 
have periods of accelerations. In addition, statistical modeling of a longitudinally 
followed cohort of patients over a 10 year period, with careful adjustment for disease 
activity, would suggest that the rate of erosive burden co-determines physical 
function in addition to the inflammatory load.
New imaging modalities such as ultrasound and MRI have been shown to have more 
sensitive at detecting erosions of small joints of the hands and wrists82. These are 
therefore attractive imaging alternatives. However, radiographs are reproducible 
easily  administered and have a wealth of validation. Until the other imaging 
modalities can match this body  of work a place remains for radiographs in both 
clinical practice and trials.
Figure 1-2: Hand radiographs of a patients with RA
Radiographs of the hands and wrist demonstrating erosive disease at the MCP 
joints and wrists with marked loss of joint space.
1.2.4 MRI
MRI is a sensitive imaging modality  and can assess many  aspects of inflammation 
within the Rheumatoid joint including synovial inflammation, erosions, bone edema. 
There is no ionizing radiation and the multi-planar capabilities provides further 
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detailed assessment of the region of interest83 84. Its incorporation into clinical studies 
has facilitated further validation as an outcome measure and help refine its use. 
Despite the significant benefits of MRI, the significant costs associated with the initial 
purchase of the machine make its utility  limited to larger resourced centers. Low  field 
MRI scanners are now becoming available at reduced cost and would appear to be 
more tolerable for patients. The reduction in the magnet strength does generate 
noise however newer machines can perform a Short Tau Inversion Recovery (STIR) 
to improve sensitivity  to synovitis in the context of inflammatory  arthritis. There is also 
a time constrain with limited number of joints which can be suitably  imaged in a 
reasonable time frame.
MRI has been validated against synovial histology  in both the knee and small joints 
of the hands (MCPs) demonstrating a clear relationship between post gadolinium 
enhancement on MRI and macroscopically  visualized synovitis. In addition, boney 
change was shown to be correlated with MRI determined erosions85 86. An interesting 
observation by  Brown and colleagues demonstrated that subclinical inflammation 
seen on MRI but not detected clinically  increased the risk of erosive progression on 
that cohort87. Bone marrow edema also seem to be a predictor of erosive disease in 
RA patients with it representing the only  independent predictor of radiographic 
progression in a number of longitudinal studies88-90. Detection of erosions by MRI has 
also been correlated with CT erosions (accepted ‘gold standard’)  as well as 
ultrasound in small joints91 92. There is certainly  greater sensitivity  compared to plain 
radiography  in detecting erosions and loss of joint space91 93. This has been 
demonstrated with both high field and low field MRI94. 
Scoring of MRI images in RA has been extensively  examined by  the OMERACT 
(Outcome Measures in Rheumatoid Arthritis Clinical Trials ) task force with the 
publication of the RA MRI scoring system (RAMRIS). This score has been validated 
extensively  showing itself to be reliable and sensitive to change following therapeutic 
intervention95-97. The use in this context is potentially  a significant step forward in 
clinical trials. Currently  both disease activity  assessment and radiographic 
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progression require a large population of patients with a clinical trial setting. The use 
of a more sensitive imaging modality  may reduce the number of patients need to 
treat. MRI has been incorporated into a number of clinical trials of both DMARDS and 
biologic agents with promising results98-101. Some work is still to be done with regards 
to the validation with functional outcome but there are clear advantages associated 
with this imaging modality102.
1.3 Ultrasound Imaging
Ultra - from the Latin meaning ‘beyond’
Sound - vibrations transmitted through an elastic solid, liquid or gas (also defined as 
a ‘meaningless noise’)
1.3.1 Historical Perspective
Echolocation is a method utilized by  a variety  of animals to pinpoint objects and 
perceive their environment by  means of reflection of ultrasonic sounds. Echolocation 
used by  bats was observed in the early  19th century by  Lazzaro Spallanzani, an 
Italian scientist, who would release blind bats in a room and observe the way they 
avoided colliding into objects directly  in their path. Spallanzani’s interpretation of 
these findings prompted him to describe a ‘sixth sense’ afforded to bats103. The 
puzzle of the ‘sixth sense’ was finally solved by  Donald Griffin in 1938 who first 
coined the term “echolocation”. Echolocation is widely known to be used by  bats, 
dolphins and whales but many  other species such as owls, rodents, seals, and the 
platypus have been found to use this evolutionary ‘sixth sense’. There has also been 
some evidence that blind humans can use echolocation to aid orientation and 
mobility104 105. 
The use of ultrasound in a commercial setting can be traced to the sinking of the 
Titanic when in 1913 when British scientist L.F. Richardson filed a patent to detect 
icebergs with underwater echo ranging106. Following the First World War, C. 
Chilwosky  and P. Langvin, developed the first practical echo ranging in water using 
the combination of piezoelectric technology  and vacuum tube amplifier. Further 
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developments, towards the end of the Second World War, applied the pulse-echo 
ranging technology to electromagnetic waves producing the first RADAR (RAdio 
Detection And Ranging). The subsequent development of real-time scanners in the 
1960s and 70s superseded the old static b-mode scanners and heralded an age of 
miniaturization. In 1981 the Hewlett Packard produced a phased array system which 
was the forerunner of future systems, having wheels, microprocessors and 
programmable capabilities which were up-gradable. The late 1990’s brought the 
development of three dimensional (3D) imaging and subsequent arrival of four 
dimensional (4D – ‘real-time 3D’) imaging. 
1.3.2 Doppler Ultrasound
The Doppler effect (or Doppler shift), was named after Christian Doppler, an Austrian 
physicist who first described the concept in 1842. The ‘Doppler Effect is a change in 
the frequency of a wave, resulting from motion of the wave source or receiver. This is 
practically demonstrated by  the audible change in frequency  heard as a Police siren 
comes towards you (high frequency  sound) and then drops to a lower frequency 
sound as it moves past and away  form you (low frequency sound). Doppler US 
imaging involves detecting and measuring blood flow107. The main reflector within 
blood tissue is the red blood cell. The Doppler shift (fDop) can be expressed by  the 
equation below and is dependent on the transmitted frequency  (ft) of the acoustic 
wave, the velocity  of moving blood (v), the speed of sound (c) within the tissue and 
the angle between the sound beam and direction of moving blood (θ).
The equation can be rearranged, as below, to express blood velocity. This is the 
fundamental equation on which the US Doppler image is generated. 
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The angle of insonation ‘θ’ is estimated by  the controller by aligning an indicator on 
the duplex image along the longitudinal axis of the vessel, also known as ‘angle 
correction’. It is important to note that the cosine of 90° is zero, which has an 
immediate clinically  relevant effect of giving a false impression that no flow can be 
detected if the ultrasound beam is held perpendicular to the direction of blood flow. 
This is a product of not being able to detect a Doppler shift. The incorporation of a 
cosine function into the equation would also suggest that an angle of greater than 60 
degrees might produce an inaccurate estimation of the Doppler signal due to the 
rapid escalation of the cosine function curve above this figure. Therefore, an error in 
the estimation of the angle of insonation can be greatly  multiplied if care is not taken 
when assessing the selected vascular structure. 
Figure 1-3: The Doppler effect
Cartoon of US beam and reflection of transmitted pulse form moving red blood 
cells. The transducer acts as both transmitter and receiver for the sound wave. The 
change in the frequency of the wave is calculated and expressed as Doppler signal 
on the display.
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Modern equipment filter out the high amplitude, low-frequency Doppler signals which 
usually  result from tissue movement. This can be due to vessel wall motion or small 
movement of nearby  musculature often under the effects of the vascular impulse 
especially  with respects to major vessels e.g. carotid arteries. These high amplitude, 
low  frequency  waves can however be exploited for the purposes of Power Doppler 
which will be discussed later. There are several forms of Doppler imaging available to 
the sonographer: 
• Continuous-wave Doppler ultrasonography
• Pulsed-wave Doppler ultrasonography
• Color Doppler ultrasonography
• Duplex ultrasonography
• Power Doppler ultrasonography
Of particular interest to the Rheumatologist is power Doppler which is discussed 
further below.
1.3.3 Power Doppler
Power Doppler imaging (also known as energy  mode Doppler) is a variation on color 
flow imaging in which the displayed intensity is not based on the intensity  of the 
Doppler frequency  signal. In Power mode, there is a summation of all of the Doppler 
shift frequencies and this is represented on the visual display  as varying colour 
intensities of a pixel108. This pixel effectively  is a measure of the power (or energy) 
returning from the Doppler shifted signal. Directional information is lost but this 
modality provides greater sensitivity  of Doppler detection at low flow  rates. As a 
result of the addition of Doppler shifted frequencies, a greater signal to noise ratio is 
reached. This permits for greater receiver gain to be applied across the image with 
little background interference. However, the greater sensitivity  to slow blood flow is 
achieved with a trade off to noise from mechanical movements from the probe 
produced by the technician. This balance is favorable provided the gain and PRF are 
set appropriately. This modality  is ideal for imaging blood flow in with small vessels 
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and in particular the synovium. The use of contrast agents such as Levovist 
(Schering, Germany) increases the sensitivity  of Doppler US, but also implies 
considerable additional costs, time, and invasiveness to any procedure and has a 
few potential side-effects109 110. The future role of contrast media remains unclear, 
particularly  with the development with B-flow imaging technologies which are more 
sensitive.
Figure 1-4: US image of an MCP joint showing Power Doppler Signal
2D image of the left second Metacarpal-phalengeal joint, showing synovial 
hypertrophy and power doppler signal both at the joint articulation and posterior to 
the metacarpal head.
1.3.4 Qualitative and quantitative scoring of Power Doppler Signal
The accurate assessment of PDS is a key component of any clinical study  engaging 
US as a measure of synovitis. There are a number of studies in the literature which 
have used various methods and these will be briefly discussed below. 
Semi-Quantitative score
This is method has been used most frequently  to grade PDS in the literature111-117. It 
is relatively  quick with reasonable inter-observer variability. Pre-defined criteria may 
be used or an image atlas used as reference images for scoring114 118. This Likert 
scoring system parallels the semi-quantitative score for MRI images devised and 
validated by  the OMERACT group (Outcome Measures in Rheumatoid Arthritis 
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Clinical Trials)119. This type of scoring can be performed whilst imaging the patient in 
real time. The draw back is that it artificially  divides a continuum of PDS. This type of 
scale is considered an interval rather than an ordinal as both the order of the 
elements and the distance between values on the scale provides relevant information 
to the researcher. As applied to US imaging scoring, there is an inherent weaknesses 
with a degree of overlap at the extremes of each category  and the deviation from the 
notion that each step along the interval scale represents the same quantified 
difference i.e. 0 to 1 equates to 2 to 3 in terms of the degree of Doppler signal or 
synovial thickness increment between each step. Where a small change in US signal 
is important this tool is likely  to be too insensitive. A number of reports have shown 
this score to detect change and have predictive value both terms of disease flare and 
erosive outcome in a dedicated joint data set at the cohort level114 120-124.
Table 1-4: Table of OMERACT B mode and Power Doppler scoring
Proposed OMERACT semi-quantitative score proposed by wakefield et.al. for grey 
scale and Power Doppler scoring117.
Pixel Count / Area
A number of studies have used software to count the number of coloured pixels seen 
with PDS125-129. The measurements depend upon reproducible image collection. 
Usually, a short video file is recorded of the desired image and this is later frozen at 
the point of maximum PDS signal which will have a beat to beat variation vary 
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according to cardiac output. Although this improves upon the observer variability 
inherent in the semi-quantatative score there remains a degree of variability  with 
judgment being needed as to the maximum signal displayed during the video loop. 
Using 2D PDS images recorded, only  a glimpse of the synovial blood flow can be 
viewed. There is a significant assumption that this is representative of the overall 
vascular flow within the joint. This can be in part inferred by  histological studies in 
patients undergoing joint replacements where the PDS was proportional to the 
vascularity of the synovium specimens130. The correlation of the change in PDS, 
measured by pixel number, with clinical improvement with in the confines of a 
randomized controlled clinical trial, also supports its validity131. 
Resistance index
This  method of assessing vascular flow has been used less frequently113 132 133. It 
requires the ability  of the sonographer to accurately  image a synovial vessel and, using 
Duplex US, calculate the resistance index from a standard equation. This gives a relative 
number which has been shown to change with therapeutic intervention. The significant 
limitations of this technique are that it is time consuming and ideally  a number of vessels 
should be sampled to gain a representative value for each joint. However, often detecting 
signal from a single vessel can be extremely  challenging. This assessment of vascular 
flow may  be useful in combination with other scoring modalities if extra synovial vessels 
are to be assessed to compare response to physiological or therapeutic interventions.
1.4 Three Dimensional Ultrasound imaging
Three dimensional (3D) US imaging has been used for some time in the field of 
Obstetrics but is a relatively  tool for musculoskeletal imaging50 51. It potentially may 
provide a solution for the persistent criticism of US variability  with respects to image 
acquisition. Until recently  3D images were generated by  free hand movement of the 
probe over the anatomical site producing variable results. The attachment of a 
magnetic sensor was required to allow reconstruction of accurate 3D images. The 
production of a 3D probe which has an in built mechanical motor capable of moving 
an internal array  has significantly  improved the quality of images (Figs. 3-H). The 
40
sonographer need only  hold the probe still and the internal mechanical engine 
sweeps across a predetermined angle. The approximate volume of tissue sampled 
by  this probe is 20mm x 20mm x 10mm. This is sufficient to assess the dorsal or 
palmer surface of a small joint.
Figure 1-5: Cartoon of tilt and freehand 3D US image generation
Representation of A) freehand and B) mechanical tilt 3D volume imaging (cartoons 
kindly donated by Horst-Peter Johae, General Electric Healthcare).
A           B  
               
1.4.1 Topographical US imaging (TUI)
Tracking erosive disease in patients with early  inflammatory  arthritis by  US imaging is 
difficult. Returning to the exact position to assess the same erosion is virtually 
impossible using 2D reference points. With MRI and CT it is possible to produce 
topographical images of the joint which allow  for repeated imaging of a particular 
area of interest over time. The capacity  to view multiple images, in three planes, 
through a volume of joint tissue will greatly  aid interpretation and scoring of various 
aspects of synovitis (synovial fluid, thickening and vascularity). The use TUI for this 
purpose is yet to be investigated.
1.4.2 3D Doppler imaging
The application of 3D technology  can be applied equally  to Doppler signal as to Grey 
scale (B-mode) images. The resultant 3D image is effectively  a reconstructed angiogram 
of vascular flow through the block of sampled tissue (Figure 1-5) . Although this  is 
appealing and will undoubtedly  give a more representative impression of vascular flow 
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within the synovium, there are a number of issues which require to be addressed. The 
sweep  of the probe requires approximately  six seconds for completion. This allows a 
number of cardiac cycles to pass with the resultant fluctuation in vascular flow. It may  be 
possible to trigger the scanning process at a specific part of the cardiac cycle or alter the 
speed of the mechanical sweep to reduce the variation in signal detected. This is a 
critical aspect of this new  technology  which will need to be resolved for it to become a 
convenient and robust method of accessing PDS. The resultant image can once again be 
scored semi-quantitatively  or, with dedicated software, a quantitative calculation of the 
voxel number (3D pixel). Once again this has not been addressed in the literature.
Figure 1-6: 3D reconstruction of 3D Power Doppler Signal
3D volumetric reconstruction of PD signal within a MCP joint demonstrating digital vessel signal, feeding vessel and 
synovial doppler signal. 
Digital Vessel
Synovial Doppler
Signal
Feeding vessel
Recently, Naredo has reported a high level of agreement between readers for 3D US. 
The kappa values for 3D volumetric US were appreciably  higher than 2D US in the 
detection of synovitis / tenosynovitis (0.41 vs. 0.37) and PD signal (0.82 vs 0.45)134. 
She also went on to show that in a cohort of patients receiving Rituximab therapy, 3D 
volumetric analysis of PD signal was responsive to change. The superior agreement 
seen with this particular imaging modality  may  suggest that it has a role to play  in the 
assessment of patients in multi-centered clinical trials although more work is needed 
to address other aspects of validity135. 
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1.5 US assessment in inflammatory arthritis
Musculoskeletal US imaging has emerged as a useful tool in the assessment of 
inflammatory  arthritis. The parallel evolution of the micro-processor, Doppler 
technology, miniaturization and development of high frequency  probes has enabled 
US to deliver high quality  images of small superficial structures such as joints, 
tendons and ligaments136. These developments have permitted its exploitation in the 
arena of musculoskeletal imaging and in particular inflammatory  arthritis. It is non-
invasive, relative inexpensive, lacks ionizing radiation and is easily  repeatable, 
making it potentially  useful for both diagnosis and monitoring of patient137. There has 
been much work on validating the use of US imaging in the sphere of Rheumatology 
over the past 20 years. Although this body of work encompasses imaging of tendons, 
enthesitis, nerves and muscle I will focus principally  on the imaging of synovitis in the 
subsequent sections below. 
Clinically  evident joint swelling makes a considerable contribution to the ultimate 
diagnosis of a patient suffering from an inflammatory  arthritis. Indeed, the 2010 joint 
ACR/EULRA classification criteria for RA gives points on a scoring system for the 
number and distribution of swollen, inflamed joints. US imaging clearly demonstrates 
the synovial changes which takes place in the small joints of the hands and wrists in 
patients with Rheumatoid Arthritis with demonstrable increase in synovial thickness, 
Doppler signal and boney  erosions120 138 139. Cartilage can also be clearly 
demonstrated in small and large joints with characteristic ultrasonographic changes 
demonstrated in crystal arthropathic140 141. To this extent MUSK US imaging in 
inflammatory arthritis has considerable content and face validity. 
1.5.1 Ultrasound imaging and synovial histopathology
Criterion validity requires a clear relationship to be established between the imaging 
modality and a ‘gold standard’ assessment of synovitis, such as histological 
manifestations of joint inflammation. The two features, most commonly  examined in 
this respect, are synovial vascularity and cellular infiltrates. 
43
Synovial vascularity was investigated by Walther et al., who found a good correlation 
between histological vascularity  and visual grades of PDU signal in the synovium of 
both knee and hip joints in patients undergoing arthroplasty  (r - 0.81 p <0.001)142. 
Schmidt et al. found good agreement between presence of colour Doppler signal and 
histologically  verified pannus tissue in knee joints of RA and osteoarthritis patients 
undergoing joint replacement surgery143. Pannus in this study  was histologically 
defined as ‘synovial proliferation with invasive destruction of cartilage and bone’. A 
study  by  Fiocco et al.  found a significant correlation between B-mode US synovial 
thickness and the macroscopic grade of synovitis on arthroscopy  in arthritic knee 
joints144. The studies by  Walther and Schmidt, both used a convenient method for 
harvesting synovial tissue following ultrasound examination i.e. joint replacement 
surgery, which has limitations. There is certainly  criterion validity with respect to 
Doppler signal matching synovial vascularity  but the presence of secondary  OA does 
limit the relevance of these findings in early  inflammatory  arthritis. In addition, 
synovial vessels can be demonstrated histologically  in the normal synovial joint, 
therefore an important question is the relationship of Doppler signal in an 
earlyinflammatory arthritis cohort and whether this relationship remains fixed 
following treatment. 
Koski et. al. have provided the most extensive assessment to date of ultrasound and 
cellular changes in synovial histopathology130. This study  examined the relationship 
of ultrasound parameters and synovial histological findings in patients undergoing a 
percutaneous synovial biopsy  of the designated joint. Forty-four patients with either 
monarthritis or polyarthritis were recruited with a majority  of knees (25 /44) being 
biopsied. In this study a robust assessment of the synovial tissue was made with only 
sections with an intact synovial lining layer being assessed. Seven histological 
parameters of each specimen was scored (multiplication of synovial lining, villous 
hypertrophy  of the synovial surface, surface fibrin deposition, sub-synovial infiltration 
of polymorphonuclear leucocytes, sub-synovial infiltration of mononuclear 
leucocytes, proliferation of blood vessels and fibrosis). Each histopathological and 
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ultrasound parameter was graded on a semiquantitative scale, with the 7 histological 
parameters summed to provide an overall score for the biopsied tissue. Grey-scale 
ultrasound showed synovial proliferation in 39 of 44 (89%) the patients however no 
significant correlation was found between the degree of synovial proliferation 
detected with ultrasound, and the overall histopathological score (r = 0.222, p = NS). A 
positive Doppler signal was detected in 34 of 44 (77%) of the patients and once 
again no significant correlation was found between the amount of the power Doppler 
signal in the synovium and the overall histopathological score (r = 0.239, p = NS). The 
amounts of sub-synovial infiltration of polymorphonuclear leucocytes did correlate 
with the amount of power Doppler signal (0.328, p<0.05). Whilst this study makes a 
more detailed histological assessment of the synovium there is a lack of 
homogeneity of patients and joints being sampled. A standarised assessment of each 
joint was not described but significant differences in doppler sensitivities are likely  to 
have arisen between knee, wrist and tendon PDS assessment. The use of a 8MHz 
probe may also have diminished the US sensitivity and contributed to the lack of 
correlation in some parameters. With its acknowledged limitations, this study 
importantly  attempts address the question as to the relevance of grey  scale synovitis 
and Doppler signal. However, the cellular infiltrate may differ significantly  depending 
upon the disease entity  being investigated. Krenn et. al. were able to differentiate 
between RA and non-RA (PsA or Reactive arthritis) synovial samples  based on a 9 
point scoring system for synovial lining layer hypertrophy, cellular infiltrate and 
organisation145 146. Whilst these features were not mutually  exclusive of each other 
there was signifiant difference in the the population as whole. More recently an MRI 
based study  examining the response of PsA patients to Etanercept showed that CD3 
lymphocytes appear to be a superior biomarker of response to therapy  rather than 
CD68 sub-lining macrophages typically  seen in RA147. Thus the differences in 
synovial histomorphology and cellular behaviour demonstrated within various 
arthropathies would suggest caution in attributing a universal relationship, at least 
with grey scale synovitis, and synovial infiltrate.
45
1.5.2 The relationship of ultrasound imaging and clinical assessment of  disease 
activity
Another important aspect of validating US imaging in inflammatory  arthritis is testing 
the relationship between existing measures of RA synovitis and disease activity. This 
is problematic as no ‘gold standard’ clinical assessment tools exist. The clinical 
indices of disease activity  such as the DAS and ACR were originally  validated 
against long-term patient outcome measures such as the Health Assessment 
Questionnaire (HAQ) and radiographic erosions148-151. In this respect, the ultimate 
validation of US imaging will have to be against these standards, however given the 
current adoption of DAS28 as a measure of disease activity  routinely  used in clinic 
US imaging needs to be compared with this composite score.
A number of authors have demonstrated a moderate correlation of US assessment 
and DAS28. Hameed et.al. scored 10 MPC and 10 PIP joints in established RA 
patients (mean disease duration 11 years) with relatively  active disease clinically  -
mean DAS28  5.1 (range 2.87-7.33)152. Both the Grey  scale and Doppler scores 
were correlated as a joint count (binary, absence or presence) and a summed score 
(0-3 / joint; total score of 0-60). Only a modest correlation was found with the US 
grey-scale joint summed score (r = 0.34; p=0.01), however no correlation was found 
with the summed power Doppler summed score. The components of the DAS 28 
also performed poorly with only  the tender joint count being correlated significantly  to 
the grey  scale joint count (r = 0.38; P = 0.006). The swollen joint count and VAS 
failed to show any relationship with any  of the US parameters in this study. In 
keeping with these findings, Salaffi showed that US detected a higher number of 
joints with US defined synovitis than did clinical examination with an average of 19.1 
out of 44 joints being deemed inflamed on US and only  an average of 12.6 (P = 
0.01)153. A study  by Shio, examined the relationship of US Power Doppler in both 
knee joints and MCP joints in 10 patients before and after infliximab therapy132. A 
significant correlation was found at baseline with knee joints doppler and the CRP (P 
< 0.01), ESR (P < 0.01), and 3 variable DAS28 (P < 0.05), but not with the MCP US-
46
PD scores. Interestingly, none of the US parameters correlated with clinical or 
biochemical response. A single joint approach to relating US findings to clinical 
disease activity  was also taken by  Ellegaard et. al. who use the colour fraction in a 
single wrist joints to correlate with clinical parameters of disease activity129. The 
colour fraction represents the ratio of colour pixels / synovial area. There was a 
significant, but small, correlation between the colour fraction and DAS28 (r = 0.29; P 
< 0.01), CRP (r = 0.5; P < 0.001) and ESR (r = 0.5; P < 0.001) but no correlation with 
the tender joint count. This finding may  suggest the presence of a sentinel joint which 
may be a useful indicator of overall disease activity. 
When a greater number of joints is assessed with US it would appear that the 
relationship between clinical and US parameters is stronger. In a longitudinal study, 
Naredo examined 28 joints, corresponding to those assessed for DAS28 scoring, for 
the presence of PD and graded them on a 0-3 score154. The summed PD score 
correlated with the DAS28 and CRP (r=0.48 and r=0.32 respectfully) at baseline but 
not HAQ. At 12 months from follow up the correlation remained with the DAS28 and 
CRP but also showed a significant correlation with the HAQ  score (r=0.39). In 
addition, Kawashiri et. al. correlated PDUS scores of 24 synovial sites with DAS28, 
simplified disease activity  index (SDAI) and clinical disease activity  index (CDAI). All 
positively  correlated with the PDUS score as did a number of serum biomarkers such 
as VEGF and MMP-1. Moreover, using a regressional approach they  identified 6 
joints which continued to reflect overall clinical activity155.
Therefore, whilst there is some degree of construct validity  with US assessment of 
synovitis, some discrepancy  does exist with the DAS28 clinical assessment of 
disease activity. Correlations are generally  poor / moderate and require an extensive 
assessment of joints, although moderate correlations are noted with inflammatory 
markers. Correlations with tender and swollen joint scores are inconsistent. This may 
suggest that US assessment of disease activity  provides additional information to 
DAS28 alone and as such may  supplement clinical disease assessment in specific 
patients111 112 156. The greater sensitivity  of US imaging in detecting synovial swelling 
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has been confirmed by  a number of authors112 157-160. Sub-clinical inflammatory 
disease is certainly  a well established concept in RA with some suggestion that a 
stricter level of remission should be applied to patients to include both clinical and 
imaging remission161-163. Wakefiled et. al. described the presence of US synovitis in a 
cohort of 80 patients that subclinical US synvoitis could be detected in over 30% of 
clinically non-involved joints. In a follow up study, Brown demonstrated that RA 
patients in clinical remission, but persistent Power Doppler signal, had an increased 
chance of having erosive progression on plain x-ray  after 12 months follow  up121. 
This may not be surprising as DAS28 assessment was developed primarily  based on 
therapeutic decisions to escalate treatment by  Rheumatologist in a clinical trial. 
Therefore it is likely that a spectrum of patients with low DAS28 have on going low 
grade synovitis which US imaging may be well placed to detect. The integration of 
DAS and US parameters still requires further work and with particular focus of 
responsiveness and predictive value.
1.5.3 The relationship of ultrasound imaging and other imaging modalities
The agreement of ultrasound imaging with other imaging modalities provides 
convergent validity of this technique in the setting of inflammatory arthritis. MRI 
imaging has been validate in RA both in terms of its predictive value, detection of 
erosions, its relationship  with histologically  defined synovitis and detecting change 
over time85 91 164-169.
Synovitis
A number of studies have compared US and MRI findings in RA finger joints have 
shown a high level of agreement with respect to bone erosions and synovitis, as 
assessed by  B-mode (grey  scale) and PDS. Specifically, Backhaus et al. found US to 
be more sensitive than MRI for detection of synovitis in the finger joints with MRI 
being more sensitive at detecting very  small erosions170. In a similar study  form the 
same group demonstrated that bursitis, tenosynovitis and erosions in the shoulder 
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joint were more often detected by  MRI and US than conventional radiology 
techniques171. Szkudlarek et al. has shown that the PDS and early  MRI 
enhancement in rheumatoid metacarpophalangeal (MCP) joints were very closely 
correlated172. The sensitivity  and specificity  of PDS, using MRI as a reference, was 
89% and 98% respectively. Similarly, a recently  published by  Schmidt et. al. 
demonstrated good correlation between US and low field MRI for MCP and MTP joint 
synovitis173. 
Despite this encouraging correlation between US and MRI in small joints, when the 
correlation is examined in large joints such as the shoulder or knee, it would appear 
that MRI more reliably detects synovitis and erosions171 174 175. 
Tenosynovitis
US appears to be a sensitive method for imaging tendons176. Normal tendon 
ultrasound anatomy  shows a densely  packed fibrillar pattern of fibres in the 
longitudinal plane. In tendinosis there is a loss of this pattern, hypoechogenecity  and 
thickening of the tendon and frequently  doppler signal demonstrated within its 
substance. Tenosynovitis, refers to the inflammatory  changes seen primarily  within 
the tendon sheath such as fluid accumulation, hypoechoic synovial thickening and 
Doppler signal177-179. It would appear that it is certainly  superior to clinical 
examination but may also has an edge on MRI imaging. In the study  by  Schmidt et. 
al. described above, in addition to showing good correlation with synovitis at MTP 
and MCP joints a superior detection rate of tenosynovitis was noted with US imaging 
(30 vs 15 patients)173.
49
Figure 1-7: Images of normal and inflamed digital flexor tendon
Tendon ultrasound anatomy A: normal tendon ultrasound anatomy showing the 
typical fibrillar structure overlying the MCP joint (volar aspect). B: Flexor 
tenosynovitis demonstrated with Doppler signal, fluid and synovial thickening at the 
level of the PIP joint (volar aspect).
A
B
Bone erosions
US technology  is capable of imaging bone erosions in the both small and large joints. 
with one of the first published description of US detected bone erosions was by 
Fornage in 1988180. US determined bone erosions are seen as a break in the cortex 
of the bone and should traditionally  be viewed in two directions (transverse / 
longitudinal views) before being confirmed181. Szkudlarek has suggested a 0-3 score 
for bone erosions. Bone erosions were defined as changes at the bone surface at the 
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point adjacent to the joint (0= regular bone surface, 1 = irregularity  of the bone cortex 
in 1 plane only, 2 = formation of a cortical defect seen in 2 planes, 3 = large bone 
defect creating extensive bone destruction). Whilst this is a helpful step in better 
characterising bone erosions by  US it remains to be seen is such a classification is 
workable in the clinical or research context. Conceptually, the variation in size of 
erosions detected in patients with RA would suggest that the interval distance 
between grade 2 and 3 require further sub-division to facilitate a more sensitive 
scoring system.
Figure 1-8: longitudinal and transverse images of MCP head erosion.
Bone erosion on the right 2rd Metacarpal head in a patient with seropositive RA A: 
Longitudinal view of MCP showing erosion on the metacarpal head B: Transverse 
view of metacarpal head
A% % % % % %
B
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The detection of bone erosions is considered a poor prognosis when see on 
standard radiographs of the hands and feet19 182. There have been a number of 
studies comparing US imaging, radiography and MRI. US has compared favourably 
with MRI in detecting bone erosions in finger joints and with a single study 
suggesting similar detection rates at the shoulder82 171 183-185. US imaging is clearly 
better than plain radiographs at detecting bone erosions with some studies 
suggesting a 20 – 30% discrepancy in early  arthritis patient populations82 186. This 
clearly  has significant implications for patients being assessed in an early  arthritis 
clinic. 
US bone erosions were followed systematically by  Backhaus et al. in 49 patients with 
various arthritides170. Comparisons were made between MRI, US, and radiography of 
wrist, MCP and PIP joints and after 2 years. Synovitis as detected by  MRI and US 
decreased, whereas the number of bone erosions increased. As previously  reported 
more patients showed erosive progression on US compared with radiography 
suggesting a higher sensitivity  to change. However, it is possible that the inter-
observer variability, which was not investigated, was in part contributing to these 
results. However, Wakefield et. al. has proposed an US score for erosions and 
shown fair inter-observer agreement and in addition that US detection of erosions in 
small joints is superior to conventional radiology  and comparable to MRI imaging187. 
Others have reported similar findings in hands and feet, however the multi planar 
advantage inherent with US imaging is limited to the most medial and lateral of the 
MCP joints (MCP 2+5). Here the ultrasound probe can successfully  negotiate the rim 
of the MCP joint where as at the 3rd - 4th MCP there is limited access to the lateral 
margins.
In established RA patients, the ability  to monitor and track bone erosions in response 
to therapy  can be a useful tool. The development of new erosions is often used as a 
clinical end point in studies based on plain radiographic imaging. The ability  to 
observe these changes more sensitively  may  provide a new tool for assessing 
patient outcomes at an earlier time point. Once again a number of issues 
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surrounding the reliability  of such observations exist, however with new 3D 
technology  these potentially  can be addressed137 (Fig 1-9). The joint surface may  be 
mapped and therefore remove the inherent variability  of US imaging using a 2D 
linear probe with no exact anatomical landmarks to guide probe positioning and 
image acquisition. A topographical assessment can be performed which may improve 
inter-reader reliability.
Figure 1-9: Topographical ultrasound image and  3D reconstruction of MCP 
erosion
3D reconstruction of a metacarpal head showing 2 erosions on the medial and 
lateral aspect. The topographical image (right hand side) is manipulated to show 
coronal sections through the metacarpal head. The reference image can be seen on 
the top right hand corner.  A 3D reconstruction of the grey scale image in seen on 
the left hand image with prominence given to the large erosions on the medial 
aspect of the joint.
  
1.5.4 Ultrasound as an aid to diagnosis and prognostic biomarker
The predictive value of US in RA is a critical aspect of its validation if it is ever to be 
formally  incorporation into routine clinical care. Classically, outcome measures in RA 
refer to functional ability  and structural joint damage over time. Whilst these 
endpoints are of importance, a challenge for the Rheumatologist is often teasing out 
patients with true  inflammatory  arthritis versus non-inflammatory  disease. In a 
seminal paper by  Freeston et. al. they  examined the use of US as an additional  tool 
in predicting patients with inflammatory vs non-inflammatory  arthritis188. In a relatively 
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small cohort of patients (50), the addition of ultrasound data to clinical, serology and 
plain radiographs increased the probability of an inflammatory  arthritis being 
diagnosed in a seronegative patient from 30% to 94%. Similarly, van de Stadt LA, 
showed an predictive value for US, and in particular power Doppler, at a single joint 
level in predicting the development of clinically apparent synovitis. Unfortunately  th 
study  did not reach significance at the patient level189. In a cohort with definitive 
clinical evidence of synovitis, Filer et. al. showed that in patients with very  early 
arthritis (less or equal to 3 months duration), the addition of US parameters, 
specifically  power Doppler and grey  scale synovial thickening of the MCPs, MTPs 
and wrists predicted the fulfilment of the 1987 American College of Rheumatology 
(ACR) if used in conjunction with the Leiden algorithm39. The studies above 
collectively  show the utility  of US data in the diagnosis and classification of patients 
presenting with either arthralgia or frank arthritis at an early stage. 
Whilst the diagnosis and classification of a patients symptoms are important, this 
inherently  should prompt a consideration of the long term outcome. A number of 
factors are classically  used to help  the clinician to formulate a predictive view such as 
erosions on radiographs, seropositive (RF / CCP), insidious onset of symptoms and 
high DAS score21 190-192. However, US seems to have a role to play  in this context. In 
2007, Naredo et. al. evaluated the predictive value of PDUS parameters in disease 
activity  and radiologic outcome in patients with early  RA114. The time-integrated 
values of PDUS parameters demonstrated a significant correlation with DAS28 and 
radiographic progression after 1 year. This would suggest a role for US assessment 
at an early  stage which may  influence therapeutic intervention. Whether US based 
decisions in an early  arthritis cohort benefit outcome is still under investigation. It is 
likely  that using US in addition to clinical predictors of outcome a more tailored 
approach to early arthritis patients can be implemented.
In established RA patients, the response to therapy  and progressions of erosive 
disease is pertinent question. Taylor et. al. showed in a randomised controlled study 
with Infliximab, that baseline US synovial thickening and power Doppler predicted 
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erosive changes using the van der Heijde modified Sharp score for the placebo 
group. This relationship was abolished in the active treatment arm131. Also in a 
prospective study, Ellegaard has also shown that the baseline US characteristics of 
patients treated with anti-TNF therapy  predict response and on going treatment at 1 
year193. These findings would argue that US assessment of patients prior to anti-TNF 
therapy  may provide clinicians with the ability  to stratify  patients and tailor therapy  to 
those where the likelihood of success is greater. This may  be a welcome tool in this 
current climate of economic strain. 
The predictive value of US imaging therefore would argue for its incorporation by 
Rheumatologists to decision making processes both in terms of diagnosis, 
classification and therapeutic response. 
1.5.4.1 Reliability of ultrasound imaging
Multiple reports indicate that ultrasound grading can be reliably  conducted117 194 195. 
Reliability  is an integral aspect of an assessment tools validity. While an assessment 
tool may  fulfil a number of aspects of validity, it may  not be reliable. However, a 
reliable and reproducible assessment tool does not signify  that it is a valid test. The 
reliability  of any  assessment tool is inextricably  linked to the scoring method used to 
assess it. In the case if US a number of scoring methods have been employed and 
reported in the literature. The simplest assessment is a binary  outcome of absence or 
presence of detectable pathology  with the resultant score represented as a joint 
count similar to the ender or swollen joint count seen in the DAS28 assessment111 114 
152. Others have sought to categorise synovial thickening and doppler in a 4-point 
ordinal score while a few groups have suggested a 5-point score118 196 197. In addition, 
quantitative methods for assessment can also be used with dedicated imaging 
processing software198-200. Power Doppler however is most often reported using a 
Likert scale of 0-3, where 0 indicates no synovial blood flow, 1 mild synovial blood 
flow, 2 moderate synovial blood flow, and 3 extensive synovial blood flow115. Naredo 
reported the results of a training session of ultrasound where the agreement for 
55
shoulder, wrist, ankle, foot and knee assessments were evaluated by  ‘experts’. The 
agreement varied somewhat between the anatomical region being scanned and the 
lesion being assessed. The Kappa however scores were comparable between region 
(hand and wrist - Kappa 0.61)201. Others have also reported similar robust levels of 
agreement202-207. Naredo again demonstrating not only  high levels of agreement for 
US assessment but also that this was superior to clinical assessment112. The 
interobserver reliability  for MCP joint US scoring had a reported kappa of 0.88, 
whereas the reliability of the individual clinical examination of MCP swelling had a 
reported kappa of only 0.36.
Table 1-5: Agreement between ultrasonographers for various pathologies at 
different joints.
Overall agreements by ultrasonographic diagnosis in each region and in all regions. 
NE, diagnosis not evaluated. Reproduced from Naredo et. al. Ann Rheum Dis 
2006;65:14-9 201.
Diagnosis
Shoulder
Wrist/
hand
Ankle/foot Knee All regions
Joint eﬀusion/synovitis 88.5% 95% 89% 91.5% 91%
Bony cortex 
abnormalities
84.5% 88.5% 92% 84.5% 87%
Tenosynovitis/
paratenonitis
76% 88.5% 88.5% NE 84%
Tendon lesions 88% NE 92% 94% 91%
Bursitis/cyst 85.5% NE 73.5% 92% 83.5%
Power Doppler signal NE 92.5% 73.5% NE 83%
The majority  of the studies examining the reliability of US have been performed using 
a binary  outcome or qualitative assessment of synovitis. However, others have 
shown that both qualitative, quantitative scoring techniques and resistance index 
calculations can also be shown to be reproducible128 200 208-210. 
The normal approach to acquiring US images involves a number of steps which may 
contribute to the overall agreement in scores. A list of 5 variables is given below:
56
1. Machine / probe - different machines have differing doppler sensitivities and 
contrast resolution.
2. Image optimisation and probe settings for depth, pulse frequency and gain.
3. Positioning of patient and joint.
4. Timing of scan (morning / afternoon).
5. Position of probe for image recording.
Many reported reliability  data combines a number of aspects of US image acquisition 
and scoring. This combinatorial approach is likely  to weaken the agreement between 
individual as the dedicated image acquired is not standardised. This ‘free hand’ 
scanning may  increase sensitivity  of the imaging technique to detect pathology  but 
will have an impact on agreement. In this thesis I present data from a randomised 
controlled, multi-centered study  examining both the issue of imaging acquisition and 
scoring from different ultrasonographers / readers and repetitive scanning and 
scoring from the same ultrasonographer.
1.5.5 Limited ultrasound data sets
Having shown over the past 15 years that US imaging has a valid part to play in the 
assessment and diagnosis of patients with inflammatory  arthritis, a significant 
question still remains unanswered. In many of the studies described above various 
joints were imaged and scored but no systematic approach has dominated the 
literature. The number of joints imaged varies considerably, with a one author 
demonstrating a relationship between clinical parameters of disease activity  and a 
single wrist joint while others have examined up  to 78 joints. A list of publications and 
joints counts can be seen in the table below.
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Table 1-6: List of published US data sets and joints counted
Authors of publications along with the joints data set imaged are shown below. The 
patient cohort (early RA vs Established RA) is noted and whether there is evidence 
of the data set being responsive to therapeutic intervention.
Author Number of joints scanned Early / Established RA 
Response to 
Therapy
Naredo et al. 
2008396
12 joints 
(Elbow, Wrist, 2 + 3 MCP, Ankle, knee)
Established RA Anti-TNFa
Backhaus et al. 
2009405
7 joints 
(2 + 3 MCP, 2+3 PIP, wrist, 2+5 MTP - dominant 
side)
Established RA DMARD / Anti-TNFa
Filer et al. 
201139
38 joints (MCP, PIP, wrists, elbow, shoulder, 2-5 
MTP)
Early RA DMARD
Scire et al. 
2009124
44 joints 
(MCP, PIP, wrist, elbow, shoulder, knee, ankle, 
MTP, sternoclavicular, acromioclavicular)
Established RA DMARD
Hammer et. al. 
2011404
78 joints 
(PIP, MCP, CMC, wrist, elbow, shoulder,  hip, 
knee, ankle, Mid-foot x 4, TMT, MTP, PIP)
Established RA none
Naredo et al. 
2005112
28 joints 
(MCP, PIP, Wrist, elbow, shoulder, knee)
Established RA none
Seymour et. al. 
2011128
10 joints 
(MCP)
Established RA Biologic NO 
inducible agent
Ellegaard et al. 
2011193
1 joint 
(wrist)
Established RA Anti-TNFa
The wrist and MCP joints have been incorporated most often in scoring systems and 
this reflects the typical joint involvement detected clinically. Unlike the DAS28, a 
number of US data sets have included the ankles and feet (including MTP joints). 
There does appear to be value in extending the examination to the lower limb 
however this does require more time. Using a distal upper limb data set has its 
attractions as it requires no undressing of patients and as such should be easily 
incorporated into routine clinical practise. Therefore, more work is required to clarify 
the optimal joint data set to be imaged. However, it is likely  that the optimal US data 
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set may  change depending upon the clinical scenario and purpose of the 
assessment. For example, the assessment of a patient with new onset of 
inflammatory symptoms is likely  to merit a more comprehensive data set than a 
patient with established RA commencing anti-TNF therapy. A more focused data set 
may be used following the initial assessment to include a core joint count + a sentile 
joint. Conversely, If the data set is designed to detect change following therapy  in a 
clinical trial setting, a smaller data set may be sufficient. In this scenario a baseline of 
US defined disease activity  may  be required to facilitate a sufficient change and 
avoid a flooring effect. This is already done in clinical studies with a pre-specified 
number of swollen and tender joints along with adequate levels of CRP / ESR 
required before patients can be enrolled. Currently  this is designed to provide a 
minimum DAS28 score ensuring a controlled population of patients entering the 
study. A similar criteria may need to be applied to an US driven therapeutic study.
1.6 Synovial biopsy
Synovial biopsy  is a safe and generally  well-tolerated procedure. Synovial tissue is 
most often acquired from knee joints in affected patients but with the development of 
minimally  invasive procedures, a greater number of joints may be exploited for the 
harvesting of synovial tissue. Synovial tissue examination is not considered a routine 
investigation for most patients attending the Rheumatology  clinic. Occasionally  this 
investigation is required when a joint infection is considered and synovial fluid and 
blood cultures have been unable to identify  an infectious organism. In a study  in 
patients with suspected infected knee replacement synovial fluid analysis had a 
sensitivity  of sensitivity  of 72.5%, a positive predictive value of 85.3% and a negative 
predictive value of 90.1%. Synovial tissue analysis showed a  sensitivity  of 100%, a 
positive predictive value of 95.2% and a negative predictive value of 100%211.
Examination of synovial biopsies may  also help to make a diagnosis in some 
relatively  rare infiltrative and deposition diseases afflicting the joints such as 
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amyloidosis212, ochronosis213, haemochromatosis214, and proliferative disorders such 
as pigmented villonodular synovitis (PVNS)215. 
1.6.1 Blind needle biopsy
This procedure can be performed under local anaesthetic and essentially  involves 
the insertion of a trochar into the joint cavity  through a small incision in the skin. The 
usual apparatus used is the Parker-Pearson needle216 although other modified 
needles have been used and reported to achieve reasonable synovial samples. The 
procedure appears to be relatively  safe and tolerable however, the lack of 
visualisation of the tissue being sampled may  be a problem. It may be less 
favourable in the setting of a clinical trial setting given a failure rate of 15%  in terms 
of suitable harvested synovial tissue217. 
If the supra-patella approach is to be used, it is usual for the pouch to be expanded 
with 30-50 mils of normal saline before passage of the trochar. Once in place, the 
biopsy forceps are then introduced through the trochar and the biopsies are 
performed with multiple samples being taken by changing the angulation of the 
apparatus. Other joints can be biopsied using this technique but small joint of the 
hand are exceedingly difficult due to the blinded nature of such a procedure. 
1.6.2 Arthroscopic biopsy
Synovial tissue obtained by  an arthroscopic procedure has been used extensively  in 
the context of synovial tissue harvesting within clinical trials on new therapeutic 
agents. A survey by Kane et. al. showed that this technique was being performed by 
a significant number of Rheumatologists within Europe218. Both large and small joints 
are accessible to this technique which may  be performed under local anesthetic. 
Typically, the biopsy  forceps require to be inserted via a second portal; however 
some equipment allows this through the same introducer as the small bore camera. 
An infra-patellar portal for the camera insertion is usual with a second supra-patellar 
portal for the biopsy procedure. This makes it possible to obtain synovial biopsy 
samples under direct visualisation. This has the advantage of being able to guide the 
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biopsy forceps to a number of anatomical sites with great accuracy e.g. the 
cartilage–pannus junction or patellar gutters. Arthroscopy  would appear to be 
reasonably well tolerated with the commonest complain being of mild post procedural 
pain in the joint in approximately  35% of patients219. More serious complications such 
as haemarthrosis, deep vein thrombosis and joint infection have been quoted as 
0.9%, 0.2% and 0.1% respectively218. In a study examining diagnostic arthroscopies 
of the knee alone, an overall complication rate of 1.2%  was quoted220. Whilst this 
procedure returns good quality  synovial tissue and has been validated as useful tool 
in harvesting synovial tissue221, it required a moderate financial outlay  for equipment 
and the need for dedicated surgical suites. 
1.6.3 Ultrasound guided synovial biopsy
Once again this procedure can be performed under local anesthetic. A similar 
approach is taken to that of a blind needle biopsy but with the added advantage of 
being able to view both the needle insertion into the joint and the biopsy forceps 
when introduced. Koski et. al. described an ultrasound technique in 2005 using a 
portal and forceps approach to performing synovial biopsies222. This technique was 
used to biopsy  37 patients with mono- or polyarthritis, with suffcient amounts of 
synovial tissue harvested in 33/37 cases. One case of skin infection was reported in 
this small cohort. Van Vugt also demonstrated that, using a Tru-Core needle, an 
ultrasound guided approach to wrist synvoial biopsies could be achieved with 
suitable tissue being sampled in 7 patients. However only  2 passes were made with 
this particular needle technique during the procedure and no specific histological 
validation was performed on the biopsied tissue223.
An ultrasound guided technique still requires an aseptic approach and to be 
performed with the appropriate clothing (sterile gown, mask, gloves and head cover). 
The ability  to guide needles and biopsy  forceps improves the safety  of this procedure 
as does the use of a single portal of entry. The added benefit of this procedure is that 
not only  can the biopsy  samples be harvested from different compartments of the 
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joint but using PDS, biopsies can be taken from areas of high vascular signal. The 
single portal of entry  and ability  to monitor all aspects of the procedure under US 
guidance makes this technique particularly  suited to sampling tissue from small 
joints. A recent publication by  Scirè et al. showed that US-guided synovial biopsy   in 
small joints represents a reliable approach for good quality  tissue collection and that 
the tissue harvested was representative of the joint cellular infiltration in these 
joints224. 
1.6.4 Are synovial biopsy samples representative of the whole joint?
The definition of a 'Representative Sample' is: a subset of a statistical population that 
accurately  reflects the members of the entire population. A representative sample should 
be an unbiased indication of what the population is like. There are a number of different 
ways of sampling, however the most common is a simple random sampling method. 
Sampling ‘without replacement’ is common within biological systems as opposed to 
sampling ‘with replacement’. The theoretical disadvantage of sampling without 
replacement is that the probability  of sampling an individual or object on each 
subsequent pick becomes reduced. In large populations this  change in the population 
number is relatively  small, and as such can be ignored. This is a reasonable approach 
when researchers know very  little about the characteristics of the population being 
sampled. An alternative sampling method can be used where specific subgroups within 
the population are well established with random sampling taking place within each group 
or strata. 
Taking this into consideration, an important question to be addressed is the number of 
samples required at biopsy  to be representative of the synovium as a whole. This is a 
particular important question in the context of clinical trials  in early  stage drug 
development where changes in the sub-lining CD68+ macrophage number are thought to 
be a good indicator of therapeutic response. With respect to synovium sampling within a 
diarthrial joint, the knee joint has been most extensively  investigated. Pannus formation 
can be detected at the cartilage pannus junction (CP-J), commonly  the site of erosions, 
and as such may  represent a discrete population of inflammatory  cells with its own 
characteristic synovial pathobiology. A number of studies have examined tissue from the 
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CP-J and the rest of the synovium. Whilst an exhaustive comparison of cellular infiltrates 
has not been made, there is some suggestion that subtle differences may  exist. Yousef 
et. al. examined the distribution of CD3+ and CD68+ mononuclear cells within the 
suprapatelar pouch (SPP) and at the CP-J225. While there was no significant difference 
detected in CD3+ and lining CD68+ cells a difference was seen between the SPP and 
CP-J with CD68+ sub-lining cells. However, only  5 out of the 14 patients recruited to this 
study  had tissue harvested form the CP-J providing a relatively  small sample size for 
comparison. Contradictory  findings were reported by  Smeets  also compared the SPP 
and CP-J in 17 patients226. Using a more comprehensive immunohistochemistry  staining 
panel, including T cells, B cells and macrophages along with metalloproteinases, no 
significant difference was detected between these two sites. In support of this  Kane et. 
al., showed that in addition to there being little difference in MMP and TIMP synovial 
expression between PsA and RA patients, no significant difference was found within 
patients  at the SPP and CP-J227.  In line with this, Rooney  et. al. recruited 29 clinically 
active RA patients to a study  examining the variability  of a number of synovial parameters 
(synoviocyte hyperplasia, fibrosis, vessel proliferation, perivascular infiltrates, focal 
aggregates, and diffuse infiltrates of lymphocytes) between biopsy  samples. All 
parameters, scored on a 1-10 semi-quantitative scale, performed well with similar overall 
involvement. A good level of agreement was also seen within synovial tissue samples 
suggesting that there is a degree of homogeneity  within and between synovial biopsy 
samples form the knee joint. Work by  Dolhain has suggested that  minimum of 6 samples 
of synovial tissue are required to be a representative sample size. Dolhain used synovial 
tissue form 3 patients undergoing knee joint replacement surgery  and sampled 4 sties in 
1 patient with 6 samples in two others. An important observation in this report is that the 
variance between immunohistochemistry  markers reducing significantly  when slides  from 
different samples  were used for scoring rather than samples form the same tissue 
specimen. They  suggest 6 tissue samples  as a minimum number required to reduce the 
variance between markers within the synovium. However the sampling procedure here is 
was not arthroscopic and may  not be whole applicable to the in vivo scenario of 
arthroscopic or ultrasound guided procedures. An attempt to address this issue and 
validate ultrasound guided synovial biopsies  in small joints was undertaken by  Scire et. 
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al. following a US guided biopsy, patients received a arthroplastic procedure on the 
same joint with the total sample being processed for a number of cellular infiltrates 
including CD68, CD3 and CD20 by  immunohistochemistry.  A comparison was made 
between the US guided synovial tissue samples and with the total tissue analysed 
from the arthroplastic procedure. The number of high powered fields required to 
reduce the US guided tissue sample mean to within 10% of the overall arthroplastic 
sample mean was set as the efficiency  threshold for the analysis. This analysis would 
suggest an area of 1.2mm2 for CD68 macrophages and 2.5mm2 for CD3 
lymphocytes and CD20 B cells is required to provide a representative assessment of 
the overall synovial lining224. This equated to a minimum of 7 samples being retrieved 
at a single sitting. These findings however are relevant to the sampling procedure 
employed and not necessarily  relevant to alternative techniques as tissue sampled 
may vary  considerably  depending upon the gauge of instrument and sampling 
method used.
64
1.7 The Rheumatoid joint
1.7.1 Normal synovium
Synovium can be found lining diarthrodial joints and tendons. It also seen within bursae 
at various locations at points of bone and ligament or tendon interaction. The normal 
synovium has a lining (intima) and sub-lining (subintima) layer. The lining layer consists 
of CD68+ macrophages (type A synoviocytes) and CD55+ fibroblasts (type B 
synoviocytes)228 229. In the non-inflamed joint there is normally  a predominance of Type B 
fibroblast-like synoviocytes in the intima with this ratio changing dramatically  during 
inflammation to favor a predominance of Type A synoviocytes230 231. 
Figure 1-10: Microscopic view of normal and RA synovium
Normal and RA synovium. A: Normal synovium stained for CD55+ fibroblasts (red). 
Synovial fibroblasts make up most of the cells in the lining layer in the normal 
synovium intimal layer B: RA synovial tissue stained for CD55+ fibroblasts (red). RA 
synovial tissue contains fewer fibroblast than macrophage lineage cells. C: Normal 
synovium stained for CD68+ macrophages D: RA synovial tissue stained for CD68+ 
macrophages (red). The majority of the lining layer cells in RA synovial tissue are of 
macrophage origin. Reproduced from Smith et. al. The normal synovium Open 
Rheumatol J 2011;5:100-6.
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The intimal matrix contains a number of types of collagen (I, III - VI) but importantly  no 
basement membrane. The lack of entactin, essential for binding basement membrane 
components, would appear to be missing in the intima explaining to some extent this 
aberration. This presumably  facilitates the movement of cells  through the intimal layer, 
although the up  regulation of VCAM-1 on intimal type B synoviocytes  may  inhibit 
mononuclear cell transit such as macrophage and lymphocytes expressing the 
complementary  ligand (α4 β1 integrin)232. Hyaluronan is also found in the matrix but the 
concentration drops of as deeper layers of the subintima are reached233. The non-
αdherent intima surface certainly  owes its this  mechanical property, in part, to the 
production of hyaluronan by  fibroblast-like synoviocytes. Singh et. al. demonstrated by 
immunohistochemistry  that CD4+ and CD8+ lymphocytes can also be seen in normal 
synovial tissue234. However in 9 normal controls, no B cells were identified in the lining or 
sublining. Another report by  Smith et. al. However demonstrated similar findings but also 
showed a small number of B cells (CD22+) to occasionally  to be present within the 
synovium but no plasma cells (CD38)235. The patients identified in this study  were form 
sports clinics with unexplained knee pain undergoing a subsequent arthroscopic 
investigation and therefore not arguably  ‘normal’ knee joints. Smith also confirmed high 
levels  of IL-1 receptor antagonist in addition to low levels  of RANK ligand and OPG 
expression important in promoting osteoclastic activity.
Normal synovium is vascular and has a rudimentary  lymphatic drainage system located 
in the deeper sub-lining layer. Cell trafficking and the provision of oxygen and nutrients is 
certainly  provided by  this network of capillaries. Deeper in the sub-lining these vessels 
begin to form arterioles and venules in a plexus before ultimately  merging with local joint 
feeding vessels233 236. IL-1, TNF-α and IL-6 can all be detected in normal synovial tissue 
albeit in vastly  reduced concentrations as that seen in the actively  inflamed joint234. There 
is a significant elevation in levels of IL-1 receptor antagonist levels seen in the normal 
joint which may  mediate an anti-inflammatory  cytokine profile inhibiting up regulation of 
adhesion molecules, cellular activation and recruitment of leukocytes into the joint237.
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Figure 1-11: Microscopic appearances of synovial vascular and lymphatic vessels.
Vascular and lymphatic network in normal synoviumA: Normal synovium stained 
with factor VIII (red) to demonstrate the vascular network. B: Normal synovium 
stained with LYV-1 antibody (red) to demonstrate the lymphatic network. 
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1.7.2 RA synovium
Within RA patients, synovial tissue analysis confirms the hypertrophy  of the synovial 
lining layer with a reverse in the ratio of type A and type B synoviocytes. In addition there 
is significant influx of many  other mediators of inflammation such as T cells, B cells, 
plasma cells and macrophages. Neutrophils  and mast cells are also found in the sub-
lining layer. The archetypical synovial pannus consists of synovial lining, synovial stroma 
with inflammatory  cells and fibroblasts and is  directly  responsible for the erosions seen in 
the rheumatoid joint. The organization of these cells  into lymphoid aggregates in some 
patients  has been well described and will be discussed later. A number of authors have 
compared histological changes in both early  and late RA. The number of cellular types 
seen within the synovium are broadly  similar and independent of the disease duration 
although few studies have suggested at a tendency  for chronic synovial changes to be 
represented by  a greater macrophage number and more synovial organisation of T / B 
cells into lymphoid like structures. In addition, little difference is seen in cytokine and 
adhesion molecule expression depending upon disease duration. In a cross-sectional 
study  Kraan et. al. demonstrated in 95 patients with inflammatory  arthritis and OA, CD68 
macrophages in the sub-lining and CD22+ B cells were helpful in differentiation of RA 
and non-RA samples although these findings were not exclusive of PsA and OA 
synovium.  A high number of B cells and plasma cells  have also reportedly  been seen in 
early RA compared to other non-RA inflammatory arthropathies. 
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Increased vascularity  is also a feature of the RA synovium although this  is also seen in 
other arthropathies. A few  studies have suggested that the development of new  vessels 
in the RA synovium tends to result in relatively  straight vessel formation rather than a 
more tortuous morphology  seen in PsA and other SpA’s. In addition others  have reported 
higher levels  of VEGF expression in non-RA synovium than in RA. The up  regulation of 
adhesion molecules are also seen in ealry  and late disease with ICAM-1 and VCAM-1 
expression being of particular importance. VCAM-1 is up  regulated on both endothelial 
cells and lining layer cells with ICAM -1 expressed through out the synovium. αvβ3 and 
αvβ5 integrins are also up regulated in both early  and late disease with similar 
distribution and profile suggesting any  differences form early  to late disease cannot be 
fully explained on differential integrin expression alone.
Histological evidence of synovitis can be see in asymptomatic joints in patients with RA 
with samples showing macrophage infiltration and synovial lining layer hypertrophy. 
Similarly, imaging studies in patients with oligoarticular showed approximately  13 percent 
of joints could be reclassified as having ultrasound determined synovitis re-enforcing the 
concept of subclinical synovitis. However in the synovial histology  studies no long term 
data is available to confirm the development of clinical synovitis in biopsied, 
asymptomatic joints and whether this consequently leads to joint damage. 
1.7.3 Synovial ectopic lymphoneogenesis and lymphoid structures (ELS)
As previously  described, there is a large influx of immune cells into the rheumatoid 
synovium during the acute inflammatory  process.  These immune-cells can be found 
either randomly  distributed within the synovial sublining or spatially  grouped into 
follicular structures238. These structures may  acquired features of secondary-
lymphoid-organs-(SLO) to include high-endothelial venules (HEV), T/B-cell 
segregation, follicular-dendritic-cells networks and are defined as ectopic/tertiary 
lymphoid-like structures (ELS/TLS)239-242. Notably, these structures are also seen in 
other autoimmune diseases besides RA such as Sjogren’s syndrome (SS) and 
Hashimoto‟s thyroiditis. The true distinction and functional consequences of the 
presence or absence of ELS/TLS within the synovium is still debated240-244. Here we 
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would like to emphasize that these two patterns, defined as “follicular” and “diffuse”, 
are not necessarily  mutually  exclusive and individual tissues may  feature variable 
levels of diversity  or overlap243. Nevertheless, while in some tissues large, densely 
distributed ELS predominate, in others ELS are undetectable despite a prominent 
diffuse tissue inflammation. Studies in large cohorts of RA patients, demonstrate a 
variable  incidence of ectopic/tertiary  lymphoid-like structures within the synovium in 
approximately  30% - 73% of the specimens after arthroscopic biopsy from knee 
joints deemed clinically  inflamed245-249. Some difference is seen depending upon the 
sampling method although e.g. arthroscopic vs arthroplastic samples (36%, n = 29, 
68%, n = 22 respectively) although given that arthroplastic sampling tends to occur in 
patients with long standing disease with concomitant OA and may  be a confounder 
for these findings249.  Treatment with anti-TNF therapy  has also been shown to 
disrupt such aggregations and this change to be associated with good clinical 
response250. 
CXCL13 and CCL21 appear to be important chemokines in regulating the inter-
cellular interaction within these structures251 252. Examination of their mRNA and 
protein expression demonstrates a clear relationship  between CXCL13 and CCL21 
expression and the development of ELS with T-β compartmentalisation, CD21(+) 
follicular dendritic cell differentiation and germinal center formation239. A mouse 
model of SS (C57BL/6 mice) development of ELS was shown to be preceded by 
expression of lymphoid chemokines CXCL13 and lymphotoxin-β253. Similar findings 
were demonstrated in the NOD mouse model with up-regulation of lymphotoxins β 
and CXCL13 and CCL19 chemokines with subsequent infiltration of follicular B cells 
expressing CXCR5254. In addition to chemokine expression, our group have 
demonstrated that these ectopic lymphoid structures do have the ability  to function 
independently  as true ectopic lymphoid structures255. Activation-induced cytidine 
deaminase (AID), the enzyme required for class switch recombination and somatic 
hypermutation, expressed within follicular dendritic cell (FDC) networks, was shown 
to be present in salivary tissue with ELS but not expressed in its absence. 
69
Figure 1-12: Examples of follicular, diffuse and pauci-immune synovitis
Image of ectopic/tertiary lymphoid-like structures within the Rheumatoid synovium. 
Microphotographs of prototypical examples of Follicular, Diﬀuse and Pauci-immune 
synovitis. Three μm sections of paraﬃn embedded RA synovial tissues were stained 
with Haematoxylin and Eosin (H&E) and by Immunohistochemisty (IHC) for B cells 
(CD20), T cells (CD3), Macrophages (CD68) and Plasma cells (CD138). IHC 
performed by Dr. B. Hands (Experimental Medicine and Rheumatology, William 
Harvery Research Institute).
Furthermore, in synovial tissue from 55 patients with RA, we demonstrated that FDC
+ GC like structures invariably  expressed AID with a distribution resembling 
secondary  lymphoid organs255.  Specifically, AID+/CD21+ follicular structures were 
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surrounded by  ACPA+/CD138+ plasma cell. Transplanted SCID mice with RA 
synovium demonstrated persistent expression of AID with synovial mRNA levels of 
AID within the mouse closely associated with circulating human IgG ACPA in sera. 
This would suggest that these structures are functional and have the molecular 
machinery to support local autoantibody production and B cell expansion.
Additionally, Prof. Pitzalis group has described a third pattern other than 
aggregational / diffuse, termed “pauci-immune” synovitis that shows hardly  any 
infiltrating immune-cells (Figure 1-12) and is also found in active disease and early-
untreated arthritis therefore not simply the result of “burned out” synovitis256. 
Immunophenotypic characterization of these three histomorphological patterns 
demonstrates B-cells principally  in “follicular” synovitis (30-40%  of patients) but 
absent/low  in the “pauci-immune” and “diffuse” pathotypes (60-70% combined), the 
latter predominated by CD68+ve monocytes256. 
Importantly  these histomorphological patterns appear to segregate with specific 
transcriptomic signatures. In a cross-sectional cohort of arthroplasty  samples from 49 
RA patients, Genentech scientists observed transcriptomic clustering into: 
Lymphoid-(L), Myeloid-(M) and two Fibroblast-(F,F/A) prevalent patterns together 
with a mixed-(X) pattern containing biological aspects of the other 4 as defined using 
gene set modules (Fig.1-12). The F,F/A patterns are consistent with previous 
publications reporting diverse transcriptomic profiles associated with specific 
fibroblast-like synoviocytes (FLS) subsets257. Notably, FLS isolated from highly 
inflamed synovium displayed a transforming-growth-factor-β/activin-α inducible 
signature characteristic of myofibroblasts, whilst FLS from tissues with low 
inflammation displayed principally  an insulin-like-growth-factor regulated genes 
signature257. The transition from healthy  FLS to smooth-muscle actin-positive 
myofibroblasts is associated with the expression of matrix degrading proteases258 
that might explain the diverse FLS invasive/destructive phenotype described among 
RA patients 258-260.
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Figure 1-13: Transcriptomic clustering of RA synovial subtypes
Transcriptomic clustering of RA synovial subtypes Cross-sectional cohort of 
arthroplasty samples from 49 RA patients observed transcriptomic clustering into 
several subtypes:  Lymphoid (L), Myeloid (M) and two Fibroblast (F, F/A) prevalent 
patterns together with a mixed (X) pattern containing biological aspects of the other 
4 as defined using gene set module (Michael Townsend, Sarah Kummerfeld, David 
Fox & Flavius Martin)
1.7.4 Scoring synovial cellular infiltration
The cellular infiltration with in the synovium can be scored both quantitatively and 
semi-quantitatively. A number of semi-quantitative inflammatory scores exist. The 
Rooney and the Tak scoring system have been most widely  studied261 262. Using a 
semi-quantitative score it has been possible to show a correlation between the 
presence of synovitis and degree of histological inflammation in both early  and 
established RA whilst other cross-sectional studies have also shown a correlation 
with erosive damage263. Krenn has also described a synovitis score based on a 9 
point synovitis score for lining layer hypertrophy, synovial stroma cell density  and the 
degree of organisation of the infiltrate145. These scoring systems will be discussed 
further in the next section.
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Quantitative analysis can be performed using Digital Image Analysis (DIA) and Prof. 
Pitzalis group have developed a novel quantitative aggregational scoring system 
(QAS) that quantifies both the degree of aggregation within the SM and degree of 
diffuse infiltrate in the remainder of the tissue100. The aggregational score (AS) 
relates to the area fraction of ST occupied by  mononuclear cells in aggregate form 
and the diffuse score (DS) relates to the area fraction occupied by mononuclear cells 
in the remaining tissue. 
Table 1-7: Krenn histological synovitis score
Krenn scoring system adapted from Krenn et al. Synovitis score: discrimination 
between chronic low-grade and high-grade synovitis. Histopathology 2006;49(4):
358-64.
Enlargement of the synovial lining cell layer
 0 points The lining cells form one layer
 1 point The lining cells form 2–3 layers
 2 points The lining cells form 4–5 layers, few multinucleated cells might occur
 3 points The lining cells form more than 5 layers, the lining might be ulcerated and multinucleated cells might occur
Density of the resident cells
 0 points The synovial stroma shows normal cellularity
 1 point The cellularity is slightly increased
 2 points The cellularity is moderately increased, multinucleated cells might occur
 3 points The cellularity is greatly increased, multinucleated giant cells,  pannus formation and rheumatoid granulomas might occur
Inflammatory infiltrate
 0 points No inflammatory infiltrate
 1 point Few mostly perivascular situated lymphocytes or plasma cells
 2 point Numerous lymphocytes or plasma cells, sometimes forming follicle-like aggregates
 3 points Dense band-like inflammatory infiltrate or numerous large follicle-like aggregates
Sum 0 or 1 No synovitis
Sum 2–4 Low-grade synovitis
Sum 5–9 High-grade synovitis
1.7.5 Prognostic potential of the synovial membrane
Cross-sectional data from histomorphology  studies have suggested an association of 
histomorphology with particular disease phenotypes. Klimiuk et al. have reported 
that, in established disease, the more organized forms of synovitis with T-β cell 
aggregates and/or germinal centres (GC) are associated with a more severe disease 
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phenotype clinically  and radiologically77. The authors have suggested that all joints 
in an individual patient share the same pattern and these remain stable during the 
course of the disease. However there is little prospective data to confirm this. In fact 
using the Rooney  score to prospectively  evaluate histomorphology  as a potential 
prognostic marker, no statistical correlation with erosive disease over a 2 year period 
was found. It remains to be seen if the QAS performs better in a prospective study  in 
early or established Rheumatoid arthritis.
As already described macrophages have been more widely  studied with studies 
indicating that the intensity  of CD68+ macrophage synovial infiltration at baseline is 
associated with progressive joint damage. Recently  a study  of patients with early 
arthritis demonstrated a good correlation between the proportion of macrophages at 
baseline and the appearance of new joint erosions101. In early  arthritis matrix 
metalloproteinase-1 gene expression was correlated with the development of 
erosions in a study  involving patients with RA. The macrophage number also 
correlated with MMP-1 expression and erosive damage after 1 year of follow  up. 
However, despite this promising observation a larger study has failed to confirm the 
usefulness of these findings in a cohort of early arthritis.
1.7.6 Synovial biomarkers response to therapy
A number of candidate biomarkers exist within the synovium which may be 
responsive to therapeutic intervention. Some authors have attempted to produce a 
collective score for  a number of histological variables such as Krenn145 146 and 
Pettit264. Pettit produced a 1 - 10 score for a number of histomorphological features 
of the synovium and examined the ACR response in 18 patients undergoing knee 
arthroscopic procedures following treatment with DMARDS. He did not demonstrate 
a signifiant correlation with the change in any  synovial biomarkers e.g. CD68SL or 
lymphocytic infiltrate and change in ACR score, however, there was a significant 
correlation with clinical response and his synovitis score. Despite this, over the past 
decade work by  a number of authors have settled on CD68 sub-lining macrophages 
74
as the most responsive and reproducible biomarker in RA patients undergoing 
treatment. 
Tak et. al. demonstrated in two distinct cohorts of RA patients (early  < 1 year vs late 
>5 years disease duration) that there was little difference in the immunohistochemical 
analysis of the synovium but they  did show a correlation betweeen synovial 
macrophage number and IL-6 with knee pain262. Subsequently, the same group 
examined the peformance of this biomarker against DAS28 in the context of a 
randomized controlled clinical trial using Prednisolone therapy  over a 2 week period. 
21 patients with active RA were randomised to either oral prednisolone (n = 10) or 
placebo (n = 11) for 2 weeks265. The effect of prednisolone was large in comparison 
to DAS28 response suggesting that synovial macrophage numbers could be used as 
a biomarker for clinical efficacy. Bresnihan et. al. also demonstrated that this 
biomarker and histological processing  across a number of centers was reliable221. 
This is an important step forward in facilitating its use as potential outcome measure 
in clinical trials. Further work by  Tak, in a pooled cohort of 88 patients undergoing a 
number of therapeutic interventions showed a good correlation with the change in 
CD68SL macrophages and the patients EULAR clinical response (Pearson 
correlation 0.874, p<0.01) 266 (fig 1-14). There were no correlations between the 
change in intimal macrophages and the change in DAS28. Linear regression 
analysis, showed that the mean change in sublining macrophages could significantly 
explain 76% of the variance in the mean change in the pooled DAS28 scores 
(p<0.02)266 (figure 1n).
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Figure 1-14: Relationship of sublining CD68+ macrophages and mean change in DAS
A: Mean change in CD68+ macrophages within the lining layer of synovial tissue 
following therapeutic intervention with various medication including biological 
agents and DMARDS. B: A: Mean change in CD68+ macrophages within the 
sublining layer of synovial tissue following therapeutic intervention with various 
medication including biological agents and DMARDS. There is a significant 
diﬀerence in patients with good, moderate and no response to therapy. C: Plot of 
regressional analysis of mean change in DAS28 and mean change in sublining 
CD68+ macrophages. Note: legend should read T1 CCR1 antagonist
A% % % % % B
C
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In addition, Baeten et. al. showed in twelve patients with active RA receiving placebo, 
as part of a placebo controlled trial, over a 14 week duration showed no change in 
synovial T cell , B cell, plasma cell, dendritic cell or sub-lining macrophages248. There 
was however a trend of decrease in the components of the DAS28 score including 
ESR suggesting that histological assessment of the synovium may  provide greater 
clarity  of response in such placebo controlled studies with the impact of fewer patient 
recruited with an early read out of response.
Klaasen et. al. examined the presence of synovial germinal centers as baseline 
predictors to infliximab therapy and showed only  a modest relationship using linear 
regression analysis in a model containing clinical, histological and biochemical 
parameters (r2 = 0.1)267. In a similar cohort the same group used large-scale gene 
expression profiling on synovial tissue samples and identified high levels of synovial 
inflammation and associated gene up regulation and a significant associated factor in 
Infliximab response268. Although, in a study  by  Buch et. al. no correlation was seen 
between baseline synovial tissue TNFα levels and anti-TNFa reposne269. The 
synovial response to anti-TNFa therapy  has also been investigated in a cohort of 10 
patients undergoing treatment with Adalimumab + MTX vs MTX alone.  MMP-3 and 
CD68 macrophage numbers showed a significant decrease in those treated with the 
Adalimumab270. 
In patients treated with Rituximab, peripheral blood B cells are shown to be depleted 
rapidly  and almost undetectable at 4 weeks post infusion271-273. Within the synovium, 
Thurlings et. al. demonstrated a significant decrease in CD68L and SL macrophages 
numbers,  CD3+ lymphocytes, B cells (CD20) and plasma cells (CD138). Whilst none 
of the baseline histological features predicted clinical response there was a trend to 
B cell numbers being significant274. The change in CD68SL macrophages and 
plasma cells at 4 weeks post treatment predicted clinical response at 24 weeks. A 
disruption of lymphoid aggregates was also seen at 16 weeks post Rituximab 
treatment. It is interesting to note that in a study  investigating the synovial and MRI 
response in 16 patients treated with Abatacept, while there was a reduction in pro-
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inflammatory gene expression (particularly IFNγ), no change was seen in the 
synovial cellular infiltrate at 4 months following treatment275. 
The lack of a unifying biomarker of synovial histological response to therapy  is clearly 
demonstrated by the number of studies showing the utility  of various cellular and 
biochemical markers depending upon the drug in use. Further prospective studies 
are required in larger cohorts to better understand the kinetics of synovial response 
to differing biological therapies and provide the optimal marker ofresponse. 
Depending upon the mode of action, particularly  in the era of targeted biologic 
therapy, different biomarkers may  be required at varying stages of treatment and 
disease evolution.
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1.8 Angiogenesis
Angiogenesis is a fundamental process, critical for the sustained development of 
foetal life but also contributing to wound healing and granulation tissue in the adult. 
Strictly  speaking, angiogenesis is the formation of new blood vessels from a pre-
existing vascular network. Vasculogenesis, however refers to the de novo formation 
of endothelial cells form mesodermal cell precursors276. 
1.8.1 Vasculogenesis
Within the foetus, the development of a vascular plexus requires the differentiation of 
mesodermal angioblasts to form primitive blood vessels. Angioblasts are thought to 
develop under the influence of VEGFR-2 from a bi-potential stem cell 
(Haemangioblast). The role of VEGFR-2 is suggested by  the consequent lack of 
vasculogenesis and haematopoiesis seen in both mice and humans with a defect in 
this receptor277. The angioblast cell line facilitates the development of a vascular 
capillary  plexus under the influence of a number of angiogenic factors and receptor 
including VEGF, TGF-β, VEGFR-1, Tie-1, Tie-2, TGF-β receptor278. 
VEGF-R1 absence does not inhibit angioblast formation but the mature arrangement 
and development of a capillary  plexus is disrupted279. In addition, a threshold of 
VEGF expression appears to be of equal importance with mice with only  1 gene copy 
do not survive gestation with resultant aberrant vessel formation280. It would seem 
that the interplay  of VEGF expression and VEGF - R1 and R2 is a critical part of 
normal vascular development de novo. 
Once the primary capillary plexus has formed further differentiation and modification 
is required to facilitate a mature vascular network. This can be achieved in 2 distinct 
processes:
1. Sprouting angiogenesis: this process occurs most commonly in organogenesis 
with degradation of the local extracellular matrix, proliferation of endothelial cells 
along a chemotaxtic induced path, lumen formation and subsequent maturation.281 
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2. Intussusception (non-sprouting angiogenesis): this process involves the splitting of 
a pre-existing vascular bed by transcapillary pillars of the extracellular matrix281.
The process of angiogenesis differs form organ to organ, with the lung predominantly 
developing a vascular network by  non-sprouting angiogenesis and the brain using 
sprouting angiogenesis due to the lack of angioblasts within its substance282 283. Both 
processes may  occur together during organogenesis. Tie-2 (endothelial receptor 
tyrosine kinase) is necessary  for sprouting. Tie-2 knockout mice do not sprout 
vessels within the brain leading to embryological death at day 10284. Angiopoeitins 
act as Tie-1 and 2 receptor agonists and this interaction may underpin the effects of 
VEGF in determining sprouting or non-sprouting angiogenesis285.
Figure 1-15: Scanning electron micrographs of sprouting and transcapillary 
pillars
Scanning electron micrographs of methyl methacrylate corrosion casts of the 
vasculature in mammary gland tumors of c-neuT transgenic mice. (a, b) The 
sprouting phenotype, capillary sprouts are indicated by arrows. (c, d) The 
intussusceptive phenotype, transcapillary pillars are indicated by arrowheads. Scale 
bars: a=150 μm, b=100 μm; c, d=25 μm. Reproduced from Burri PH, I Molecular 
aspects of medicine 2002;23(6S):S1-27281.
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As the vascular plexus matures it undergoes pruning and remodeling. This was first 
described in the embryonic retina with the process being encouraged with hyperoxia 
states. Hyperoxia can reduces the expression of VEGF. The withdrawal of this 
important survival factor results in vessel regression however injection of VEGF 
inhibits this process286. Following the formation of a suitable vascular supply, vessel 
integrity  and stability  becomes less dependent upon VEGF287. It appears that cell 
adhesion molecules play  an important role in vessel stabalisation and continuing 
maturation.
1.8.2 Neoangiogenesis
The formation of new vessels form pre-existing vascular network is an integral part of 
many pathological states including inflammatory arthritis, tumor development and 
angiogenic ocular disease. It is also seen in the context of response to injury and 
wound healing288.
The formation of new vasculature in the Rheumatoid joint occurs by  sprouting of new 
vessels (neovascularisation) in response to angiogenic mediators289. Endothelial cell 
activation results in the release of proteolytic enzymes which degrade the 
surrounding extracellular matrix and basement membrane290. Endothelial cells 
reproduce and migrate into the extracellular matrix forming a sprout. These primary 
sprouts form a capillary  loop and, following the production of a basement membrane 
by  endothelial cells, form a mature vascular capillary. These early  features of 
angiogenesis are heavily  VEGF dependent291 292. New vessel sprouting is along a 
VEGF A concentration gradient with tip and stalk endothelial cells showing differential 
expression of delta-like 4 (DLL4) - expressing tip endothelial cells and NOTCH1 - 
expressing sprout stalk endothelial cells293 294. Within tumors there is a clear 
relationship with the stability  of immature, developing vasculature and VEGF but this 
dependency is lost with a more mature vascular network295-298.
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1.8.3 Angiogenic factors
VEGF
VEGF has a central role in the mediation of angiogenesis. The loss of a single VEGF 
allele in mice results in malformation of the primitive vascular system in utero with a 
subsequent non-viable phenotype299. The early  phases of angiogenic sprouting and 
vascular destabilization show a similar VEGF dependency300. Later, following 
maturation of the newly  formed vessels, the expression of VEGF is less important for 
normal vascular stability. Senger et al. were the first to describe a protein able to 
induce vascular leakage. This protein was termed ‘tumor vascular permeability 
factor’ (VPF) as it was isolated from a tumor cell line301.  The term ‘vascular 
endothelial growth factor’ was first coined by Ferrara and Henzel in 1989 when they 
reported an endothelial cell-specific mitogen from bovine pituitary follicular cells302. 
VEGF Ligands
VEGF A
The human VEGF-α gene is localized in chromosome 6p21.3. Alternative splicing 
may result in the generation of four different isoforms which are charachterised by 
the number of amino acids in their sequence (121, 165, 189 and 206 amino acids)303. 
VEGF165 is the most predominant isoform. VEGF165 is secreted by  endothelial 
cells, however it may  remain bound to the cell surface and extracellular matrix 
(ECM)304. The ECM-βound isoforms may  be released in a diffusible form by  heparin 
or heparinase with the loss of the heparin binding domain in VEGF has been shown 
to be critical in maintaining its affect as a survival factor for EC305 306. In pathological 
states, VEGF A has been demonstarted to acts on tumour endothelial cells causing 
proliferation, inhibiting vessel maturation and providing a positive mitogenic stimulus 
in hypoxic tissues307-311. 
82
VEGF B
VEGF-β is expressed early  during fetal development and is widely distributed, being 
prominently  expressed in the cardiac myocytes, in skeletal muscle and smooth 
muscle cells of large vessels312. VEGF-β is also expressed in the perichondrium of 
developing bone and in the nervous system312-314. VEGF-β is a selective ligand for 
VEGFR-1. VEGF-β and VEGF-α have only  partially  overlapping receptor specificities 
and as indicated by  the lethality of VEGF knockout in embryos, no other growth 
factor could compensate for the loss of even a single VEGF allele299. 
VEGF C
As well as signaling through VEGF-R2, VEGF-C is a potent inducer of 
lymphangiogenesis when bound to its principal target - VEGF-R3315. Transgenic mice 
over expressing VEGF-C have a selective hyperplasia of the superficial lymphatic 
vasculature, however, VEGF164 from the same promoter generates a pure 
angiogenic anomaly316. VEGF-C is also a potent chemotactic for macrophages 
expressing VEGF-R3, at the sites of inflammation317. It has been suggested that pro-
inflammatory cytokines, TNF-α or IL-1, stimulate these myeloid cells to produce 
VEGF-C thus encouraging synovial lymphangiogenesis although these pro-
inflammatory cytokines have also been shown to up regulate VEGF-C expression in 
vascular endothelial cells and fibroblast like synoviocytes318. However, a report from 
Polzer et. al. suggested that lymphangiogenesis was encouraged following treatment 
of humans with anti-TNF α with a greater expression of lymphatic vessels in synovial 
tissue when examining pre and post treatment synovial tissue319. 
VEGF D
VEGF-D is a ligand for both VEGF receptors (VEGFRs) VEGFR-2 (Flk1) and 
VEGFR-3 (Flt4) and can activate these receptors. However, VEGF-D does not bind 
to VEGFR-1. Expression of a truncated derivative of VEGF-D demonstrated that the 
receptor-βinding capacities reside in the portion of the molecule that is most closely 
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related in primary structure to other VEGF family  members and that corresponds to 
the mature form of VEGF-C. In addition, VEGF-D is a mitogen for endothelial cells. 
The structural and functional similarities between VEGF-D and VEGF-C define a 
subfamily  of the VEGFs. VEGF-D appears to have a negligible role in development in 
mice. Recent experimental evidence strongly  suggests that tumors can actively 
induce lymphangiogenesis via production of lymphangiogenic factors such as 
vascular endothelial growth factor (VEGF)-C and VEGF-D, and that the extent of 
tumor lymphangiogenesis is directly  correlated with the extent of experimental 
metastatic tumor spread to regional lymph nodes. Homozygous deletion of Vegfc 
leads to the complete absence of the lymphatic vasculature in mouse embryos, 
whereas Vegfc+/- mice display  severe lymphatic hypoplasia16. In Vegfc-null mice, 
lymphatic endothelial cells initially  differentiate in the cardinal veins but fail to migrate 
and to form primary lymph sacs. This demonstrates that VEGF-C is an essential 
chemotactic and survival factor during embryonic lymphangiogenesis16. By  contrast, 
deletion of Vegfd does not affect development of the lymphatic vasculature, although 
exogenous VEGF-D protein rescues the impaired vessel sprouting in Vegfc-/- 
embryos16, 34. Vegfr3 deletion leads to defects in blood-vessel remodelling and 
embryonic death at mid-gestation, indicating an early blood vascular function
Placenta Growth Factor (PLGF)
PLGF binds only VEGF-R1.  PLGF enhances the recycling of VEGF-R21 and αvβ3 
by  endothelial cells by  phosphorylation of GSK-3β320. This may  indicate that 
endothelial cell adhesion and migration during angiogenesis is influenced by  integrin 
expression and activation along side VEGF receptors. 
VEGF mediates endothelial cell survival and can be demonstrated both in vitro and in 
vivo. In vitro, endothelial cell apoptosis induced by serum starvation is inhibited by 
VEGF and has been shown to up regulate a number of anti-αpoptotoic proteins such 
as Bcl-2, A1 and survivin321 322. In vivo, as already  described the lack of VEGF results 
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in a lethal phenotype. Other, non-eptithelail cell types also respond to VEGF as a 
positive mitogen such as Schwann cells and pancreatic duct cells323.  Recently, it has 
been suggested that VEGF A may  act as a neuronal survival factor based on the 
observation that reduced VEGF expression is an associated risk for amyotrophic 
lateral sclerosis324.
VEGF has a number of physiological roles in the normal vascular system over and 
above endothelial cell stabalisation and triggering angiogenesis. VEGF produces 
vasodilatation, tachycardia and hypotension if infused into monitored rats. A role for 
endothelial derived Nitous Oxide (NO) in the mediation of these effects has been 
suggested325. A supportive observation in patients undergoing therapy with anti-
VEGF antibodies often have a  modest elevation of blood pressure. Vascular 
permeability  is also thought to be mediated by NO. Fukumura et. al. demonstrated 
that endothelial derived Nitrous oxide synthetase knockout (eNOS - / -) mice do not 
show a significant response to VEGF but inducible  NOS (iNOS) and wild type 
animals do when measuring angiogenesis, blood flow rate, and vascular 
permeability326. Both the eNOS-/- and iNOS-/- mice show normal development 
suggesting that while NO is an important mediator of VEGF function in the normal 
physiological processes, it is not necessary  for vasculogenesis and development of a 
competent vascular system. 
Regulation of VEGF Expression
Oxygen tension
Tissue hypoxia plays an important role in mediating the expression of VEGF and 
some similarities with the regulation of erythropoietin (Epo) production. A similar 
binding site is seen on the VEGF and Epo promoter. In response to hypoxia, HIF-1 
binds to DNA binding sites within regulatory sequences of hypoxia-inducible genes 
such as VEGF327. HIF-1 is a heterodimeric protein consisting of two subunits, HIF-1α 
and HIF-1β. HIF-1α is continually  produced but just as quickly degraded. This 
process is mediated by  von Hippel–Lindau tumor suppressor factor328. The effect of 
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hypoxia is to inhibit the function of this factor, allowing the survival and stabalisation 
of HIF1- α followed by  it’s binding to the appropriate DNA site in conjunction with HIF 
1- β. Loss of the expression of VHL tumor suppressor factor, as seen in von Hippel–
Lindau disease, results in continued availability  of HIF-1α, over expression of 
angiogenic factors and disorganized vascular growth manifest clinically  as multiple 
capillary  haemagiomas. Whilst HIF-1 up regulates VEGF and other related peptides, 
it also functions to prepare cells for anaerobic conditions. This is achieved by  by 
inducing glycolytic enzymes and glucose transporters which improves cells energy 
production in such hypoxic states329. HIF-1 also decreases mitochondrial oxygen 
consumption and halts the citric acid cycle.
Hypoxia-independent regulation
A number of growth factors are known to up regulate the expression of VEGF such 
as TGF-α, TGF-β, FGF, and PDGF330. A number of authors have also reported the 
ability  of inflammatory cytokines such as IL-1-α and IL-6 and TNF-α to induce 
expression of VEGF in a number of cell linages including synovial fibroblasts in a 
HIF-1 dependent fashion. Interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α), 
stimulate HIF-1 dependent gene expression even in normoxic cells331 332. It would 
appear that, although HIF-1a degradation is not inhibited in the normoxic scenario, 
the increased transcription of the gene is sufficient to alter the balance with the cell to 
favour dimerization with HIF-1β and fulfill its combined function. In addition, TNF-α 
may activate HIF-1 by radical oxygen species and NO production and/or NF-κB 
activation332. 
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VEGF receptors
All VEGF splice variants bind in an overlapping pattern to three receptors (VEGF-
R1,2,3). All three VEGF receptors are expressed on vascular endothelial cells to 
differing degrees. 
VEGFR1
Also known as Flt-1.
In addition to endothelial cells, VEGFR1 expression can also be found on dendritic 
cells, osteoclasts, monocytes and macrophages. VEGFR1 null mutant mice die at 
the embryonic stage as a result of endothelial cell proliferation and disorganized 
vascular overgrowth280. This would suggest that VEGF-R1 may have a regulatory 
effect (negative) on vasculogenesis. However, mice expressing the transmembrane 
and extracellular component of VEGF-R1 but not the intracellular signaling domain 
develop normally  suggesting that VEGF-R1 tyrosine kinase has redundancy. It has 
been postulated that the mopping up of VEGF is the critical aspect of the receptor 
during embryogenesis thus preventing VEGF signaling through VEGF-R2333. 
VEGFR1 transduces weak signals for endothelial cell and pericyte growth and 
survival as well as for cell migration of macrophages334 335. This may  have a role to 
play  in the on set and sustained inflammatory  component seen in Rheumatoid 
Arthritis. 
VEGF-R2
Up regulation of VEGF-R2 expression can be seen on vascular endothelial 
progenitors in early embryogenesis. During later stages of vascular development, 
VEGFR2 expression declines but can be up regulated in pathological angiogenesis 
such as in malignancy336. Up regulation of VEGF-R2 expression is seen principally 
on tip  endothelial cells in keeping with vascular VEGF A mediated response337. The 
subsequent release of Ang 2 from activated endothelial cells further destabalises the 
local vascular network facilitating loss of the local basement membrane, cell 
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migration and sprouting. If the VEGF-R2 gene is inactivated in mice, embryonic 
death occurs due to a lack vascular development especially  within the yoke sac338. 
Comparing this to the VEGF-R1 knock out mice who die of a over growth of poorly 
organized vessels, it would appear that a balance is maintained between the binding 
and signaling of VEGF- R1 and R2. Once again VEGF-R2 has been identified on 
other cell lines including osteoblasts, megakaryocytes and neuronal cells. Their role 
on these cells remains unclear however on vascular endothelium, VEGF A binding to 
VEGF-R2, promotes endothelial cell differentiation339.
VEGF-R3
VEGF-R3 has a more limited pattern of expression, being principally  found on 
lymphatic endothelial cells and fenestrated capillaries. Although the initial stages of 
lymphatic development form the cardinal vein in the embryo appears not to be 
significantly  influenced from VEGF-R3 signaling, sprouting of lymphatics at a later 
stage does requires the interaction of VEGF C and R3340 341. Dysfunction of VEGF-
R3 can be seen in congenital lymphedema due to mutations in the gene resulting in 
defective signal transduction342. This condition, characterised by  a decrease in the 
lymphatic systems ability  to collect and transport lymph form the extracellular matrix 
back into the circulation. Within tumours, VEGF-C expression, binding to VEGF-R3 
may increase lymphatic vessel development within the tumour microenvironment. 
Certainly  in orthotopic mice models, over expression of VEGF-C and D results in 
peritumoral lymphatic vessels formation and increases metastasis to regional lymph 
nodes343 344. 
VEGF co-receptors
Neuropilins (NRPs)
There are two NRP homologues, NRP1 and NRP2. The NRPs are a family  of soluble 
molecules with neuronal guidance functions, and subsequently  have been suggested 
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to be important receptors for normal vascular systems. NRPs are VEGF receptors 
and in help mediate the pro-αngiogenic and lymphangiogenic effects of VEGF. 
NRP1 is a co-receptor for VEGFR1/2 and NRP2 is a co-receptor for VEGFR3. NRP1 
contributes to VEGFR2 signaling with the subsequent effects of increased endothelial 
cell survival, vascular permeability and promotes cell migration345 346
1.8.4 Angiopoietins - TIE signalling system
The Angiopoietin (Ang) - Tie signaling system consists of two tyrosine kinase 
receptors and 2 principal ligands (Ang 1 and 2). Ang 3 is the mouse orthologue of 
human Ang 4. Ang 4 is thought to influence vascular remodeling and maturation as 
an angiogenic inhibitor. Ang 3 and 4 will not be discussed further in this section.
Ang 1 would appear to have a stabalising effect on vascular endothelium. Ang 1 
binding to Tie 2 tyrosine kinase, resulting in dimerisaton of the receptor and is 
autophosphorylated347. Activated Tie 2 on endothelial cells activates a number of 
downstream effectors important in maintaining endothelial cell stability  and 
equilibrium. Ang 1 interaction with Tie-2 appears to act as a survival signal in 
endothelial cells in mature vascular networks348 349. Under physiological it has a role 
in the integrity  of existing vessels through maintenance of the contacts between 
endothelial cells and mural cells. If there is a lack of Ang 1 signaling there is 
loosening of tight junctions permitting greater vascular permeability  in the presence 
of on going VEGF expression349. This is obviously  a favorable situation with 
leukocyte migration in infection but not ideal in the context of a persistent 
inflammatory condition such as RA. 
Ang 2 has an antagonistic effect, compared to Ang 1, on endothelial cell function 
despite studies confirming that it binds to Tie 2350 351. It would seem that the 
competitive binding of Ang 2 is a negative regulator of Tie 2 signaling resulting in 
degradation of the endothelial basement membrane. However this relationship 
cannot be viewed in isolation with the presence of VEGF significantly  modifying the 
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endothelial response to the Angiopoietin.  VEGF stimulates the release of Ang 2 from 
Weibel-Palade bodies352. These are storage granule of endothelial cells which 
contain Ang 2, von Willebrand factors, P-selectin and several other chemokines. This 
facilitates the disrupted intercellular endothelial junctions, sprouting of endothelial 
cells and degradation of the basement membrane353 354. The formation of vessel 
lumen are also vital for the maturation of new vessels and seem to be under the 
influence of epidermal growth factor-like domain multiple 7 (EGLF 7). EGLF 7 
promotes the movement of angioblasts and the formation of EC tube lumens. In its 
absence vessels continue to appear but lack a functional lumen.
1.8.5 Lymphangiogenesis
The lymphatic system is an essential component of our normal vascular system 
acting as a collection and return system for excess extracellular fluid and cells to the 
circulatory  system via the thoracic duct. Inhibition of this process quickly  result in 
extracellular fluid accumulation and the clinical picture of lymphodema. The lymphatic 
system also acts as a conduit for the movement of immune cells and antigens 
through out the body355. Although there are some similarities between the endothelial 
cells of he lymphatic and vascular system, many difference have been elicited. 
Endothelial cells lining lymphatic vessels have less tight intercellular junctions and 
fragments of broken basement membrane intergity355. VEGEF-R3 seems to play an 
important role in lymphangiogenesis although its expression is seen in the early 
stages of angiogenesis its role becomes more restricted to lymphatic endothelial 
cells356. VEGF C and binding with VEGF-R3 also play an important role in 
encouraging lymphatic sprouting from the embyologic venous system with VEGF C 
knockout mice failing to form any  lymphatic vessels, developing severe oedema341 356 
357. 
The lymphatic vessels also have smooth muscle cells located around the vessels 
although less concentrated than in normal vessels. Smooth muscle cell recruitment 
to the lymphatic vessels is inhibited in the absence of Ang 2 as seen in the knockout 
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mouse358 359. Ang 1 can also promote lymphangiogenesis,  and the abnormalities of 
Ang 2 deficiency  can be completely  reversed by  the administration of Ang 1. 
Interestingly, this may suggest that both angiopoeitins, acting via Tie 2 within the 
lymphatic system, have agonistic effects rather than the previously  described the 
agonist / antagonist roles seen on the normal vascular system358.
1.8.6 Angiogenesis and lymphangiogenesis in Rheumatoid Arthritis
There are many  mediators of angiogenesis within the inflamed RA synovium. Normal 
synovium has a small number of vessels which supply  sufficient nutrients and 
oxygen for its optimal function. In the pathological state, there is a significant 
increase in the vascular density  which facilitates the continued synovial proliferation 
and on going inflammatory  response360. A common analogy  is drawn with tumour 
growth and development although the vascular supply  here develops de novo 
(combination of both angio- and vasculogenesis) rather than a pre-existing vascular 
network361 362. 
Within the inflamed synovial joint there are many mediators of angiogenesis. Table 
1-8, outlines the plethora of mediators and some inhibitors of angiogenesis within the 
RA joint.
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Table 1-8: List of mediators and inhibitors of angiogenesis within the 
Rheumatoid synovium
Modified from: Szekanecz Z, et. al. New insights in synovial angiogenesis. Joint 
Bone Spine 2010;77:13-9.360
Mediators Inhibitors
Growth factors VEGF, aFGF, bFGF, HGF, HIF-1, HIF-2, PDGF, EGF, 
KGF, IGF-I, TGF-β
-
Cytokines TNF-α, IL-1, IL-6a, IL-8, IL-15, IL-17, IL-18, G-CSF, GM-
CSF, oncostatin M, MIF
IFN-α, IFN-γ,IL-4, IL-12, 
LIF
Chemokines/receptors IL-8/CXCL8, ENA-78/CXCL5, groα/CXCL1, CTAP-III/
CXCL6, SDF-1/CXCL12a, MCP-1/CCL2, fractalkine/
CX3CL1 CXCR2, CXCR4a, CCR2
PF4/CXCL4, Míg/CXCL9, 
IP-10/CXCL10, SLC/
CCL21, CXCR3
Matrix molecules Type I collagen, fibronectin, laminin, vitronectin, tenascin, 
proteoglycan
Thrombospondin-1
Cell adhesion molecules β1 and β3 integrinsa, E-selectina VCAM-1, ICAM-2, CD34, 
Lewisy/H, MUC18, PECAM-1, endoglin, JAM-α, JAM-C
-
Proteolytic enzymes MMPs, plasminogen activators TIMPs, PAIs
Environmental factors Hypoxia -
Others Angiopoietin 1 /Tie-2, angiotropin, pleiotrophin, 
angiogenin, survivin, COX/prostaglandin E2, PAF, Nitric 
oxide (NO), endothelin-1, 
Angiopoietin 2, 
angiostatin, endostatin, 
taxol, osteonectin, 
opioids, troponin I, 
chondromodulin, etc.
VEGF: vascular endothelial growth factor; FGF: fibroblast growth factor; HGF: 
hepatocyte growth factor; HIF: hypoxia-inducible factors; PDGF: platelet-derived 
growth factor; EGF: epidermal growth factor; KGF: keratinocyte growth factor; IGF: 
insulin-like growth factor; TGF-β: transforming growth factor-β; TNF: tumor necrosis 
factor; G-CSF: granulocyte colony-stimulating factors; GM-CSF: granulocyte-
macrophage colony-stimulating factors; MIF: migration inhibitory  factor; JAM: 
junctional cell adhesion molecules; PECAM-1: platelet-endothelial cell adhesion 
molecule-1; MMP: matrix metalloproteinases; TIMP: tissue inhibitors of 
metalloproteinases; PAI: plasminogen activator inhibitors.
Numerous growth factors are found within the RA synovium with VEGF playing a 
central role in the development of new vessels in response to inflammation. The 
release of TNF-α by  synovial macrophages and fibroblasts has been shown to 
increase VEGF levels with the result of endothelial cell proliferation and subsequent 
92
degradation of the basement membrane with a rudimentary sprout formation363 364. 
Taylor et. al. has also reported a significant correlation with serum VEGF levels and 
radiographic damage, as measured by a modified Sharp’s score, over the course of 
one year365. Furthermore, this group have also described elevated serum VEGF 
levels at presentation, in a cohort of RA patients with persistent disease activity 
despite conventional therapy. In addition, Klimiuk et al. have shown correlation 
between soluble adhesion molecules and VEGF366. Soluble adhesion molecules 
such as intercellular adhesion molecule-1(ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and E-selectin play  a key  role in activation, circulation, and 
migration of mononuclear cells to inflammatory  sites perpetuating the immune 
response.
VEGF would appear to have 3 main receptors within the RA synovium including 
VEGF-R1, VEGF-R2 and neuropilin-1 (NP-1). VEGF-R1 and R2 are both expressed 
on the majority  of endothelial cells. VEGF-R2 would seem to be a driver of 
endothelial cell proliferation and activation. This enhances cell surface expression 
molecules increasing peripheral leukocyte adhesion and migration into the inflamed 
joint367 368. VEGF-R2 promotes endothelial cell release of chemokines, such as TNF- 
a, IL-6, and MCP-1, critical for the on going inflammatory  response369. NP-1 is also a 
co-receptor of VEGF, and has been shown to regulate VEGF-R2370. NP-1 has anti-
αpoptotic functions in breast carcinoma suggesting that ligation of this particular 
receptor may act as a survival signal for endothelial within the joint.
Hypoxia plays a key role in neoangiogenesis that is typically  seen in the rheumatoid 
synovium and contributes to the tissue hypertrophy by supplying oxygen and 
nutrients to the proliferating synovial cells. Etherington et al. demonstrated 
exceptionally  low levels of pO2, using silver micro-electrodes, in the synovium of 
mice with established collagen-induced arthritis and similar levels in patients with 
inflammatory arthritis371. Lund-Olesen et al. reported the mean synovial fluid pO2 in 
RA knee joints to be as low as 27 mm Hg compared with 43 mm Hg in osteoarthritis 
patients372. Other authors support these findings and have recorded pO2 values 
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below 15 mm Hg373. VEGF, under the control of hypoxia-inducible factor (HIF), 
appears to mediate the hypoxic effects found within the RA joint. Cultured synovial 
cells are able to secrete VEGF under hypoxic conditions or when stimulated with 
IL-1, IL-6374. The induction of HIF-1 is highly  specific and sensitive to tissue hypoxia. 
HIF-1 is a heterodimer consisting of HIF-1α and HIF-1β subunits. HIF-1α, in the 
normoxic state, is undetectable because of rapid ubiquitination followed by 
proteosomal degradation mediated by  von Hippel–Lindau tumor suppressor factor 
(VHL)373. This is inhibited in hypoxic conditions allowing the dimerisation with the 
constitutively expressed β subunit. The resulting HIF-1 dimer up-regulates several 
genes including VEGF promoting angiogenesis332. The up-regulation of HIF through 
NF-κB also occurs in the response to pro-inflammatory cytokines such as TNF-α, 
IL-1 and IL-6 which may occur in a relative normoxic conditions. 
Chemokine-driven recruitment of inflammatory cells is seen in the Rheumatoid 
synovium. Chemokines containing glutamyl-leucyl-αrginyl (ELR) amino acid 
sequences (CXC) have been shown to stimulate angiogenesis as well as 
lymphangiogenesis. These include, but not limited to, IL-8/CXCL8 and epithelial 
neutrophil activating protein-78 (ENA-78)/CXCL5, while Stromal cell-derived factor-1 
(SDF-1)/CXCL12 seems to be important in promoting lymphangiogenesis375-377. 
1.9 Vascular vasodilatation and constriction
The control of peripheral vascular tone is an important homeostatic process which 
facilitates appropriate tissue perfusion and maintenance of systemic blood pressure. 
This control is exerted at a number of levels and includes neuronal, hormonal and 
local mediators of vascular constriction and vasodilatation. Excessive peripheral 
vasoconstriction certainly  contributes to systemic hypertension and is considered a 
pathological extension of the normal appropriate, physiological response 
encountered in low cardiac output states such as hemorrhage or cardiogenic shock. 
In Raynaud’s phenomenon a more subtle aberration exists with profound 
vasoconstriction with eventual correction of the digital vessel excessive tone.  A 
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neuronal mediated response is the principal driver of vasoconstriction in Raynaud’s 
phenomenon. 
Vasodilatation is seen in the setting of acute inflammation. While neovascularisation 
is seen in chronic synovial inflammation, this may  only  partly  explain the rapid 
alteration in vascular signal seen in patients with a ‘flare’ of their rheumatic disease. 
Patients can rapidly oscillate between low, stable disease and significant joint 
inflammation characterised by the classic calor, dolor, rubor and tumor (heat, pain, 
redness and swelling). The infrastructural changes in tissue vasculature take 
significant time to develop as a chronic inflammatory  response takes hold. It is likely 
that subclinical disease facilitates this significant vascular ingress however the 
dramatic and sudden change in vascular flow, which can occur with a disease flare, 
is likely to be mediated by  local pro-inflammatory  mediators and local vasodilatation. 
The opposite observation is seen in with the administration of steroid therapy during 
disease flares with rapid resolution of swelling and redness within 24-48hrs. This 
once again this suggests a down regulation of local inflammatory  mediators and 
improved tonal control of afferent vessels.
Vasodilatation may not be sufficient to explain all aspects of clinically  observed joint 
inflammation.  Acute swelling of joints during a flare or reduction in size following 
therapy  is not likely  to be purely  related to vasodilatation but include a reduction / 
increase in vascular permeability  with a resultant fluid shift. Synovial lymphatics have 
been demonstrated in synovial samples of both normal joints and in Rheumatoid 
Arthritis. It is likely  that these vessels would promote the rapid redistribution of 
excessive intercellular fluid generated by  both increased vascular permeability  and 
increase hydrostatic pressure from greater blood flow  during periods of inflammation 
and subsequent low  disease activity. Polzer et. al. demonstrated that in both animal 
and human studies that lymphatic tissue expansion occurs on successful 
suppression of the joint inflammatory  response319. This would indicate a role for this 
network in promoting the efflux of fluid and cells from the synovium.
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Neuronal control of vascular tone
Dual vasoconstrictor nerves and vasodilator nerves in skin were first suggested in 
1931 by  Lewis and Pickering. To date cutaneous vascular control being the most 
extensively  investigated. This is in part due to easy  access of the organ involved and 
simple thermoregulation techniques which can be employed to manipulate the 
underlying vasculature. Neuronal vascular control of cutaneous vessels is mediated 
by  a nor-αdrenergic sympathetic vasoconstrictor system, and a non-noradrenergic 
vasodilator system. In the normothermic state the nor adrenergic system is active to 
maintain vascular tone although this often is dependent upon the ambient 
environment temperature. Stephens et al. showed that complete postsynaptic 
blockade of adrenergic receptor mediated vasoconstriction did not completely  inhibit 
the vasoconstrictor response to cold but required the additional use of a pre-synaptic 
blockade suggesting that nor-αdrenergic mediated vasoconstriction is dependent not 
only  upon nor-αdrenaline but also co-transmitters. Neuropeptide Y, was identified as 
the likely  co-transmitter since antagonism of this molecule with BIBP-3226, in 
addition to α 1 and α 2 blockade of adrenergic receptors, completely  abolished the 
vasoconstrictor response. 
The control of vasodilatation is less well understood but once again co-transmitters 
have been implicated along side acetyl-choline as important mediators of neuronal 
mediated affects. It is interesting to note that post-synaptic blockade of muscarinic 
receptors completely  abrogates sweating but has almost no effect on cutaneous 
reflex vasodilatation suggesting additional mediators of this phenomenon. Vasoactive 
intestinal peptide (VIP), Nitrous oxide (NO) and substance P have all been shown to 
act as co-transmitters. McCord et al. (58) used intradermal ketorolac (a nonselective 
cyclooxygenase inhibitor) and l-NAME (NOS inhibitor) in a model of vasodilatation 
and found that both treatments significantly reduced the vasodilatory  response in 
their model with some additional synergistic effects demonstrated by  combination 
therapy.
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A number of disease processes have a modifying effect on both vasodilatation and 
constriction. Patients with systemic hypertension and diabetes tend to have a 
diminished response to reflex vasodilatation. Holowatz et. al. showed that in 
hypertensive patients the administration of arginase (which may  compete with NOS) 
improves reflex vasodilation thermoregulation but not in a normotensive cohort. In 
addition the same group showed that older individuals have both an inhibited 
vasodilation and vasoconstriction to warming and cooling respectfully. 
Local mediators of vascular tone
The release of endothelium-derived contractile mediators is governed by a number of 
steps including an increase in intracellular calcium concentration and activation of 
cyclo-oxygenase-1 (COX-1). One of the first identified endothelial derived vasoactive 
mediators was prostaglandins and Thromboxane A2. Increased intra-luminal 
pressure or mechanical shear force can cause hyperactivation of COX-1 with the 
subsequent effect of prostaglandin synthesis and increase in smooth muscle 
activation and vascular tone. A counter balance exist with NO being at the centre of 
endothelial derived vasodilatation. However in the pathological state, such as 
systemic hypertension, there seems to be an imbalance between these two control 
mechanisms. COX-1 is constitutively  expressed in cells although following shear 
stresses hyper-expresion may  occur. COX-2 in normally  inducible but in vascular 
endothelial cells it appears to be constitutively expressed also. 
Thromboxane A2 is the most potent inducer of smooth muscle contraction and 
increase in vascular tone through activation of smooth muscle TP receptors. This 
tends to be derived form platelet COX-1 but can be produced form endothelial cells. 
Conversely, Prostacyclin is a potent vasodilator and over expression of prostacyclin 
synthase in mice prevents injury-induced intimal hyperplasia, pulmonary 
hypertension and vascular remodeling. 
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1.9.1 Endothelial permeability
Vascular smooth muscle is the muscular component of blood vessels but no smooth 
muscle cells are found in capillaries. Instead, arterioles and to a lesser extent 
venules control the pressure differential across capillary  networks directly influencing 
the hydrostatic pressure within them.  In the setting of acute inflammation, arteriolar 
dilation causes an increase in hydrostatic pressure in combination with endothelial 
cell up-regulation of adhesion molecules and reduction in cell-cell junctions. Changes 
to the cytoskeleton and alterations in the plasma membrane of endothelial cells are 
responsible for the changes in vascular permeability. These changes are thought to 
be mediated by  protein kinase C  (PKC) activation and tyrosine-kinase-regulated 
pathways. Pro-inflammatory  cytokines, such as IL-1β, IL-6 and TNF-α, mediate NF-
κB  up-regulation and subsequent expression of both VCAM-1 and ICAM-1 on the 
endothelium during inflammation. This facilitates both an exudative fluid shift into the 
extracellular space and cellular trafficking. Up regulation of endothelial adhesion 
molecules (ICAM-1,  allow circulating neutrophils to initially  roll along the endothelial 
surface, become apposed to endothelial cells (pavementing), followed by  migration 
through the vessel basement membrane to access the intercellular space. These 
changes can occur within 6 hours on the initial stimuli.  Vascular permeability  can be 
though of in three separate scenarios, although there will be significant overlap  in 
these constructs at various times.
BVP - Basal Vascular Permeability
In the normal setting vascular movement of small molecules takes place at the level 
of the capillary  bed. Small molecules, such as gases, salts and sugars, pass through 
the endothelial barrier relatively  easily. Capillary  endothelial cells contained small 
vesicles referred to as caveolae (Fig.  2a, b) which appear to transport molecules 
across the endothelial cells. The normal hydrostatic pressure permits movement of 
fluid in the inter-cellular spaces but with a continuous basement membrane and 
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relatively  firm adherent junctions cellular trafficking or the movement of large 
molecules are not typical features in this setting.
AVH - Acute Vascular Hyperpermeability
The local production and release of vasoactive molecules such as TNF-α, bradykinin, 
VEGF-α or histamine has a dramatic effect on the local vascular network and its 
permeability  to large molecules and cellular trafficking. These changes can be rapid 
(within 30mins)  and produces an exudative fluid leak. The importance of eNOS in 
the signaling pathway for PAF and VEGF mediated vessel permeability  has been 
clearly  demonstrated in eNOS knockout mice and may  be an attractive target in 
chronic inflammatory  conditions with persistent elevated VEGF expression. 
Paradoxically  eNOS and NO appear to have a stabilizing effect on intercellular 
junction in the normal basal vascular permeability  state as shown by  Predescu et. al. 
while others have shown that increased NO synthesis in the acute inflammatory  state 
results in vasodilatation, changes in the cytoskeleton and effective loosening of the 
same intercellular junctions.  An important finding by Majno et. al. was that  maximum 
vascular permeability  occurs at post-capillary venules rather than at the capillary 
level. This region is highly specialized with cuboidal endothelial cells, which readily 
undergo cytoskeleton changes to disengage producing inter-cellular spaces. In 
addition, dedicated organelles have been described as alternative routes for larger 
molecules to pass through the cell itself into the extracellular space. In the acute 
setting however there is persistence of the basement lamina and pericyte adhesion 
further limiting movements of cells and large proteins.
CVH - Chronic Vascular Hyperpermeability
Chronic inflammation brings about further changes to the post-capillary  venules 
which are important adaptations. These are often seen in neoangiogenesis in the 
context of tumors and inflammatory  arthritis. New vessels form so called mother 
vessels (MV). These vessels form by a process of pericyte detachment and 
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degredation of the basla lamina, likely  to be in part encouraged by  the release of 
MMPs from inflammatory cells and fibroblasts. These greatly  enlarged sinusoids 
arise from preexisting normal venules by  a process that involves pericyte 
detachment, vascular basal lamina degradation, and a 4–5-fold increase in lumen 
size that is accompanied by  extensive endothelial cell thinning. Large molecules still 
pass through the endothelial barrier by  the trans-cellular route already  described with 
pores developing as cellular reorganization of the cytoskeleton infrastructure 
disengages cells form one another and more readily facilitates cellular trafficking.
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Figure 1- 16: Diagram of a normal venule architecture and following acute and 
chronic inflammatory changes.
(a) Schematic diagram of a normal venule comprised of cuboidal endothelium with 
prominent VVOs and closed inter-endothelial cell junctions. Basal lamina (BL) is 
intact and the endothelium is completely covered by pericytes. (b) AVH. Acute 
exposure to VEGF-α causes VVO to open, allowing transcellular passage of plasma 
contents, possibly by mechanical pulling apart of stomatal diaphragms (3). Others 
have suggested that fluid extravasation takes place through an opening of 
intercellular junctions (4, here shown closed). BL and pericyte coverage are as in (a). 
(c) CVH. Prolonged VEGF-α stimulation causes endothelium to transform into mther 
venules, greatly thinned, hyperpermeable cells with fewer VVOs and VVO vesicles/
vacuoles, degraded BL, and extensive loss of pericyte coverage. Plasma may 
extravasate either through residual VVO vesicles (5) or through fenestrations (6). 
Reproduced from Nagy JA, et al. Vascular permeability, vascular hyperpermeability 
and angiogenesis. Angiogenesis. 2008;11:109-119. 
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2. General methods
2.1 Ultrasound Guided Synovial biopsy
2.1.1 Equipment
2.1.2 Personnel
Ultrasonographer performing the biopsy
Technician / nurse / clinical fellow for tissue processing and assisting
2.1.3 Consent and adverse events
Consent should be gained prior to the patient attending for the synovial biopsy. This 
can ideally  be done during clinic with the patient’s permission to perform he biopsy is 
initially sought.
There are no large prospective studies of complication rates for Ultrasound (US) 
guided synovial biopsies using this particular technique. Our own experience would 
suggest that this procedure is well tolerated and safe. We have listed the quoted 
complications for diagnostic arthroscopy, however we expect the complication rate 
for this procedure to be significantly  better. An audit of our practice in 400 patients 
revealed only 1 wound infection with no other serious complications
Approximately  25% of patients will have minor discomfort after the procedure. This is 
effectively  managed with simple analgesia (non-steroidal anti-inflammatory  drugs / 
• Quick-Core biopsy needles (16G)
• 21G / 19G needles 
• Sterile drapes 
• Sterile Ultrasound sheath 
• Sterile gown and gloves 
• Procedure pack 
• Face mask / hair cover 
• Sterile swabs 
• Antiseptic solution 
(Chlorhexidine 2%)
• 10mls / 20mls syringes
• 1 % Lignocaine (20-30mls)
• Non-αdhesive dressing
• Sample container for processing
102
Paracetamol) and should dissipate after 24hrs. Patients are able to walk after the 
procedure and can go home on the same day. Patients are asked to refrain from 
overuse of the biopsied joint and should ideally  be accompanied home by  a friend / 
relative.
Below is a list of most commonly  experienced complications with arthroscopic 
procedures (approximate frequency in brackets) and should be discussed with the 
patient as potential complications.
i) Joint infection (0.2%) 
ii) Deep venous thrombosis (0.2%) 
iii) Haemarthrosis (1%)
iv)Neurological damage (0.02%)
v) Wound infection (0.5%)
vi)Thrombophlebitis (0.08%)
Patients be given a contact telephone number if they have any  concerns following 
the synovial biopsy, specifically  if there is pain, swelling, warmth or redness from the 
joint which may indicate infection.
2.1.4 Biopsy procedure
Orientation of patient
Wrist
The patient should be placed supine on a bed. The patient may  remain recumbent at 
45 degrees, with the hand placed on a table next to the bed. Care should be taken 
not to elevate the hand or abduct the shoulder significantly  as this will cause patient 
discomfort during the procedure. The hand should be place with the palm 
downwards.
Knee
The patient should be placed supine on a bed. The patient may  remain recumbent at 
45 degrees or preferably  lie completely  flat during the procedure.  With the knee 
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slightly  flexed (25-30 degrees) to improve imaging of the supra-patella pouch and a 
suitable point marked on the patient for introduction of the biopsy needle. 
Preparation
Wrist
With the patient suitably  placed on the bed, suitable absorbent pads should be 
placed under the wrist. The skin should be prepped with appropriate sterilization fluid. 
A wide field should be sterilized in excess of the immediate area of interest, approx. 
Hand to mid-forearm (dorsal and ventral aspects).
Sterile drapes should be positioned below the wrist on the table and a sterile drape 
used as a cuff at the mid forearm. 
The wrist should be placed in slight palmar flexion to improve access and 
identification of the synovial recesses. This can be facilitated by  placing a few sterile 
sections of gauze under the wrist
The operator should now evaluate his equipment tray  including biopsy  needle and 
commence personal preparations for the procedure (hand washing, gloves, face 
mask, hair net, sterile gown). 
The US probe should be placed within the sterile sheath. US gel should be placed 
first upon the probes foot-print and slowly  lowered into the sheath. The upper end of 
the sheath should be secured with a sterile tie or elastic band usually  provided with 
the sheath.
10mls of 1% lignocaine should be aspirated into a syringe.
US examination of the wrist should be performed prior to the biopsy  to identify  the 
extensor tendons of the 4th, 5th and 6th compartments, the scaphoid lunate junction 
and suitable synovial tissue. A suitable path should be planned as the normal 
anatomical relations may  be disturbed in chronic Rheumatoid Arthritis. A suitable 
path can usually  be identified inserting the needle superior to the Extensor Carpi 
Ulnaris (ECU) tendon and passing inferior to the Extensor Digiti Quinti Proprius 
(EDQ) and Long flexors (Extensor Digitum longus). The typical region for biopsy lies 
just superior to the scaphoid lunate ligament (Figure 1).
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Knee
With the patient suitably  placed on the bed, suitable absorbent pads should be 
placed under the knee. The skin should be prepped with appropriate sterilization 
fluid. A wide field should be sterilized in excess of the immediate area of interest, 
approx mid-thigh to mid calf both anteriorly and posteriorly. 
Sterile drapes should be positioned above, below, medial and lateral to the knee 
leaving sufficient space for access to the supra-patella pouch and placement of the 
U.S. probe for the purposes of imaging.
The operator should now evaluate his equipment tray and commence personal 
preparations for the procedure (hand washing, gloves, face mask, hair net, sterile 
gown).
The US probe should be placed within the sterile sheath. US gel should be placed 
first upon the probes foot-print and slowly  lowered into the sheath. The upper end of 
the sheath should be secured with a sterile tie or elastic band usually  provided with 
the sheath.
10mls of 1% lignocaine should be aspirated into a syringe and a second syringe of 
40mls of normal saline mixed with 10mls 1%  lignocaine prepared which will be 
introduced into the synovial space later.
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Procedure
Wrist
Inject the 2-5mls of 1% lignocaine into the subcutaneous tissue up to the extensor 
retinaculum. Leave a minimum of 3-5 mins for effect. 
Using a 19G needle and under US guidance, aspirate any  fluid. This should be 
stored for analysis. This is an opportunity  to plan for the biopsy needle insertion. Now 
introduce 2-5 mls of 1% lignocaine. This will enable a better image to be acquired 
during the procedure and facilitate clear identification of synovial tissue.
The quick core biopsy  needle should be primed before its introduction to the synovial 
space.
Introduction of the biopsy needle into the wrist can now  be performed under 
ultrasound guidance. This is best achieved by imaging the needle in a longitudinal 
plane as seen in figure 1.
The needle should be extended and the throw identified on the US images (Figure 
2). The throw of the needle should be placed against the surface of the synovium to 
maximize the opportunity for capturing the lining layer. Gentle pressure should be 
placed on the needle to oppose the throw and synovium. Triggering of the needle 
mechanism should be performed with a small forward movement of the whole 
needle. NOTE: if the tip of the extended needle is abutting a boney  surface, 
backwards movement of the needle will occur at this stage with poor retrieval of 
tissue.
After sufficient numbers of specimens have been harvested, any remaining fluid 
should be aspirated. 
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Figure 2-1: US guided synovial biopsy of the right wrist
Figure 2-2: US image of wrist joint with Quick CoreTM biopsy needle in situ.
EDL - extensor digitorum longus, EDQ - extensor digiti quinti
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Figure 2-3: US image of wrist joint with Quick CoreTM biopsy needle open with throw 
lying within the synovium.
Knee
Inject the 10mls of 1% lignocaine into the subcutaneous and deep tissue at the 
predetermined point of incision as previously  identified by  the initial US scan. Leave 
for 3-5 mins for the effect to take hold.
Using a 19G needle and under US guidance, aspirate as much fluid as possible from 
the supra-patella pouch. This should be stored for analysis if required. Disconnect 
the syringe leaving the needle in situ. Now introduce the 30-50ml mix of normal 
saline and lignocaine. A total of 10mls of 1% lignocaine can be introduced mixed with 
normal saline into the suprapatella pouch. This will enable a better image to be 
acquired during the procedure.
Introduction of the biopsy  needle can be performed through the anesthetized skin on 
the lateral aspect of the suprapatella pouch. The needled should be identified by  the 
ultrasound probe in the longitudinal position as soon as it enters the subcutaneous 
tissue. The needle should then be advanced into the supra patella pouch. Repeated 
biopsies can be taken using the same tract. 
Chlorhexidine can be used as a suitable contact medium for the ultrasound probe . A 
syringe (20mls) containing Chlorhexidine can be used to cover the skin during the 
procedure acting as a contact medium and maintaining sterility. 
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2.1.1 Post procedure care
1. A small dressing can be used to cover the wound.
2. A Neurovascular assessment should be made of the hand following the procedure 
and documented on the patients notes
3. The patient should remain in the department for a minimum of 30 mins post 
procedure. No specific monitoring is required.
4. Contact details in case of complications should be provided to the patient. 
Specifically, patients should be asked to contact the team if there is significant 
pain, swelling or redness of the biopsied joint within the next 5-7 days.
It is recommended that patients are followed up 3-5 days following the procedure 
either in person or by telephone.
2.1.2 Tissue processing
Tissue should be collected in the appropriate method for processing as described 
below depending upon local study protocols. Typically  for studies described in this 
thesis I have harvested approximately  20-30 samples per joint biopsy. The tissue 
was processes for both histological evaluation and gene microarray analysis.
2.2 Ultrasound image scoring
2.2.1 2D Qualitative score MCP / Wrist / knee joints
Synovial thickness measurement
2D images were stored and analyzed according to a standardized image set on an 
ordinal scale ranging from 0 to 4: 0, no synovial thickening; 1, minimal; 2; mild; 3, 
moderate; 4, severe. (appendix 1) which represented the spectrum of synovial 
thickening for both longitudinal and transverse images at MCP, wrist and knee joints. 
Synovial fluid was not considered in the scoring of these still images. Images were 
displayed using Image J viewing platform (NIH, http://rsb.info.nih.gov/ij/. 1997-2008). 
The images were reviewed in a standard format with pixel area of 1024 x 768. 
Synovium was defined as hypoechoic structure lying between the bone and tendons. 
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This measurement is referred to in thesis thesis as the STi (synovial thickness index). 
The scores from each of the 10 MCPJs were summated to create a Synovial 
Thickness Index (minimum score of 0 and a maximum of 40) for each plane; the 
10MCP Trans STi and 10MCP Long STi.
Power Doppler Signal
2D power doppler images were acquired using a 2D M12L (2D settings). A 3 second 
cine loop was acquired after resting the probe on the joint. The cine loop represented 
the previous 3 seconds of data capture. This loop was stored and analysed using 
Image J viewing platform. This platformed displayed the cine loops in a constant 532 
x 434 pixel constraint allowing for consistent interpretation of the images. The cine 
loop was played and the frame with the greatest doppler area chosen and scored 
using a semi-quantitative 0-to-4 vascularity  scale: 0, no PD signal; 1, minimal; 2; 
mild; 3, moderate; 4, severe. As for the PDA the longitudinal and the transverse 
region of interest at the MCPJs were the same as the respective STA region of 
interest. Images were graded against a library  of representative images i.e. for each 
selected image I visually  estimated the amount of coloured pixels within the joint 
capsule, compared this with the library, decided which representative image was the 
closest fit and allocated a score. The scores from each of the 10 MCPJs were 
summated to create a Vascularity  Index (minimum score of 0 and a maximum of 40) 
for each plane; the 10MCP Trans VASCi and 10MCP Long VASCi. 
2.2.2 2D Quantitative score (MCP / Wrist / Knee)
Synovial thickness measurement
Still images were recorded and Images were displayed using Image J viewing 
platform (NIH, http://rsb.info.nih.gov/ij/. 1997-2008). The images were reviewed in a 
standard format with pixel area of 1024 x 768. The synovial area was outlined as 
described above using a free hand drawing tool and the total pixel area recorded. 
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The Synovial Thickness Area (STA), is a count of the number of pixels within a 
defined region of interest  in a standardized 2-dimensional image of the joint. For the 
Longitudinal STA the region of interest should envelop the synovium over the 
phalangeal base, triangular structure, metacarpal head and metacarpal notch. For 
the transverse STA the region of interest should envelop the MCP joint synovium 
from the lower border of the triangular structure (if bone this is indicated by  a 
continuous hyperechoic line or if cartilage by  a homogenous anechoic line above 
bone) to the joint capsule superiorly.
Power Doppler Signal
Recorded ultrasound cine clips were recorded and quantitate analysis performed 
using Image J (NIH, http://rsb.info.nih.gov/ij/. 1997-2008) with a customised macro 
application for pixel area measurement.  The macro enabled sequential 
measurements of all cine loops within each file and the output file saved as an excel 
spreadsheet. For each recording the cine loop was played and the frame 
representing the maximum doppler signal selected by  the reader. The Power Doppler 
Area (PDA) is a count of the number of pixels with PDUS signal, uncorrected for pixel 
intensity, within a defined region of interest in a standardized 2-dimensional image of 
the joint (figure 2-4). Separate Quantitative measurements provided included power 
doppler pixel area (PDA), doppler pixel area over a predetermined colour threshold 
(PDThA) and a ratio of synovial to doppler area (PDA/STA). 
 
2.2.3 Power doppler Pixel intensity calculation 
This is a measure of  the  luminance of the color scale seen in the left hand side of 
the still image in figure: 2-4. This reflects the intensity of the PD signal. Yellow 
indicates a higher flow (and therefore intensity) than red according to the colour 
scale used. In order to extract the luminescence of the PD pixels the RGB (Red, 
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Green, Blue) image was split into their individual components. The Red and Green 
channels  were subsequently combined (minus Blue) according to the formula below:
Image Intensity: Y = 0.35*(R-β) + 0.65*(G-β)
This provided a luminescence score for each pixel. This calculation was performed of 
a spectrum of cine loops with varying PD signal and intensity. Using a step wise 
approach, a threshold of 100 was deemed to identify > 98% of high intensity pixels. 
The resultant number is recorded as the PD pixel intensity (PDThA).
Figure 2-4: Quantitative assessment of MCP Power Doppler signal using Image J.
A: Frame 9 / 27, selected still image of MCP with maximum PD signal. A yellow free 
hand drawn line depicts the region of interest equivalent to the synovial area. B: A 
graphic representation of the analysis indicating the maximum PD pixels analysed 
for each frame of the cine loop. C: Spreadsheet output from the Image J macro 
indicating the frame analysed, the pixel area drawn as the region of interest, the PD 
pixels within this region of interest, the number of PD pixels over a designated 
threshold and the frame chosen as the maximum representative PD signal (in this 
case frame 9).
A
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2.2.4 3D Qualitative score MCP / Wrists
3D images were acquired from MCP an wrist joints. Only  the vascular score was 
examined in this thesis. The acquired 3D volumetric DICOM image was processed in 
a DICOM viewing platform (4D View® GE Healthcare). The resultant DICOM image 
was displayed as three 2D images (longitudinal x axis, transverse z axis and coronal 
y  axis) and as a 3D composite image. The reconstructed image was set to ‘3D 
angio’ which removed all grey  scale voxels leaving only  Power Doppler Voxels and 
producing a ‘3D angiogram’. The resultant image was analyzed according to a 
standardized image set on an ordinal scale ranging from 0 to 4: 0, no synovial 
thickening; 1, minimal; 2; mild; 3, moderate; 4, severe. (appendix 1) which 
represented the spectrum of 3D vascularity.
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2.2.5 3D Quantitative score MCP / Wrists
The 3D volume data was acquired using the dedicated 4D16L Probe (3D Settings). 
This provided a standard 19 degrees mechanical sweep from the baseline (38 
degrees from start to finish of volume data acquisition). This took approximately  5 
seconds whilst the probe was lightly  held over the joint being imaged. For MCP joints 
a transverse 2D image through the centre of the joint was used as the mid reference 
point of the 3D probe. Once this image was acquired, the 3D settings were activated. 
The linear array within the probe swings to the edge of the probes foot print to being 
the mechanical generated sweep. Provided there is no movement of the probe the 
mid point should correspond to the centre of the joint as identified on with the 2D 
settings.
The acquired 3D volumetric DICOM image was processed in a DICOM viewing 
platform (4D View® GE Healthcare). The resultant DICOM image was displayed as 
three 2D images (longitudinal x axis, transverse z axis and coronal y  axis) and as a 
3D composite image.
The 3D image was selected and the VOCALTM function on the software enabled to 
provide volumetric measurements. The grey  scale component to the 3D image was 
removed leaving only the PD signal (3D angiogram). Using the scalpel mode the 
digital vessels were removed leaving only the synovial 3D vascular signal.
The remaining volume was calculated in cm3. The PD volume calculation was made 
by  using the vascular index (VI). This is the percentage of voxels within the defined 
region of interest. Therefore the PD volume (cm3) was measured by:
PD volume = (Histogram Volume x VI) / 100
Flow Index (FI) was also recorded and is a measure of the intensity  of the doppler 
signal and an attempt to quantify the velocity of blood flow. 
Vascularization flow  index (VFI) is a related calculation which attempts to quantify  the 
number of high intensity (fast moving) voxels in the Histogram Volume. 
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Figure 2-5: Quantification of 3D Power Doppler volume data set
A: 3D reconstruction of volumetric data to provide longitudinal, coronal and 
transverse images. There is a 3D reconstruction of the Power Doppler image which 
can be manipulated and rotated about each axis. B: identification and outline of the 
right digital vessel using the scalpel function. This allows the region encircled to be 
eliminated from the 3D reconstruction. C: Further use of the scalpel function to 
remove other vessels. D: Remaining synovial Power Doppler voxel signal for 
analysis.
A% % % % % % B
   
C % % % % % % D
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2.2.6 Topographical Image Scoring (TUI)
The 3D volume data may be analysed by  topographical sections as well as the 
reconstructed global image described in the sections above. To facilitate the 
topographical scoring of the volumetric data set the 3D DICOM viewing platform (4D 
View® GE Healthcare) can be selected to display  the topographical image by 
selecting TUI on the viewing menu. This produces a topographical display  of 
longitudinal images through the acquired volume data. Further manipulation can be 
performed by  modification of the central reference slice, the number of slices and 
distance between slices. The display  shows 9 images at any  given moment but 
sections can be scrolled through to gain an overall view of the data set. Care was 
taken on acquiring the data set that the mid point of the 3D probe was placed in the 
transverse position within the centre of the joint in a similar fashion as the 2D 
transverse probe position. This allows the 19 degrees sweep to cover the extent of 
the dorsal surface of the joint and the subsequent topographical longitudinal images 
to extend form the head of the proximal phalange to the synovial recess behind the 
neck of the metacarpal bone. 
For standardisation the topographical settings used were:
No. Slices - 15
Distance between slices - 0.5mm
Central slice - positioned on the mid point of the metacarpal head
Topographical scores recorded were based on the TUI slice deemed to show 
maximal PDS. include:
TUI - PDS score  - 0-4
TUI - ST score - 0-4
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Figure 2-6: Topographical imaging of the 2nd MCP joint showing PDS.
Topographical display of the an MCP joint form a 3D volumetric data set. A 
reference image is positioned in the top left hand corner in a transverse view with 
longitudinal sections displayed in the remaining 8 spaces. The reference image can 
be used to orientate and aline the central slice as the number and distance between 
each slice can be adjusted.
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2.3 Clinical Efficacy Assessments
2.3.1 Disease Activity
The primary  measure of disease activity  in this study  is the DAS28(CRP). The 
components of the DAS28(CRP) are the number of tender joints (28 joint count), the 
number of swollen joints (28 joint count), a Global Health index (100 mm VAS), and 
the CRP (in mg/L). An example of the form that can be used for the DAS28(CRP) 
calculation is found in Appendix 6.8. The formula for determining the DAS28(CRP) is 
as follows:
DAS28(CRP) = 0.56*√(TJC28) + 0.28*√(SJC28) + 0.36*ln(CRP+1) + 0.014*GH 
(VAS) + 0.96
Assessment of Tenderness – 28 Tender Joint Count (TJC28): The following 28 joints 
will be assessed for tenderness in response to pressure and/or passive motion.
Finger Proximal Interphalangeal Joints (8), thumb interphalangeal joint (2), 
metacarpophalangeal (MCP) (10), wrists (2) (includes carpometacarpal, intercarpal, 
and radiocarpal), elbows (2), shoulders (2), and knees (2).
During the assessment of pain on passive motion, no concurrent pressure will be 
applied to the joint margin. During pain on passive motion testing, the joint will be 
moved through the full available range in order to detect any end range pain.
Joint pain with palpation or pain on passive motion (either is sufficient) will be scored 
according to the following scale:
No pain (0)
Patient states that there is pain (1)
Assessment of Swelling – Swollen Joint Count (SJC): 28 joints will be assessed for 
the presence of swelling. The joints to be evaluated will be the same as those 
evaluated for tenderness. Joint swelling on palpation will be scored according to the 
following scale:
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No swelling (0) Swelling (1)
Examination of the upper extremities will be performed with the patient in the sitting 
position. Any joint that has undergone a replacement arthroplasty, small joint
synovectomy, or has had an intraarticular corticosteroid injection within the last 3 
months, should not be included in the SJC/TJC or ultrasound measures.  NA will be 
used to grade such joints.
Patient’s Global Assessment of Arthritis Condition
The patient will be evaluated for their global status of arthritis condition using the 100 
mm ungraded visual analogue scale (VAS). 
2.3.2 Health Assessment Questionnaire (HAQ; Disability Scales)
The HAQ  is usually  self-αdministered, but may  also be given face-to-face in these 
clinical studies. The Disability  Index consists of eight categories assessed by  the 
Disability  Index are 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) 
hygiene, 6) reach, 7) grip, and 8) common daily  activities. For each of these 
categories, patients report the amount of difficulty  they have in performing two or 
three specific activities. Patients usually  find the HAQ Disability  Index entirely  self-
explanatory. The HAQ – Disability Index questionnaire is in Appendix 6.6.
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2.4 Ethics
All studies described in this thesis were reviewed and approved by local ethics 
committees. All study procedures, patient management and data collection was 
performed according to Good Clinical Practice (GCP). 
Relevant ethics approvals are listed below:
1. An exploratory investigation into the molecular mechanisms of Response-Relapse-
Resistance to Rituximab therapy in RA patients (R4-RA study) - REC reference 
number: 10/H1109/23
2. Clinical responsiveness to anti-TNFα therapy and modulation of synovial lymphoid 
structures and B cell function in RA - REC reference number: 10/H0801/47
3. Lymphoid Neogenesis In Rheumatoid Arthritis: The histomorphological pattern of 
the synovial membrane (SM) predicts disease outcome - REC reference number:
05/Q0703/92
4.  A Randomized, Double-βlind, Parallel Group, Placebo Controlled Study to Assess 
the Effects of Oral Prednisone on Clinical Efficacy and the Power Doppler 
Ultrasound Signal of Synovium in Patients with Rheumatoid Arthritis - REC 
Reference Number: 08/H0718/37
5. Mechanisms of joint inflammation in rheumatic diseases - Guys Hospital REC 
Reference Number: 01/05/02
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3. Reliability of 2D and 3D ultrasound imaging endpoints
3.1 Introduction
The acquisition and scoring of ultrasound images is an important aspect of its validity 
and utilization in both clinical and research settings. Previous authors have examined 
the variability  of reading images but few have attempted to address the issue of 
variability  in respects to image acquisition and the consistency  of agreement 
between readers at different points in the study timeline. 
In collaboration with a colleague, Matt Seymour - based at the Kennedy  Institute of 
Rheumatology, we incorporated in to the design of a randomized controlled study 
serial ultrasound assessments at baseline and the end of study assessment (Day 15) 
to address these questions.
3.2 Aims
This component of the study evaluated a number of the systematic processes 
involved in image acquisition and interpretation. Specifically, we investigated the 
reliability  of 2D and 3D ultrasonographic endpoints (quantitative and qualitative 
measures of synovial thickness and vascularity) in MCPJs and wrists.
3.3 Reader Definitions
Assessment of reliability  has been complicated by  a diversity  of nomenclature 
employed by different investigators. Terms for assessment of reliability are redefined 
below to avoid confusion. The ultrasonographer also a reader of the anonymised 
images. Imaging was performed at two centers (Barts Health NHS Trust - BH and 
Kennedy  Institute of Rheumatology  - KIR) by  two ultrasonographers Stephen Kelly 
(SK) and Matt Seymore (MS). Both myself and Matt have over 5 years of US 
experience as ultrasonographers. We were both blinded to the subjects’ group 
allocation (i.e. Placebo or treatment group). We spent approximately  five, three hour 
sessions before the study  to gain consensus on image acquisition and analysis. A 
data set denotes 2D (longitudinal and transverse) and 3D images of the MCP and 
wrists.
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Within scan intra-reader
1 patient, 1 ultrasonographer acquires one data set, 1 reader reads the scan set 
twice; each reading is separated by  a fixed time period (previously  called intra-reader 
and intraobserver).
Within scan inter-reader 
1 patient, 1 ultrasonographer acquires one scan set, 2 independent readers 
(previously called inter-reader, interobserver and inter-investigator).
Parallel scan intra-reader 
1 patient, 1 ultrasonographer acquires two scan sets sequentially, 1 reader 
independently reads both scan sets (previously called intraobserver).
Parallel scan inter-reader
1 patient, 2 ultrasonographers each acquire a scan set independently, 2 readers 
each read their own acquired scan set independently  (previously  called 
interobserver).
To determine reliability  (within scan inter-reader, parallel scan intra-reader and 
parallel scan inter-reader) three scans were sequentially  acquired at Day  1 (baseline) 
and on Day 15 according to table 1.  
3.4 US endpoint definitions
2D US endpoint definitions
A detailed description of these measurements can be found in chapter 2 .
 2D Trans PDA - Sum of 10MCP Joints Quantitative Transverse Power Doppler Area 
 2D Long PDA - Sum of 10MCP Joints Quantitative Longitudinal Power Doppler Area 
 2D Long VASCi - Sum of 10MCP Joints Qualitative Longitudinal Synovial Vascularity
 2D Trans VASCi - Sum of 10MCP Joints Qualitative Transverse Synovial Vascularity
 2D Long STi - Sum of 10MCP Joints 2D Qualitative Longitudinal Synovial Thickness
 2D Trans STi - Sum of 10MCP Joints 2D Qualitative Transverse Synovial Thickness 
 2D Long STA - Sum of 10MCP Joints Quantitative Longitudinal Synovial Thickness Area. 
 2D Trans STA - Sum of 10MCP Joints Quantitative Transverse Synovial Thickness Area. 
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3D US measures definitions
 3D VASCi - Sum of 10MCP Joints 3D Qualitative Synovial Vascularity Score
 3D PD Vol - Sum of 10MCP Joints 3D Quantitative Power Doppler Volume
3D VFI - Sum of 10MCP Joints 3D Quantitative Power Doppler Volume qualified for 
a predetermined thresholded of signal intensity.
3.5 Method
The study  design is shown in figure 3-1. This was a randomized, double-βlind, 
parallel group, placebo controlled study  to assess the effects of oral prednisone on 
clinical efficacy  and power Doppler ultrasound signal of synovium in patients with 
Rheumatoid Arthritis. The study  was divided into a Panel A (18 patients receiving 
15mg of Prednisone daily  or placebo) and Panel B (27 patients receiving 7.5mg 
Prednisone daily  or Placebo). The ICC data was collected form Panel A patients 
only. This study  was conducted over 2 centers both using a GE Logiq9 ultrasound 
machine. The treatment group received 15mg of Prednisone daily  for the duration of 
the study. 2D images were acquired with a 2-dimensional M12L transducer and 3D 
images with a 4D16L Probe. Subjects were imaged over the dorsum of all 10 MCPJs 
and the dorsum of the wrist for 3D scans only. 
Serial scanning (3 scans, 2 ultrasonographers) occurred at Days 1, and 15 in the 
longitudinal and transverse planes for 2D imaging and for all MCPJs and wrists for 
3D imaging.  Longitudinal images were recorded in the midline with the hand of the 
metacarpal bone, proximal phalenge and extensor tendon in view. Transverse 
images were acquired through the centre of the joint with the image centralised to 
show both the medial and lateral aspects of the joint. Settings were identical on both 
GE Logiq9 ultrasound machines (appendix 1).  To standardise data acquisition, the 
hands were maintained in a position of rest by a splint (identical at both sites). The 
time of day  of scanning at each visit was within 1 hour of the time of the baseline 
visit. Care was taken when scanning to avoid undue pressure with the probe in case 
this altered blood flow in the joint. This was achieved by  maintaining a distance of at 
least 1 mm of gel between the probe and the subject as visualised on the US 
monitor. Three scans were sequentially  acquired at baseline and on Day  14 
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according to the scheme described in table 3-1. Each 2D scan data set consists of a 
grey  scale still images and power doppler movie clip that covers 3 or 4 cardiac cycles 
of all 10 MCPjs. The 3D scan data set involved all 10 MCPJs and both wrists. Each 
data set was identified with a unique ID number for blinding purposes.
Figure 3-1: Overview view of randomised controlled study design showing ultrasound 
and clinical assessments.
Product:  Non-Product 12
Protocol/Amendment No.: 088-00
0000_088-00_ProtCore  VERSION 4.0 APPROVED 11-Apr-2008
Non-U.S. IND, Ex-U.S. Study Restricted Confidential – Limited Access
blind, placebo controlle  study to compare the effects of daily d sing of prednisone on
synovial blood flow, measured by power Doppler ultrasound of metacarpophalangeal
joints with a conventional in ex of overall isease activity, the disease activity score 
(DAS), in patients with rheumatoid arthritis.  Figure 2-1 shows an overview of the study 
design.
Figure 2-1
Overview of the Study Design
Daily Prednisone 15 mg
Daily Placebo
Follow-UpScreening
14 days following last 
study drug 
administration
PDUS and Clinical Assessment
Baseline
Day 1
Day 2 Day 8 Day 15*
Up to 14 days prior to 
randomization
Randomization
Daily** 
Prednisone 
10 mg 
3 days
Daily** 
Prednisone
 5 mg 
2 days
Daily**
Placebo
*Visit 5 should ideally occur on Day 15 of treatment with study medication.   
However, if the patient is unable to attend this visit during the protocol specified 
visit window, the patient must be scheduled for this visit as soon as possible up to 
Day 20.   The patient must consume the study medication once daily until Visit 5 is 
completed.  
** Only patients who have had systemic glucocorticoid treatment lasting 3 weeks 
or longer within 1 year of prestudy visit will be tapered off study medication 
following Visit 5.  
Patients suitable for this trial will meet the 1987 ACR criteria for diagnosis of 
Rheumatoid Arthritis and will have at least moderate disease activity, measured by a 
DAS28(CRP) score of at least 3.2 at screening.  In addition, patients will have evidence 
of moderately active synovitis in at least 2 MCP joint characterized by a score of ≥2 or 
high synovial activity in at least 1 MCP joint characterized by a score = 4.  The synovial 
activity will be assessed by a 2-dimensional Transverse Synovial Vascularity Score (2D 
Trans VASCi) of synovial blood flow on PDUS of the MCP joint, using a 0 to 4 scale, 
with 4 being severe PDUS signal.  
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Table 3-1: Table describing the scan order at each site and from each 
ultrasonographer during the coarse of the study for panel A only.
Site Scan Ultrasonographer Reader
BH
1 SK SKMS
2 MS MS
3 SK SK
KIR
1 MS SKMS
2 SK SK
3 MS MS
Patients suitable for this study all met the 1987 ACR criteria for diagnosis of 
Rheumatoid Arthritis and will had at least moderate disease activity, measured by a 
DAS28(CRP) score of at least 3.2 at screening. In addition, patients had evidence of 
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moderately  active synovitis in at least 2 MCP joint characterized by  a score of ≥2 or 
high synovial activity  in at least 1 MCP joint characterized by  a score = 4. The 
synovial activity  was assessed by a 2-dimensional Transverse Synovial Vascularity 
Score (2D Trans VASCi) of synovial blood flow on PDUS of the MCP joint, using a 0 
to 4 scale, with 4 being severe PDUS signal (Appendix 1 for US atlas). Rather than 
investigating the reliability  on an individual joint basis, the of a summation of 10 
MCPJs was used as this represented the primary  outcome measure. 3D MCP joints 
scans were also treated similarly  with a summation of the scores over 10 MCPJs 
whilst the wrists were treated as a sum of 2 scans.  
Both myself and MS were blinded in the reading of the scan data set to both the 
patient and the timing of the scan (e.g. Day  1 / 2 / 8 / 15). Unblinding took place after 
all data sets had been scored.
3.6 Results
3.6.1 2D US Endpoints
Within scan intra-reader reliability  was not examined in this study  i.e. reading of the 
same scan by  the same reader on 2 occasions. The results of all the baseline and 
Day  15 Interclass Correlation Coefficients (ICC) values and Coefficient of Variation 
(CV) can be found in table 3-1 and 3-2.
Within scan inter-reader: 
For the primary  end point of the study  the (2D Trans 10MCP PDA) the intraclass 
correlation coefficient for the readings made in the 2 centers was very  high, 0.99 (CI 
0.98 - 1.00) (Table 3-1). Visual inspection of Bland-αltman plots (scatterplots of the 
average of the two baseline measurements read by  the 2 readers versus the 
difference of the 2 measurements) didn’t provide any  evidence that the magnitudes 
of the differences are not constant throughout the range of baseline measurements. 
The mean difference (bias) between the readings of the baseline value was 0.54 with 
a 95% CI equal to (-0.01, 1.1); the 95% limits of agreement were equal to (-1.7, 2.8) 
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i.e. approximately  10% of the measurement scale. At Day 15, the ICC remained high 
1.00 with a lower bound for the 95% CI greater than 0.99 (table 3-1). Generally, the 
synovial greyscale, qualitative and quantitative, measurements for synovial area 
were less robust than for their corresponding PD measurements. As already 
described, the primary end point of this study showed near perfect agreement (ICC 
0.99) as did the qualitative Trans VASCi score (ICC 0.92, CI 0.84-0.99), however 
both the Trans synovial thickness measures showed moderate agreement (Trans 
STA - 0.52, Trans STi - 0.48).  
At Day  15, there was similarly good / excellent agreement between all longitudinal 
endpoints with the best results seen with 2D Trans PDA (ICC 1.00, CI 0.99-1.00) 
followed by  2D Long VASCi ( ICC 0.94, CI 0.88 - 1.00). For the primary  endpoint (2D 
Trans PDA), the Bland-αltman plots didn’t provide any  evidence that the magnitudes 
of the differences are not constant throughout the range of measurements; see 
Figure 3-2.  The mean difference (bias) between the readings of the difference value 
was -0.13 with a 95% CI equal to (-0.6, 0.3) in the placebo group and was 0.08 with a 
95% CI equal to (-0.9, 1.1); the 95% limits of agreement were (-1.5, 1.2) and (-2.3, 
2.5) in the placebo and prednisone groups respectively; these limits are therefore 
between 5% and 10 % of the measurement scale.
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Figure 3-2: Bland-αltman Plot of the primary end point (2D Trans PDA) for two readers 
evaluation of baseline data set.
The red line represents the diﬀerence between the 2 readings (bias) for both groups 
combined, the green lines are the limits of agreement.
Figure 3-3: Bland-αltman Plot of the primary end point (2D Trans PDA) for two readers 
evaluation of the Day 15 data set for placebo and treatment groups
The red continuous lines present the diﬀerence between the 2 readings (bias) and 
limits of agreement for the placebo group; the green dashed lines present the 
diﬀerence between the 2 readings (bias) and limits of agreement for the prednisone 
group. (  - Prednisone, * - Placebo).
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Parallel scan intra-reader:
Agreement between the 2 baseline scans readings by  the same reader was good 
e.g. ultrasonographer SK performs 2 scan data sets on day 1 and SK scores both) 
The ICC values were > 0.70 for all endpoints; the coefficient of variation was smallest 
for the 2D Long STA (7%) and largest for the 2D Long PDA (57%). 
At Day  15, a good or excellent agreement was seen with all end points, ICC > 0.76, 
except for  2D Long PDA which showed moderate agreement ICC  0.62 ( 0.36;  0.88). 
Visual inspection of the Bland-αltman plots didn’t provide any  evidence that the 
magnitudes of the differences are not constant throughout the range of 
measurements both at baseline and Day  15. The coefficient of variation at baseline 
for all endpoints was less than 30% but increased significantly to Day 15. 
Parallel scan inter-reader:
Agreement between the 2 baseline scans readings by  different readers was good 
with ICC values > 0.68 for all endpoints except for Trans STA and STi. The coefficient 
of variation was smallest for the 2D Long STA (12%) and largest for the 2D Long 
PDA (60%). Significant differences between the 2 readings were detected for each of 
the endpoint. 
At Day  15, the endpoints concerning synovial thickness and in particular Trans STi 
shoed poor agreement. Trans VASCi continues to show excellent agreement 
between readers, ICC 0.85 (CI 0.72 - 0.99) with a coefficient of variation of 40%.
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Table 3-1: Inter class correlation coefficient (ICC) baseline results for all US 
endpoints
Inter class correlation coeﬃcient (ICC) baseline results for all US endpoints (95% CI) 
and co-eﬃcient of variation (CV) expressed as a percentage with 95% CI.
End Point Scan and reader ICC 95% CI CV 95% CI
2D Long PDA Within scan inter-reader  0.89  (  0.80;  0.99)  30.8  ( 23.7;  44.7)
Parallel scan intra-reader   0.80  (  0.64;  0.96)  57.3  ( 42.5;  90.4)
Parallel scan inter-reader  0.78  (  0.59;  0.97)  60.1  ( 44.4;  96.0)
2D Long STA    Within scan inter-reader  0.76  (  0.56;  0.95)  12.4  (9.7;  17.4)
Parallel scan intra-reader   0.95  (  0.90;  1.00)   7.1  (5.6;  10.0)
Parallel scan inter-reader  0.85  (  0.72;  0.98)  11.6  (9.1;  16.3)
2D Long STi    Within scan inter-reader  0.67  (  0.40;  0.93)  14.0  (11.0;  19.8)
Parallel scan intra-reader   0.87  (  0.75;  0.99)  10.9  (8.5;  15.3)
Parallel scan inter-reader  0.67  (  0.42;  0.93)  14.8  (11.6;  20.9)
2D Long VASCi  Within scan inter-reader  0.90  (  0.81;  0.99)  18.7  (14.6;  26.6)
Parallel scan intra-reader   0.93  (  0.87;  0.99)  16.8  (13.1;  23.8)
Parallel scan inter-reader  0.83  (  0.67;  0.98)  27.9  (21.5;  40.2)
2D Trans PDA   Within scan inter-reader  0.99  (  0.98;  1.00)   7.7  (6.0;  10.8)
Parallel scan intra-reader   0.75  (  0.57;  0.93)  43.7  (33.1;  65.7)
Parallel scan inter-reader  0.72  (  0.51;  0.93)  51.0  (38.2;  78.7)
2D Trans STA   Within scan inter-reader  0.52  (  0.33;  0.72)   6.1  (4.8;   8.6)
Parallel scan intra-reader   0.83  (  0.68;  0.98)   9.7  (7.6;  13.6)
Parallel scan inter-reader  0.57  (  0.24;  0.89)  13.8  (10.8;  19.5)
2D Trans STi   Within scan inter-reader  0.48  (  0.19;  0.76)  20.2  (15.7;  28.7)
Parallel scan intra-reader   0.83  (  0.68;  0.98)  15.3  (12.0;  21.7)
Parallel scan inter-reader  0.00
 ( -0.46;  
0.46)   32.1  (24.7;  46.7)
2D Trans VASCi Within scan inter-reader  0.92  (  0.84;  0.99)  15.7  (12.3;  22.2)
Parallel scan intra-reader   0.73  (  0.52;  0.94)  30.8  (23.8;  44.8)
Parallel scan inter-reader  0.68  (  0.45;  0.92)  32.4  (25.0;  47.3)
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Table 3-2: Inter class correlation coefficient (ICC) results for all US endpoints at  
DAY 15 
Inter class correlation coeﬃcient (ICC) results for all US endpoints at DAY 15(95% 
CI) and co-eﬃcient of variation (CV) expressed as a percentage with 95% CI.
End Point Scan and reader ICC 95% CI CV 95% CI
2D Long PDA Within scan inter-reader  0.98  (  0.95;  1.00)   21.8  (  16.9;  31.6)
Parallel scan intra-reader   0.62  (  0.36;  0.88)  259.8  ( 126.1; 788)
Parallel scan inter-reader  0.68  (  0.45;  0.92)  153.5  (  92.3; 496.3)
2D Long STA    Within scan inter-reader  0.81  (  0.65;  0.97)   13.0  (  10.1;  18.6)
Parallel scan intra-reader   0.83  (  0.68;  0.98)   12.4  (   9.6;  17.7)
Parallel scan inter-reader  0.71  (  0.48;  0.95)   17.6  (  13.6;  25.2)
2D Long STi    Within scan inter-reader  0.54  (  0.20;  0.88)   20.5  (  15.9;  29.6)
Parallel scan intra-reader   0.82  (  0.66;  0.98)   12.9  (  10.1;  18.5)
Parallel scan inter-reader  0.46  (  0.07;  0.85)   23.9  (  18.4;  34.7)
2D Long VASCi  Within scan inter-reader  0.94  (  0.88;  1.00)  27.4  (  21.1;  40.0)
Parallel scan intra-reader   0.94  (  0.88;  1.00)  31.9  (  24.4;  47.1)
Parallel scan inter-reader  0.85  (  0.72;  0.99)  40.5  (  30.6;  61.2)
2D Trans PDA   Within scan inter-reader  1.00  (  0.99;  1.00)  10.2  (   7.9;  14.5)
Parallel scan intra-reader   0.76  (  0.57;  0.94)  83.4  (  58.4; 152.1)
Parallel scan inter-reader  0.75  (  0.55;  0.96)  74.3  (  53.0; 129.0)
2D Trans STA   Within scan inter-reader  0.57  (  0.36;  0.79)   7.9  (   6.2;  11.2)
Parallel scan intra-reader   0.92  (  0.85;  0.99)   7.6  (   5.9;  10.8)
Parallel scan inter-reader  0.40  (  0.01;  0.80)  18.0  (  13.9;  25.9)
2D Trans STi   Within scan inter-reader  0.36  (  0.10;  0.62)  21.7  (  16.8;  31.4)
Parallel scan intra-reader   0.77  (  0.58;  0.97)  22.9  (  17.7;  33.1)
Parallel scan inter-reader  0.01  ( -0.46;  0.48)  35.1  (  26.8;  52.3)
2D Trans VASCi Within scan inter-reader  0.96  (  0.92;  1.00)  20.1  (15.6;  29.0)
Parallel scan intra-reader   0.91  (  0.84;  0.99)  23.4 ( 21.4; 61.3)
Parallel scan inter-reader  0.78  (  0.60;  0.96)  37.1 ( 12.6; 84.9)
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3.6.2 3D US Endpoints
For the selected 3D vascular endpoints, Within scan intra-reader reliability  was also 
examined. The results of all the baseline and Day  15 Interclass Correlation 
Coefficients (ICC) values and Coefficient of Variation (CV) can be found in table 3-3 
and 3-4. 
Within scan intra-reader
The baseline and Day 15, 3D US endpoint data set was read and re-read after a 2 
month delay. The agreement between these two readings at baseline were excellent 
with a 3D PD Vol ICC of 0.98 (CI 0.97 - 1.00) and 3D VASCi, qualitative measure, of 
0.95 ( CI 0.91 - 0.99). The agreement continued to be excellent following treatment at 
Day  15. The Bland-αltman plots didn’t provide any evidence that the magnitudes of 
the differences are not constant throughout the range of measurements Figure 3-4 
and 3-5
Within scan inter-reader
Excellent ICC results were obtained with all 3D endpoints ICC > 0.89. This was 
observed at baseline and at Day 15.
Parallel scan intra-reader
This reading provided the poorest agreement with all endpoints giving only  moderate 
agreement with 3D VASCi having an ICC of 0.53 (CI 0.22- 0.84) and a coefficient of 
variation  59% % ( CI 43.8-94.4).
Parallel scan inter-reader
Excellent ICC  results were obtained with all 3D endpoints and this was observed at 
baseline and at Day 15.
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Figure 3-4: Bland-αltman Plot of the 3D VASCi endpoint for two readers evaluation of a 
baseline data set.
Figure 3-5: Bland-αltman Plot of the 3D Power Doppler volume (3D PD Vol) endpoint for 
two readers evaluation of a baseline data set.
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Table 3-3: Inter class correlation coefficient (ICC) baseline results for all 3D US 
endpoints
Inter class correlation coeﬃcient (ICC) baseline results for all 3D US endpoints (95% 
CI) and co-eﬃcient of variation (CV) expressed as a percentage with 95% CI.
Endpoint Comparison ICC 95% CI CV 95% CI
3D PD Vol     Within scan intra-reader 0.98 (0.97; 1.00) 9.3 (4.2; 17.9)
Within scan inter-reader  0.97  (  0.95;  1.00)   18.9  (  14.7;  26.8)
Parallel scan intra-reader    0.69  (  0.44;  0.94)  121.7  (  79.2; 277.2)
Parallel scan inter-reader  0.85  (  0.73;  0.98)   49.2  (  37.0;  75.4)
3D VASCi     Within scan intra-reader 0.95 (0.91; 0.99) 12.1 (6.8; 22.6)
Within scan inter-reader  0.89  (  0.79;  0.99)   22.4  (  17.4;  32.0)
Parallel scan intra-reader    0.53  (  0.22;  0.84)   59.3  (  43.8;  94.4)
Parallel scan inter-reader  0.84  (  0.70;  0.98)   26.4  (  20.5;  38.0)
3D VFI    Within scan intra-reader 0.99 (0.98;1.00) 9.8 ( 3.2; 15.7)
Within scan inter-reader  0.97  (  0.93;  1.00)   22.8  (  17.7;  32.5)
Parallel scan intra-reader    0.70  (  0.45;  0.94)  124.8  (  80.7; 291.4)
Parallel scan inter-reader  0.83  (  0.69;  0.98)   54.5  (  40.6;  85.2)
Table 3-4: Interclass correlation coefficient (ICC) Day 15 results for all 3D US 
endpoints
Interclass correlation coeﬃcient (ICC) Day 15 results for all 3D US endpoints (95% 
CI) and co-eﬃcient of variation (CV) expressed as a percentage with 95% CI.
Endpoint Comparison ICC 95% CI CV 95% CI
3D PD Vol     Within scan intra-reader 0.98 ( 0.94; 1.00) 10.4 (  7.8; 19.3)
Within scan inter-reader  0.96  (  0.92;  1.00)   42.5  (  32.1;  64.8)
Parallel scan intra-reader    0.72  (  0.51;  0.93)  468.9  ( 163.0;    . )
Parallel scan inter-reader  0.91  (  0.83;  0.99)   79.0  (  55.8; 140.8)
3D VASCi     Within scan intra-reader 0.94 (0.88; 0.97) 10.5  (6.2; 15.3)
Within scan inter-reader  0.91  (  0.82;  0.99)   29.8  (  22.8;  43.7)
Parallel scan intra-reader    0.39  (  0.03;  0.76)   97.9  (  66.4; 194.8)
Parallel scan inter-reader  0.94  (  0.89;  1.00)   22.3  (  17.2;  32.2)
3D VFI    Within scan intra-reader 0.96 (0.92; 0.99) 14.2 (4.7; 23.4)
Within scan inter-reader  0.93  (  0.87;  0.99)   42.2  (  31.8;  64.1)
Parallel scan intra-reader    0.63  (  0.37;  0.89)  743.0  ( 187.5; - )
Parallel scan inter-reader  0.86  (  0.74;  0.98)   99.4  (  67.2; 199.8)
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3.7 Discussion
Interclass correlation coefficient (ICC) was calculated for a number of measurements 
outlined above at baseline and at Day 15 of this placebo controlled, randomised 
study  (Panel A). As a ultrasound measurement of disease activity  was chosen as the 
primary  end point it was important to identify  if the ICC  remained constant over the 
course of the study  and specifically  if a significant change to the US scores  following 
treatment resulted in a deterioration in the reliability  of the endpoint. Therefore all US 
endpoints were calculated at baseline and day 15.
2D US endpoints
The ICC results for the 2D data set used in this clinical study  showed good to 
excellent agreement in many  of the US endpoints examined. Generally, the synovial 
thickness measurements performed less well than the power Doppler counterparts at 
both baseline and Day  15. In particular the 2D Trans STi showed no agreement for 
‘Parallel scan inter-reader’ measurements and only  poor to moderate agreement for 
‘Within scan inter-reader’ measurements. There was a high degree of consistency for 
all endpoints, including Trans STi ,for ‘Parallel scan intra-reader’ measurements. The 
dimensions of the transducers available for use in this study  may have been a 
limitation resulting in weak inter-reader reliability  (within-scan or parallel scan) for the 
Trans STi and Trans STA endpoints. The transducer used in this study  had a large 
foot print relative to the deepest point of the triangular structure (which is a narrow 
precise location), more than one hyperechoic line, representing bone, is often 
observed on the saved gray-scale image. This is often the co-localisation of the head 
of the MCP and PIP joint coming into view. Therefore, myself and MS may  have 
chosen different region of interests depending on which line was selected to 
represent the lower border of the triangular structure, even though a consensus to 
use the lowest hyperechoic line was instigated at the beginning of the study. 
Most US studies have investigated reliability  on a joint by  joint basis. Few have 
assessed reliability  of a summation of scores for a selected group of joints. Naredo et 
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al assessed within scan intra-reader reliability  with a resultant excellent ICC value of 
0.99 [10] for summated 4-point semi-quantitative PDUS imaging of 28 joints, called 
the “overall US joint index for power Doppler signal”. Backhaus et al (2009) [31] 
developed a composite US score called the “German US7 score”. They  measured 
US grey  scale synovitis and PD synovitis using 4-point semi-quantitative scales in 7 
joints and the within scan inter-reader reliability  kappa value was 0.6.  The most 
clinically relevant measure of reliability  is the “parallel scan inter-reader”  because it 
is a comparison between two ultrasonographers acquiring and reading their own 
scans. The images are read independently, as might be the case in multi-site clinical 
trial or routine clinical practice. As expected the overall reproducibility  for ‘parallel 
scan inter-reader’ reliability was lower than ‘within scan inter-reader’ reliability; the 
difference between these two methods most likely  representing the loss of 
concordance due to image acquisition.  A similar observation was reported by 
Kamishima et al [32]. Despite this shortfall, in the current study  good agreement was 
observed for the overall ‘parallel scan inter-reader’ reliability. This would suggest that 
the greatest variable is the source of the US examination i.e. a second 
ultrasonographer acquiring the data set. This has implications for multi-centered 
studies using US imaging a dedicated endpoint however the excellent ‘Within scan 
inter-reader’ agreement would suggest that this effect can be minimized by  central 
analysis of acquired images. 
Visual inspection of the The Bland - Altman plots may provide evidence that the 
magnitudes of the differences in scores are not constant throughout the range of 
measurements. This was performed at baseline and at the end of the study  on Day 
15 for all US endpoints . As describe above, 4-point score has been widely  used in 
published US studies. This 5-point score, based upon a standard atlas of images, 
was used with the hope that it may  be more sensitive to change than a 4-point scale. 
However, with a larger scale there is an inherent risk of reducing the level of 
agreement between readers. Whilst generally  this was not seen, agreement between 
readers can vary  at different points along the scale. The  Bland - Altman plots provide 
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a visual interpretation of agreement by  plotting the average of the two baseline 
measurements read by  the 2 readers versus the difference of the 2 measurements. 
This may  also give an indication of bias between the 2 readers. Within this study, 
there was no indication of significant bias although with 2D Trans STi and Long STi 
baseline endpoints, some diversion was seen at the high end of the scale.
Quantitative ultrasonographic measures of synovitis demonstrated better overall 
reliability  than semi-quantitative measures although the difference was not 
statistically  significant. Therefore, within future studies there may  still be a place for 
more time-consuming measures of synovitis, by  computationally  quantifying pixel 
counts, but quicker semi-quantitative scales may be an acceptable substitute. Power 
Doppler measures of synovitis were significantly  more reproducible than gray-scale 
measures of synovitis in this study and thus I would advocate that future ultrasound 
studies include power Doppler vascularity endpoints to deliver optimum reliability.
3D US endpoints
All 3D endpoints showed good to excellent agreement for both baseline. At Day  15 
the 3D VASCi  ‘Parallel scan intra-reader’ endpoint had reduced from 0.53 to 0.39 
from baseline. All of the other 3D endpoints performed well at both time points. No 
synovial grey  scale 3D images were scored as this was felt that the virtual 
reconstruction of the image showed insufficient grey scale definition to appreciate 
synovial and extra-synovial tissue. 
The vascular power doppler endpoints were easily  identified by  the subtraction of all 
grey  scale information on the image leaving only the power doppler voxels, so called 
‘3D angio’. There was excellent agreement in all endpoints for ‘within scan intra-
reader’, ‘Within scan inter-reader’ and ‘Parallel scan inter-reader’. Surprisingly  the 
‘Parallel scan inter-reader’ ICC values were consistently less both at baseline and 
Day  15. Given the excellent ‘Within scan intra-reader’ results for all the endpoints the 
lack of agreement in the ‘Parallel scan inter-reader’ would suggest a that the lack of 
correlation was due to the image acquisition rather than the reading of the scan data 
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set. There are two possible explanations for this observation. Firstly, the 3D probe is 
a single linear array  which sweeps through the chosen region of interest at a 
constant speed recording still images at every  1 degree step. The reconstruction of 
these still images provides the ‘3D angio’ which is then scored and manipulated. 
Synovial blood blow varies according to heart rate (figure 3-6).  Given that only  a 
single still image is recorded during each increment of the swing of the linear array, it 
is conceivable that at a number of points along its path a diastolic image is acquired. 
Should this occur at a site of significant vascular PD signal there may  be up to a 50% 
reduction in signal recorded. As the PD within the synovium is often localised rather 
than confluent, especially  at low grades of signal, there is a significant possibility  of 
signal being completely  missed during the 3D sweep of the probe. One possible 
improvement on current technology is Spatio-temporal image correlation (STIC). This 
is an automated volume acquisition similar to the 3D technology used in this study 
however there is a significantly  high number of 2D frames recorded (approximately 
150 / second). This technology  is currently used in foetal heart imaging due to the 
small region of interest required. This essentially  facilitates the alignment of images 
according to time and space, providing a 4D ‘real - time’ image. The region of interest 
is necessarily  small and for doppler signal registration, high rates of flow are required 
which are not seen in the synovium. However, with regards to the reduced ICC seen 
in the ‘Parallel scan intra-reader’ 3D endpoints, if a systematic error occurred one 
might expect that the ‘Parallel scan inter-reader’ endpoints would have been similarly 
affected and this was not the case. The large foot print of the 3D probe covers all the 
MCP dorsal surface and it was not likely  that positioning of the probe has a 
contribution to the variability of image acquisition.
A second possibility, and perhaps more likely, was that there was a thermo-regulatory 
influence. Each data set required approximately  30mins of scanning. This included 
2D images and 3D imaged of MCPJs and Wrists. Warm gel was used at the 
beginning of the scan data set acquisition, after 90 mins of imaging patients often 
remarked that their hands felt cold suggesting a degree of cooling may  have 
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occurred reducing the vascular signal seen. The ‘Parallel scan intra-reader’ ICC 
results were marginally  less than the ‘Within scan inter-reader’ results for the 2D data 
set suggesting that this may have an effect here as well.
Figure 3-6: Graphical representation of the change in power doppler pixel count over a 
27 frame cine loop 
A graph showing the variation of PD pixels over a 3 second cine loop from a 
longitudinal 2D PD scan within the synovium. 27 frames are recorded in the cine 
loop (9 frames per second). Patient’s heart rate was 62 bpm at the time of the scan.
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The reproducibility  of the clinical examinations was not collected or tested in this 
study, and so a formal comparison of the precision of synovial US with clinical 
examination is not possible. Literature references demonstrate that the reproducibility 
of joint examination is poor. The reliability  of the individual clinical examination of 
MCP swelling had a reported kappa of only  0.36 (Naredo, 2005). A published study 
examining the ICC for a number of clinical and US measures of disease activity 
came to the similar conclusions that ultrasound was at least as relevant as clinical 
examination in the assessment of disease status of patients in an open-label 
longitudinal treatment study  of Humira in rheumatoid arthritis (Dougados, 2009). 
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Reproducibility  was determined for physical examination and ultrasound.  The 
reproducibility  of physical examination of MCP and metatarso-phalangeal joint 
swelling (0-2 score) had a weighted kappa of 0.48 (-0.11 to 1.00) and the 
reproducibility  of Power Doppler ultrasound score (0-3 score) had a weighted kappa 
of 0.90 (0.78-1.00).  
The Ultrasound measures of synovitis used in this clinical study  are reliable and 
perform well in a multi-centered clinical trial. The objective assessment of synovitis in 
patients with inflammatory arthritis underpins the development of new therapies for 
Rheumatoid Arthritis and as such ultrasound imaging in this study  has shown to be a 
reproducible imaging modality.
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4. Thermoregulation attenuates 2D and 3D power Doppler signal in 
inflamed Rheumatoid joints. 
4.1 Introduction
Joint inflammation is a focal point of the systemic inflammatory  disease process 
known as Rheumatoid Arthritis. In addition to cellular infiltration, one of the first 
pathological adaptations to take place is the development of new vessels supplying 
the synovium. This in parts facilitates the influx of cellular mediators of inflammation 
whilst sustaining the process by  delivering essential  nutrients and oxygen. Synovial 
inflammation can be seen clinically  as swollen, red warm joints. On ultrasound 
examination synovial thickening is often marked with evidence of vascular signal 
within the synovium on power Doppler examination. Histological examination of  joint 
synovium demonstrated a small number of blood vessels in the normal, un-inflamed 
state but these become greatly expanded in the inflamed joint. Histologically  these 
capillaries are often poorly formed, leaky  and lack the mature infrastructure seen 
elsewhere. 
Changes in vascular density  may  contribute to changes in doppler signal in patients 
receiving treatment, however dismantling of this network is not immediate following 
therapy. Reduction in local inflammatory  mediators will affect afferent vasculature 
reducing blood flow however changes in synovial blood flow are often seen 
immediately  in response to cold stimuli suggesting a neuronal mediated afferent 
control in vascular flow. Thermoregulation of vascular has been most extensively 
explored in the setting of cutaneous vascular changes with evidence that underlying 
systemic disorders such as hypertension and Diabetes may inhibit normal vascular 
reflexes. Little information exists regarding the control of vascular tone in patients 
with RA although resistance indices within larger vessels in patients with RA have 
been shown to be consistently higher.
Prior to the advent of effective pharmacotherapy, thermoregulation was used for 
symptomatic relief of both pain and swelling. The application of an ice pack on an 
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inflamed joint relieves discomfort within a few minutes with gradual reduction in 
swelling after sustained application. Thermoregulation is employed less often today 
in the setting of acute inflammatory  arthritis. However manipulation of temperature 
may provide a reasonable platform on which to test, in vivo, the utility  of various US 
parameters such as 2D and 3D Doppler signal. The assessment of responsiveness 
for most clinically  relevant parameters in patients with RA require the administration 
of a pharmacological therapy  to provide sufficient biological change.  In this study I 
will investigate the sensitivity  to change of both three dimensional (3D) and two 
dimensional (2D) ultrasound imaging of power Doppler signal (PDS). The use of 
thermoregulation, as a broadly  physiological stressor, provides an inexpensive, safe 
and consistent stimulus for a preliminary  exercise in examining these vascular 
assessment imaging tools.
4.2 Aims
The aims of this study were:
1. Correlate 2D longitudinal and transverse power doppler scores with 3D volumetric 
and topographical scores in a limited US data set (10 MCP joints).
2. To demonstrate the effects of cooling on Power doppler signal (2D & 3D) and 
synovial thickness (2D) within a limited US data set (10 MCP joints).
3. To determine the responsiveness of 2D (longitudinal and Transverse) and 3D 
Doppler signal (3D volume rendering and TUI) following cooling.
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4.3 Definitions
i) Long STi - Synovial thickness index scored from longitudinal orientated images 
summed over 10 MCP joints
ii) Trans STi - Synovial thickness index scored from transverse orientated images 
summed over 10 MCP joints
iii) Long VASCi - Vascular index score from longitudinal orientated images summed 
over 10 MCP joints
iv) Trans VASCi - Vascular index score from transverse orientated images summed 
over 10 MCP joints
v) 3D  VASCi - Vascular index score from 3D rendered images summed over 10 
MCP joints
vi) TUI (max) VASCi - Maximum vascular index slice determined by  topographical 
ultrasound imaging vascular index summed over 10 MCP joints.
vii) TUI (mid) VASCi - Vascular index score from the midline image determined by  a 
topographical ultrasound imaging midline slice summed over 10 MCP joints.
4.4 Methods
Patients
13 patients fulfilling the ACR diagnostic criteria (1987) for Rheumatoid Arthritis with a 
DAS 28 > 3.2 were recruited from the weekly US clinic based at the Rheumatology 
Department, Barts Health NHS trust, Mile End Hospital. All patients had grade 2/4 
PDS in a least 2 MCP joints at enrollment. Patients were excluded if they  had a prior 
diagnosis of, or symptoms suggestive of, Raynauds phenomenon, peripheral 
vascular disease, diabetes mellitus or systemic hypertension. Patients were also 
excluded if they were receiving therapy  which potentially  may have a peripheral 
vasodilatory  effect e.g. Calcium channel antagonist or received recent escalation in 
their current corticosteroid therapy  within the last 2 weeks (including intra-muscular 
depomedrone).
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US assessment and scoring
All US images were acquired using a Logiq 9 (GE Healthcare) machine with a 
4D16L transducer (3D data) and a M12L transducer (2D) probes. At each time point 
all 10 MCP joints were imaged by  2D (longitudinal and transverse views) and 3D 
volumetric scans. 2D US images were scored qualitatively  as described in Section 
2.2.1. 3D rendered volumetric imagines were analysed qualitatively  and as described 
in section 2.2.4. Topographical scores were performed using the maximal PDS signal 
slice and the midline reference image as described in section 2.2.6.
Each data set was analysed by  2 readers (SK and MW) both with more than 3 years 
of US experience. 2D and 3D data was read in a paired fashion (non-chronological). 
ICCs were calculated for each data set before and after cooling. For statistical 
analysis the scores of SK we used for the outcome measures of response.
Time schedule
Prior to assessment patients were resting at an ambient room temperature (180C) for 
at least fifteen minutes. The temperature of the room was measured using a 
standard room thermometer.
A baseline data set was acquired prior to cooling. The patients hands were immersed 
in a water bath at 50C for 5 minutes and an US data set acquired immediately. 
Following this, after 5 mins and again after 15 mins another US data set was 
acquired. A 4 litre water bath was used with constant temperature monitoring 
providing a sufficiently  large volume to minimise temperature rises during the 5 mins 
of hand submersion.
4.5 Statistical analysis
Multiple comparisons procedures are used to control for the familywise error rate. For 
example, suppose that we have four groups and we want to carry  out all pairwise 
comparisons of the group means. There are six such comparisons: 1 with 2, 1 with 3, 
1 with 4, 2 with 3, 2 with 4 and 3 with 4. Such set of comparisons is called a family. If 
we use, for example, a t-test to compare each pair at a certain significance level 
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4.6 Results
4.6.1 Patient demographics
61.5% of patients recruited were female with an overall average age of 48   (73 - 29). 
There was a relatively  high mean DAS score (5.01 +/- 0.7) with an average ESR of 
36 +/- 13.65). 9/13 patients were receiving Methotrexate either alone or in 
combination with other DMARDs or biological therapy  with 4 pateints currently 
receiving a biologic (1 Rituximab, 3 anti-TNF therapy). 5 patients were currently 
receiving Prednisolone therapy with at and average dose of 6.5 mg daily.
Table 4-1: list of patient receiving cryotherapy including demographics  
Patient baseline demographics. MTX - Methotrexate, SZP - Sulpahasalzine, HCQ - 
Hydroxychloroquine, Pred - Prednisolone.
Patient Age Gender DAS28(ESR) ESR RF Erosions Duration of RA (months) Current therapy
1 56 M 5.4 49 + + 96 MTX, HCQ, Pred, 
2 65 M 4.5 23 + + 55 MTX, HCQ, Pred, 
3 34 M 5.31 65 - + 69 SZP, Pred
4 37 F 6.23 51 - + 23 MTX, HCQ, Pred, 
5 29 F 4.75 28 + + 65 MTX, Adalimumab
6 48 F 3.91 15 + + 77 HCQ
7 51 F 4.76 29 + + 113 MTX, Rituximab
8 57 M 5.32 35 + + 12 MTX, Etanercept
9 62 F 5.68 31 - + 9 MTX, SZP
10 30 M 3.78 27 - - 6 MTX, SZP, Pred, 
11 53 F 5.73 49 - + 19 MTX
12 73 F 5.39 38 + - 38 SZP, HCQ
13 30 F 5.21 35 + + 29 Adalimumab
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4.6.2 Good to moderate reliability of 2D, 3D and topographical VASCi scores
Both readers scored all US images and reliability was calculated using Inter class 
correlation coefficients (ICC) at baseline and following cooling. Both 2D VASCi 
scores showed excellent within scan inter-reader reliability  (Long VASCi - 0.96, Trans 
VASCi - 0.92). Similarly good reliability  was demonstrated for both the topographical 
VASCi scores (TUI (max) VASCi - 0.89, TUI (mid) VASCi - 0.95), however the 3D 
VASCi was least reliable (0.79). 
ICC measurements repeated following cooling of the MCP joints showed some 
improvement in the 2D image ICC  readings but a marked improvement in respect to 
the 3D VASCi (0.79 to 0.85).
Table 4-2: ICC results for Pre and Post cryotherapy VASCi for 10 MCP joint 
scores
ICC results and 95% confidence intervals for all VASCi US parameters prior to and 
following cooling of peripheral MCP joints in 50C water bath. Pre-Cryo: Prior to 
application of cryotherapy, Post-Cryo: After application of cryotherapy.
A
Pre-Cryo ICC 95% CI
Long VASCi 0.96 (0.89; 0.99)
Trans VASCi 0.92  (0.90; 0.95)  
3D VASCi 0.79 (0.73; 0.85)
TUI (max) VASCi 0.95 (0.91; 0.99)
TUI (mid) VASCi 0.89 (0.82; 0.92)
B
Post-Cryo ICC 95% CI
Long VASCi 0.97 (0.95; 1.00)
Trans VASCi 0.98  (0.97; 1.00)  
3D VASCi 0.75 (0.73; 0.77)
TUI (max) VASCi 0.95 (0.91; 0.98)
TUI (mid) VASCi 0.97 (0.96; 0.99)
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Inspection of the Bland - Altman plot would suggest that there is some deviation at 
the lower level of 3D VASCi scores which has contributed to the moderate ICC 
values for 3D VASCi scoring. 4 data points below a mean of 5 demonstrate 
movement in the same direction.
Figure 4-1: Bland - Altman plot for 3D VASCi scores at baseline prior to cryotherapy.
Bland - Altman plot for 3D VASCi scores at baseline demonstrating some deviation 
at the lower 3D VASCi scores. This may suggest a systematic error or discrepancy 
in scoring by one of he readers at low levels of 3D doppler scores.
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4.6.3 2D VASCi scores correlate with 3D VASCi and TUI(max) VASCi scores
Table 4-3 shows a correlation matrix between the 2D VASCi, 3D VASCi and 
topographical VASCi scores at baseline prior to cooling. There is a significant 
correlation between 3D VASCi and both 2D VASCi scores and this greater than for 
the TUI(max) VASCi score. The TUI (mid) VASCi did not correlate with either of the 
2D VASCi scores although a modest relationship was detected between it and the 
TUI(max) VASCI (Pearson's coefficient - 0.31, p <0.045). The correlations were 
generally  weaker following cooling at time 0 with 3D VASCi scores continuing to be 
correlated with 2D long and Trans VASCi scores but no significant relationship was 
detected for any of the TUI VASCi scores.
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Table 4-3: correlation matrix for 2D, 3D and TUI VASCi parameters at baseline 
prior to cryotherapy.
A: Table showing a correlation matrix for 2D, 3D and TUI VASCi parameters at 
baseline prior to cooling. Significance at p <0.05 B: table showing a correlation 
matrix for 2D, 3D and TUI VASCi parameters following cooling in water bath for 5oC 
cooling. Significance at p <0.05
* - no significant correlation demonstrated using Pearson's Correlation coeﬃcient
A
2D US images 3D VASCi TUI (max) VASCi TUI (mid) VASCi
Long VASCi 0.69 0.64 0.07*
Trans VASCi 0.84 0.50 0.014*
B
2D US images 3D VASCi TUI (max) VASCi TUI (mid) VASCi
Long VASCi 0.65 0.40* -0.23*
Trans VASCi 0.68 0.13* -0.08*
Figure 4-2: Graphical representation of the correlation of 2D and 3D scores prior to 
cryotherapy
A: Correlation of 2D VASCi and 3D VASCi (Pearson's Correlation coeﬃcient r=0.84, 
p<0.001) B: Correlation of 2D Long VASCi and TUI(max) VASCi (Pearson's 
Correlation coeﬃcient r=0.64, p<0.001).
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4.6.4 VASCi but not STi scores show a significant change from baseline
All power Doppler indices showed a significant change form baseline with the 
magnitude of change being greatest for 2D long VASCi (50% change). Synovial 
thickness scores showed no significant change from baseline (two tailed t-test, Long 
STi p  =0.54, Trans STi p=0.32). The TUI(mid) mean VASCi score was significantly 
lower at baseline compared to all other baseline VASCi scores (Repeated-measures 
ANOVA p < 0.0001) but still showed a significant change following emersion of the 
hands in the water bath.
Figure 4-3: change in VASCi parameters pre and post emersion of patients hands in a 
50C water bath.
A: No change is demonstrated from baseline following water bath emersion for 
mean STi scoresB: Longitudinal and and Transverse VASCi change following 
cryotherapy. C: Change in 3D data set including 3D rendered PD volume, TUI (max) 
and TUI (mid) VASCi. STi - synovial thickness index, VASCi - Vascular index, TUI 
(max) - topographical ultrasound imaging maximum signal slice vascular index. TUI 
(mid) - topographical ultrasound imaging midline signal slice vascular index
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Examining the change in individual scores, it is noticeable that patients number 4 and 
12 did not show only  a modest reduction in any VASCi following crypotherapy for all 
of the VASCi parameter scores (figure4-4). Patient 12 showed an increase in VASCi 
only for longitudinal VASCi scans.
Figure 4-4: Before and after cryotherapy plots of individual patients VASCi scores 
A: Individual longitudinal VASCi scores. Patient 4 showed only a small reduction in 
VASCi while patient 12 shows a small increase in VASCi. B: Individual transverse 
VASCi scores demonstrating a small decrease in both patients VASCi. (Pre) - prior to 
cryotherapy, (Post) - immediately following cryotherapy.
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4.6.5 Reduction of mean VASCi score persists following re-warming
A significant reduction was seen with all VASCi scores following cooling. 3D VASCi 
was the only variable to show a significant increase form time 0 to 5 mins post 
cooling (Paired T test, p < 0.001). However, a significant increase in VASCi score 
was seen for all parameters from Time 0 to 15mins (Paired T test, p < 0.003). Using 
2D Long VASCi scores, patient no. 4 achieved only  a 20% reduction in signal with 
patient no. 12 having a 14% increase immediately  after cooling at time 0. Similar 
modest responses were observed with other VASCi scores for both these patients 
with patient 12 demonstrating a maximum of 13%  reduction in 3D VASCi. Overall 
4/13 patients achieved an similar of greater VASCi score at 15mins compared to 
baseline. Patient no. 3 consistently  showed a higher VASCi score at 15mins on all 
parameters compared to baseline with a maximal increase of 40% detected with the 
2D Trans VASCi score. Patient no. 7 had a reduction of 65% in Long VASCi following 
cooling at time 0 with no change at 15mins. This was similarly  observed with other 
VASCi scores with only 2D Trans VASCi showing a small improvement at 15mins.
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Figure 4-5: Kinetics of response to cryotherapy and change in VASCi parameters on re-
warming
A: Graph of change in mean VASCi over time for 2D Long and Trans VASCi scores. 
(Mean and 95%CI) B: Graph of change in mean VASCi over time for 3D VASCi, TUI 
(max) and TUI (mid) VASCi scores. (Mean and 95%CI). A clear decrease in all cores 
can be seen between baseline and time 0. Subsequent warming over a 15 min 
period causes a return of doppler signal within the synovium demonstrated by the 
gradual increase in VASCi scores. Day 15 VASCi scores however do not return to 
pre-cryotherapy levels.
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4.6.6 2D VASCi scores are more responsive than 3D scores
The Standardised Response Mean (SRM) was calculated for each Power Doppler 
score as the mean change in VASCi score form baseline to time 0 divided by  the 
standard deviation of the change in VASCi. As expected the TUI (mid) VASCi 
performed poorly  in comparison with the other VASCi scores with an SRM of 0.72. 
2D Longitudinal and transverse VASCI and 3D VASCi performed similarly  with a 
SRM of approximately  2. The TUI(max) VASCi was less responsive but still 
demonstrated a significant change. Table 4-4 summaries the SRM for each VASCi 
score.
Table 4-4: Standardised response mean (SRM) for all US parameters following 
cryotherapy
SRM (standardised response mean) results for VASCi scores. Change from baseline 
to Time 0 following cooling was used to calculate the mean change in VASCi score 
and standard deviation.
2D Long VASCi 2D Trans VASCi 3D VASCi TUI (max) VASCi TUI (mid) VASCi
2.12 2.07 1.92 1.62 0.72
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4.7 Conclusions
Cryotherapy has been used in the setting of arthritis since antiquity and is still a 
central theme in the management of acute sporting injuries. Application of 
cyrotherapy  can take many forms including, ice and gel packs, inflatable splints as 
well as complete submersion in ice baths. There is purported benefits to recovery 
time and improved rehabilitation after injury with cryotherapy although a number of 
authors have questioned the lack of stringent randomised controlled trials to support 
some of these claims378-380. 
Cryotherapy is a convenient method for inducing change in vascular perfusion as 
demonstrated by  variation in power Doppler signal381 382. This study  exploits a 
physiological response to cryotherapy to induce change in a limited ultrasound joint 
set of 10 MCP joints. This platform was used to examine the relationship  of 2D and 
3D vascular index scores and their response following application of cryotherapy. 
Patients with potentially  confounding factors, such as anti-hypertensive agents or 
systemic disease processes, known to effect vascular response were excluded. 
Patients recruited had a minimal PDS score of 2/4 in at least 2 joints. Given the 
potentially  dramatic reduction in vascular flow anticipated, only  1 patient completely 
abated all doppler signal from the 10 MCP joints on 2D imaging following immersion 
in the 5oC water bath. This would suggesting the selected benchmark of baseline PD 
signal provides some protection against a flooring effect in this model.  A significant 
reduction in vascular flow was noted with all VASCi scores which allows the 
responsiveness of each modality  to be compared. Both 2D Long and Trans VASCi 
scores performed well, with a SRM of 2.12 and 2.07 respectfully. The 3D VASCi and 
TUI (max) VASCi were also demonstrated to be responsive, however the utility  of TUI 
(mid) VASCi was limited in this model. The incorporation of the TUI (mid) VASCi 
score was planned in an attempted to identify  a similar region interest as would 
normally  be assessed by the 2D Long VASCi score. This would provide a 
comparison between the PDS generated by  2D US, and that captured with 3D 
volumetric imaging within a strict region of interest. A 50.6% difference in mean 
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VASCi score can be seen between the baseline Long VASCi and TUI (mid) VASCi 
which reduces to 34.8% following cryotherapy. This would suggest a significant loss 
in Doppler signal detection with 3D PD imaging. The fact that 3D VASCi is still 
responsive, is likely to relate to the  volume of tissue being imaged rather than the 
sensitivity  of the technique in detecting PDS. Despite its shortcomings, the TUI 
VASCi endpoints appear to be reliable with excellent ICC values generated for both 
TUI (mid) and TUI (max). The poor 3D VASCi ICC value may  reflect the lack of 
experience of MW with 3D imaging. Both myself and MW spent time prior to scoring 
discussing a number of standard images however the variability  on 3D signal is much 
more difficult to capture on 2D images which may have lead to discrepancies when 
scoring. The Bland-αltman graph does suggest that scoring for lower 3D VASCi 
scores may be less reliable between myself and MW. The clustering of 4 data points 
in the same direction may represent a systemic scoring tendency  for one of the 
readers. 
2 patients failed to demonstrate a significant fall in vascular signal following 
cryotherapy. The aberration of normal control of vascular tone may explain these 
finding although I cannot exclude the possibility  that an initial reduction in vascular 
flow did occur with subsequent loss of the neuronal mediated vasoconstriction. This 
has been previously  observed in 2 scenarios. Beste et.al. showed that initial 
reduction of the US pulsitile index of the doralis pedis artery  could be mediated 
through application of cryotherapy to the knee and lower leg383. After 5 mins of 
therapy  a slow improvement in pulsitile index was noted despite continued 
application of the cyro-pack. Similarly, Albrecht et.al. demonstrated that cooling of the 
skin over an inflamed wrist joint resulted in minimal vasodilatation and reduction in 
PDS on US examination but curiously  a marked increase in PDS was seen after 10 
mins of withdrawing the cooling agent381. However, in this study a clear reduction in 
the PDS was demonstrated in the wrist if a more potent cooling method was used 
such as an ice pack presumably  allowing greater penetration rather than only 
superficial dermal cooling.
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A number of limitations exist within this model. Following cooling of the hands in a 
water bath, the patients hands were place on the bench to facilitate the US 
examination. This examination required approximately  2 mins to complete. 2D 
images were acquired first followed by  3D images. The subsequent warming over 
this period may  have been responsible for artificially  reducing the SRM given an 
increase in PDS at time 0 with the 3D VASCi score. Two containers of US gel were 
used for each patient - one maintained at 50C and the other at room temperature. 
The initial assessment at time 0 was preformed using the cooled US gel with all 
subsequent assessments using gel at room temperature. In addition, the on going 
depletion of doppler signal seen after 15 mins would argue for a longer time  frame of 
assessment. An important question to address is the time that is required for patients 
to return to their pre-cooling state. This has significant implications for clinical trial 
assessments using US as well as the sensitivity  of US to detect Doppler signal in 
clinical practice. Presently, from this data set a recommendation can only  be given 
that patients should wait more than 15 mins in at ambient room temperature prior to 
US examination. Our current practice is for patients to wait a minimum of 30 mins 
prior to US assessment in the setting of a clinical trial. To standardise imaging 
acquisition the response of synovial vasculature to temperature changes should be 
bourn in mind when integrating US imaging into therapeutic study design.
Cryotherapy is not the only  potential physiological variable which may alter patients 
vascular flow on PD examination. Diurnal variation has been shown to have an 
impact on synovial flow and doppler detection with in the MCP joints of the hands384. 
In addition, many of our patients receive daily  therapy  which is often administered 
first thing in the morning and may have an impact on vascular tone such as anti-
hypertensive agents. Diurnal variation of endogenous cortisol and bioavailability  of 
anti-inflammatory  medication such as Prednisolone or NSAIDS may  significantly  alter 
the baseline characteristic of patients synovial vascularity. More work is needed to 
document the influences of these parameters of synovial vascular flow. 
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This model is a safe and convenient method of applying a physiological stressor to 
synovial blood flow. Within this model, the ability  of 2D and 3D US parameters to 
detect change in synovial vascular flow over a relatively  short period of time can be 
demonstrated. The vascular index scores used over 10 MCP joints would seem to be 
both responsive and reliable. 
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5. Ultrasound assessment of Rheumatoid synovitis is more 
responsive than clinical assessment to Prednisolone therapy. A 
randomised, placebo controlled study
5.1 Introduction
The development of new therapeutics for RA involves clinical assessment of 
response by  endpoints that include composite measures of disease activity, such as 
the Disease Activity  Score (DAS28)46, a continuous measure, and American College 
of Rheumatology (ACR) categorical responses148 385. 
For early  testing of novel therapeutics, we require a sensitive method to distinguish 
between treatment groups in cohort studies that permit small patient numbers and 
provide a reliable, early  indicator of efficacy. Ideally, such measures would be quick, 
non-invasive, objective, predict longer-term response to repeated medication and 
give an early  indication of disease modification. Due to ethical constraints of 
performing placebo controlled trials and the resultant trend towards comparator 
controlled trials, the requirement for sensitive endpoints is greater than ever. 
Synovial inflammation in Rheumatoid Arthritis, has as a hallmark, a number of 
pathological features including inflammation, angiogenesis, synovial proliferation and 
tissue destruction386 387. The detection of synovitis is of great importance to optimize 
patient therapy  with the purpose of suppressing this process completely  to help 
prevent joint damage388. Techniques that quantify  synovial inflammation and are 
sensitive to treatment effects may  allow  faster decision-making and more efficient 
clinical trials.
Swollen joints are a characteristic feature of RA but they  are not well-correlated with 
longitudinal outcome or disability  or radiographic erosions.  In part, this is probably 
because clinical examination is not very sensitive for synovial inflammation (Hansen 
1979).  Current composite indices of disease activity, such as Disease Activity  Score 
(DAS) or the American College of Rheumatology (ACR) responder criteria, 
themselves based on aggregating individual clinical findings such as swollen joint 
counts to derive a more responsive and valid outcome measure46 389. As a 
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consequence, using such a dichotomous outcome measure, the sample sizes to 
detect moderate drug effects using the ACR20 responder endpoint are approximately 
100 patients per treatment group, representing a substantial challenge when 
prolonged dosing regimens and placebo controls are required390.  
Power Doppler Ultrasound (PDUS) is proposed as a valid, reliable method for 
quantifying synovial blood flow.  As such, it has the potential to serve as a broadly 
applicable pharmacodynamic marker of synovial inflammation. In Chapter 3, I have 
already  discussed the reliability  of a number of ultrasonographic endpoints used in 
this study  for both 2D and 3D imaging modalities. For early testing of novel 
therapeutics, we require a sensitive method to distinguish between treatment groups 
in cohort studies that permit small patient numbers and provide a reliable, early 
indicator of efficacy. Ideally, such measures would be quick, non-invasive, objective, 
predict longer-term response to repeated medication and give an early  indication of 
disease modification. Due to ethical constraints of performing placebo controlled 
trials and the resultant trend towards comparator controlled trials, the requirement for 
sensitive endpoints is greater than ever. 
There is only  one single-center, double-blind, placebo controlled clinical trial that 
included both PDUS and conventional clinical endpoints in RA (Taylor, 2004).  There 
are numerous open-label treatment studies, but none that have explored the ability  of 
PDUS to identify  a dose-response for an efficacious therapeutic agent (Newman 
1996, Fiocco 2005, Stone 2001, Filippucci 2004, 2006, Salaffi 2004).  
This study  compared the responsiveness of PDUS and the traditional composite 
endpoint of disease activity, the DAS, in a randomized, parallel group, double blind 
trial of prednisone in patients with rheumatoid arthritis. This study  involved two 
clinical centers to assess the feasibility  of conducting a multi-center study using 
PDUS with centralized grading. 
Metacarpophalangeal joints (MCPJs) are invariably involved in RA and so their 
evaluation is important. These superficial joints are amenable to assessment with 
ultrasound utilizing frequencies that produce high resolution images. High-frequency 
ultrasonography (HFUS) and power Doppler ultrasonography  (PDUS) are 
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reproducible tools for determining synovitis and more sensitive than clinical scoring in 
determining disease activity. The synovial vascular signal on PDUS closely  correlates 
with the dynamic contrast enhanced MRI in RA MCPJs and synovitis detected by 
ultrasound (US) predicts erosive disease. 
5.2 Aims
By using a known efficacious treatment for RA, our objectives were:
i) To determine the potential of 2D ultrasonographic endpoints to provide an early 
and objective indication of a therapeutic response to treatment intervention in 
rheumatoid arthritis (RA). 
ii) Using two different doses of Prednisone (15 mg and 7.5 mg) to investigate 
whether ultrasonographic endpoints are able to demonstrate a dose-response 
relationship of two relatively low doses of corticosteroid.
iii) To compare the ultrasound endpoints with DAS28(CRP) and to explore the 
potential of composite endpoints (DAS28 combined with US endpoints) to improve 
the registration of a significant treatment effect.
iv) To explore the responsiveness of 3D ultrasound imaging in response to 
therapeutic intervention.
5.3 Methods
5.3.1 Patients 
This was a randomized, double-βlind, parallel-group, placebo-controlled trial 
conducted at 2 academic research centres in UK (clinicaltrials.gov  identifier: 
NCT00746512). 
Two panels were planned for the study: 
1. Panel A:  Subjects were randomized in a 1:1 ratio to oral prednisone 15 mg daily 
or matching placebo for 15 days. After a total of 18 subjects completed the study, 
an interim analysis was planned to determine if this smaller sample size could 
significantly  (α = 0.03, 1-sided) discriminate prednisone 15 mg from placebo based 
on the primary endpoint. 
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Figure 5-1: Diagrammatic representation of the study schedule for Panel A patients
2.  Panel B: If Panel A was able to discriminate treatment form Placebo, then 
enrollment in the prednisone 15 mg group would cease. Panel B would recruit 27 
additional subjects and be randomized (2:1 ratio) to prednisone 7.5 mg or 
matching placebo for 15 days.
Figure 5-2: Diagrammatic representation of the study schedule for Panel B patients
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Men and non-pregnant women ≥18 years with RA ≥6 months duration meeting the 
1987 American College of Rheumatology criteria for the diagnosis of RA were 
eligible. Subjects were required to have at least moderate disease activity 
[DAS28(CRP≥3.2] and moderate dorsal transverse  synovial vascularity  in 2 MCPJs 
(score≥2) or severe in 1 MCPJ (score=4) as measured on a semi-quantitative 0-to-4 
scale.  
Non-steroidal anti-inflammatory  drugs (NSAIDs) at stable doses ≥4 weeks were 
permitted, as were disease modifying anti-rheumatic drugs (DMARDs) at stable 
doses for ≥6 weeks, topical or inhaled glucocorticoids at stable doses for ≥2 weeks, 
and opiates at stable doses ≥2 weeks. Acetaminophen (paracetamol) was allowed 
for breakthrough pain, but NSAIDs were not to be taken on an as-needed basis.
Pertinent exclusion criteria included intra-αrticular glucocorticoid injections to MCPJs 
within 3 months or to non-MCP Js within 6 weeks of baseline; oral glucocorticoid use 
within 4 weeks; and current biological therapies. 
Tolerability was assessed by  clinical and laboratory  examination and adverse event 
(AE) reporting during the study.  After baseline measures subjects were randomized 
(by  a sponsor statistician using a computerised Clinical Allocation Schedule System 
[CASS] with blocking factors to ensure blinding based on a multiple of the number of 
treatment groups and subjects) and then received their first dose of study 
medication.  
All subjects gave informed written consent to participate. The study  was conducted in 
accordance with principles of Good Clinical Practice and approved by  the institutional 
review board for human research. 
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5.4 Ultrasonography
2D ultrasound images were obtained as described in chapter 2.  
Synovial thickness and Power doppler quantitative and qualitative scores are 
described in chapter 2.
Quantitative vascularity  and synovial thickness measurements were described in 
chapter 2.
3D US assessment of patients is described in chapter 2. All patients were scanned in 
the same order depending upon the location of the ultrasound examination. The 
primary  US assessment used for analysis of the primary endpoint in the study  was 
the 1st scan at each site, read by SK.
Table 5.1: Table describing the scan order at each site and from each 
ultrasonographer.
This table represents the scanning order of patient assessments for Panel A at each 
intitution. Also descibed is the reading of scans for ICC results. BH - Barts Health 
NHS Trust, KIR - Kennedy Institute of Rheumatology, SK- Stephen Kelly, MS - Matt 
Seymour
Site Scan Ultrasonographer Reader
BH
1 SK SKMS
2 MS MS
3 SK SK
KIR
1 MS SKMS
2 SK SK
3 MS MS
5.4.1 Clinical Efficacy Assessments
Clinical efficacy  was assessed by the DAS28(CRP), which includes the number of 
swollen and tender joints (28-joint count), a patient’s global assessment of arthritis 
index (visual analogue scale) and CRP. Assessments were performed by  a single 
rheumatology  research nurse in each centre, independent of the ultrasound 
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examinations. Each study  nurse attended a DAS28 standardization training course 
within the preceding year of the study start.
5.4.2 Composite Endpoint
Exploratory  analyses carried out on data from Panel A identified a composite of the 
PDUS and DAS28 component endpoints which improved precision for discrimination 
of active treatment at the 15 mg dose from placebo; the composite endpoint was the 
average of the standardized z-scores across the DAS28(CRP), 2D Trans VASCi and 
2D Long STA endpoints. Analysis for this composite endpoint were performed also in 
a similar manner to the one for the primary and secondary endpoints.
5.5 Statistical Analysis
The primary  hypothesis for both panels was that prednisone (15 mg or 7.5 mg) would 
have a greater change from baseline in 10MCP Trans PDA (the primary  endpoint) 
after 15 days of treatment. The analysis was performed using an analysis of 
covariance model with panel and treatment nested within panel as factors, and 
baseline value included as a covariate. Only  observed data were analyzed; missing 
data were not imputed. The analyses were carried out for change from baseline at 
each of Days 15, 8, and 2. Interpretation of p-value testing for each endpoint was 
made in a step-down fashion, in that order, at α = 0.05 (1-sided) for the primary 
endpoint. For Panel A Days 1 and 15, the first scan set acquired and read by  the 
ultrasonographer-reader associated with the clinical site was used for analysis of 
treatment effects and for correlation with other endpoints; there was one scan set per 
visit for all other study time points.   
For the interim analysis following Panel A, if the true underlying effect size for the 
primary  endpoint was 1.0, the overall power, accounting for the interim and a 
potential final analysis if the study continued as originally  planned, was ~88% for 
n=18 subjects per treatment, and ~83% for 15 subjects per treatment. The probability 
of stopping at the interim analysis was ~63%. These computations employ  the 
Hwang, Shih, deCani gamma=1 stopping criteria which yields α=0.03, 1-sided at the 
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interim and, if applicable, final analyses. This controls the overall α level at 0.05, 1-
sided. If the study  continued after the interim analysis, a sample size of 15 subjects 
per group had 80% power to detect a statistically  significant (α = 0.05, 1-tailed) 
difference between prednisone and placebo assuming an effect size of 0.93.
Significance for the effect of the secondary  imaging endpoints and DAS28(CRP) was 
not error-protected from chance significance associated with multiple comparisons.  
Rationale for this choice is to minimize the chances of false negatives because of the 
exploratory  nature of these secondary  endpoint analyses. Thus, they  are viewed as 
hypothesis generating rather than conclusive. 
Pearson correlation coefficients were computed among pairs of endpoints, including 
DAS components, with ultrasound endpoints, to assess association among them. 
For the analysis of creating a composite PDUS and DAS28 endpoint, precision was 
measured by  effect size (average effect of the 15 mg and 7.5 mg prednisone effects 
minus placebo divided by pooled standard deviation) using a model with panel and 
treatment nested within panel as factors. The method for building composites was 
the O’Brien global statistic which is the average of the standard z-scores across the 
endpoints. All tests were performed one-sided at level 0.05. 
5.6 Results - Panel A
5.6.1 Patients
Baseline subject and disease characteristics are shown in table 5-2. There were no 
significant differences between subjects baseline characteristics between those in 
each treatment assignment in Panel A. All treatments were generally well-tolerated. 
Demographics
The baseline demographic characteristics for the study  population are summarized 
below in Table 5-2. An error in the randomization code yielded uneven patient 
allocation in this study with 10 patients allocated to placebo and 8 to treatment
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Table 5.2: Demographics of patient treatment groups by Age and Gender 
(Panel A)
Treatment N (%)
Placebo 10 (55.6)
Prednisone 15 mg 8 (44.4)
Gender N (%)
Female 11 (61.1)
Male 7 (38.9)
Age (years) Mean (SD)
45 to 86 60 (10.3)
Mean (or median) baseline values for DAS28(CRP), number of tender joints, number 
of swollen joints, CRP and rheumatoid factor are given in table 5.3. There was no 
significant difference in the baseline demographics in each of the two randomized 
groups.
Table 5.3: Description of baseline CRP, Rheumatoid factor and DAS28 with its 
components (Panel A). 
Description of baseline CRP, Rheumatoid factor and DAS28 with its components. 
With 90% CI expressed in brackets. † Median and quartiles are reported for CRP and 
Rheumatoid factor
Placebo Prednisone 15 mg Combined
DAS28(CRP) 5.5 (+/-1.6) 5.2 (+/- 1.3) 5.3 (+/- 1.5)
Number of Tender Joints 13 (+/- 4.1) 10.9 (+/- 3.4) 12 (+/- 3.8)
Number of Swollen Joints 12.5 (+/- 5.7) 10.1 (+/- 4.4) 11 (+/- 5.4)
CRP (mg/L)† 14.0 (3.5-37.2) 8.4 (4.2-25.3) 9.8 (3.8-32)
Rheumatoid Factor(KU/L)† 241 (63-305) 186 (71-234) 220 (67-290) 
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5.6.2 Endpoint Responsiveness
2D US endpoints
The comparison between prednisone 15 mg daily  and placebo after 15 days of 
dosing using Panel A yielded a statistically  significant treatment effect (effect size = 
1.17, P=0.013) for the primary  endpoint of change from baseline in the transverse 
Power Doppler Area summed over 10 MCPs (10 MCP 2D Trans PDA); no statistically 
significant treatment effect was detected after 8 days or 1 day  post baseline on this 
endpoint (Figure 5-4). The effect sizes for 7 other secondary  imaging endpoints at 1, 
8 and 15 days from baseline are in Figure 5-4.  A significant treatment effect for 15 
mg prednisone after 14 days was observed for all endpoints with the exception of the 
transverse synovial thickness index, STi.   Significant treatment effects after 7 days 
after baseline were detected by the longitudinal and transverse Synovial Thickness 
Areas (STA) and the transverse Vascular Index, VASCi.   Significant treatment effects 
were seen at 1 day  after baseline for the longitudinal but not transverse STA.  The 
90% CI for the effect sizes of the DAS28(CRP) and the imaging endpoints all 
overlap. 
A significant effect of prednisone 15 mg was also observed for the secondary 
endpoint of DAS28(CRP). Compared with placebo, prednisone 15 mg showed an 
effect size of 0.95 14 days after baseline for DAS28(CRP); no statistically  significant 
effect was detected 7 days or 1 days after baseline on this endpoint. In this study  the 
placebo group had relatively  stable DAS28(CRP) score across the two week 
treatment period. Analysis of the CRP component of the DAS28(CRP) shows a 
significant difference between the 2 treatment groups in CRP at Days 14, 7, and 1. 
There was a borderline difference in VAS score at Days 14, 7, and 1. There was also 
no significant difference between the Placebo and Prednisone groups in the number 
of swollen joints or in the number of tender joints at Day 14. 
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Figure 5-3: Kinetics of US, DAS28 and its components response to Prednisone and 
Placebo (Panel A)
A: 10MCP 2D Trans PDA; Baseline, Day 1, 7, and 14 after start of treatment B: 
DAS28(CRP)  (Score) C: CRP (mg/L) (Back-transformed from logarithm) D: Number 
of Swollen Joints E: Number of Tender Joints F: VAS Score. 
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Figure 5-4: Forrest plot of the effect size for all US parameters - Day 1, Day 8, Day 15 
for Panel A only
Day 1
Day 8% % % % %   %
Day 15 
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3D US endpoints
The effect size of prednisone 15 mg daily  on 3D PDUS endpoints (3D VASCi, 3D PD 
Vol, 3D VFI) was numerically  smaller than the effect size on the 2D endpoints (figure 
5-6). None of the endpoints showed treatment was statistically  significantly  different 
from placebo at any of the time points assessed in this study.
Figure 5-5: 3D VASCi kinetics of response to 15mg of oral Prednisone or Placebo.
A : 3D VASCi Baseline, Day 1, 7, and 14 after start of treatment B: 3D PD Vol, Panel 
A C: Eﬀect size of all power Doppler 3D endpoints at Day 14.
A " " " " " " B
B
169
5.6.3 Correlation of 2D and 3D VASCi
There was good correlation of the baseline 2D longitudinal and baseline with the 3D 
data sets. The correlation with the 2D LONG data set was superior with a Pearson's 
correlation coefficient of 0.91 (figure 5-6). This correlation seems to hold at Day  15 
but the effect size of the 3D VASCi endpoint was not significant .
Figure 5-6: Panel A baseline and Day 15 correlation for 2D and 3D endpoints
A: Panel A: 3D VASCi against 2D TRANS VASCi at baseline. Pearson r 0.75 (0.43 to 
0.90) P value 0.0003 B: Panel A: 3D VASCi against 2D LONG VASCi at baseline. 
Pearson r 0.91 (0.78 to 0.96) P value < 0.0001 C: 3D VASCi against 2D TRANS 
VASCi at Day 15 . Pearson r 0.87 (0.67 to 0.95) P value < 0.0001 D: 3D VASCi 
against 2D LONG VASCi at Day 15. Pearson r 0.95 (0.87 to 0.98) P value < 0.0001
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5.6.4 Correlations Between DAS28(CRP) and US endpoints 
Table 5-4: Baseline correlation's of 2D US outcome measures with 
DAS28(CRP).
Correlation matrix showing the relationship of all baseline US outcome measures 
with baseline DAS28(CRP). 2D Long VASCi performs best with a  Pearsons 
correlation coeﬃcient r = 0.68 (p<0.001). (n=18)
2D Trans PDA 
(90%CI)
2D Long PDA 
(90%CI)
2D Trans VASCi 
(90%CI)
2D Long VASCi 
(90%CI)
0.62  (0.29, 0.82)  0.55  (0.19, 0.78)  0.64  (0.32, 0.85)  0.68  (0.38, 0.85)  
2D Trans STA 
(90%CI)
2D Long STA 
(90%CI)
2D Trans STi     
(90%CI)
2D Long STi 
(90%CI)
0.66 ( 0.36; 0.84) 0.59 (0.25; 0.80) 0.59 (.25,0.80) 0.52 (.14, 0.76)
5.7 Results - Panel B
Two thirds of patients recruited to Panel B were placed in the treatment group. There 
was no significant difference any  of the baseline characteristics again between each 
allocated group.
Table 5-5: Demographics of patient treatment groups by Age and Gender 
(Panel B)
Treatment N (%)
Placebo 9 (33.3)
Prednisone 7.5 mg 18 (66.7)
Gender N (%)
Female 18 (66.7)
Male 9 (33.3)
Age (years) Mean (SD)
32 to 81 60 (13.0)
Mean baseline values for DAS28(CRP), number of tender joints, number of swollen 
joints, CRP and rheumatoid factor are given in Table 5-5. There is no significant 
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difference between enrollment criteria between Panel A and Panel B, nor within 
Panel B for patients allocated to different treatments Table 5-6.
Table 5-6: Description of baseline CRP, Rheumatoid factor and DAS28 with its 
components (Panel B).
Description of baseline CRP, Rheumatoid factor and DAS28 with its components. 
With 95% CI expressed in brackets. † Median and quartiles are reported for CRP and 
Rheumatoid factor 
PANEL B Placebo Prednisone 7.5 mg Combined
DAS28(CRP) 5.6 (+/- 1.8) 5.3 (+/- 1.2) 5.4 (+/- 1.4)
Number of Tender Joints 18.4 (+/- 10.1) 13.6 (+/- 8.6) 15.2(+/- 9.2)
Number of Swollen Joints 16.3 (+/- 8.6) 11.3 (+/- 5.6) 13.0(+/- 7.0)
CRP (mg/L)† 3.7(0.7 -11.4) 6.9 (1.7 -14.6) 6.3 (1.6 -14.6)
Rheumatoid Factor(KU/L)† 178 (82-298) 210 (129 - 288) 186 (84-299)
5.7.1 Endpoint Responsiveness
2D US endpoints
Panel B failed to demonstrate treatment effects on the primary ultrasound endpoint 
(10 MCP 2D Trans PDA) or the secondary  clinical endpoint - DAS28 (CRP). There 
were however significant differences on numerous secondary  imaging endpoints at 
Day  8 and 15. Day  7 showed significant effect size for all the 2D US endpoints 
except for 2D Trans STi (figure 5-8). At Day 15, the treatment effects assessed by  the 
endpoints 2D Trans VASCi, 2D Long STi and 2D Long STA were statistically 
significant with effect sizes ranging from 0.93 to 2.23. 
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Figure 5-7: Kinetics of 2D Trans PDA and DAS28 response to Prednisone and Placebo 
(Panel B)
A: 10MCP 2D Trans PDA; Baseline, Day 1, 7, and 14 after start of treatment B: 
DAS28(CRP) - Panel B patients randomised to either 7.5mg Prednisone or Placebo
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Figure 5-8: Forrest plot of the effect size for all US parameters - Day 1, Day 8, Day 15 
for Panel B only
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Day 7
% Prednisone 7.5 mg
Day 14
% % Prednisone 7.5 mg
5.8 Exploratory composite endpoint responsiveness
Each composite endpoint is a simple sum of the standardized score corresponding to 
the DAS28(CRP) and two US endpoints, each summed across 10 MCPJs. The 
composite endpoint of interest had been pre-specified as the DAS28(CRP), 
the 2D Trans VASCi and the 2D Long STA. In addition we explored the effect 
sizes at Days 15, 8 and 2 for a number of composite endpoints constructed using the 
DAS28(CRP) and either Trans PDA/VASCi or Long STA/STi. These results from 
Panel A displayed in table 5-7. These were selected as they  generally had the largest 
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effect sizes at the three post-treatment time points. All four composite endpoints 
demonstrated statistical significance after only  a single day of dosing i.e. at Day  2. 
DAS28(CRP) is recorded for each of the 3 time points as a comparison. This 
exercise was repeated using both the first scan performed at baseline and Day  15 
and the second US scan. This shows similar effect size and significance.
The effect of prednisone 7.5 mg, Panel B, on the relatively easy-to-score pre-defined 
composite endpoint taken from the analysis of Panel A, Z-score (DAS28+Trans 
VASCi+Long STi), was significant at Days 15 and Day  8 (effect sizes 1.84 and 1.80 
respectively). No composite endpoint could detect a significant difference between 
doses at each time point for Panel B -- Day  14, Day 7 and Day  1.  A significant 
difference between doses at Day  1 is detected in most of the composites in Panel A, 
driven by the difference in the DAS28(CRP) endpoint.  The effect size of the 
between-dose difference at Day 1 was numerically  higher in the pre-defined sum of 
DAS28(CRP), 2D Trans VASCi and 2D Long STA compared to the effect size of the 
DAS28 (CRP), see table 5-8.
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Subgroup Analyses
Post-hoc analyses including subjects with DAS28(CRP) scores less than the median 
were performed to assess the treatment effect on this less severe subgroup 
population. Treatment effect was assessed using the ‘best’ composite endpoints 
defined in section D4. above e.g. the sum of the standardized score of DAS28, Trans 
VASCi, Long STi; the sum of the standardized score of DAS28, Trans VASCi, Long 
STi , the sum of the standardized score of DAS28, Trans VASCi, Long STA, the sum 
of the standardized score of DAS28, Trans PDA, Long STi, or the sum of the 
standardized score of DAS28, Trans PDA, Long STA. 
Based on theses endpoints, effect sizes for the subgroup of subjects with 
DAS28(CRP) < 5.65 at baseline, were approximately equal to 1 at Days 1 and 7, and 
between 1 and 1.4 at day 14.Table 10
Table 5-7: Effect Size for Composite Endpoints (Panel A) Day 14, Day 7 and Day 
1 
§ Significant treatment eﬀect compared to placebo
Endpoint (Z score) Scan Day 15 Day 8 Day 2
DAS28+Trans VASCi+Long STi 1  1.96 (0.97;  2.90)§ 1.41 (0.46;  2.32)§  1.28 (0.40;  2.13)§
DAS28+Trans VASCi+Long STA 1  2.05 (1.05;  3.01)§ 1.53 (0.56;  2.46)§  1.14 (0.28;  1.98)§
DAS28+Long STA+Trans PDA 1  2.14 (1.12;  3.10)§ 1.17 (0.25;  2.05)§  1.14 (0.28;  1.98)§
DAS28+Long STi+Trans PDA 1  1.93 (0.95;  2.87)§ 0.98 (0.09;  1.84)§  0.95 (0.11;  1.76)§
DAS28+Trans VASCi+Long STi 2 1.78 (0.82;  2.69)§ 0.89 (0.01;  1.74)§ 0.73 (-0.09;  1.53)§
DAS28+Trans VASCi+Long STA 2 1.86 (0.89;  2.79)§ 0.98 (0.09;  1.84) 0.90 (0.07;  1.71)§
DAS28+Long STA+Trans PDA 2 1.39 (0.49;  2.25)§ 1.10 (0.19;  1.97)§ 1.25 (0.37;  2.09)§
DAS28+Long STi+Trans PDA 2 1.35 (0.46;  2.21)§ 0.91 (0.03;  1.77)§ 1.01 (0.16;  1.83)§
DAS28(CRP) -  1.19 ( 0.11; 1.76)§ 0.95 ( -0.12; 1.59)§ 0.37 ( -0.15; 1.46)
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Figure 5-9: Kinetics of composite endpoint response and effect size (z- scores) for 
Panel A and Panel B
A: Mean change in composite endpoint: (DAS28(CRP), 2D Trans VASCi and 2D Long 
STA) at baseline, Day 1, 7, and 14 after start of treatment for Panel A and B B: Z-
score (DAS28(CRP) 2D Trans VASCi and 2D Long STA) Eﬀect Size and 90% CI 
Within-panel Comparisons, Day 1 Prednisone 15 mg and  C: Prednisone 7.5mg
A
B " " " " " " C
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Table 5-8: Effect size for various composite endpoints using DAS28 and alternative US 
endpoint pairings.
Eﬀect size of selected composite Endpoints, subgroup of subjects with baseline 
DAS28(CRP) < median (5.65), 5 Placebo and 4 Prednisone Subjects - Day 14, Day 7 
and Day 1 Effect Size (90% CI)
Endpoint Day 14 Day 8 Day 1
DAS28+Trans PDA+Long STA       1.09 ( -0.15;  2.25)  0.88 ( -0.39;  2.08)  0.91 ( -0.29;  2.05)
DAS28+Trans VASCi+Long STA    1.12 ( -0.12;  2.29)  1.05 ( -0.25;  2.27)  1.01 ( -0.21;  2.17)
DAS28+Trans PDA +Long STi        1.35 (  0.06;  2.56)  1.83 (  0.33;  3.21)  1.23 ( -0.03;  2.42)
DAS28+Trans VASCi+Long STi  1.40 (  0.10;  2.62)  2.03 (  0.47;  3.46)  1.38 (  0.08;  2.59)
DAS28(CRP) 0.62 (-0.23; 2.43)  0.41 (  -0.32;  2.76)  0.33 (  -0.48;  2.59)
5.9 Discussion
We have demonstrated that a wide range of grey  scale US measures of synovial 
thickness and PDUS measures of synovial vascularity  at the MCPJs are reproducible 
and capable of detecting treatment effects of oral prednisone (15 mg and 7.5mg 
daily) after a week, and two US measures after only  one day, in small panels of 
subjects (n=18 and n=27 respectively) with moderate to severely  active RA. 
DAS28(CRP) was only  able to detect a significant treatment effect after two weeks in 
the 15 mg cohort. Ultrasound may  therefore be a leading indicator of therapy 
response occurring before a clinical response. At present, over 50% of drugs tested 
fail at phase III and the expense of the traditional drug development pathway  has 
become prohibitive for numerous novel compounds developed to selectively  inhibit a 
range of potential therapeutic targets that have been identified for RA . This study 
has extensively  investigated the sensitivity  of a diverse range of 2-dimensional 
ultrasonographic endpoints at the metacarpophalageal joints and their potential as 
tools to provide an early  and objective indication of a therapeutic response to 
treatment intervention in rheumatoid arthritis. We have confirmed that 
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ultrasonography of metacarpophalageal joints is an early, reliable indicator of 
therapeutic response in RA and it thus has the potential to reduce patient numbers 
required as well as the duration of clinical trials designed to give a preliminary 
indication of efficacy. Such an approach to early  drug development in RA might 
enrich for the chances of success in later phase studies designed to meet the 
regulatory endpoints that are required to achieve approval.
In the present study, correlations between the majority  of different US endpoints and 
DAS28(CRP) at base line showed only  moderate correlation. On treatment, there 
was some improvement in the correlation coefficient between DAS28(CRP) and 
mainly  the vascular US endpoints whilst other endpoints were less well correlated. 
This may suggest that they  measure somewhat different constructs. Combining US 
endpoints with DAS28(CRP) increased effect sizes at all time points and identified 
treatment effects earlier. Composite endpoints increased the endpoint sensitivity  for 
15 mg in Panel A. The DAS28(CRP) had an effect size of about 1.0, which would 
take 13 subjects per group to identify  a treatment difference (α 0.1; 80%  power).  In 
combination with an ultrasound endpoint with combined effect size of ~1.5 the 
sample number drops to six per group.  Some combinations of ultrasound endpoints 
with effect sizes of ~2.0 would require four subjects per group. Likewise, single dose 
effects of 15 mg prednisone were identifiable with some combinations of endpoints. 
These findings strongly  suggest a potential value in employing such composite 
endpoints in future prospective small studies designed to establish an early  indication 
of efficacy. Composite endpoints were selected from Panel A on how well they 
performed. They  were tested in Panel B in a in a predefined way but in a limited 
capacity. These composite endpoints need to be tested in future studies to confirm 
their utility. 
15 mg and 7.5 mg prednisone both represent relatively low corticosteroid doses and 
it would be notable if an endpoint could differentiate their effect. Overall there was a 
trend towards a dose-response. Greater numbers of subjects may  have 
discriminated the two doses. Other factors that may  have decreased the study’s 
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ability  to differentiate the two doses include the fact that there were two centres, the 
scanning rooms of which for example may  have been at different temperatures, and 
there were two ultrasonographers, the first scans of each in their respective centres 
were used to determine treatment effect.        
For Panel B the 10MCP Trans PDA demonstrated a significant treatment effect 
earlier than in Panel A. This may  be because there were more subjects in Panel B 
who received active treatment, albeit at a lower dose. To support this, at Day 8 more 
US endpoints registered a significant treatment effect for Panel B than Panel A.  
For Panel A, 7 out of 8 US endpoints demonstrated a consistent time-response to 
15mg of Prednisone. Within Panel B more US endpoints registered a significant 
effect size at Day  8 in comparison with Day  15 perhaps due to waning of therapeutic 
response to low dose corticosteroid in some subjects. The observed transient 
response of the US endpoints to 7.5 mg of prednisone was mirrored in the effect 
sizes of the DAS28(CRP) even though this latter endpoint did not show significance 
at any time point. We postulate that for some subjects in Panel B, 7.5mg 
of  Prednisone may  be just below the threshold dose for a sustained anti-
inflammatory effect. The biological response to prednisone at low  doses (≤ 7.5 mg/
day prednisone or equivalent), is not necessarily  predictable in inducing and 
sustaining an anti-inflammatory  effect in RA [29].  If we had used larger doses of 
prednisone in the study  e.g. 40mg we would have undoubtedly  seen more consistent 
time-responses but this would have weakened the impact of the study as it would not 
have permitted a demonstration of the sensitivity of US to detect change.
The Long STA endpoint performed especially  well in the current study. Previous 
investigations of gray-scale synovial thickness have shown inferiority  to power 
Doppler vascularity  in detecting a treatment effect; with respect to the kinetic and the 
extent of change. However, those studies measured synovial thickness semi-
quantitatively  in the transverse plane only. Semi-quantitative indices may constrain 
the detection of change in joints if synovial thickening greatly  exceeds the largest 
score by  delivering static scores when genuine reduction in synovial thickening can 
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be detected quantitatively. The greater area afforded by  the longitudinal view versus 
the transverse may  have also benefited the registration of a treatment effect by  the 
Long STA endpoint. The data in the current study  support these theories: semi-
quantitative measures of synovial thickening had smaller effect sizes than 
quantitative measures (only exception was Day  2, panel B); transverse measures of 
synovial thickness had smaller effect sizes than longitudinal measures (only 
exception was Day  2, Panel A) [Figure 2]. Treatment effect was less at Day 2 and 
therefore these factors would have had less influence at this early time point.  
Due to the time constraints of scanning we restricted our US evaluation to the 
dorsum of the MCPJs. It may  have been valuable to have assessed endpoints 
derived from imaging over the palmar surface also.
5.10 Conclusions
Our study  confirms that ultrasonographic imaging of MCPJs could be used as an 
early  and reliable indicator of a therapeutic response to a new treatment intervention 
in RA early  phase clinical trials with small patient cohorts over a 2 week test period 
and decrease the time-to-decision for progressing clinical development. By 
addressing the issues surrounding the reliability  of US to objectively  measure 
synovitis this study  brings us closer to approving this tool as a recognised endpoint 
for confirming treatment effect in RA clinical trials. The semi-quantitative US 
endpoints demonstrated in this study, whether used alone or together with clinical 
measures as composite endpoints, could be used in centres not possessing 
quantitative analysis tools. The study  also illustrates the potential utility  of US to 
stratify  patient selection by detecting those with potentially  reversible baseline joint 
inflammation, an important consideration given concerns about bias introduced in 
trials by  recruitment of patients with equivocal clinical swelling. Moreover, composite 
endpoints have the potential to further reduce patient numbers and study  duration in 
early phase trials. 
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6. Safety and tolerability of US guided synovial biopsies 
6.1 Introduction
Joint synovium is a clear focal point for the inflammatory process in Rheumatoid 
Arthritis. Despite significant progress in our understanding of the mechanisms 
controlling the inflammatory  pathway, harvesting of synovial tissue is currently  not 
routinely  performed in clinical practice. However, there is great interest in retrieving 
synovial tissue for research purposes and early  phase drug development studies221 
391 392. 
The ability  to successfully  harvest good quality  synovial tissue must be in the context 
of a well tolerated and safe procedure. Historically, synovial biopsies have been 
performed by  a blind needle approach or conventional arthroscopy. Blind needle 
biopsies are well tolerated and relatively simple to perform217 225 393. Arthroscopic 
biopsies are technically more complicated and require theatre time but have 
significant advantages in being able to harvest tissue under direct visualization. This 
procedure has been extensively  validated with respect to tissue quality  in therapeutic 
studies making it the accepted gold standard for synovial tissue acquisition 221 265 391 
394 395.  This has led to the emergence of relatively  small number, proof of concept 
studies affording an early  go/no go decision in drug development. Once again, this 
technique tends to be performed in larger joints (knee and ankle) limiting recruitment 
of patients with suitably involved joints. 
More recently, advances in ultrasound (US) imaging have facilitated the development 
of a minimally  invasive ultrasound guided synovial biopsy  technique222-224. A similar 
technique has previously  been described in a small case series using a single portal 
and forceps approach in 9 patients with established RA224. The authors concluded 
that tissue harvested form small joints using this technique represented a reliable 
approach for good quality  tissue. There is a need to replicate these findings in a 
much larger cohort of patients and show that it has an acceptable safety  and 
tolerability  profile. If proven, the ability  to reliably  sample synovial tissue from both 
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large and small joints would have an impact on recruitment for early  phase 
therapeutic studies and broaden the usefulness of synovial biopsies if clinical utility  is 
shown with respect to disease classification or therapeutic drug selection. 
6.2 Objectives
The main  aim of this study  was to determine the tolerability, safety  and yield of 
synovial tissue in ninety three consecutive minimally  invasive ultrasound guided 
synovial biopsies of both small, medium and large joints using an US guided 
technique in an early arthritis cohort.
6.3 Materials and methods 
6.3.1 Patients
93 sequential ultrasound guided synovial biopsy procedures were included in the 
study. All patients were recruited as part of the Pathobiology  of Early  Arthritis Cohort 
(PEAC: www.peac-mrc.mds.qmul.ac.uk) within the department of rheumatology  at 
Barts Health NHS Trust. PEAC is a prospective multicenter study  and recruits 
treatment naive patients with early arthritis (<1 year duration) with at least one 
clinically swollen joint for a baseline and 6 month follow up synovial biopsy, along 
with the collection of a number of radiographic and clinical parameters. Data was 
available from 57 patients undergoing baseline synovial biopsy, 36 of these patients 
had received a second biopsy  procedure performed at a 6 month follow up visit 
during this period. All procedures were performed following written informed consent 
and were approved by the hospitals ethics committee (REC 05/Q0703/198). 
6.3.2 Ultrasound Guided Synovial Biopsy Technique
US guided synovial biopsy  was performed using a GE Logiq 9 ultrasound machine 
with a 2-dimensional M12L transducer. Three operators (SK, FH and NN) performed 
all 93 biopsies . Pre-βiopsy standard longitudinal ultrasound images of each biopsied 
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joint were recorded with power Doppler switched on and off. Synovial tissue was 
defined as hypoechoic non-compressible intra-αrticular tissue. Power Doppler 
settings were adjusted to the lowest permissible pulse repetition frequency  to 
maximise sensitivity. Maximum colour gain was used without creating artifactual 
noise. Each procedure follows a similar routine with 1-3 mls of local anaesthetic 
injected into the soft tissues up to the joint capsule, visualized under US guidance. A 
further 2-5mls of local anaesthetic (1%  lignocaine) is instilled into small joints, 
10-15mls for large joints. For larger joints a suitable coaxial outer needle may be 
used in addition to the Quick-Core® Biopsy  Needle (Cook medical, Limerick, 
Ireland), placed within the joint capsule - 16 / 14G (Figure 1A). A longitudinal US 
image is used to detect the needle and guide it to an appropriate pre-determined site 
for biopsy. For smaller joints a Quick-Core® biopsy  Needle (16G, throw length 
10mm) was used without a coaxial sheath. The maximum tolerated number of 
biopsies per joint was attempted with the aim for a minimum of 12 biopsies were 
aimed to be retrieved per procedure. Six to eight biopsies were immediately  fixed in 
4% paraformaldehyde for paraffin embedding and a further six immersed in 10:1 v:v 
of RNA-Later (Ambion) for later RNA extraction. Following the procedure, a small 
sterile dressing was placed over the site of the needle insertion (online video - 
www.synovialbiopsy.com).
A standard questionnaire was administered to all patients immediately  pre and post 
biopsy and at their post-βiopsy clinic review (3-7 days). Patients indicated pain, 
swelling and stiffness of the biopsied joint pre and post procedure using a visual 
analogue score with tolerability  being assessed using a 5-point Likert scale. At their 
post-βiopsy clinic review patients were also asked to record how likely  they  were to 
consider a repeat biopsy in the future using a scale of highly  likely, somewhat likely, 
unsure, somewhat unlikely and highly unlikely.
184
6.3.3 Ultrasound synovitis score
Standard longitudinal images of individual joints prior to the ultrasound guided 
procedure were viewed by  an observer blinded to patient data. Synovial thickening 
and degree of power Doppler signal was scored using a previously  reported semi-
quantitative score (0-3)396.
6.3.4 Synovial Histopathological Assessment
From each paraffin embedded block of synovial tissue 3μm thick sections obtained 
from three different cutting levels 50µm apart underwent routine staining with 
haematoxylin and eosin. Sections were considered valid for further histological 
scoring only  if an intact cell lining layer was visible. A synovitis score was then 
assigned to each valid tissue section according to a previously  described scoring 
system145. Each section underwent semi quantitative assessment for three synovial 
membrane features; i) thickness of the synovial lining cell layer, ii) stroma cell density 
and iii) inflammatory cell infiltrate using a scale of 0-3 (Figure 1B). A composite score 
integrating these three features was then determined and samples categorized as no 
synovitis (0-1 points), low-grade synovitis (2-4 points) and high grade synovitis (5-9 
points). 
6.3.5 RNA extraction
RNA was extracted from synovial tissues biopsies using a Trizol separation protocol. 
A minimum of 10mg of synovial tissue was homogenised in cold Trizol reagent (Life 
Technologies, Invitrogen Division, UK). Chloroform was mixed with the lysate and 
following centrifugation the aqueous RNA layer was transferred to a new 
microcentrifuge tube. Pre-chilled isopropanol was then mixed with the RNA layer. 
Following incubation and centrifugation, the isopropanol was removed and the RNA 
pellet washed with 70% ethanol. The pellet was re-dissolved in RNase-free water. 
The concentration/purity of the RNA sample(s) were measured using the NanoDrop 
2000C (Lab Tech, UK) and the quality  (RIN) was assessed using the Agilent 2100 
Bioanalyser (Agilent Technologies, UK) (Figure 1B).
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6.4 Statistical analyses
Demographic characteristics of patients, safety and tolerability  data were described 
with mean (+/-Standard Deviation [SD]) values or relative frequencies. As RNA yield 
was a non-parametric variable, median (interquartile range=IQR) or relative 
frequencies were used for descriptive analyses for the tissue quality data. Univariate 
analyses were performed using Fisher’s test, Mann Whitney U and Kruskal-Wallis 
when appropriate. Multiple linear regressions were performed to model the 
percentage of graded biopsies and the quantity  of RNA yield (log transformed) 
according to the ultrasonography  score of synovial thickening (from 1 to 3), the 
biopsy site (small, medium or large) and the biopsy rank. P values <0.05 were taken 
as statistically significant.
All statistical analyses were performed using GraphpadPrism version 3.03 (Graph 
pad software for mac version 5.0).
6.5 Results
Characteristics of the study patients
Demographic and clinical features of the 57 patients included within the study  are 
shown in Table 1. Of these patients 36 had undergone a second biopsy. 5 different 
joint sites were biopsied (Table 1), with the knee (34.5%) and wrist 44.1%) most 
frequently biopsied. 
6.5.1 US guided synovial biopsy is safe and is well tolerated by patients
Of the 93 ultrasound guided procedures performed the only  reported complication 
was 3 patients feeling faint during the procedure however after a suitable period of 
time all 3 allowed the procedure to be completed. Potential complications assessed 
at the post-procedure follow  up visit were infection, haemarthrosis, deep venous 
thrombosis, thrombophlebitis, post procedure arthralgia and flare of the underlying 
disease. Importantly there were no reported cases of wound or joint infection and no 
evidence of a flare of the underlying disease. At the post-procedure follow up visit 18 
patients (19.4%) reported mild arthralgia following the procedure, however this 
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resolved within 24hrs with simple analgesia. Patients were also asked to indicate the 
tolerability  of the procedure using a 5-point likert scale ranging from no discomfort to 
severe pain (Table 2). There was a significant difference in the number of patients 
reporting discomfort during biopsy  of a large joints (elbow, knee) compared to small 
and medium sized joints (Wrist, MCP and PIP) (Fisher exact test p = 0.03). There 
were no significant differences between any  of the other patient reported outcomes. 
Only  1 patient described mild pain during the biopsy  and his was attributed to a 
prolonged procedure.
Patients were asked to complete pre and post procedure VAS assessments of pain, 
stiffness and swelling. While there was a small trend to reduction in all post 
procedure assessments this did not reach statistical significance (Figure 2A).
The majority  of patients were agreeable to having a subsequent US guided synovial 
biopsy at a later date with 81.7% of patients either ‘very  likely’ or ‘somewhat likely’ to 
have a repeat procedure (Figure 2B). However in practice, 54 of the 57 patients 
surveyed following their first biopsy have subsequently consented to a second biopsy 
as part of the PEAC study, representing more than 95% compliance with two US 
guided synovial biopsies at baseline and at 6 months follow up.
6.5.2 US guided synovial biopsy yields high quality synovial tissue suitable for 
histopathological characterisation 
A median of 14 biopsies samples were retrieved from each procedure (range 4-32). 
Three H and E stained sections 50μm apart from each synovial biopsy  were 
examined at x40 magnification and sections with a visible lining layer underwent 
semi-quantitiative assessment for degree of synovitis (scale 0-9)145. Of all 93 
procedures performed 85 (91.3%) procedures yielded synovial tissue suitable for 
undergoing further histopathological classification for synovitis, these are 
subsequently  referred to as “graded biopsies”. Patients were classified as high 
grade, low grade or uninflamed dependent on the predominant synovitis score 
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between tissue sections. 43%  of procedures yielded tissue classified as low grade 
synovitis and 34% high grade synovitis, 9% of patients were classified as uninflamed.
A median number of 15, 14 and 13 samples were taken respectively  from small joints 
( MCP / PIP / MTP), medium joints (wrists) and large joints (knees and elbows). In 
order to determine whether yield of graded synovial tissue was dependent on size of 
joint biopsied procedures were then classified into those performed on small (MCP, 
PIP and MTP), medium (wrist) and large (elbow and knee) joints. For each group, the 
mean percentage of graded tissues was reported (Figure 3A).  Although there was a 
trend for small joint biopsies to yield a smaller percentage of graded biopsies (40%) 
versus medium (51%) and large (58%) this did not reach statistical significance. 
6.5.3 US guided synovial biopsy yields tissue sufficient for high quality RNA 
extraction
In order to determine whether us-guided synovial biopsy  yielded sufficient quantity 
and quality  of synovial tissue for RNA extraction synovial tissue stored in RNA-Later 
underwent processing for extraction of RNA (need MB to word this correctly  not sure 
which method they used). Quality of RNA was determined via the RNA integrity score 
(Figure 1B) (RIN) and quantity  of RNA determined per us-guided biopsy  procedure. 
The median RNA yield for each joint varied according to joint size (large - 0.89 μg/10 
mg tissue, medium - 0.69μg/10 mg tissue, small - 0.54 μg/10 mg tissue), however no 
statistical difference was demonstrated between total RNA yield in each group joint 
size despite a tendency  for smaller joints to provide a lower yield (p=0.22) (Figure 
3B).
Tissue quality and RNA yield is maintained in subsequent biopsies
Thirty-six patients within this study  were patients undergoing a second synovial 
biopsy at 6 months post recruitment to the PEAC study. As the second us-guided 
synovial biopsy  was performed in all cases on the same joint biopsied at baseline, a 
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comparison of tissue quality  between procedures was feasible. Similar numbers of 
samples were taken at both first and second biopsies (median of 14 [range 6-32] and 
14 [range 4-24] samples respectively). When number of procedures yielding graded 
synovial tissue per total procedures performed following first biopsy  (93%) and 
second biopsy  was compared (88.9%), no significant difference was seen 
(p=0.70). Additionally, although total RNA yield varied from first to second 
biopsy this did not reach statistical significance, 1st biopsy - 1.14µg/10mg 
tissue (IQR: 0.46; 2.07), 2nd biopsy 0.61 μg/10mg tissue(0.26 - 0.89) 
(p=0.08), (figure 3C).
6.5.4 Synovial tissue quality varies with pre-βiopsy ultrasound assessment of 
synovial thickening
In order to determine whether pre-βiopsy  US assessment of synovitis determined 
yield of either graded synovial tissue or RNA quantity  us-guided biopsy  procedures 
were segregated according to the pre-βiopsy US grey scale synovial thickness and 
power Doppler score (semi-quantitative 0-3). Differences in yield of graded synovial 
tissue per total procedures performed and mean yield of RNA (ug/mg) were then 
examined within each US-GS group. There was a significantly  higher yield of graded 
synovial tissue in those with grade 3 synovial thickening versus grade 2 and grade 1 
(p<0.01) (figure 4A). Similar results were seen when RNA yield was examined with 
grade 3 synovial thickening associating with a significantly  higher RNA yield than 
grade 2 and grade 1 (Figure 4B). A similar analysis was performed when segregating 
procedures according to pre biopsy  power Doppler signal but no significant 
differences in either graded synovial tissue or RNA yield were seen (results not 
shown). 
Using synovial thickness score, power doppler score and and joint size as variables, 
the degree of US detected synovial thickening was the only independent predictor of 
tissue RNA extraction and grading using multi variant analysis (Figure 4A and 4B). A 
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single MCP joint of US synovial thickness grade 3 was biopsied and thus excluded 
from the analysis.
6.6 Discussion
Harvesting of good quality synovial tissue is an important step along the path of 
understanding the pathogenesis and disease evolution of Rheumatoid Arthritis. To 
date the most convenient method for tissue collection has been either at the point of 
joint replacement surgery  or by  arthroscopic intervention. By definition, joint 
replacement surgery  is usually  required in established disease with clinical 
manifestation of inflammatory  joint pathology  for many years. The ability  to retrieve 
synovial tissue of good quality, by a safe and tolerable method, at the initial onset of 
inflammatory joint disease will help dissect the pathological process evolving in our 
patients. Additionally, the ability  to harvest good quality  tissue from smaller joints, 
such as wrist and MCP joints, may improve recruitment to small proof of concept 
studies in context of early drug development. 
In this paper we have demonstrated that a minimally  invasive approach to synovial 
tissue harvesting using US guided approach can be both safe and tolerable to 
patients. Tolerability  appears to be better in small and medium sized joints (MCP/ 
PIP / Wrists) which is likely to represent the relationship of joint size to local 
anesthetic instilled. PIP joints are often biopsied using a ‘ring block’ technique 
providing total anesthesia to the digit. Tissue quality  appears to be preserved in 
subsequent biopsies following therapeutic intervention as shown by  the 36 patients in 
our cohort who received a second synovial biopsy. This is an important finding in the 
context of using such a technique to monitor changes in synovial biomarkers with 
response to therapy. While we did not demonstrate a statistical difference in terms of 
joint size and tissue quality, there is a suggestion that smaller joints such as MCP or 
PIP joints may yield less graded tissue with a lower total RNA yield extracted. This is 
likely  to reflect the technical difficulties in performing the biopsy  at this level but 
190
encouragingly  at least 40%  of all tissue samples are graded with sufficient RNA 
extracted for laboratory analysis. 
Ultrasound as a pre-αssessment tool appears to improve tissue yield with joints 
demonstrating greater synovial thickening performing better on tissue grading and 
total RNA yield. Once again this is likely  to reflect the mechanics of sampling joints 
with small amounts of ultrasound detectable synovial thickening regardless of joint 
size. Therefore, to inform the choice of joint to be biopsied and maximise tissue 
quality we suggest a decision tree based upon our findings (figure 5).
Our overall success rate of 92.5% patients with graded synovial tissue seems to 
compare favorably  with similar invasive diagnostic procedures. Renal biopsies are 
performed routinely  as part of the diagnostic work up with a variable success rate. 
Suitable tissue for analysis being harvested in 83% - 97% of case series 
reported397-401. A similar results are seen in the context of liver biopsies with 
adequate or diagnostic liver tissue obtained in 81%  - 97% of cases402. In addition, 
major complications of renal biopsies have been quoted as between 18% and 28 % 
in these series. Arthroscopic procedures performed by  Rheumatologists or 
Orthopaedic surgeons reportedly  runs approximately  1% risk of a significant port -
procedure complication218. Our data compares favorably  to this with no patients 
presently  reporting a significant complication following this minimally  invasive 
ultrasound guided biopsy  technique, however 3 patients did report feeling faint during 
the procedure. While 93 biopsy  procedures represents the largest published cohort 
of patients undergoing this procedure to date, we are aware that as a developing 
technique, safety  remains an important outcome to be monitored and reported. 
Importantly, this report refers to a single units experience of this procedure. Further 
work is needed to confirm these finding in different sites, specifically  confirming the 
safety and quality of harvested tissue.
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Table 6-1: Summary of patient demographics undergoing synovial biopsy. 
Clinical characteristics of 57 patients were recruited to the study 
N (%)
Gender
- Female
- Male
36 (63.2)
21 (37.8)
Age (years) 
mean+/- SD 50.7 +/- 7.9
Disease duration (months) 
mean +/-SD 7.2 +/- 1.3
Clinical diagnosis
- Rheumatoid arthritis
- Psoriatic arthritis
- Undifferenciated arthritis
- Monoarthritis
40 (70.2)
6 (10.5)
10 (17.6)
1 (1.7)
Serology
- Rheumatoid factor
- Anti-CCP
19 (33.3)
14 (24.6)
Biopsied joint
Large
-- Knee
-- Elbow
Medium
--Wrist
Small
-- PIP
-- MCP
33 (35.5)
      -- 32 (34.4)
      -- 1 (1.1)
41 (44.1)
      -- 41 (44.1)
19 (20.4)
      -- 2 (2.2)
      -- 17 (18.3)
Table 6-2: Patient reported pain / discomfort during the ultrasound guided 
synovial biopsy. 
Percentages in each group are noted in brackets.
None (%) Mild     discomfort (%)
Moderate 
discomfort (%) Mild pain (%) Severe pain (%)
All biopsies  72 (77.7)  14 (15.1)  6 (6.5)  1 (1.1)  0 (0)
Small Joints 18 (81.8)  1 (4.5)  3 (13.6)  0 (0)  0 (0)
Medium Joints  35 (87.5)  4 (10)  0 (0)  1 (2.5)  0 (0)
Large Joints  19 (61.3)  9 (29)  3 (9.7)  0 (0)  0 (0)
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Figure 6-1: Histopathological scoring of synovial tissue acquired during us-guided 
synovial biopsy 
A. Image illustrative of patient undergoing ultrasound guided synovial biopsy of right wrist with 
needle placement at the scaphoid lunate junction B. Representative images of synovial tissue 
sections x4 magnification from ultrasound-guided synovial biopsy procedures of patients 
biopsied within this study cohort. 3μm sections underwent routine staining with haematoylin 
and eosin and were semi-quantitatively assessed using a previously validated synovitis 
score145. A composite score of 0-9 was determined following assessment of increasing lining 
layer thickness (panels A,D and G), density of the resident sublining cellular infiltrate 
(fibroblasts, endothelial cells and macrophages)(B, E and H) and sublining inflammatory cell 
infiltrate (lymphocytes and plasma cells), (C, F and I). IHC performed by Dr. B. Hands 
(Experimental Medicine and Rheumatology, William Harvery Research Institute).
A
B
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Figure 6-2: US-guided synovial biopsy is a safe and well tolerated procedure. 
A. Patients were also asked to complete a Visual analogue score (VAS) assessing 
immediately prior to and following the procedure, joint pain, stiffness and swelling. No 
significant differences in any of the 3 variables pre and post procedure was reported (n=93). 
B: At their post procedure clinic visit 3-7 days following the synovial biopsy patients were also 
asked to record the how agreeable they were to having a subsequent synovial biopsy: Very 
likely (VL), Somewhat likely (SL), Not sure (NS), Somewhat unlikely (SU), Very unlikely (VU). 
Results are expressed as percentage of total patients (n=93). C: Patient reported discomfort 
during the biopsy procedure
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Figure 6-3: Percentage of gradable tissue and RNA yield from small medium and large 
joints 
A: Percentage of graded synovial tissue within each procedure by joint size, B: Total yield of 
RNA from biopsy samples by joint size, C: Average total RNA yield of per biopsy procedure of 
1st and 2nd biopsy procedures
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Figure 6-4: Synovial tissue quality varies with pre-βiopsy ultrasound assessment of 
synovial thickening 
A: Tissue gradability by pre-βiopsy US grey scale (US-GS 1-3) synovial thickening 
assessment. B: Average total RNA yield by pre-βiopsy US grey scale synovial 
thickening assessment.
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Figure 6-5: variation of tissue grading and RNA yield by joint size and US determined 
synovial thickness
A: Variation of graded tissue as demonstrated by joint size and US grey scale synovial 
thickness score. B: Variation of average total RNA yield as demonstrated by joint size and US 
grey scale synovial thickness score. L - Large joint, M - medium joint, S - Small joint. US GS 
synovial thickness grade 1 - 3 e.g. M2 - medium joint with US grade 2 synovial thickness
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Figure 6-5: Suggested decision tree for guiding joint selection for US guided synovial 
biopsies and MCP, Wrist and Knee grading atlas
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7. The relationship of ultrasound imaging to small joint synovial 
histopathology in patients with active Rheumatoid arthritis
7.1 Introduction
The assessment of synovial inflammation in patients with inflammatory  arthritis is a 
critical aspect of everyday, routine clinical care. This assessment may  take the form 
of a simple clinical examination of tender or swollen joints but more frequently 
Rheumatologists are employing other modalities, such as MRI or Ultrasound (US), to 
better define the presence of on going synovial inflammation. The most convincing 
comparator or gold standard for any  assessment of joint inflammation is microscopic 
or macroscopic pathologic evidence of synovial inflammation. This is not a feasible 
routine investigation and as such, surrogate markers are required to provide 
physicians with the tools to classify  patients and monitor response to interventions. 
One of the simplest surrogates employed by  Rheumatologists is the assessment of 
joints by clinical examination. Swollen, tender, warm metacarpal-phalengeal (MCP) 
joints reflecting underlying synovial inflammation does have an inherent appeal with 
considerable face validity. The inclusion of the tender and swollen joint count as a 
component of the DAS28, a validated clinically  relevant disease activity  measure, 
does confirm its function as an important bedside assessment tool. Despite the 
considerable validation of DAS28 as a useful tool to monitor RA disease activity  and 
guide therapeutic decisions, it has become clear that it has many  deficiencies. Joint 
tenderness is very  subjective and the physicians assessment may  vary  with the 
patients threshold for pain and on the examiners force of palpation. Swelling is often 
impossible to assess in larger patients or where joint inflammation in minimal. 
The introduction of MRI and US as additional assessment tools has provided greater 
options for the Rheumatologist when determining the degree of disease activity  and 
response to therapy. Despite the additional information afforded to Rheumatologists, 
there is still much work to be done to provide a suitable framework of integration for 
these imaging modalities. Many  investigators have examined the use of US in 
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inflammatory arthritis and shown it to be a sensitive assessment tool which is 
responsive to therapeutic intervention and predictive of disease outcome in early 
arthritis. Few, however have addressed the validity  of US imaging with respect to 
underlying histological features of synovial inflammation. Synovial vascularity  was 
investigated by  Walther et al., who found a good correlation between histological 
vascularity and visual grades of PDU signal in the synovium of both knee and hip 
joints in patients undergoing arthroplasty  (r - 0.81 p <0.001). Schmidt et al. found 
good agreement between presence of colour Doppler signal and histologically 
verified pannus tissue in knee joints of RA and osteoarthritis patients undergoing joint 
replacement surgery. Pannus in this study was histologically  defined as ‘synovial 
proliferation with invasive destruction of cartilage and bone’. A study by Fiocco  et al. 
found a significant correlation between B-mode US synovial thickness and 
arthroscopic grade of synovitis in arthritic knee joints. 
Koski et. al. have provided the most extensive assessment to date of ultrasound and 
synovial histopathology. This study examined the relationship of ultrasound 
parameters and synovial histological findings in patients  undergoing a percutaneous 
synovial biopsy  of the designated site. Forty-four patients with either monarthritis or 
polyarthritis were recruited with a majority  of knees (25 /44) being biopsied. In this 
study  a robust assessment of the synovial tissue was made with only sections with 
an intact synovial lining layer being assessed. Seven histological parameters of each 
specimen was scored (multiplication of synovial lining, villous hypertrophy  of the 
synovial surface, surface fibrin deposition, sub-synovial infiltration of 
polymorphonuclear leucocytes, sub-synovial infiltration of mononuclear leucocytes, 
proliferation of blood vessels and fibrosis). Each histopathological and ultrasound 
parameter was graded on a semiquantitative scale, with the 7 histological 
parameters summed to provide an overall score for the biopsied tissue. Grey-scale 
ultrasound showed synovial proliferation in 39 of 44 (89%) the patients however no 
significant correlation was found between the degree of synovial proliferation 
detected with ultrasound, and the overall histopathological score (r = 0.222, p = NS). A 
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positive Doppler signal was detected in 34 of 44 (77%) of the patients and once 
again no significant correlation was found between the amount of the power Doppler 
signal in the synovium and the overall histopathological score (r = 0.239, p = NS). The 
amounts of sub-synovial infiltration of polymorphonuclear leucocytes did correlate 
with the amount of power Doppler signal (0.328, p<0.05). Whilst this study makes a 
more detailed histological assessment of the synovium there is a lack of 
homogeneity of patients and joints sampled. A standarised assessment of each joint 
was not described but significant doppler sensitivities are likely  to have arisen 
between knee, wrist and tendon PDS assessment. The use of a 8MHz probe may 
also have diminished the US sensitivity and contributed to the lack of correlation.
Characteristic features of RA synovitis include hypertrophy  of the lining layer, neo-
αngiogenesis and infiltration of immune-cells of both the innate and adaptive immune 
system. Immune-cells can be found either randomly  distributed within the synovial 
sublining or spatially  grouped into follicular structures (25). These structures may 
acquired features of secondary-lymphoid-organs-(SLO) to include high-endothelial 
venules (HEV), T/B-cell segregation, follicular-dendritic-cells networks and are 
defined as ectopic/tertiary lymphoid-like structures (ELS/TLS). 
A number of histologically  determined synovitis scores have been proposed in 
patients with Rheumatoid Arthritis. The Rooney  score assesses 6 histological 
features of the synovial membrane and was assessed in a prospective RA 
population. Unfortunately, no correlation with joint damage was demonstrated over a 
2-year period in a cohort of 60 RA patients. Koizumi et al. described a synovitis score 
which was aimed at allowing reliable differentiation of RA and OA synovium. To this 
end it was successful and additionally  having showed a moderate correlation with the 
degree of erosive damage and levels of CRP but was based on a purely  cross-
sectional population with no prospective validation performed to date with regards to 
disease activity  and sensitivity  to change. Krenn et. al. described a 9 point synovitis 
score based upon lining layer hypertrophy, synovial stroma cell density  and the 
degree of organisation of the infiltrate. These components are scored 0-3 and 
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summed to achieve the overall score. This score was described in a study  attempting 
to differentiate inflammatory  and non-inflammatory  joint pathology. A high-grade 
synovitis on the Krenn score was strongly  associated with rheumatic joint diseases 
(P<0.001) as a-posed to OA synovium. These 2 scoring systems described above for 
have not been examined in a prospective fashion and there is no indication if they 
respond significantly to treatment. 
A number of inflammatory  cells can be seen within the synovium of patients with 
active RA (CD3 - T cells, CD20 - B cells, CD138 - Plasma cells CD68 - 
macrophages). Sub-lining CD68+ macrophages (CD68SL) were shown by Tak et. al. 
to be a correlated with disease response to active therapy  and importantly  minimize 
the placebo effect in a randomised controlled trials. A number of placebo controlled 
studies have confirmed the relationship of change in DAS28 and change in CD68SL 
macrophage numbers. In a small prospective study  in patients with early 
inflammatory arthritis, the number of synovial sub-lining layer macrophages at 
baseline was associated with the number of new erosions on radiographs of the 
hands and feet at 1 year later (P = 0.002). A similar finding in established  RA was 
also demonstrated. In addition, the histological processing and assessment of this 
particular synovial biomarker seems to be reliable and reproducible as determined in 
a multi-site examination of the technique. This measurement of synovial inflammation 
has come to be regarded as the optimal synovial characteristic in describing synovial 
disease activity  and detecting response to therapy in patients with RA and as such is 
often used in the context of early phase drug development.
It is therefore within two cohort of patients we seek to examine the relationship of 
ultrasound measures of synovitis with histological and clinical parameters prior to 
treatment. An Early RA population was recruited (treatment naive) in addition to an 
established cohort (DMARD inadequate response). In addition, we will attempt elicit 
any favorable baseline characteristics which predict patients response to therapy 
within each cohort. Additionally, I will describe a wrist ultrasound score and its 
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relationship to synovial markers of inflammation, facilitating its incorporation into a 
limited US joint data set.
7.2 Aims
Within a cohort of patients, naive to treatment and with inadequate response to 
DMARDs I wished to examine:
i) The variation of ultrasound parameters (grey  scale and power doppler synovitis) 
within a single wrist joint and determine the optimal assessment of US synovitis in 
relation to synovial histology.
ii) The relationship of histologically  defined synovial inflammation, and in particular 
CD68SL macrophage and Krenn score, to a single joint and limited US joint data 
set.
iii)Whether patients’ clinical, ultrasound or synovial histomorphology  parameters 
correlate with the mean change in DAS28 and identify  any  baseline predictors of 
response.
7.3 Methods
7.3.1 Patient selection
Early Arthritis Cohort: 20 patients with a new diagnosis of RA (ACR 1998 criteria) 
were recruited to an on going early inflammatory  arthritis study (PEAC; Pathobiology 
of Early  Arthritis Cohort, REC ref: 05/Q0703/198) in which patients were assessed 
clinically and with ultrasound imaging at baseline and at 6 months from recruitment. 
Patients also received an ultrasound guided synovial biopsy  as previously  described 
at baseline prior to treatment and at 6 months. All patients recruited has inflammatory 
joint symptoms for 3 - 12 months prior to recruitment and had at least one suitable 
joint for biopsy.
All patients with RA were treated with combination therapy  of Methotrexate and 
sulphasalazine and low dose prednisolone 7.5mg. Patients were eligible for anti-TNF 
therapy at 6 months if they fulfilled NICE guidelines. 
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Established RA: 20 patients with RA (1987 revised ACR classification criteria) who 
fulfilled the NICE guidelines for TNF Blocking therapy  were recruited to a synovial 
biopsy based study. All subjects were receiving MTX for at least 4 months, with a 
stable dose of 7.5-25 mg/week for a minimum of 4 weeks. In addition, all patients 
were on a stable doses of oral steroids (prednisone ≤10 mg/day, or equivalent 
corticosteroid) for 4 weeks prior to recruitment. All patients received screening for TB, 
Hepatitis and HIV prior to anti-TNF therapy  initiation as per normal NHS guidelines 
and were excluded if they  failed any  of these screening tests. A synvoial biopsy was 
taken at baseline and after 3 months.
7.3.2 Clinical Disease Activity assessment
The primary  measure of disease activity  in this study  was the DAS28(CRP).  The 
components of the DAS28(CRP) are the number of tender joints (28 joint count), the 
number of swollen joints (28 joint count), a Global Health index (100 mm VAS), and 
the CRP (in mg/L).  The formula for determining the DAS28(CRP) is as follows:
DAS28(CRP) = 0.56*√(TJC28) + 0.28*√(SJC28) + 0.36*ln(CRP+1) + 0.014*GH 
(VAS) + 0.96  
DAS 28 Response criteria
Non-responders – patients were designated non-responders if their DAS28 has not 
improved by > 1.2 from baseline six months after treatment;
Partial responders – patients will be designated partial responders if their DAS28 
improves by >1.2 from baseline but remains >3.2. 
Good responders – patients will be designated good responders if their DAS28 falls 
by >1.2 to a level <3.2 (i.e. into a ‘low disease activity state’ [LDAS])
Remission – patients will be designated as in remission if their DAS28 falls to <2.6.
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Health assessment questionnaire (HAQ)
The HAQ  was self-αdministered at study baseline. The Disability  Index consists of 
eight categories assessed by  the Disability  Index are 1) dressing and grooming, 2) 
arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip, and 8) common daily 
activities. For each of these categories, patients report the amount of difficulty they 
have in performing two or three specific activities. 
7.3.3 Ultrasound Assessment
Patients received a baseline US assessment of the biopsied joint and in addition a 
limited US joint set using a GE logiq 9, ultrasound system and the 2D M12L Probe. 
The limited US set consisted of MCP 1-5 (Left and Right), Wrists (Left and Right). 
The MCP examinations were performed in both longitudinal and transverse 
orientations as described in the appendix. Wrist assessment was in a longitudinal 
direction from 3 pre-defined regions of interest:
1. Midline: encompassing the distal radius, Lunate and Capitate bones and common 
extensor tendons.
2. Radial: Encompassing the distal radius, Scaphoid, Trapezium and 1st carpal-
metacarpal joint (CMC).
3. Ulna: encompassing the distal ulna, Pisiform, Hamate and the 5th CMC joint.
A summed 10 joint US score (10 MCP joints) and a 12 joint US score (10 MCP + 2 
Wrists) were derived form the available US data. 
The grey scale and power doppler images images were stored on the Logiq 9 US 
system and transferred to a suitable repository. Images were analysed both 
qualitatively  and quantitatively  as described in the appendix. Definitions of US 
parameters are given in chapter 2. To facilitate correlation of a categorical score for 
the histological parameters the continuous variables of synovial thickness area (STA) 
and PDA (power doppler area) were subdivided. This was modeled on the published 
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data by  Walther et. al. who categorized the doppler signal in his study  to facilitate 
correlation with a semi-quantitative 0-4 vascular histology  score. Table 7-1 shows the 
PDA and STA scales and corresponding categorical values. 
Current experience would dictate that in normal individuals , with no evidence of 
inflammatory arthritis, no doppler signal should be detectable on US imaging. 
Therefore the lowest category, score ‘0’, relates to 0 PD pixels on the continuous 
variable. 
The same cannot be assumed for the STA. Many  normal joint have small amounts of 
synovial thickening which is deemed within normal limits for the purposes of 
differentiating between normality  and pathology  at a single joint level. Therefore an 
examination of 92 single MCP joints were undertaken and a threshold for normal 
quantitative assessment of was derived. The mean area of synovial thickening was 
5.8 x103 (S.D. 1.6x103). A threshold was therefore determined as mean + 2.5 x S.D. 
(10,000 pixels). 
Figure 7-1: Histogram showing the distribution of quantitative assessment of synovial 
thickening within normal joints.
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Table 7-1: Ordinal reference ranges for continuous variables of STA and PDA.
STA - Synovial thickness area, PDA - Power Doppler Area
Ordinal scale STA PDA
0 0-10000 0
1 10,000 - 20,000 1- 500
2 20,001 - 30,000 501- 1000
3 30,001 - 40,000 1001 - 1500
4 > 40,000 > 1500
7.3.4 Synovial biopsy
An ultrasound guided synovial biopsy  was performed on patients prior to the 
commencement of therapy  as described in chapter 2. Early  RA patients received a 
synovial biopsy  prior to the initiation of any  therapy including corticosteroids and 
again after 6 months. The established cohort of RA patients received their ultrasound 
guided synovial biopsy prior to receiving anti-TNF therapy and after 3 months. 
7.3.5 Histopathological processing of synovial tissue
Tissue processing
Synovial tissue biopsy  samples were fixed in 4%  formalin overnight and processed 
on an automated vacuum TP1050 tissue processor (Leica) the following on a routine 
overnight cycle. The processed biopsy  specimens were transferred to an SLEE 
tissue embedding centre and were embedded in paraffin wax blocks (FFPE tissue 
blocks). 
FFPE tissue blocks were sectioned on a Leica RM1235 microtome. Sections were 
cut at a thickness of 3μm and mounted on to Superfrost plus (+) slides. Sections 
were cut for subsequent Haematoxylin and Eosin (H&E) staining/assessment as well 
as IHC staining. Sections for immediate use were left to dry  in a slide rack at room 
temperature for 30 minutes and then  transferred to a heating plate (60ºC) for a 
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minimum of 30 minutes prior to staining. Tissue sections were H&E stained for initial 
grading and synovitis scoring and viewed/imaged using an Olympus BX61 
microscope.
Histological Assessment 
H&E-stained specimens
The aggregational phases of the synovial lymphoid tissue were defined using an in-
house grading score. All specimens that exhibited a synovial cell lining layer were 
graded and synovitis scored. Cell aggregates are initially  categorised into three 
groups according to the radial cell count. The radial cell count was determined by 
counting the number of cells from the centre of an aggregate to the identifiable edge. 
The determination was made at the point of widest infiltration. Cell aggregates with a 
radial cell count between 2 -5 cells are classified as Grade 1. Grade 2 specimens 
have a radial count of 6 -10 cells, while Grade 3 specimens have a radial count of 
more than 10 cells. 
In conjunction with the grading, an inflammatory score (synovitis score) was also 
assigned according to the three synovial membrane features (thickness of the 
synovial lining cell layer, stroma cell density  and inflammatory infiltrate). The ranking 
of alterations is on a scale from none (0), slight (1) and moderate (2) to strong (3) for 
each feature. The values of the parameters are summarised and interpreted as 
follows: 0–1, no synovitis; 2–4, low grade synovitis; and 5–9, high-grade synovitis 
(Krenn et al., 2006). 
Scoring of IHC-stained Specimens
IHC-stained specimens for T-cells, macrophages and plasma cells (CD3, CD68 & 
CD138 respectively) are scored on a 5 point scale: 0-4 depending on the increasing 
number of positively  stained cells calibrated against a standardised atlas (minimal 
infiltration = 0 and infiltration by  numerous inflammatory  cells = 4 (Tak et al., 1997). 
The level of B cell infiltration (CD20) was categorised as B Cell Poor (0-1), B Cell 
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Rich (2-3) and Germinal Centre (GC) Rich (4). Accordingly, where B cell aggregates 
were observed for CD20, synovial biopsies were IHC-stained for CD21 to for the 
presence of GC (CD21 positive follicular dendritic cells (FDC) networks).
Figure 7-2: Image Atlas of synovium stained by Immunohistochemistry for CD3, CD20, 
CD68 and CD138
RA synovium stained by Immunohistochemistry for CD3, CD20, CD68 and CD138. A 
qualitative 0-4 score is demonstrated with typical reference image atlas below. IHC 
performed by Dr. B. Hands (Experimental Medicine and Rheumatology, William 
Harvery Research Institute).
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7.4 Results
7.4.1 Patient demographics
Table 5-2 gives an overview of the patient demographics for both cohorts. No 
significant difference was detected for age, sex inflammatory  markers or DAS28. 
Reflecting the inclusion criteria for each cohort, a significant difference was seen for 
the duration of symptoms with the treatment naive cohort having a mean of 0.51 
years as expected.
Table 7-2: Patient demographics of recruited patients to both treatment naive 
and DMARD inadequate response arms.
Treatment Naive (S.D.) DMARD IR (S.D.) P value
Female : Male 15 : 5 14 : 6 0.4
Previous DMARDs 0 1.6 (0.5) -
Age 51.2 (21) 50.8 (12.1) 0.61
Duration (years) 0.51 (0.24) 6.9 (6.1) < 0.0001
ESR 40 (23) 29.2 (22) 0.09
CRP 21 (18) 13.6 (14.4) 0.18
RF 119 (145) 49.8 (58) 0.12
CCP 234 (258) 241 (261) 0.53
Pain (VAS) 58 (29) 63 (18) 0.58
Global Health (VAS) 64 (28) 65 (21) 0.61
Tender Joint 11 (7.3) 13 (5.2) 0.47
Swollen Joints 7.9 (5.4) 9.1 (6.3) 0.32
DAS28 (CRP) 5.8  (S.D. 1.3) 6.4 (0.9) 0.41
HAQ 1.3 (0.7) 1.6 (0.7) 0.29
210
7.4.2 Reliability of qualitative synovial immunohistochemistry score
BH and SR scored all immunohistochemistry  slides. Each reader was blinded to the 
others result and to the clinical and ultrasound data. Inter class correlation co-
efficient were calculated for consistency. Each parameter was scored individually  and 
ICC scores tabulated. Excellent agreement was seen between both readers for all 
qualitative scores table 7-3.
Table 7-3: ICC results for immunohistochemistry markers scored according to 
the standard image atlas.
Krenn score CD3 CD20 CD68L CD68SL CD138
ICC    
(95% CI)
0.87 
(0.82-0.94)
0.94 
(0.83-0.98)
0.99 
(0.97-0.99)
0.95 
(0.82-0.98)
0.98 
(0.93-0.99)
0.98 
(0.94-0.99)
7.4.3 Wrist joint score
Of the 40 patients recruited, 32 received a wrist synovial biopsy. The three regions 
imaged for the wrist joint were compared for the degree of synovial thickening and 
power doppler signal (qualitative and quantitative). There was a significantly  great 
score for both VASCi and STi scores when comparing the midline versus radial or 
ulnar regions (repeated measures anova; p = 0.001, p= 0.003 respectively) figure 
7-3. This was also reproduced for qualitative assessments for STA and PDA 
(repeated measures anova; p  = 0.002, p= 0.001 respectively). When each cohort 
was treated separately, a similar significant difference was detected between regions.
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Figure 7-3: Bar chart of ultrasound scores for each region of interest within the wrist 
joint (Average score, SEM)
A: Ultrasound vascular index score (VASCi) for each region of interest. B: Ultrasound 
synovial thickness index (STi) for each region of interest.
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Histological parameters were correlated with both quantitative and qualitative 
ultrasound scores. The correlation was performed using a summed score for all three 
wrist regions for both synovial thickness and power doppler. In addition, the 
histological correlation was also run using only  the midline wrist US scan. A summary 
of the correlation data can be seen in table 7-4. All correlations were performed using 
Spearman rank as all variables represented ordinal scores.
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Table 7-4: Correlation matrix of histological and ultrasound parameters for 
wrist joints only
Table showing the correlation of synovial histological parameters as determined by 
immunohistochemistry and ultrasound assessment of the wrist. Spearmans rank 
correction. Total scores represent a summed result for 3 regions of interest within 
the wrist (radial, midline and ulna). Midline scores refer to the midline wrist image 
only. Asterix (*) denotes statistically significant result.
Histology 
variable
STi 
(total)
VASCi 
(total)
STA
(total)
PDA 
(total)
STi 
(Midline)
VASCi 
(Midline)
STA
(Midline)
PDA 
(Midline)
Krenn score 0.67* 0.69* 0.67* 0.71* 0.63* 0.68* 0.78* 0.69*
CD3  0.46* 0.55* 0.31 0.43 0.31 0.52* 0.52* 0.55*
CD20 0.62* 0.73* 0.53 0.7* 0.53* 0.71* 0.69* 0.76*
CD68L 0.71* 0.74 0.71* 0.75* 0.63* 0.74* 0.63* 0.75*
CD68SL 0.83* 0.81* 0.82* 0.84* 0.73* 0.69* 0.72* 0.8*
CD138 0.58* 0.71* 0.62* 0.74* 0.67* 0.8* 0.65* 0.72*
Figure 7-4: Correlation of wrist VASCi (total) score and qualitative CD6SL macrophage 
score
Correlation of total wrist VASCi score and qualitative CD6SL macrophage score in 
32 wrist joints form patients with active inflammation. Spearmans rank correction r = 
0.81, p<0.001.
0 1 2 3 4 5
0
2
4
6
8
10
VA
SC
i
CD68SL
213
A significant association was seen both qualitative and quantitative US parameters 
and the CD68SL macrophage with the STi and VASCi both showing a strong 
correlation (0.83; p <0.001and 0.81; p  < 0.005 respectively). The midline US scan 
also correlated with the CD68SL score but only moderately  (STi 0.73; p < 0.012, 
VASCi 0.69 p<0.004). The majority  of all other immunohistochemistry  variables 
correlated with the ultrasound parameters except for the CD3 score which showed 
only  a moderate correlation with STi and VASCi (total). The 3 variable, ‘Krenn score’, 
also correlated with all ultrasound parameters but to a lesser extent than the 
CD68SL score.
7.4.4 US parameters predict synovial CD68SL macrophage score.
To calculate the positive and negative predictive value for both STi and VASCi a 
binary separation of the data was required. All wrist joints were assessed using a 
summed VASCi and STi score. A significant VASCi was considered a score of 1 or 
more. A score of grade 1 in each wrist region was permitted (total score of 3 or more) 
when separating the STi score into binary  categories. The sensitivity  of the VASCi 
score in the wrist was 0.96 with a specificity  of 0.8 (Fisher exact P = 0.0007). The 
positive predictive value for the presence of CD68SL macrophages in patients with a 
significant VASCi score was 0.96 with a negative predictive value of 0.8 if the VASCi 
was 0. Similarly, the sensitivity  and specificity  of STi in reflecting the presence of 
CD68SL macrophages within the synovium was 1.0 and 0.6 with a positive predictive 
value of 0.93 and negative predictive value 1.0.
214
Table 7-5: Chi squared  (2x2) table showing the number of patients with 
Doppler signal present on US examination and presences or absences of 
synovial CD68 SL macrophages.
 A: 2x2 table of patients with VASCi / no VASCi and presence / absence of CD68SL 
macrophages within the synovium. B: 2x2 table of patients with STi / no STi and 
presence / absence of CD68SL macrophages within the synovium. CD68SL+ 
presence of CD68+ macrophages in sublinig, CD68SL- no CD68+ macrophages 
seen in sublining.
A
VASCi + VASCi -
CD68SL+ 25 2
CD68SL - 1 4
B
STi + STi -
CD68SL+ 26 1
CD68SL - 0 5
7.4.5 Correlation of a limited US data set with synovial and clinical parameters of 
disease activity.
A limited 10 joint US data set (10 MCPs) was correlated with synovial histological 
parameters in both the early  RA and established RA cohorts. The US data set was 
calculated using transverse and longitudinal images for both cohorts and presented 
in table 7-6. A moderate correlation was seen with CD68SL and all of the 10 joint 
longitudinal US data sets in both cohorts with the Early  RA - 10 long STi performing 
best (correlation coefficient of 0.58; p <0.001). In both cohorts, only  the STi and STA 
US scores of the 10 joint longitudinal data set correlated with the Krenn score (0.52; 
p <0.01 and 0.57 p < 0.02 respectively). 
Within both cohorts, the 10 joint transverse US scores correlated with CD68SL 
expect for 10 Trans Sti (0.41 p  = 0.23). Similarly, only  STi and STA scores correlated 
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with the Krenn score using the transverse data set. Overall, the longitudinal US data 
sets typically  out perform the corresponding transverse data set in both established 
and early disease.
Extending the US joint set to include both wrists provided a 12 joint US data set. The 
relationship of this extended US data set to histological parameters was examined. 
The US parameters for this summed data set were based upon the MCP joints 
longitudinal data. 
Two variations of this score were used:
1. 12 Joint score (weighted wrist): 10MCPs + Left Wrist (ulna + midline + radial 
score) + Right Wrist (ulna + midline + radial score) 
Effectively the wrist is weighted x3 compared to a single MCP joints
2. 12 joint score (average wrist): 10 MCPs + Left Wrist ([ulna + midline + radial 
score] / 3) + Right Wrist ([ulna + midline + radial score] / 3). 
The wrist score is averaged and weighted x1 compared to a single MCP joints
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Table 7-6: Correlation of Longitudinal and Transverse VASCi and STA scores 
with histological parameters in an early and established RA cohort.
A: Early Arthritis Cohort; 10 joint US data set (longitudinal images only) correlated to 
the Krenn score and CD68SL macrophage score (Spearman rank ). B: Early Arthritis 
Cohort; 10 joint US data set (transverse images only) correlated to the Krenn score 
and CD68SL macrophage score (Spearman rank ). Asterix (*) denotes 
statistically,significant result.
A
Early Arthritis Cohort 10 long STi 10 long VASCi 10 long STA 10 long PDA
Krenn score 0.56* 0.31 0.62* 0.36
CD68SL 0.61* 0.62* 0.6* 0.68*
Early Arthritis Cohort 10 Trans STi 10 Trans VASCi 10 Trans STA  10 Trans PDA
Krenn score 0.35 0.20 0.53* 0.27
CD68SL 0.4* 0.46* 0.43* 0.5*
B
Established RA 10 long STi 10 long VASCi 10 long STA 10 long PDA
Krenn score 0.4* 0.23 0.5* 0.20
CD68SL 0.41* 0.49* 0.43* 0.48*
Established RA 10 Trans STi 10 Trans VASCi 10 Trans STA  10 Trans PDA
Krenn score 0.42* 0.25 0.46* 0.21
CD68SL 0.29 0.4* 0.47* 0.42*
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Table 7-7: Correlation of 12 joint VASCi and STA scores (averaged and weighted 
wrists scores) and histological parameters in an early and established RA cohort.
A: Early Arthritis Cohort; 12 joint US data set (total wrist score) correlated to the 
Krenn score and CD68SL macrophage score (Spearman rank). B: Established 
cohort; 12 joint US data set (Average wrist score) correlated to the Krenn score and 
CD68SL macrophage score (Spearman rank). Asterix (*) denotes 
statisticallysignificant result.
A
Early Arthritis Cohort
12 joint STi
(weighted wrist)
12 joint VASCi
(weighted wrist)
12 joint STA
(weighted wrist)
12 joint PDA
(weighted wrist)
Krenn score 0.74* 0.60* 0.82* 0.60*
CD68SL 0.70* 0.66* 0.64* 0.57*
Early Arthritis Cohort
12 joint STi
(average wrist) 
12 joint VASCi
(average wrist) 
12 joint STA
(average wrist) 
12 joint PDA
(average wrist) 
Krenn score 0.59* 0.32 0.57* 0.19
CD68SL 0.62* 0.58* 0.50* 0.42*
B
Established RA
12 joint STi
(weighted wrist)
12 joint VASCi
(weighted wrist)
12 joint STA
(weighted wrist)
12 joint PDA
(weighted wrist)
Krenn score 0.46* 0.53* 0.58* 0.49*
CD68SL 0.21 0.47* 0.39 0.51*
Established RA
12 joint STi
(average wrist) 
12 joint VASCi
(average wrist) 
12 joint STA
(average wrist) 
12 joint PDA
(average wrist) 
Krenn score 0.31 0.12 0.35 0.27
CD68SL 0.34 0.42* 0.31 0.39
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A significant correlation was found more frequently  using a 12 joint data set involving 
a weighted wrist sum for both CD68SL and Krenn score in both early  and established 
populations. The 12 joint STA (weighted) score performed best (0.81; p < 0.01) within 
both early  and established RA cohorts (Early  RA 0.81; p  < 0.01, Established 0.58; p< 
0.02). Within the established RA cohort of patients the 12 joint US scores (averaged 
wrist) did not perform well and was only significantly  correlated to the 12 joint VASCi 
and PDA scores (0.42 p<0.03, 0.39 p<0.045 respectfully).
None of the histological or US scores correlated with either the baseline DAS28 or 
HAQ score within the Early  RA population. No correlation was detected with any  of 
its components including ESR, tender joint, swollen joint or patient global. Within the 
Established RA cohort, a significant correlation was seen between the DAS28 score 
and the 10 joint VASCi (long), 12 joint VASCi (weighted wrist) and 12 joint VASCi 
(averaged wrist), (0.45, p < 0.015; 0.61, p < 0.03; 0.48, p < 0.025 respectfully). None 
of US scores for synovial thickness were significantly  correlated with the DAS28. 
Once again the HAQ  at baseline did not correlate with any  of the histological or 
imaging scores.
7.4.6 Change in DAS28 correlates with the change in US parameters and 
histological scores.
All clinical, ultrasound and histological parameters showed a significant mean 
change from baseline in both the early  and established patient cohorts (Paired t-test 
P<0.001).
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Figure 7-5: Mean score for all histological parameters at first and second synovial 
biopsy
A: Mean score for all histological parameters at first (1) and second (2) biopsy (Krenn 
score, CD3, CD20, CD68L, CD68SL, CD138) - Early RA cohort B: Mean score for all 
histological parameters at first (1) and second (2) biopsy (Krenn score, CD3, CD20, 
CD68L, CD68SL, CD138) - Established RA cohort
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In both cohorts the mean change in DAS28 was significantly  correlated with the 
mean change in both US and histologic parameters. A table below describes the 
signifiant correlations with the mean change in DAS28. Within both cohorts the 12 
Joint VASCi (weighted wrist) performed well when correlated with DAS28 (Early RA, r 
= 0.56; P < 0.003, Established RA r = 0.48; P <0.01). Within the Early  RA cohort the 
histological parameter which correlated best was the change in the synovial CD3 
score (r = 0.43: P < 0.031) however, within the Established cohort CD68SL appeared 
to correlate best (r = 0.39; P < 0.011). 
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Table 7-8: Correlation matrix of mean change in DAS 28 with US and 
histological parameters
Table showing the correlation of the mean change in ultrasound and histological 
parameters with the mean change in DAS28. Asterix (*) denotes 
statistically,significant result.
Early RA Established RA
US data sets Delta DAS Delta DAS
12 Jt VASCi 
(weighted wrist) 0.56* 0.48*
12 Jt STi 
(weighted wrist) 0.42* 0.39*
10 Long VASCi 0.44* 0.41*
10 Long STi 0.38* *0.4
Histology
Krenn score 0.39* 0.33*
CD3 0.43* 0.38*
CD20 0.27 0.31
CD68L 0.41* 0.32*
CD68SL 0.38* 0.39*
CD138 0.32 0.38*
7.5 Relationship of clinical response to synovial histology, ultrasound and baseline 
clinical parameters
Linear regression modeling was used to predict the change in DAS28 at 6 months 
following treatment with baseline characteristics of patients. 38 out of 40 patient had 
a DAS28 available at 6 months for analysis (20 Established RA, 18 Early  RA). The 
analysis was run separately  for early  and established RA cohorts. The model 
generated from the early  RA cohort was tested in the established RA group. 
Histological parameters (Krenn score, CD3, CD20, CD68DSL and CD138) and 
Ultrasound scores (10 joint STi and VASCi long,12 joint STi and VASCi [weighted 
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wrists]) and clinical parameters (CRP, ESR, DAS28, Rheumatoid factor, anti-CCP 
antibodies) were used as variables.
Within the Early  RA cohort, synovial CD3 score and 12 joint VASCi were both 
significantly  associated with the change in DAS28 (r2 - 0.45, p< 0.02 and 0.39, 
p<0.04 respectfully). This provided a predictive model with a value of 76.7%.
Testing the same model within the established RA cohort resulted in a reduction in 
the models ability to predict the change in DAS28 (value 38.9%). 
An independent model generated from the Established RA cohort subsequently 
treated with anti-TNF therapy  suggested that the baseline 12 joint STi (weighted 
wrist), CD68SL and CRP (r2 - 0.35, p< 0.001, r2  - 0.29,  p<0.03 and r2- 0.31 p<0.01 
respectfully) levels were independently  related to the mean change in DAS28. This 
model suggested a predictive value of 73.2%. 
7.5.1 Histomophological segregation of synovial tissue suggests a dichotomous 
population
Using the histomorphological phenotype of the synovial tissue to segregate the 
patients, US and histological parameters of patients shows evidence of a 
dichotomous population. Significant differences were seen with the Krenn score, 
CD68SL macrophage score with a G2/G3 phenotype predominant in the patients 
with high synovial inflammatory  scores (Chi Squares test p  = 0.003 and p= 0.002 
respectfully). Likewise, a G2/G3 histomorphological phenotype seems to be 
associated with a high VASCi and STi score at an individual joint level (Chi Squares 
test p = 0.0018 and p= 0.0029 respectfully) Table 5-9.
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Table 7-9: Table showing ultrasound and parameters according to the synovial 
histomorphology.
Table showing ultrasound and parameters according to the synovial 
histomorphology. There is a significant diﬀerence in the Diﬀuse, G1 group compared 
with the G2,G3 grouping (chi sq) for histological and US parameters as well as RF.
Diffuse, G1 G2, G3 Chi Sq, p value
Krenn score
< = 3
> 3
13
5
1
21
p = 0.003
CD68 SL
0 - 2
3 - 4
15
3
4
18
p = 0.002
STi
0 - 2
3 - 4
14
4
6
16
p = 0.0029
VASCi 
0 - 2
3 - 4
13
5
3
19
p = 0.0018
RF (%) 6 (33%) 17 (78%) p = 0.0029
7.6 Discussion
This study  examines a number of aspects of the relationship of ultrasound imaging to 
synovial histological parameters both at a single joint level and using an extended 
US joint data set. All patients had a high disease activity  score on recruitment, prior 
to receiving a synovial biopsy, which inevitably  limits correlation with clinical  disease 
activity  parameters. However, both cohorts of patients represent clear clinical 
scenarios in which the use of ultrasound imaging is used frequently  to characterise 
patients and influence management decisions. 
The wrist is a frequently  involved joint in RA. The wrist joint poses a particular 
problem for ultrasonographers due to the multiple synovial articulations present 
within a ‘single joint’. The score derived from such a complex joint is likely  to require 
the assessment of more than 1 single region of interest. My  results demonstrate a 
difference in ultrasound parameters between three regions of the wrist joint, 
examined from the dorsal aspect. The midline scan of the wrist encompassing the 
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distal radius, lunate and capitate demonstrated greater synovial thickness and 
vascular scores compared to the radial or ulnar regions. Despite this, it is interesting 
to note that whist a single midline image for STi and VASCi correlated with the 
CD68SL macrophage qualitative score, the VASCi score encompassing three 
regions of interest was superior. A similar result was not seen by using the Krenn 
score, CD20 or CD3 for either US wrist scores. In addition, the integration of the wrist 
US score into a 12 joint US data set performed better in terms of histological 
correlation, but more importantly  was shown to be an indicator of a change in DAS28 
at 6 months. When an averaged score or single midline image was used no 
association was demonstrated. Therefore the scoring of the wrist joint, either singly 
or as part of an extended joint data set, would argue for it being weighted in favour of 
a summed score of a radial, midline and ulnar regions of interest. Further work is 
required to determine if a summed score for the wrist performs well as an indicator of 
therapeutic response, if the histological correlations remain consistent following 
treatment and whether it parallels clinical disease activity over time.
Both qualitative and quantitative scores performed similarly  at a single joint level. The 
artificial categorisation of the continuous vascular and synovial thickness scores 
(PDA and STA) was necessary  to correlate with these parameters with the ordinal 
scale used for the histological variables. There is an assumption in using an ordinal 
scale that the difference between values remains relatively  constant whether 
transitioning form 1 to 2, or form 3 - 4. With this in mind, the categorisation of the 
continuous variables was undertaken. In practical terms, this has the potential to 
underestimate the relative value of PDA or STA at the limits of the scale. Ideally, a 
continuous variable should be generated for the histological scores using digital 
imaging analysis which would facilitate a more meaningful correlation. Despite these 
limitations the quantitative score performed well at the single joint level although only 
the the VASCi appeared to be predictive of a change in DAS28 over time.
The positive predictive value of ultrasound imaging was explored in all patients with a 
high DAS28 score undergoing wrist synovial biopsies at baseline. The presence of a 
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VASCi score of 1 or more had a high positive predictive value - 0.96, for the presence 
of CD68SL macrophages whereas a STi score of 1 or less for the wrist had a 
negative predictive value of 1.0. This result may  have significant implication on the 
interpretation of ultrasound findings in a clinical and research context. 32 wrist joints 
represents a reasonable sample size for this dichotomous distinction, however as all 
patients were deemed clinically  to have active disease there is typically  a small 
number of patients with an absence of CD68SL histologically  with a predominance of 
CD68SL +, VASCi + individuals. It will be important to explore this relationship in a 
more diffuse RA population at varying degrees of clinically  assessed disease activity. 
Whilst a high negative predictive value is seen in this model for the absence of 
significant STi, it may not be as robust in the context of low disease activity.
There has been much interest in establishing a representative, limited US joint data 
set for use in the context of routine clinical care and clinical trial setting which 
provides further information on RA disease activity. A number of data sets have been 
examined in the literature and been shown to be response to to change with varying 
degrees of reliability. In Chapter 5, I demonstrate the responsiveness of a limited US 
data set (10 MCP joints) in a randomised controlled clinical trial. The implication  form 
these studies is that US assessment of joint synovitis is a surrogate biomarker for 
synovial inflammation. I have already discussed the excellent correlation between 
synovial biomarkers and the ultrasound grey  scale and doppler scores, however a 
valid, representative US data set would also be expected to correlate with 
histologically  defined synovial inflammation. This study examined a number of US 
data sets and their relationship to synovial inflammation. A limited joint data set of 10 
MCPs were examined with US images being collected form a longitudinal or 
transverse orientation as described in appendix 1. For all parameters the longitudinal 
10 MCP score preformed better than the corresponding transverse score although all 
scores were significantly  correlated with CD68SL macrophage score except for the 
10 MCP Transverse score in the established RA cohort. Given the superior 
performance of the longitudinal imaging for the MCP joints the 12 joint data set 
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utilised only  these images whilst including both wrists. The 12 joint data set was 
analysed using 2 wrist scoring methods; 1) summed score for the wrist and 2) 
averaged score for the 3 compartments. Using a summed score for the wrist based 
on 3 regions of interest effectively  weights the wrist contribution of this data set. An 
average score only  equates the wrist with a single MCP joint. The correlation co-
efficients demonstrate a closer relationship for the synovial biomarkers and the 
weighted 12 joint US scores. Both 12 joint STi (total) and 12 joint VASCi  (total) 
scores demonstrated a good correlation with CD68SL macrophages in the early  RA 
cohort (0.7, p<0.001; 0.66 P<0.001 respectfully) with all histological parameters 
recording a significant correlation. 
Comparing the relationships of US synovial thickness and vascularity  measurements, 
a distinct difference can be seen on inspection of the correlation matrix between the 
early  and established RA cohorts. The correlations are generally  weaker in the 
established cohort with no significant correlation seen with CD68SL macrophages 
and either the qualitative or quantitative assessments of synovial thickness. The 
correlations are preserved for the vascular assessments albeit at a moderate level. 
The disease duration is significantly  longer in the established cohort compared to the 
early  RA patients (0.51 years and 6.9 years respectfully). This may  suggest that, over 
time, grey  scale synovial thickening may be a less effective surrogate of synovial 
inflammation. Certainly, a chronic inflammatory  process predisposes to fibrosis and 
scaring which may  be in part responsible for the synovial thickening seen bot on US 
examination and clinically. The potential uncoupling of the relationship of grey  scale 
synovial thickening with synovial inflammation is an important finding and warrants 
further examination. These two cohorts of patients represent cross-sectional data, 
therefore a prospective follow up of an early  RA cohort over time may  address this 
question if paired with serial synovial biopsies. In addition to the duration of disease, 
all of the established cohort have received DMARD therapy. Consequently  I must 
also consider the possibility that treatment has a role to play in altering this dynamic. 
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 The relationship of US and histological parameters to disease activity  was examined 
using linear regression and subsequent modeling of DAS28 response form baseline 
characteristics. Within the early  RA cohort, all of the synovial biomarkers and Krenn 
score had a positive relationship with both qualitative and quantitative US outcome 
measures. The linear regression model isolated CD3 and the 12 joint VACSi score as 
contributing significantly  in a predictive model (Predictive value 76.7% of DAS28 
change at 3 months following therapy) with CD3 contributing 82.3% to the model 
compared to 17.7% for the 12 joint VASCi. Using this model in the established RA 
cohort provided little predictive value (37.9%). There are a number of limitations of 
this model. The DAS response for methotrexate is likely  to be better assessed at 6 
months rather than 3. This may  under weight a number of the variables in the model. 
In additon, both cohorts received different treatment regimes with the established RA 
population going on to have anti-TNF therapy.  It is conceivable that different synovial 
and US signatures may predict response to different DMARDS and biological agents. 
This is a major limitation of the model and thus a separate model was constructed 
from the same baseline parameters within the established RA cohort. This revealed a 
CD68SL macrophages, 12 Joint VASCi and CRP as significant predictors of DAS28 
response (Predictive value 73.2%  of DAS28 change at 3 months following therapy). 
To register in a predictive linear model in such a small cohort of patients, these 
significant parameters would suggest a large effect. Despite this, both models only 
predict approximately  75% of the overall DAS28 response to treatment. This would 
suggest that whilst synovial histology  and US data have a role to play  in predicting 
response to treatment other factors are certainly  relevant and influencing patient 
response. 
7.7 Conclusion
To summarise, this study  examined a number of histological and ultrasound 
parameters in two distinct cohorts of patients. The use of a limited US data set 
including the wrist performs better when weighted. The correlation between synovial 
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histological markers of inflammation, including CD68SL, and US parameters appears 
to differ in the two populations with an excellent correlation seen with in the early  RA 
cohort and a moderate correlation in the established cohort. The lack of synovial 
thickness assessments to correlated with any of the synovial biomarkers in the 
established cohort may  have implications for the use of this parameter in clinical 
studies. A clinical predictive model base upon baseline clinical, ultrasound and 
histological data was only  moderately  successful at predicting response but did 
confirm both imaging and synovial histology as important contributors in the change 
of DAS28 following 3 months of treatment.
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8. The relationship of ultrasound and synovial neoangiogenesis 
within the Knee joint.
8.1 Introduction
Neovascularization is the development of new blood vessels from the existing 
microvascular bed. It involves a number of steps including endothelial cell division, 
selective degradation of vascular basement membranes and the surrounding 
extracellular matrix, and endothelial cell migration. In addition, up-regulation of 
angiogenesis promoters and down-regulation of inhibitors an be detected. This is a 
early, critical aspect to synovial pannus formation and facilitates the perpetuation of 
the inflammatory process within synovial joints.
Ultrasound imaging of synovial joints provides information regarding synovial 
hypertrophy  (referred to as grey  scale synovitis) and vascular flow within the 
synovium (Doppler ultrasound). Doppler ultrasound is of particular importance to the 
assessment of synovial vascularity. Power Doppler ultrasound differs from colour 
doppler by  negating the directional information by  summation of the positive and 
negative waveforms generated, providing a greater signal to noise ratio. This 
facilitates the detection of flow  at low velocities commonly  encountered within the 
synovium. Previous authors have shown correlation of PDU and synovial vascularity. 
Walther et.  al. showed that in patients undergoing knee joint arthroplasty  (OA and 
RA), qualitative histological synovial vascularity  scores correlated with qualitative PD 
ultrasound of the supra-patella pouch. Others have confirmed a relationship between 
synovial inflammation and ultrasound PD. Schmidt et al. found good agreement 
between presence of colour Doppler signal and histologically  verified pannus tissue 
in knee joints of RA and osteoarthritis patients, whereas Fiocco et al. found a 
significant correlation between B-mode US synovial thickness and arthroscopic 
grade of synovitis in arthritic knee joints. 
There are number of factors which drive new vessel formation within the synovium. 
Tissue hypoxia is certainly  a factor with an expanding hyper-cellular, metabolically 
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active synovium. Lund-Olesen et. al. demonstrated that synovial fluid pO2 in RA 
knee joints had a partial pressure as low  as 27 mm Hg compared with 43 mm Hg in 
patients with osteoarthritis and 63 mm Hg in patients with a traumatic effusions. 
Some studies have suggested the partial pressure could be as low as 15 mm Hg. 
This is a profound driver of neovascularisation. Hypoxia inhibits the constitutional 
degradation of HIF-1a allowing it to bind to its constitutively  expressed partner, 
HIF-1b. This stable complex translocates to the nucleus, where it upregulating 
angiogenesis related genes. VEGF, HIF-1, HIF-2, Ang1, Tie2 are all expressed in the 
synovium of patients with Rheumatoid Arthritis. VEGF and angiopoietin-1 (Ang1)/
Tie-2 interaction is critical for the stabilization of newly formed blood vessels within 
the rheumatoid synovium. In contrast, Ang2 antagonizes Ang1 and thus inhibits 
vessel maturation. VEGF may also act in a HIF-independent fashion. 
In addition, other soluble and cell surface-βound mediators are important. Vascular 
endothelial growth factor (VEGF) and hypoxia-inducible factors (HIFs), pro-
inflammatory cytokines (TNF-α, IL-1, IL-6), chemokines (IL-8/CXCL8, ENA-78/
CXCL5) and adhesion molecules (β1 and β3 integrins, E-selectin, VCAM-1, ICAM-2) 
play  an important roll in stimulating new vessel formation as a consequence of tissue 
inflammation.
Pro-inflammatory  cytokines can have a direct influence on new  vessel formation 
within the synovium or act via VEGF-dependent pathways. TNF-α, IL-1, IL-6, IL-8, 
IL-15, macrophage migration inhibitory  factor (MIF), granulocyte (G-CSF) and 
granulocyte-macrophage colony-stimulating factors (GM-CSF) are involved in 
angiogenesis. There is therefore a concert of angiogenic factors at work with the 
rheumatoid synovium to promote new  vessel formation and stabalisation. Whilst a 
number of mechanisms exist, a common end result is seen in the patient with a 
perfused synovial tissue which is allowed to expand with a suitable vascular supply 
network. Imaging of this network of new vessels provides indirect evidence of tissue 
inflammation however the relationship  of US measures of synovitis and synovial 
tissue angiogenic factors and vessel density has not been previously explored.
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8.2 Aims
1. To explore the relationship  of ultrasonographic measures of synovitis (GS-synovitis 
and PDU) and synovial vascularity  within the knee joint of patients with early 
Rheumatoid Arthritis.
2. To correlate the synovial tissue expression of vascular mediators an pro-
inflammatory cytokines, such as IL-6 and TNF-α, to US measures of synovitis.
3. To examine the variability  of US parameters, synovial vascular density  and 
inflammatory mediators within the knee joint.
8.3 Methods
Patients and samples
12 patients with early  Rheumatoid Arthritis were recruited as part of an ongoing study 
in patients with early  inflammatory  arthritis (Pathobiology  of Early  Arthritis Cohort). All 
patients were recruited from the Early  Arthritis Clinic (EAC) within the department of 
rheumatology  at Barts Health NHS Trust. All patients had a knee joint clinically 
involved and fulfilled the  ACR diagnostic criteria (1987) for Rheumatoid Arthritis. 
Patients were treatment naive prior to all baseline assessment. Following written 
informed consent, patients received a clinical assessment, ultrasound examination 
and ultrasound guided synovial biopsy from the supra-patella pouch. 
Synovial tissue processing
Each synovial specimen was divided into two parts: one was formalin fixed and 
paraffin embedded for immunohistologic analysis and the second was stored in RNA 
later (AMBION) at -80°C until RNA extraction and QT.PCR analysis.
Immunohistochemistry
Paraffin embedded tissue specimens were cut in consecutive 3µm-thick sections. 
The sections were then deparaffinized and rehydrated through graded ethanols. A 
haematoxylin and eosin stain was performed to ensure tissue morphology  was 
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preserved: only  tissue sections with an intact lining layer were used. To quantify 
vascular density  in the synovial tissue in terms of both number and size of vessels 
profiles, a double immunofluorescent staining for factor VIII and α-SMA was used.
The following primary antibodies were used for immunofluorescence analysis: mouse 
anti human factor VIII (clone F8/86; Dako, Glostrup, Denmark), Cy3 conjugated 
mouse anti human α-SMA (clone 1A4; Sigma, Missouri, USA). The appropriate 
secondary  antibody  for Factor VIII was obtained from Invitrogen, Paisley, UK. As 
negative control irrelevant isotype –matched antibodies (Dako, Glostrup, Denmark)
were used.
Briefly, antigen retrieval was performed by  heating for 35 minutes at 95°C in Dako 
Target Retrieval Solution. Sections when then washed in Tris Buffered saline, 
incubated with protein block (Dako, Glostrup, Denmark) and then in the first primary 
antibody  for one hour (mouse anti human factor-VIII using antibody dilution of 1:50). 
After washing, the appropriate Alexa-488 conjugated secondary  antibody  was 
applied for 30 minutes; sections were then washed and the directly  conjugated 
second primary  antibody, α-SMA, was added at dilution of 1:200.Synovial tissue was 
counterstained with 4’-6-diamidino-2-phenylindole (DAPI) and mounted with anti fade 
mounting medium.
Aimed to obtain a more representative assessment of synovial vascularity  all 
available synovial specimens were cut and stained at two different cutting levels, 
50µm apart.
Digital image analysis for synovial vascularity evaluation
One observer blinded for order, patients and clinical data, performed both image 
acquisition and subsequent image analysis for all the sections.
Digital images of immunofluorescent stained synovial blood vessels, were acquired 
at 20X magnification on a fully  automated Olympus BX60 microscope, captured 
using a video camera (figure 8-1) and then digitized using Cell P image analysis 
software.
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For the most extended synovial tissue, more than a single picture was obtained to 
capture all the part of the samples.
Each acquisition was performed in one single session for each vascular marker, 
factor-VIII and α-SMA, respectively, with fixed variable as derived from the 
calibration.
The obtained factor-VIII and α-SMA stained images were saved in jpeg format and 
used for the subsequent digital images analysis.
The images were first manually processed and, using the drawing method, a 
selected area was defined as the region of interest (ROI) for both blood vessel 
density evaluation and digital vessel size analysis.
The ROI was then use to generate a “tissue mask” by  thresholding through a value 
separating the background (DAPI staining) of histological slides from the stained 
vessels, resulting in binary black and white signal images. 
Since both factor-VIII and α-SMA signals were used to count and analyze blood 
vessels within synovium, both their green and red fluorescent color, respectively, 
were converted into solid white color for binary  bitmap images. This conversion step 
was adjusted to achieve selection of vascular structures without fragmentation or 
fusion of vessels. The vascular objects greater than 10µm in diameter were 
quantified within the selected ROI, using Cell P analysis software and expressed as 
blood vessel numerical density  (number of vessel per square millimeter) and blood 
vessel fractional area (area enclosed within and including vascular endothelium 
expressed as a percentage of the selected ROI), respectively.
Using the same digital analysis system synovial blood vessels were additionally 
divided into classes based on blood vessel surface area and each area-class was 
visualized using a unique color. Larger vessels, exceeding the maximum range of the 
blood vessel area considered, served as positive control both for immunohistology 
and for digital analysis.
Using the above detailed algorithm for blood vessel density  and size evaluation we 
analyzed synovium vascularity specifically  in the previously  described three different 
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tissue sampling sites (the midline supra- patella, the medial supra-patella and the 
lateral supra-patella areas).
QT-PCR OF ENDOTHELIAL SPECIFIC GENES
Total RNA was extracted from the remaining portion of synovial tissue stored in RNA 
later, using the RNeasy  Mini Kit (Qiagen, Chatsworth, CA)), with on column DNase I 
digestion to avoid genomic DNA contamination.
cDNA was generated from 1 ug of RNA using the Thermoscript RT-PCR System 
(Invitrogen, San Diego, CA). 
QT-PCR was performed to detect mRNAexpression levels of Ang-1, Ang 2, VEGF-α, 
VEGF-C Tie-2 and VEGFR2 using specific primers and probes (detaliled in Table….). 
The RT-PCR was run in triplicate with an equal loading of 20 ng of cDNA/well. 
Results were analysed after 40cycles of amplification using the ABI PRISM 7900HT 
Sequence Detection System Version 3. Relative quantification was measured using 
the Comparative Ct (Threshold Cycle) Method. cDNA from human placenta was used 
as a positive control. Placenta is a very good positive control tissue for several 
techniques (IHC, gene expression) as it expresses many  angiogenic factors. It has 
vascular, epithelial, stromal and hematopoietic components in the different parts of 
the placenta.  In particular, in terms of vasculature it is very  rich in new blood vessels 
with up regulation of most angiogenic factors and endothelial proteins expressed. 
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Figure 8-1: synovial tissue stained with Factor VIII demonstrating vessels and gated 
digital analysis for different sized vessels.
High powered field of synovial tissue with factor VIII staining indicating vessel wall 
fluorescence. Division of vessel size using digital imaging analysis can be performed 
based on automatic generated gates with colour diﬀerentiation. IHC performed by 
Dr. B. Hands (Experimental Medicine and Rheumatology, William Harvery Research 
Institute).
Ultrasound Guided Synovial Biopsy Technique 
US guided synovial biopsy  and standard US images were performed using a GE 
Logic 9 ultrasound machine with a 2-dimensional M12L transducer. All synovial 
biopsies were  performed  by  the  same  individual. Knee synovial biopsies were all 
carried out from a lateral approach into the supra-patella pouch with the joint in 30 
degrees of flexion. Each procedure required 1-3 mls of local anaesthetic(1% 
lignocaine) injected into the soft tissues up to the joint capsule, visualized under US 
guidance. A further 10-15mls of   local anaesthetic was instilled in to the  supra 
patella space. A 16G or 14G Quick-Core® Biopsy Needle (Cook medical, Limerick, 
Ireland), placed within the joint capsule under US guidance. A longitudinal US image 
is used to detect the needle and guide it to an appropriate pre-determined site for 
biopsy. A minimum of 18 biopsies were aimed to be retrieved per procedure (6 
samples for each 3 sites within the supra patella pouch. 12 biopsies were 
immediately  fixed   in 4% paraformaldehyde for paraffin embedding and a further 6 
235
immersed in 10:1 v:v  of RNA-Later (Ambion) for later RNA extraction. Following the 
procedure a small sterile dressing was place over the site of insertion .
Ultrasound scoring
Ultrasound images of the knee were recorded and analysed by  two independent 
examiners. Three standardised, 30 second cine loops, were recorded from i) the 
midline supra patella pouch ii) medial suprapatella pouch   iii) lateral supra patella 
pouch corresponding to region of synovial tissue sampling with the knee in 30 
degrees of flexion. All images were acquired by a single sonographer.
Pre-βiopsy, standard longitudinal ultrasound images of each biopsied joint were 
recorded with power Doppler switched on and off. Synovial tissue was defined as 
hypoechoic non-compressible intra-αrticular tissue. Power Doppler settings were 
adjusted to the lowest permissible pulse repetition frequency  to maximise sensitivity. 
Maximum colour gain was used without creating artifactual noise. A standard depth 
of 3.8cm was used for each image acquisition.
Quantitate analysis of the recorded cine loops were performed using Image J 
(NIH,  http://rsb.info.nih.gov/ij/.  1997-2008) with a customised macro application for 
pixel area measurement. The cine loop was played and the frame representing the 
maximum doppler signal selected by  the reader. The area measurement was applied 
by  outlining the total grey  scale synovial area. Quantitative measurements provided 
included synovial thickness area (STA), power doppler signal (PDA), doppler signal 
over a predetermined colour threshold (PDThA) and a ratio of synovial to doppler 
area (PDA/STA). A qualitative score was applied to both the grey  scale synovial 
thickness (STi) and total power doppler signal (VASCi) for each region of the SPP. 
Both quantitative (STA, PDA, PDThA) and qualitative scores (VASCi, STi) were 
performed by two experienced readers and the ICC reported. 
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8.4 Results
8.4.1 Patient demographics
12 patients were biopsied (9 female, 3 male) with a mean age of 47 (S.D. 5.9). All 
patients had symptoms of less than 12 months duration with an average of 7 months 
form symptom onset to recruitment. 5 patients (42%) were seropositive for 
Rheumatoid factor with 4 patients (33%) being positive for anti-CCP antibodies at 
presentation. The mean DAS28 score was 5.4 (limits 3.9 - 6.8). 
All 12 patients received synovial biopsies from each of the three specific regions of 
the SPP pouch (medial, middle and lateral) as described above. All samples were 
graded histologically  only  if an intact synovial lining was present, identifying the 
tissue sample as synovial tissue. For 2 patients there was ungraded tissue from the 
lateral compartment resulting in a total of 34 tissue samples being analysed (12 
medial, 12 middle, 10 lateral).
Table 8-1: Patient demographics (n=12)
N (%)
Gender
- Female
- Male
9 (75)
3 (25)
Age 
(years) mean+/- SD 47 +/- 5.9
Disease duration 
(months) mean +/-SD 7 +/- 0.8
Serology
- Rheumatoid factor
- Anti-CCP
5 (41.6)
4 (33.3)
DAS28 5.4 +/- 0.88
Inflammatory markers
- ESR
- CRP
43 +/- 12
23 +/- 5
8.4.2 Interclass correlation co-efficient (ICC) of knee US scores
Ultrasound images for all 36 sites (12 from each region) were analysed for grey  scale 
and power doppler parameters. The ICC values for PDA, VASCi, STA showed good 
levels of agreement. The STi (ICC 0.68; 0.34-0.89) showed moderate agreement 
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within the medial and lateral supra patella pouch but good agreement within the 
middle compartment. Visual interpretation of the Blant-αltman graph did not show 
any significant deviation of agreement at higher levels in the US score range. 
Table 8-2: Table of ICC values for qualitative and quantitative assessment of US 
parameters from each SPP region. 
SPP region of interest Med Mid Lat
VASCi 0.92 0.89 0.95
PDA 0.94 0.95 0.97
STi 0.68 0.84 0.71
STA 0.88 0.88 0.86
8.4.3 Variation of parameters within the SPP
The three areas of the supra patella pouch were analysed for angiogenic gene 
expression, vascular density  and ultrasound parameters as described above (figure 
8-2). Within the three regions of interest there was no significant difference in TNF-α 
expression within the tree regions of interest within the SPP (Kruskal-Wallis; p = 
0.31), (figure 8-2, A). There was no significant difference found in the gene 
expression profile for any  other angiogenic factors or pro-inflammatory  cytokines 
examined (Angiopoietin 1 / 2, VEGFc, VEGFa, FVIII, Tie2, IL-1 β, IL-6). In addition, 
there was no significant difference in the vascular area measurement in each region, 
although there was a tendency for the lateral compartment to have slightly  higher 
area values than the medial and middle compartments (figure 8-2 B). 
No difference was detected in the ultrasound parameters within the SPP pouch. 
However, similarly, higher levels of PDA and VASCi were noted in the lateral 
compartment along with higher levels of STA and STi (figure 8-2 C  and D). The ratio 
of PDA / STA remained stable throughout the three regions of interest with no 
significant difference detected between regions (figure 8-2 E).
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Figure 8-2: No significant variation of ultrasound, vascular area and gene expression 
between each region of the supra patella pouch (SPP) 
A: TNF α expression by by each region of interest within the SPP. B: PDA (pixels) by 
each region of interest within the SPP. C: STA (pixels) by each region of interest 
within the SPP D: Vascular area / mm2 by by each region of interest within the SPP. 
E: PDA/STA ratio by each region of interest within the SPP.
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8.4.4 Relationship of synovial vascular area to US variables and angiogenesis 
factors
The synovial vascular area was calculated for all tissue samples from each site f the 
supra patella pouch. The histological vascular area was correlated with the 
ultrasound parameters of synovitis (results shown in table 8-4). All qualitative and 
quantitative ultrasound parameters correlated with the synovial vascular area / mm2. 
The PDA vascular index correlated best of the individual parameters (Spearmans 
rank - 0.73; SD 0.53-0.89). The qualified ratio of PDA / STA also correlated well 
(Spearmans rank - 0.77; SD 0.59-0.92). Blood vessel number also correlated with 
PDA, PDThA and PD/STA but not with the STA and VASCi.
The synovial vascular area showed a good correlation with the pro-inflammatory 
cytokines, IL-1b and TNF-α but not with IL-6. There was also good / moderate 
correlation with tissue gene expression of pro-αngiogenic factors (VEGFa, 
angiopoietin-1). Synovial vascular area correlated with VEGFr3 (Spearmans rank - 
0.68; SD 0.43-0.88), a lymphogenetic receptor, but not for VEGFc its potential 
receptor. These correlations held when the data was examined as per each SPP site 
rather than as a total group.
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Table 8-3: Correlation matrix of synovial vascular area and US assessment of 
PDS and synovial thickness (STA).
All correlation's performed using Spearmans rank, significant if p <0.05
US assessment VASCi STA PDA PDThA PD / STA
Synovial vascular area / mm2 0.64* 0.47* 0.73* 0.66* 0.77*
Blood vessel no. / mm2 0.38* 0.32 0.53* 0.66* 0.61*
Figure 8-3: Graphical representation of synovial vascular area correlated with US 
vascular parameters
Synovial Vascular area / mm2 of synovial tissue correlated with US parameters. A: 
total PDA correated with synovial tissue vascular area / mm2 (Spearmans rank, r = 
0.73, p = 0.001), B: Ratio of PDA / STA correlated with synovial tissue vascular 
area / mm2 (Spearmans rank, r = 0.77, p = 0.001). PDA/STA represents an US 
equivalent to the synovial tissue vascular area / mm2.
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Table 8-4: Correlation matrix of angiogenic factors and US assessment of PDS and 
Synovial thickness
All correlation's performed using Spearmans rank, significant if p <0.05
Angiogenic factor Ang 1 Ang 2 VEGFR3 VEGFc VEGFa Tie2 IL-1 b IL-6 TNF - a
Synovial vascular 
area / mm2 0.24 0.64* 0.68* 0.44 0.60* 0.41 0.61* 0.3 0.58*
Blood vessel 
no.  / mm2 0.30 0.44 0.49 0.45 0.63* 0.22 0.60* 0.4 0.46
Figure 8-4: Graphical representation of angiogenic factors correlated with US vascular 
parameters
Synovial Vascular area / mm2 of synovial tissue correlated with angiogenic factors. 
A: VEGFa correlated with synovial tissue vascular area / mm2 (Spearmans rank, r = 
0.60, p = 0.005), B: Anti-TNFa correlated with synovial tissue vascular area / mm2 
(Spearmans rank, r = 0.58, p = 0.01).
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8.4.5 Relationship of ultrasound parameters to angiogenic factors
The US parameters of synovitis assessed in this study  have been shown to correlate 
with the synovial vascular area / mm2. In addition, these parameters were correlated 
with gene expression for a number of pro-αngiogenic factors and inflammatory 
cytokines.  STA showed a good correlation with all three pro-inflammatory  cytokines 
tested (IL-1b, IL-6 and TNF-α) and moderately  with angiogenic factors such as 
VEGFa, Tie-2 and Angipoietin 2. No significant relationship was seen between STA 
and Angiopoietin 1. PDA and PDA / STA parameters also correlated with pro-
inflammatory cytokines, with only  a modest correlation demonstrated between with 
PDA and IL-6 (Spearmans rank - 0.48; SD 0.12-0.72). The quantitative, thresholded 
PDA parameter correlated only  with IL-1b and TNF-α but not IL-6. PDThA also 
correlated with VEGFa but none of the other angiogenic factors.
The qualitative, VASCi score, performed poorly  when correlated with all the of the 
angiogentic factors and inflammatory  cytokines, showing only  an modest relationship 
to TNF-α  expression (Spearmans rank - 0.52; SD 0.23-0.85).
With respect to lymphangiogeneis, VEGFc and its receptor VEGFr3 correlated with 
both synovial thickness and PDA but not with any  of the other US parameters 
measured. Table 8-4 shows a correlation matrix for US parameters assessed and 
angio- and lymphoangiogenic factor expression.
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Table 8-5: A correlation matrix of ultrasound parameters and angio- and 
lymphoangiogenic gene expression in 12 patients with newly diagnosed RA. 
All correlations performed using Spearmans.
US assessment VASCi STA PDA PDThA PD / STA
Angiopoietin 1 0.33* 0.37* 0.22* 0.11* 0.20*
Angiopoietin 2 0.44* 0.74 0.61 0.46* 0.55
VEGF-R3 0.51 0.61 0.55 0.36* 0.47*
VEGFc 0.21* 0.62 0.39 0.14* 0.29*
VEGFa 0.3* 0.56 0.52 0.48 0.51
Tie-2 0.33* 0.51 0.46* 0.22* 0.38*
IL-1 β 0.53 0.81 0.68 0.64 0.66
IL-6 0.36* 0.70 0.48 0.46* 0.56
TNF-α 0.52 0.75 0.63 0.63 0.60
Figure 8-5: Graphical representation of PDA correlated with angiogenic factors in 12 
patients.
PDA correlated with angiogenic factors in 12 patients.. A: TNFa correlated with 
Power Doppler Area (Spearmans rank, r = 0.63, p < 0.001), B: VEGFa correlated with 
Power Doppler Area  (Spearmans rank, r = 0.52, p < 0.001).
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8.4.6 Correlation of US vascular parameters and synovial vessel size
Each synovial tissue specimen was analysed by blood vessel size as describe in 
section 6.3. Variable gating of the digital image generated form the 
immunohistochemistry staining allowed for identification of 3 sizes of vessels within 
each specimen (figure 8-6). Medium sized vessels contributed most to the overall 
vascular area (79%) within each tissue specimen with small and large vessels 
contributing on 9.5% and 11.5% respectively.
Figure 8-6: Bar chart showing the relative percentage contribution to the overall 
histological vessel area made by each vessel size.
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The vascular US parameters were correlated with the vascular area / mm2 denoted 
by  a subdivision of the overall area by vessel area for all 34 samples and table 
provides an overview of the relationships. Only  PDThA significant correlation with the 
medium vessel size.
Table 8-7: Correlation matrix of synovial vascular indices and synovial vessel 
size (small, medium and large).
Synovial Vessel size Small Medium Large
VASCi 0.40 (0.08-0.77) 0.38 (-0.08-0.70) 0.36 (-0.10-0.69)
PDA 0.43 (0.19-0.73) 0.34 (-0.11-0.67) 0.16 (-0.29-0.55)
PDA / STA 0.40 (-0.05-0.71) 0.34 (-0.13-0.67) 0.12 (-0.33-0.53)
PDThA 0.03 (-0.41-0.45) 0.56 (0.15-0.80) § 0.05 (-0.38-0.47)
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8.5 Discussion
This study  demonstrates a clear relationship between US imaging, specifically  grey 
scale and doppler assessment of synovitis, and histological synovial vascularity. 
All patients within this cohort had active rheumatoid disease with a moderate to high 
DAS 28 score prior to biopsy and a knee which was clinically  involved allowing 
successful harvesting of synovial tissue. This work parallels previous work by 
Walther et. al. who similarly  examined the relationship of synovial vascularity  at the 
knee and power doppler ultrasound. However, this previous report examined patients 
with both OA and RA, and severe degenerative arthritis requiring knee joint 
arthroplasty. This study  differs significantly  in only including patients with early  RA, 
within 1 year of symptom onset and naive to immunosuppressant therapy. Patients 
received an US guided synovial biopsy to harvest tissue from the appropriate region 
of interest previously  recorded at the pre-procedure examination. The use of US as 
both the assessment tool and facilitator of tissue sampling strengthens the legitimacy 
of correlating synovial tissue and ultrasound assessment at each separate sampling 
site. 
As with previous reports, a significant correlation was found between the synovial 
vascularity on histological analysis for both the grey  scale assessment of synovial 
thickness and power doppler signal. Previous authors have used a qualitative 
analysis of tissue sections using a semi-quantitative 0-4 score which was 
subsequently  correlated with US parameters. In this study  we favored a quantitative 
approach to tissue assessment with the vascular area being scored using Digital 
Imaging Analysis (DIA). This has a number of advantages including scoring 
standardisation and providing a fractional vascular area assessment. This intuitively 
provides greater information  as to the vessel density within the synovium rather than 
an absolute area which may vary with tissue size. 
Both histological and ultrasound parameters showed no significant difference 
between regions of interest within each joint. Previous studies have examined the 
variability  of histological markers of synovitis such as sub-lining macrophages (SL-
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CD68) within joints and reported that there seems to be a degree of homogeneity. 
The US STA and PDA did reveal a higher average signal in the lateral compartment 
of the joint. Whilst this did not reach statistical significance, the small number of 
patients within this study  may  be under powered to detect a real difference. These 
findings should be explored in a larger cohort of patients. Correction for the PDA by 
STA expressed as a fraction also remains relatively constant thought out the joint and 
may be a more appropriate measure of synovial blood flow. A similar trend was seen 
with the histological vascular area measurement but again did not reach statistical 
significance. The angiogenic factors and pro-inflammatory  cytokines did not show 
and difference when measured in different compartments.
In addition to synovial vascular area, blood vessel number was also assessed with 
DIA within all compartments. Both these variables correlated well with PDA, PDThA 
and PDA / STA (0.73, 0.66 and 0.77 respectively). Blood vessel number only  showed 
a moderate correlation with the US vascular parameters and, unlike synovial 
vascular area, gave no significant correlation with STA or VASCi. The blood vessel 
size and overall vascular area would appear to be an important factor in synovial 
expansion rather than the vessel number. Figure xxx, shows the percentage of small 
medium and large vessels. Medium size vessels clearly  make the greatest 
contribution (79%) to the vascular area score, representing more developed and a 
relatively  stable vasculature. A correlation with a number of angiogenic and pro-
inflammatory cytokines was detected (TNF- a, IL-1b, Ang 2, VEGFa and VEGFr3) but 
not with IL-6 or Ang 1. The positive correlation with VEGFa, Ang2 but not Ang1 with 
synovial vascular area and PDA may indicate a profile of synovial tissue underoing 
neovascularisation. In tumors, the over expression of VEGFa and Ang2 has a 
positive effect of growth whilst Ang1 over expression reduces tumor expansion.  Ang 
1 has a stabalising effect on new vessels and is required for vascular maturity. Within 
an inflammed joint, the synovial expansion would require the rapid expansion of a 
suitable vascular network. Up regulation of VEGFa and Ang2 in this context would 
appear to be an important factor. It would be important to to examine these 
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relationships longitudinally  and determine if this profile alters in favour of Ang1 
expression in a quiescent joint in a patient in remission.
A positive correlation is also seen with US parameters and these mediators. PDA and 
STA correlate with all factors assessed except for Ang1. STA provided a good 
correlation with Ang 2, IL-6, IL-1b and TNF-α and moderate correlation with VEGFa, 
VEGFc and VEGFr3. VEGFc and its receptor VEGFr3 are known to be important 
lymphogeneic factors and their association with STA and PDA may suggest that this 
process is seen within an expanding, inflamed synovium. However, a report from 
Polzer et. al. suggested that lymphangiogenesis was encouraged following treatment 
of humans with anti-TNF α with a greater expression of lymphatic vessels in synovial 
tissue when examining pre and post treatment synovial tissue. The expression of of 
VEGFc and VEGF-R3 were not specifically commented upon in this study.
The relationship of STA and IL-6, IL-1b and TNF-α may have a number of potential 
explanations. These pro-inflammatory cytokines have a number of functions such as 
chemoattractants, up-regulating of endothelial adhesion molecules and increasing 
vascular permeability. STA was previously  shown to be a good parameter in chapter 
5 with a considerable effect size in detecting response to therapy. Synovium, as 
imaged by  US, consists of a number of components. Hypertrophy  of the lining layer 
and infiltration of the sub-lining can be seen histologically, however complete 
resolution of these histological finding are insufficient to explain the magnitude of 
change which can be detected on US examination. In established synovitis, 
synovium is often necrotic on histological examination, or shows marked fatty 
infiltration and fibrosis. These components may be susceptible to fluid shifts and a 
reduction in vascular permeability, lead by  a down regulation of pro-inflammatory 
cytokines expression. 
The US assessment of vascularity  correlates well with the synovial vascular area and 
the mediators of angiogenesis. A moderate correlation is seen between PDThA and 
the synovial vascular area. In addition, PDThA  correlated with medium vessel size 
which in the major contributor to total vascular area. This correlation is also seen with 
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TNF-α and IL1-β expression which may  suggest that the intensity of the doppler 
signal detected on US examination relates to not only  the vascular density  of the 
synovium but also to vasoactive mediators exerting afferent vascular control. Power 
doppler signal and synovial area measurement changes can be detected within 
24hrs of treatment (chapter 5). Neoangiogenesis and vascular regression are 
processes which are unlikely  to contribute significantly  to US PDS changes within 
such a short time frame. A more likely  explanation is again the effects of vasoactive 
mediators and their down regulation. Significant reduction vascular signal can be 
seen on cooling hands by  only  a few degrees (chapter 4). Therefore, the earliest 
change in doppler signal in treated patients is likely  to be due to afferent vessel 
control rather than vessel regression. 
8.6 Conclusion
Power doppler ultrasound assessment of synovitis in patients with early  RA is a valid 
measure of synovial vascularity and shows a positive relationship  with the expression 
of pro-inflammatory  cytokines and angiogenic factors. Quantitative and qualitative 
measures (VASCi, PDA) correlate with synovial vascular area. Grey  scale US 
assessment of synovial thickening also has a close relationship  to vascular area and 
angiogenic factors. There is a degree of homogeneity  between synovial regions 
within the supra patella pouch which would suggest that a single region of interest 
may be representative both histologically and ultrasonographically.
Angiogenic mediators fluctuate during different phases of vessel development and 
maturation. Inflammatory cytokines, such as TNF-α, vary depending upon the 
disease activity within the joint. The interplay  between these factors and the synovial 
vasculature is complex with different cytokines having various effects depending 
upon co-expression of other mediators. Therefore a single snap shot of the 
angiogenic profile in this context is very difficult to interrupt with certainty.  The 
relationship of synovial vascularity, angiogenic factors and power doppler ultrasound 
imaging can only  be dissected further with serial assessments before and after 
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therapy. Specifically, the next step is to ask if following effective treatment, PDS 
reduction occurs independently  from vascular remodeling or is directly related to 
down regulation of cytokine networks.
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9. General Summary
Ultrasound imaging has an important role to play  in the modern Rheumatology 
department. Ultrasound is a relatively  inexpensive and portable imaging modality 
which can add important diagnostic and prognostic information for Rheumatologists 
in daily  practice. The initial use of ultrasound imaging in routine care was directed 
primarily  towards soft tissue lesions, muscle pathology and tendonopathy  however its 
use in inflammatory  arthritis has grown over the past 20 years along side the 
technological improvements which have produced high quality  images for 
interpretation. The OMERACT - ultrasound group have made significant steps in 
validating ultrasound imaging in this context. Despite this many  questions remain and 
require further evaluation. The two central themes of this thesis are the 
responsiveness of ultrasound imaging and the correlation between ultrasonographic 
findings and the histomorphological characteristics of the synovial tissue being 
imaged. In addition, an important on going debate continues over the most 
appropriate ultrasound data set. Therefore in this thesis I focus on a limited US joint 
data set to include 10 metacarpal-phalengeal joints (MCPJ) in an attempt to 
demonstrate that a relatively  small data set can provide addition information over 
currently  existing clinical assessment tools such as the DAS28. The incorporation of 
3D imaging into a number of the studies reflects the continued technological 
development with potential benefits for the ultrasonographer. 
Whilst an assessment tool can be a valid measure of a particular construct, if it is not 
consistent or reliable then implementation as a useful clinical test is problematic. 
Conversely, a reliable tool is not necessarily a valid one. This provides the starting 
point for this thesis. Previous authors have reported good to excellent agreement in a 
number of different settings202-207. Naredo specifically   reported the reliability of US 
imagining for MCP joint US scoring (Kappa 0.88) and demonstrated that this was 
superior to clinical assessment in detecting synovitis112. However, ultrasound imaging 
is unusual by having two clear levels of variability  - variation when the image is 
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acquired and when it is read. In order to examine these two aspects to ultrasound 
reporting myself and colleague (MS) performed multiple US assessments at various 
stages of a multi centred, randomised controlled clinical trial. All endpoints were 
examined in 10 MCPJ and included vascular and synovial thickness assessments. 
Qualitative and quantitative scores were used and agreement calculated using the 
interclass correlation co-efficient at baseline and at the end of study  (DAY 14) with all 
2D scans being performed in both a longitudinal and transverse orientation..
I am able to report that:
1. 2D vascular endpoints show excellent within scan inter-reader and parallel scan 
inter-reader and intra-reader reliability at both baseline and DAY 14.
2. 2D synovial thickness endpoints show good within scan inter-reader parallel scan 
intra-reader reliability  but poor parallel scan inter-reader reliability  for the 
transverse synovial thickness index score.
3. 3D endpoints perform well and are consistent at baseline and at DAY 14 except 
for the vascular index score parallel scan intra-reader reliability.
This reliability study  provides conformation that, as a limited joint US data set, the 10 
MCP joints are able to be scored consistently  both in 2D and 3D US imaging. The 
reproduction of this study  on 2 sites provides evidence that a well defined US 
assessment of a limited joint set may  be used in the context of a multi centered 
clinical trial.
My next aim was to establish if this limited data set was responsive to change. To this 
end I used both a physiological (cryotherapy) and pharmacological (Prednisolone) 
triggers to initiate this change. Cryotherapy  provides a convenient, inexpensive and 
a relatively  safe stimulus causing peripheral vasospasm. This allows many  of the 
vascular US endpoints to be examined in a safe in vivo setting. Once again the 10 
MCP joints were assessed both by 2D and 3D imaging. I can report that following 
cryotherapy:
1. All the vascular endpoints (2D and 3D) demonstrated a significant change.
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2. There was good correlation between 2D and 3D vascular endpoints including 3D 
topographical imaging endpoint.
3. 2D US vascular endpoints showed the greatest response to change 
All of the endpoints failed to return to pre-cooling levels 15mins after removal of the 
stimulus which would suggest that thermoregulation in an important factor which 
should be bourn in mind when integrating US imaging into therapeutic study design. 
Within this model, the ability  of 2D and 3D US parameters to detect change in 
synovial vascular flow over a relatively  short period of time can be demonstrated. The 
vascular index scores used over 10 MCP joints would seem to be both responsive 
and reliable.
Having shown that this limited US joint count responds to cryotherapy, I examined 
the ability  of this same data set to detect change in patients with active RA over a 14 
day period. Patients were prescribed either Prednisolone or Placebo and ultrasound 
assessments made at baseline, DAY 1, 7 and 14. This study  consisted of two panels. 
Panel A used Prednisolone at 15mg per day  were as Panel B used 7.5mg per day. 
This attempted to demonstrate a dose response with US endpoints. The qualitative 
transverse synovial PDS over 10 MCP joints was chosen as the primary  endpoint 
with all other synovial thickness and vascular qualitative and quantitative scores as 
secondary  end points. All patients received a clinical assessment of disease activity 
(DAS28). Within Panel A:
1. The 10MCP Trans VASCi score showed a significant treatment effect at DAY 14 
compared to placebo.
2. All 2D secondary  endpoints showed a significant treatment effect compared to 
placebo at DAY 14 except for transverse synovial thickness index (Trans STi)
3. All of the 3D endpoints produced numerically  smaller effect sizes which did not 
reach significance.
Within Panel B:
1. The primary  endpoint demonstrated a statistically  significant treatment effect at 
DAY 7 but not 14.
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2. Longitudinal 2D synovial thickness index showed a significant treatment effect at 
DAY 7 and DAY 14.
Using a composite endpoint consisting of the DAS28(CRP)+Long STi+Trans VASCi a 
significant effect size was demonstrated in both panel A and B with a suggestion that 
a dose effect could be demonstrated. 
This provides a good evidence that this limited joint US data set is responsive and 
has utility  over and above standard clinical assessments of disease activity. 
Prednisolone provides a very  demonstrable change in disease activity. However, it 
remains to be proven that similar effect sizes can be reproduced within different 
clinical settings such as following DMARDS or Biologic agents. 
There is good evidence that ultrasound assessment of joints provides greater 
evidence of pathology  than clinical assessment alone. I was also able to show that in 
this clinical trial the change in US variables were superior to the change in the 
DAS28(CRP) assessment. Whilst the DAS28 score has demonstrated value in many 
clinical situations there is evidence that some patients continue to have subclinical 
inflammation and erosive progression on x-rays despite having a low DAS28 score. 
This leads to the next aim of my  thesis. If US assessment of joint synovitis is much 
more sensitive than clinical examination, and a more faithfully  assessment of 
synovial inflammation - what are the histopathological correlates with these imaging 
findings. In order to facilitate this aspect of the thesis I developed a ultrasound 
guided synovial biopsy  technique which would provide tissue for analysis. The use of 
arthroscopy  to harvest synovial tissue is well established however there are 
limitations with larger joints being more easily  accessed, the cost of day surgical 
office space and relative patient discomfort when performed under local anesthetic. 
Using a Quick core biopsy  needle I was able perform sampling on both small and 
large joints. In a cohort of 57 patients (93 consecutive biopsies) I examined the 
safety, tolerability and quality of tissue harvested. I can report:
1. Using an Ultrasound guided synovial biopsy  technique for sampling synovial 
tissue is both safe and well tolerated by patients.
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2. There is no significant impact on joint tenderness, swelling or pain following the 
procedure.
3. Good quality tissue can be harvested form both small and large joints.
4. The quality  of the synovial tissue recovered in terms of RNA yield and tissue 
grading varies according to the pre-βiopsy  ultrasound assessment synovial 
thickness score.
Using regressional analysis I have produced a suggested algorithm to inform the 
decision process as to choosing the optimal joint for biopsy  based upon both size 
and synovial thickness score on US. The ability to acquire tissue form both small and 
large joints for suitable immunohistochemical analysis was imperative if I was able to 
examine the histopathological correlation a a limited small joint US data set.
Using a cohort of patients with both established and early RA (less than 1 year of 
symptom duration) I performed synovial biopsies prior to treatment initiation and after 
treatment. The wrist and MCP joints were most often biopsied. Histological 
assessment of the tissue was based upon a recognized scoring system developed 
by  Krenn and immunohistochemical analysis of known inflammatory  cells such as  B 
cells, plasma cells, lymphocytes and macrophages. 
At the single joint level a good correlation was seen with many  histological variables 
associated with joint inflammation, such as the CD68+ macrophage sublining cells, 
CD20 B cells and CD138 plasma cells and CD3+ lymphocytes with both PDS and 
synovial thickness. CD68+ macrophages appear to correlate best with the 
quantitative assessment of PDS (Spearmans rank r=0.84, p<0.001). Using both 
cohorts I was able to demonstrate that:
1. At a single joint level the positive predictive value for the presence of CD68SL 
macrophages in patients with a significant PDS was 0.96 with a negative 
predictive value of 0.8 in the absence of any signal.
2. Both vascular and synovial thickness ultrasound scores in 10 MCP joints correlate 
with the Krenn synovitis score and CD68+ sublining macrophages in both early 
and established RA patients.
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3. Histomorphological charcterisation by  the absence or presence of geminal center 
like structures within the synovium provides a dichotomous population. Patients 
with histomorphologically  defined Grade 2 / 3 germinal centers have significantly 
more US PDS and synovial thickening.
4. Using an extend joint count to include 10MCP joints + 2 wrists shows a closer 
relationship with histological and US variables in both cohorts, than 10MCP joints 
alone. 
5. The change in DAS28 correlates with the change in US PDS and ST scores for 
both the 10MCP joint limited US data set and 12 joint MCP + 2 Wrists US data set.
This provides concurrent validity  of US assessment of synovitis at both a single joint 
level and for an extended joint count. The 10MCP joint set does correlate with 
synovial markers of inflammation but an extend joint count does appear to perform 
better. This is likely  to in part reflect a predominance of wrist joints biopsied as the 
correlation with US parameters was superior when examined at the single joint level. 
The moderate correlation in the change in DAS28 and US parameters confirms that 
both assessments are likely  to measure different constructs and that there may  be 
additional benefit to incorporating them into a single score.
Given that US parameters correlate with histological defined synovial inflammation, it 
is important to examine the relationship with synovial vascularity  as PDS is the de 
facto result of synovial blood flow. Previous authors have examined this relationship 
macroscopically  with only one report of histologically  confirmed synovial vascular 
area being correlated with US PDS. I proposed, using the minimally  invasive US 
guided synovial biopsy technique, to explore this relationship in more depth. I harvest 
tissue from 13 knee joints in patients with early  RA. Using US guidance I was able to 
perform the biopsy  procedure in 3 distinct areas within the supra-patella pouch 
(medial, middle and lateral). The synovial tissue was analysed for synovial vascular 
area and vessel size. In addition gene expression analysis examined the levels of a 
number of pro-αngiogenic and lymphangiogenic molecules. In this limited cohort of 
13 patients I was able to show:
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1. There is a close relationship  between synovial vascular area and both US PDS 
and ST area.
2. US PDS and ST correlate with angiogenic and lymphangiogenic gene expression.
This provides further validity  to the use of US to access synovial blood flow and that 
the presence of PDS on US examination reflects an underlying synovial environment 
in which neoangiogenesis can occur.
Whilst many  aspects of US imaging have previously  been validated, a discreet US 
joint data set is a valuable addition to the Rheumatologist in both clinical practice and 
the research setting. This thesis provides a supportive body  of work which would 
suggest that a limited US data set of 10MCP joints may  have utility  in particular 
patient cohorts. The data set is reliable, responsive and correlates with synovial 
histological markers of neovascularisation and inflammation. Further work is required 
to address whether this data set has prognostic significance in terms of patients 
function and joint damage. Whether it shows the same responsiveness with different 
pharmacotherapies, including biologics, remains to be seen. Perhaps more 
importantly  is whether such a US joint data set can be incorporated easily  into the 
routine clinical care of patients with RA. Provided the information gleaned from this 
assessment is robust and meaningful then it is likely  that such an investigation will 
slowly be incorporated in to the routine care of patients with RA. The use of this tool 
in other inflammatory  arthropathies and patients presenting with an undifferentiated 
arthritis remains to be seen.
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Appendix
Ultrasound manual
MCP, Wrist and knee joint assessment©
US System and Probes
System:!GE!Logiq!9
Probes:!4D16L!/!2D!M12L
For the purposes of this study, all patients will be imaged using the GE logiq 9, 
ultrasound system and the 4D16L / 2D M12L Probes, which will allow  both 2D and 
3D image collection. Software version 7.05.
! ! !!! !
Figure!1:!GE!Logiq!9!6!so8ware!version!7.05!/!4D16L!Probe!/!2D!M12L!Probe
The the 2D M12L Probe will be used to collect 2D images of both the MCP and wrist 
joints. The 4D16L Probe will be used for collection of 3D images from MCP and wrist 
joints. 
Data Input
Data required for registration of patient details for the study prior to scanning.
• Centre and study name is pre-entered
• BLT -Mile End (St Barts and The Royal London - Mile End Hospital) / Study - xxxxxxx
• Operator initials - SK (Stephen Kelly) - pre-entered
• Date of Birth - DD/MM/YYYY
• Unique number - This will consist of the date and time of examination as shown e.g. 10th 
November 2008 at 14:30 (101108-1430) %
• Study number
258
When complete the data can be stored by pressing Register. To commence scanning, press 
the freeze button
Imaged joints - 2D assessment
2D M12L Probe settings will be pre-set and activated when the M12L Probe is 
selected in the touch screen menu. Still Grey scale images and cine clip Power 
Doppler signal images will be recorded for each scanning position and joint. 
Labelling
Labeling for 2D images - MCP / Wrist joints/ Supra patella pouch (SPP)/ knee joint 
line (Jt line)
Med - Medial, Lat- Lateral, Mid - middle
Lateralising+ Joint+ Digit+Number+or+loca4on+ Plane+
RT! MCP!! 165! LONG!(Longitudinal)
LT! Wrist! Mid! TRAN!(Transverse)
! Knee!SPP! Med!
! Knee!Jt!line ! Lat
Example:!
RT!MCP!2!LONG
RT!Knee!SPP!Mid
LT!Wrist!Mid
Recording Grey scale still images and PDS cine loops
Grey scale images will be recorded by:
Select the appropriate Pre-Set for either MCP or Wrist
Acquire the desired image using the 2D M12L Probe
Label the image appropriately
Whilst settled on this image Press Freeze
Press P1
Image will be stored to the machine hard drive
PDS cine clip will be recorded by:
Select the appropriate Pre-Set for either MCP or Wrist
Acquire the desired image using the 2D M12L Probe.
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Label the image appropriately
Activate the PDS mode by pressing the PDS button. This should provide a 
region of interest the size of the monitor window. 
Whilst settled on this image for 3 seconds, Press P1
The cine loop of 3 seconds will be stored to the machine hard drive
Probe positions - 2D
Metacarpal-phalengeal Joints (MCPJ) - This assessment will be performed in both 
Longitudinal and Transverse planes from the dorsal aspect of the joint.
MCP joints will be imaged within a molded splint to restrict movement. Longitudinal 
images will require the extensor tendon to be present and should bisect the joint. 
Transverse images will require the joint margin to be seen within the middle of the 
US image. 
! !
Figure!2:!Longitudinal!posiUon!for!MCP! Figure!3:!Transverse!view!for!MCP!
joints! ! ! ! ! ! joints
Wrist - The wrist images are acquired in 3 positions. The radial and ulnar aspects of 
the joint are imaged in a longitudinal plane. A mid position is chosen to include the 
distal radius, lunate, capitate and metacarpal bone. There are 2 synovial recesses 
which are often apparent in these positions.
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Knee - Positioning of the patient: the patient should be placed on the bed with the 
knee in 30o of flexion. A pillow may  be used to support the patient’s knee in this 
position. Use the coupling gel at 20oC. Imagine supra-patella pouch / medial and 
lateral joint lines as describe below. A single Grey  scale and PDU cine loop will be 
recorded for each position.
Probe position:
Fig 4: Probe position for imaging the supra-patella pouch in longitudinal section
Medial and lateral joint line
Probe position: the probe should be placed transversely across the joint line a
Probe position:
  
   
Fig 5: Transverse probe position   Fig 6: Transverse probe position for
for medial joint line     lateral joint line
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Imaged joints - 3D assessment
A 3-dimensional image will be generated for MCP and wrist joints. A total of 12 
images will be acquired at each visit. These will be used to explore the response to 
change and quantify  erosions volumetrically. To reconstruct a 3D vascular signal from 
the probe sweep the PDS will have to be selected in conjunction with the 3D settings.
Labeling
There is no requirement for directional information in the labeling of these images. 
The convention below should be followed
Right+or+Le8+ + Joint+ + Digit+Number+if+applicable
LT! ! ! MCP! ! 165
RT! ! ! WRIST
Example:!LT!MCP!5
Recording a 3D images of MCP and Wrist joints
Recording 3D images - MCP joints
Select the 4D16L Probe on the touch screen menu
Select 3DMCP on the PRESET menu
Select the PDU button
Select 3D/4D button
Label the probe appropriately
Position the probe transversely across the MCP joint as seen in figure 7.
Press the left view button and hold the probe steady.
Once the 10 second probe sweep has finished review the image and press P1 
to save.
Recording 3D images - Wrist joints
Select the 4D16L Probe on the touch screen menu
Select 3D wrist on the PRESET menu
Select the PDU button
Select 3D/4D button
Position the probe transversely across the wrist.
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Press the left view button and hold the probe steady.
Once the 10 second probe sweep has finished review the image and press P1 
to save.
Probe positions - 3D
Metacarpal1phalengeal5Joints5(MCPJ)515This5assessment5was5performed5in5a5
Transverse5plane.
MCP joints will be imaged within a molded splint to restrict movement. The Probe will 
be orientated transversely  and the internal sweep passing distal to 
proximal.% %
! !
Figure!7.!PosiUoning!of!probe!for!3D!!! ! Figure!8.!Quad!view!of!3D!image!
imaging!(MCP)!reconstrucUon!
Wrists515This5assessment5will5be5performed5in5a5transverse5plane
The Wrist joint will be imaged with the hand in prone position and the elbow leaning 
on the table for stability. The Probe will be orientated transversely  and the internal 
sweep passing distal to proximal. The mid line starting position should be at the 
scaphoid lunate junction.
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!
Figure!9.!PosiUoning!of!probe!for!3D!imaging!(Wrist)
Scoring US images
MCP Synovial Thickness index - STi 
Synovial!thickness!will!be!scored!on!a!5!point!score!(064).!This!assessment!will!be!
based!upon!standard!images!below!for!both!Longitudinal!and!Transverse!images.
0= normal, 1= minimal, 2= mild , 3= moderate, 4= severe 
Longitudinal STi 
! ! 0! ! ! !!!!!!!!!!!!!1! ! ! !!!!!!!!!2
      
! ! !!3! ! ! ! !!!!!!!4
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Transverse STi
! ! 0! ! ! ! !!!1! ! ! ! !2
      
  
  3    4 
  
MCP Vascular index - VASCi
Synovial!vascularity!will!be!scored!on!a!5!point!score!(064).!This!assessment!will!be!
based!upon!standard!images!below!for!both!Longitudinal!and!Transverse!images.
0= normal, 1= minimal, 2= mild , 3= moderate, 4= severe 
Longitudinal VASCi
  0       1    2
    
  3     4
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Transverse VASCi
  0        1      2
    
  
  3    4
  
Quantitative assessment of 2D PDS
Each!2D!Power!Doppler!image!will!be!analysed!using!Image!J!so8ware403.!This!allows!
the!idenUﬁcaUon!of!the!maximal!signal!intensity!of!the!2D!cine!clip!and!by!binary!
thresholding!the!Doppler!signal!against!the!grey!scale!background!its!is!possible!to!
calculate!the!pixel!number!on!each!slice.!This!data!will!be!recorded!in!an!excel!
spreadsheet!for!analysis.
Out6put!measures:
Pixel!Number
Synovial!Area
Pixel!Intensity
!!!A)!Origninal!US!image! !!!B)!Binary!image! C)!Outlined!Image
Figure!12!showing!the!A)!original,!B)!binary!and!C)!outlined!images!produced!from!the!Image!
J!analysis!so8ware
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3D MCP VASCi
Three!dimensional!synovial!vascularity!will!be!scored!on!a!5!point!score!(064).!This!
assessment!will!be!based!upon!standard!images!below!for!both!Longitudinal!and!
Transverse!images.
0= normal, 1= minimal, 2= mild , 3= moderate, 4= severe
! ! ! 0! ! ! ! ! ! 1
!!
! ! ! 2! ! ! ! ! !!!!!!!!!!!!!!!3!
!!
! ! ! !4
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Probe settings
Theses!are!the!sedngs!for!both!M12L!and!16L!probes.!These!are!pre6!recorded!and!
stored!in!the!Logiq!9.!They!can!be!retrieved!by!selecUng!the!appropriate!sedng!on!
the!touch!screen!display!a8er!selecUng!the!preset!icon!on!the!top!right!of!the!
display.
2D M12L 2D settings (Wrist and MCP)
Gray+Scale++ + + + + Power+Doppler+mode+
Frequency!12MHz!! ! ! ! Frequency!7.5!MHz
Gain!50!! ! ! ! ! Gain!45
Depth!2.0cm!! ! ! ! ! PRF!1.4kHz
Frame!Rate!24!! ! ! ! WF!127Hz
CrossBeam#!6!Low!! ! ! ! S/P!1/14
Virtual!Convex!! ! ! ! L/A!3/5
SRI!HD!–!2!! ! ! ! ! AcousUc!Output!100%
RejecUon!–!0!! ! ! ! ! Cross!Beam!Oﬀ
Edge!Enhance!–!2!! ! ! ! Middle!Focus!PosiUon!
Frame!Average!–!1!! ! ! ! Flash!suppression!1
Colorize!–!Tint!Map!D
Gray!Map!–!Gray!Map!D
RotaUon!–!Up
Frequency!–!14!MHz
Line!Density!–!3
Dynamic!Range!–!66!dB
2D probe (M12L) settings: KNEE
Gray scale
Frequency 14MHz
Gain 50
Depth 3.5cm
Frame Rate 24
Power Doppler mode 
Frequency 7.5 MHz
Gain 46
PRF 1.4kHz
WF 127Hz
S/P 1/14
L/A 3/5
Acoustic Output 100%
Cross Beam Off
Middle Focus Position 
Flash suppression 1
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4D16L Probe  3D Settings
Gray+Scale++ + + + + Power+Doppler+Mode
CrossBeam#!6!Low!! ! ! ! Frequency!7.5!MHz
Virtual!Convex!! ! ! ! Gain!45
SRI!HD!–!2!! ! ! ! ! PRF!0.9!kHz!
RejecUon!–!0! ! ! ! ! WF=!110Hz!
Edge!Enhance!–!2! ! ! ! S/P!1/14
Frame!Average!–!1! ! ! ! L/A!2/5
Colorize!–!Tint!Map!D!! ! ! AcousUc!Output!100%
Gray!Map!–!Gray!Map!D! ! ! Cross!Beam!On!
RotaUon!–!Up! ! ! ! ! Power!DI!Oﬀ
Frequency!–!15!MHz! ! ! ! Frame!average=!5
Line!Density!–!4!! ! ! ! Flash!suppression!=!2
Dynamic!Range!–!66!dB!! ! ! Quality!Hi!2
Frequency!15MHz!! ! ! ! Volume!Angle!19
Gain!50
Depth!2.0cm
Frame!Rate!26
269
Bibliography
1. Silman AJ. Epidemiology of rheumatoid arthritis. Apmis 1994;102(10):721-8.
2. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of 
treating rheumatoid arthritis: results after 20 years. Lancet 1987;1(8542):
1108-11.
3. Alessandri C, Priori R, Modesti M, Mancini R, Valesini G. The role of anti-
cyclic cytrullinate antibodies testing in rheumatoid arthritis. Clin Rev Allergy 
Immunol 2008;34(1):45-9.
4. Vane JR. The fight against rheumatism: from willow bark to COX-1 sparing 
drugs. J Physiol Pharmacol 2000;51(4 Pt 1):573-86.
5. Pasero G. The treatment of rheumatoid arthritis in this century: from spas to 
monoclonal antibodies. Clinical and experimental rheumatology 1997;15 
Suppl 17:S67-70.
6. Boers M. The COBRA trial 20 years later. Clin Exp Rheumatol 2011;29(5 
Suppl 68):S46-51.
7. Mottonen TT, Hannonen PJ, Boers M. Combination DMARD therapy including 
corticosteroids in early rheumatoid arthritis. Clinical and experimental 
rheumatology 1999;17(6 Suppl 18):S59-65.
8. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the 
treatment of rheumatoid arthritis: efficacy and feasibility. Annals of the 
rheumatic diseases 2007;66 Suppl 3:iii56-60.
9. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, 
Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four 
different treatment strategies in patients with early rheumatoid arthritis (the 
BeSt study): A randomized, controlled trial. Arthritis Rheum 2008;58(2 
Suppl):S126-35.
10. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela 
M, et al. Comparison of combination therapy with single-drug therapy in early 
rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 
1999;353(9164):1568-73.
11. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter 
Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid 
arthritis: aiming for remission. Computer Assisted Management in Early 
Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the 
rheumatic diseases 2007;66(11):1443-9.
12. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, et 
al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A 
reappraisal. Autoimmun Rev 2008.
13. Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo-Repo M, 
Laasonen L, et al. Sustained remission and reduced radiographic 
progression with combination disease modifying antirheumatic drugs in early 
rheumatoid arthritis. The Journal of rheumatology 2007;34(2):316-21.
14. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, 
Dijkmans BA. Aiming at low disease activity in rheumatoid arthritis with initial 
combination therapy or initial monotherapy strategies: the BeSt study. Clinical 
and experimental rheumatology 2006;24(6 Suppl 43):S-77-82.
15. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, 
Hakala M, et al. Retardation of joint damage in patients with early rheumatoid 
arthritis by initial aggressive treatment with disease-modifying antirheumatic 
drugs: five-year experience from the FIN-RACo study. Arthritis and 
rheumatism 2004;50(7):2072-81.
16. Borg G, Allander E, Berg E, Brodin U, From A, Trang L. Auranofin treatment 
in early rheumatoid arthritis may postpone early retirement. Results from a 2-
year double blind trial. The Journal of rheumatology 1991;18(7):1015-20.
270
17. March L, Lapsley H. What are the costs to society and the potential benefits 
from the effective management of early rheumatoid arthritis? Best practice & 
research 2001;15(1):171-85.
18. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, et al. How does 
functional disability in early rheumatoid arthritis (RA) affect patients and their 
lives? Results of 5 years of follow-up in 732 patients from the Early RA Study 
(ERAS). Rheumatology (Oxford, England) 2000;39(6):603-11.
19. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose 
rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. 
Arthritis and rheumatism 2002;46(2):357-65.
20. Schumacher HR, Pessler F, Chen LX. Diagnosing early rheumatoid arthritis 
(RA). What are the problems and opportunities? Clinical and experimental 
rheumatology 2003;21(5 Suppl 31):S15-9.
21. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys 
PE, Kerstens PJ, et al. A matrix risk model for the prediction of rapid 
radiographic progression in patients with rheumatoid arthritis receiving 
different dynamic treatment strategies: post hoc analyses from the BeSt 
study. Annals of the rheumatic diseases 2010;69(7):1333-7.
22. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical 
synovitis in an early arthritis clinic. British journal of rheumatology 1993;32(2):
97-103.
23. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA. The prognosis of 
rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a 
study of 1141 patients. The Journal of rheumatology 1993;20(12):2005-9.
24. Symmons D, Harrison B. Early inflammatory polyarthritis: results from the 
norfolk arthritis register with a review of the literature. I. Risk factors for the 
development of inflammatory polyarthritis and rheumatoid arthritis. 
Rheumatology (Oxford, England) 2000;39(8):835-43.
25. El Miedany Y, Youssef S, Mehanna AN, El Gaafary M. Development of a 
scoring system for assessment of outcome of early undifferentiated 
inflammatory synovitis. Joint Bone Spine 2008;75(2):155-62.
26. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid 
arthritis. Best practice & research 2006;20(5):849-63.
27. Bunn DK, Shepstone L, Galpin LM, Wiles NJ, Symmons DP. The NOAR 
Damaged Joint Count (NOAR-DJC): a clinical measure for assessing articular 
damage in patients with early inflammatory polyarthritis including rheumatoid 
arthritis. Rheumatology (Oxford, England) 2004;43(12):1519-25.
28. van der Helm-Vanmil AH, le Cessie S, van Dongen H, Breedveld FC, Toes 
RE, Huizinga TW. A prediction rule for disease outcome in patients with 
recent-onset undifferentiated arthritis: how to guide individual treatment 
decisions. Arthritis and rheumatism 2007;56(2):433-40.
29. Panchagnula R, Rajiv SR, Prakash J, Chandrashekara S, Suresh KP. Role of 
anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-
negative suspected rheumatoid arthritis: is it worthwhile to order the test? J 
Clin Rheumatol 2006;12(4):172-5.
30. Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H, et 
al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early 
rheumatoid arthritis. The Journal of rheumatology 2006;33(12):2390-7.
31. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, 
Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis 
antibodies recognizing a cyclic citrullinated peptide. Arthritis and rheumatism 
2000;43(1):155-63.
32. Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: 
association with severity of disease in established RA. Clinical rheumatology 
2007;26(2):201-4.
271
33. Machold KP, Stamm TA, Eberl GJ, Nell VK, Dunky A, Uffmann M, et al. Very 
recent onset arthritis--clinical, laboratory, and radiological findings during the 
first year of disease. The Journal of rheumatology 2002;29(11):2278-87.
34. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, et al. 
Independent associations of anti-cyclic citrullinated peptide antibodies and 
rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis 
Res Ther 2006;8(4):R128.
35. Ates A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic 
citrullinated peptide in patients with early arthritis. Clinical rheumatology 
2007;26(4):499-504.
36. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt 
RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic 
citrullinated peptide antibodies in early arthritis. The Journal of rheumatology 
2003;30(8):1691-5.
37. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, et al. 
Predictive value of antibodies to cyclic citrullinated peptide in patients with 
very early inflammatory arthritis. The Journal of rheumatology 2005;32(2):
231-8.
38. Harle P, Bongartz T, Scholmerich J, Muller-Ladner U, Straub RH. Predictive 
and potentially predictive factors in early arthritis: a multidisciplinary 
approach. Rheumatology (Oxford, England) 2005;44(4):426-33.
39. Filer A, de Pablo P, Allen G, Nightingale P, Jordan A, Jobanputra P, et al. 
Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in 
patients with very early synovitis. Annals of the rheumatic diseases 
2011;70(3):500-7.
40. van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van 
Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage 
and physical disability in early rheumatoid arthritis. A prospective follow-up 
study of 147 patients. British journal of rheumatology 1992;31(8):519-25.
41. van der Heijde DM, van Riel PL, van Rijswijk MH, van de Putte LB. Influence 
of prognostic features on the final outcome in rheumatoid arthritis: a review of 
the literature. Seminars in arthritis and rheumatism 1988;17(4):284-92.
42. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating 
the efficacy of diagnostic tests. The New England journal of medicine 
1978;299(17):926-30.
43. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development 
of a disease activity score based on judgment in clinical practice by 
rheumatologists. The Journal of rheumatology 1993;20(3):579-81.
44. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Validity of 
single variables and indices to measure disease activity in rheumatoid 
arthritis. The Journal of rheumatology 1993;20(3):538-41.
45. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, 
van Riel PL. Development and validation of the European League Against 
Rheumatism response criteria for rheumatoid arthritis. Comparison with the 
preliminary American College of Rheumatology and the World Health 
Organization/International League Against Rheumatism Criteria. Arthritis and 
rheumatism 1996;39(1):34-40.
46. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, 
van Riel PL. Modified disease activity scores that include twenty-eight-joint 
counts. Development and validation in a prospective longitudinal study of 
patients with rheumatoid arthritis. Arthritis and rheumatism 1995;38(1):44-8.
47. Kuper HH, van Leeuwen MA, van Riel PL, Prevoo ML, Houtman PM, 
Lolkema WF, et al. Radiographic damage in large joints in early rheumatoid 
arthritis: relationship with radiographic damage in hands and feet, disease 
activity, and physical disability. Br J Rheumatol 1997;36(8):855-60.
48. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response 
criteria. Clinical and experimental rheumatology 2005;23(5 Suppl 39):S93-9.
272
49. Fransen J, van Riel PL. DAS remission cut points. Clinical and experimental 
rheumatology 2006;24(6 Suppl 43):S-29-32.
50. Fransen J, van Riel PL. Outcome measures in inflammatory rheumatic 
diseases. Arthritis research & therapy 2009;11(5):244.
51. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome 
in arthritis. Arthritis and rheumatism 1980;23(2):137-45.
52. Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Hetland ML. 
Health-related quality of life: validity, reliability, and responsiveness of SF-36, 
15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid 
arthritis. The Journal of rheumatology 2008;35(8):1528-37.
53. Esteve-Vives J, Batlle-Gualda E, Reig A. Spanish version of the Health 
Assessment Questionnaire: reliability, validity and transcultural equivalency. 
Grupo para la Adaptacion del HAQ a la Poblacion Espanola. The Journal of 
rheumatology 1993;20(12):2116-22.
54. Hewlett S, Smith AP, Kirwan JR. Measuring the meaning of disability in 
rheumatoid arthritis: the Personal Impact Health Assessment Questionnaire 
(PI HAQ). Annals of the rheumatic diseases 2002;61(11):986-93.
55. Thorsen H, Hansen TM, McKenna SP, Sorensen SF, Whalley D. Adaptation 
into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the 
Rheumatoid Arthritis Quality of Life Scale (RAQoL). Scand J Rheumatol 
2001;30(2):103-9.
56. van der Heijde DM, van Riel PL, van de Putte LB. Sensitivity of a Dutch 
Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. 
sulphasalazine. Scand J Rheumatol 1990;19(6):407-12.
57. Taccari E, Spadaro A, Rinaldi T, Riccieri V, Sensi F. Comparison of the 
Health Assessment Questionnaire and Arthritis Impact Measurement Scale in 
patients with psoriatic arthritis. Rev Rhum Engl Ed 1998;65(12):751-8.
58. Archenholtz B, Bjelle A. Reliability, validity, and sensitivity of a Swedish 
version of the revised and expanded Arthritis Impact Measurement Scales 
(AIMS2). The Journal of rheumatology 1997;24(7):1370-7.
59. Soderlin MK, Hakala M, Nieminen P. Anxiety and depression in a 
community-based rheumatoid arthritis population. Scand J Rheumatol 
2000;29(3):177-83.
60. Peck JR, Smith TW, Ward JR, Milano R. Disability and depression in 
rheumatoid arthritis. A multi-trait, multi-method investigation. Arthritis and 
rheumatism 1989;32(9):1100-6.
61. Houssien DA, McKenna SP, Scott DL. The Nottingham Health Profile as a 
measure of disease activity and outcome in rheumatoid arthritis. British 
journal of rheumatology 1997;36(1):69-73.
62. Wolfe F, Kong SX. Rasch analysis of the Western Ontario MacMaster 
questionnaire (WOMAC) in 2205 patients with osteoarthritis, rheumatoid 
arthritis, and fibromyalgia. Annals of the rheumatic diseases 1999;58(9):
563-8.
63. Hakkinen A, Kautiainen H, Hannonen P, Ylinen J, Arkela-Kautiainen M, 
Sokka T. Pain and joint mobility explain individual subdimensions of the health 
assessment questionnaire (HAQ) disability index in patients with rheumatoid 
arthritis. Annals of the rheumatic diseases 2005;64(1):59-63.
64. Sokka T, Kankainen A, Hannonen P. Scores for functional disability in 
patients with rheumatoid arthritis are correlated at higher levels with pain 
scores than with radiographic scores. Arthritis Rheum 2000;43(2):386-9.
65. Barrett EM, Scott DG, Wiles NJ, Symmons DP. The impact of rheumatoid 
arthritis on employment status in the early years of disease: a UK community-
based study. Rheumatology (Oxford, England) 2000;39(12):1403-9.
66. Fex E, Larsson BM, Nived K, Eberhardt K. Effect of rheumatoid arthritis on 
work status and social and leisure time activities in patients followed 8 years 
from onset. The Journal of rheumatology 1998;25(1):44-50.
273
67. Gillen M, Jewell SA, Faucett JA, Yelin E. Functional limitations and well-
being in injured municipal workers: a longitudinal study. J Occup Rehabil 
2004;14(2):89-105.
68. Rodgers M ED, Bojke L, et al. Southampton (UK): NIHR Evaluation, Trials 
and Studies Coordinating Centre (UK); http://www.hta.ac.uk/research/
HTAjournal. 2011.
69. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis 
and related conditions by standard reference films. Acta Radiol Diagn 
(Stockh) 1977;18(4):481-91.
70. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the 
progression of radiologic changes in rheumatoid arthritis. Correlation of 
radiologic, clinical and laboratory abnormalities. Arthritis and rheumatism 
1971;14(6):706-20.
71. van der Heijde D. How to read radiographs according to the Sharp/van der 
Heijde method. J Rheumatol 1999;26(3):743-5.
72. Landewe R, van der Heijde D. Radiographic progression in rheumatoid 
arthritis. Clinical and experimental rheumatology 2005;23(5 Suppl 39):S63-8.
73. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. 
Deciding on progression of joint damage in paired films of individual patients: 
smallest detectable difference or change. Annals of the rheumatic diseases 
2005;64(2):179-82.
74. Eder L, Chandran V, Gladman DD. Repair of Radiographic Joint Damage 
Following Treatment with Etanercept in Psoriatic Arthritis Is Demonstrable by 
3 Radiographic Methods. The Journal of rheumatology 2011.
75. van der Heijde D, Landewe R. Imaging: do erosions heal? Annals of the 
rheumatic diseases 2003;62 Suppl 2:ii10-2.
76. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van 
Riel PL, van de Putte LB, et al. Interrelationship of outcome measures and 
process variables in early rheumatoid arthritis. A comparison of radiologic 
damage, physical disability, joint counts, and acute phase reactants. The 
Journal of rheumatology 1994;21(3):425-9.
77. van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, van de 
Putte LB, et al. Individual relationship between progression of radiological 
damage and the acute phase response in early rheumatoid arthritis. Towards 
development of a decision support system. The Journal of rheumatology 
1997;24(1):20-7.
78. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der 
Linden S, et al. The relationship between disease activity and radiologic 
progression in patients with rheumatoid arthritis: a longitudinal analysis. 
Arthritis and rheumatism 2004;50(7):2082-93.
79. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The 
relationship between disease activity, joint destruction, and functional 
capacity over the course of rheumatoid arthritis. Arthritis and rheumatism 
2001;44(9):2009-17.
80. Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, Van Zeben D, Vos 
K, Breedveld FC, et al. Long-term outcome in rheumatoid arthritis: a simple 
algorithm of baseline parameters can predict radiographic damage, 
disability, and disease course at 12-year followup. Arthritis and rheumatism 
2002;47(4):383-90.
81. Drossaers-Bakker KW, Kroon HM, Zwinderman AH, Breedveld FC, Hazes 
JM. Radiographic damage of large joints in long-term rheumatoid arthritis and 
its relation to function. Rheumatology (Oxford, England) 2000;39(9):998-1003.
82. Backhaus M, Kamradt T, Sandrock D, Loreck D, Fritz J, Wolf KJ, et al. 
Arthritis of the finger joints: a comprehensive approach comparing 
conventional radiography, scintigraphy, ultrasound, and contrast-enhanced 
magnetic resonance imaging. Arthritis and rheumatism 1999;42(6):1232-45.
274
83. Benton N, Stewart N, Crabbe J, Robinson E, Yeoman S, McQueen FM. MRI 
of the wrist in early rheumatoid arthritis can be used to predict functional 
outcome at 6 years. Annals of the rheumatic diseases 2004;63(5):555-61.
84. Eshed I, Althoff CE, Schink T, Scheel AK, Schirmer C, Backhaus M, et al. 
Low-field MRI for assessing synovitis in patients with rheumatoid arthritis. 
Impact of Gd-DTPA dose on synovitis scoring. Scand J Rheumatol 
2006;35(4):277-82.
85. Ostendorf B, Peters R, Dann P, Becker A, Scherer A, Wedekind F, et al. 
Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal 
joints: sensitive detection of morphologic changes in rheumatoid arthritis. 
Arthritis Rheum 2001;44(11):2492-502.
86. Ostergaard M, Stoltenberg M, Lovgreen-Nielsen P, Volck B, Jensen CH, 
Lorenzen I. Magnetic resonance imaging-determined synovial membrane and 
joint effusion volumes in rheumatoid arthritis and osteoarthritis: comparison 
with the macroscopic and microscopic appearance of the synovium. Arthritis 
and rheumatism 1997;40(10):1856-67.
87. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An 
explanation for the apparent dissociation between clinical remission and 
continued structural deterioration in rheumatoid arthritis. Arthritis and 
rheumatism 2008;58(10):2958-67.
88. Boyesen P, Haavardsholm EA, Ostergaard M, van der Heijde D, Sesseng S, 
Kvien TK. MRI in early rheumatoid arthritis: synovitis and bone marrow 
oedema are independent predictors of subsequent radiographic progression. 
Annals of the rheumatic diseases 2011;70(3):428-33.
89. Hodgson R, Grainger A, O'Connor P, Barnes T, Connolly S, Moots R. 
Dynamic contrast enhanced MRI of bone marrow oedema in rheumatoid 
arthritis. Annals of the rheumatic diseases 2008;67(2):270-2.
90. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, 
Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized 
magnetic resonance imaging study comparing the effects of methotrexate 
alone, methotrexate in combination with infliximab, and methotrexate in 
combination with intravenous pulse methylprednisolone. Arthritis and 
rheumatism 2007;56(12):3919-27.
91. Dohn UM, Ejbjerg BJ, Hasselquist M, Narvestad E, Moller J, Thomsen HS, et 
al. Detection of bone erosions in rheumatoid arthritis wrist joints with magnetic 
resonance imaging, computed tomography and radiography. Arthritis 
research & therapy 2008;10(1):R25.
92. Dohn UM, Ejbjerg BJ, Hasselquist M, Narvestad E, Court-Payen M, 
Szkudlarek M, et al. Rheumatoid arthritis bone erosion volumes on CT and 
MRI: reliability and correlations with erosion scores on CT, MRI and 
radiography. Ann Rheum Dis 2007;66(10):1388-92.
93. Dohn UM, Ejbjerg B, Boonen A, Hetland ML, Hansen MS, Knudsen LS, et al. 
No overall progression and occasional repair of erosions despite persistent 
inflammation in adalimumab-treated rheumatoid arthritis patients: results from 
a longitudinal comparative MRI, ultrasonography, CT and radiography study. 
Annals of the rheumatic diseases 2011;70(2):252-8.
94. Duer-Jensen A, Vestergaard A, Dohn UM, Ejbjerg B, Hetland ML, Albrecht-
Beste E, et al. Detection of rheumatoid arthritis bone erosions by two different 
dedicated extremity MRI units and conventional radiography. Annals of the 
rheumatic diseases 2008;67(7):998-1003.
95. Bird P, Conaghan P, Ejbjerg B, McQueen F, Lassere M, Peterfy C, et al. The 
development of the EULAR-OMERACT rheumatoid arthritis MRI reference 
image atlas. Annals of the rheumatic diseases 2005;64 Suppl 1:i8-10.
96. Conaghan P, Bird P, Ejbjerg B, O'Connor P, Peterfy C, McQueen F, et al. 
The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the 
metacarpophalangeal joints. Annals of the rheumatic diseases 2005;64 Suppl 
1:i11-21.
275
97. Haavardsholm EA, Ostergaard M, Ejbjerg BJ, Kvan NP, Uhlig TA, Lilleas FG, 
et al. Reliability and sensitivity to change of the OMERACT rheumatoid 
arthritis magnetic resonance imaging score in a multireader, longitudinal 
setting. Arthritis and rheumatism 2005;52(12):3860-7.
98. Ostergaard M, Emery P, Conaghan PG, Fleischmann R, Hsia EC, Xu W, et 
al. Significant improvement in synovitis, osteitis, and bone erosion following 
golimumab and methotrexate combination therapy as compared with 
methotrexate alone: a magnetic resonance imaging study of 318 
methotrexate-naive rheumatoid arthritis patients. Arthritis and rheumatism 
2011;63(12):3712-22.
99. Hetland ML, Stengaard-Pedersen K, Junker P, Ostergaard M, Ejbjerg BJ, 
Jacobsen S, et al. Radiographic progression and remission rates in early 
rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic 
progression in the 5-year extension of the double-blind randomised 
CIMESTRA trial. Annals of the rheumatic diseases 2010;69(10):1789-95.
100. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, 
et al. Very early treatment with infliximab in addition to methotrexate in early, 
poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging 
evidence of synovitis and damage, with sustained benefit after infliximab 
withdrawal: results from a twelve-month randomized, double-blind, placebo-
controlled trial. Arthritis and rheumatism 2005;52(1):27-35.
101. Zikou AK, Argyropoulou MI, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, 
et al. Magnetic resonance imaging quantification of hand synovitis in patients 
with rheumatoid arthritis treated with adalimumab. The Journal of 
rheumatology 2006;33(2):219-23.
102. Freeston JE, Bird P, Conaghan PG. The role of MRI in rheumatoid arthritis: 
research and clinical issues. Current opinion in rheumatology 2009;21(2):
95-101.
103. Lee DN, Georgopoulos AP, Clark MJ, Craig CM, Port NL. Guiding contact 
by coupling the taus of gaps. Experimental brain research. Experimentelle 
Hirnforschung 2001;139(2):151-9.
104. Ashmead DW, R.; Eaton, S.; Ebinger, K.; Snook, H.; Mary, M., et al. 
Echolocation reconsidered: Using spatial variations in the ambient sound field 
to guide locomotion. Journal of Visual Impairment & Blindness 1998;92(9):
615.
105. Hughes B. Active artificial echolocation and the nonvisual perception of 
aperture passability. Human movement science 2001;20(4-5):371-400.
106. Ainslie MA. Principles of Sonar Performance Modelling. Springer 
2010:Page 10.
107. Grassi W, Filippucci E. Ultrasonography and the rheumatologist. Current 
opinion in rheumatology 2007;19(1):55-60.
108. Schmidt WA. Technology Insight: the role of color and power Doppler 
ultrasonography in rheumatology. Nat Clin Pract Rheumatol 2007;3(1):35-42; 
quiz 59.
109. Quaia E. Microbubble ultrasound contrast agents: an update. Eur Radiol 
2007;17(8):1995-2008.
110. Rees JD, Pilcher J, Heron C, Kiely PD. A comparison of clinical vs 
ultrasound determined synovitis in rheumatoid arthritis utilizing gray-scale, 
power Doppler and the intravenous microbubble contrast agent 'Sono-Vue'. 
Rheumatology (Oxford, England) 2007;46(3):454-9.
111. Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen T, 
Ostergaard M. Power Doppler ultrasonography for assessment of synovitis in 
the metacarpophalangeal joints of patients with rheumatoid arthritis: a 
comparison with dynamic magnetic resonance imaging. Arthritis and 
rheumatism 2001;44(9):2018-23.
112. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A. Assessment 
of inflammatory activity in rheumatoid arthritis: a comparative study of clinical 
276
evaluation with grey scale and power Doppler ultrasonography. Annals of the 
rheumatic diseases 2005;64(3):375-81.
113. Kiris A, Ozgocmen S, Kocakoc E, Ardicoglu O. Power Doppler assessment 
of overall disease activity in patients with rheumatoid arthritis. J Clin 
Ultrasound 2005;34(1):5-11.
114. Naredo E, Collado P, Cruz A, Palop MJ, Cabero F, Richi P, et al. 
Longitudinal power Doppler ultrasonographic assessment of joint 
inflammatory activity in early rheumatoid arthritis: predictive value in disease 
activity and radiologic progression. Arthritis and rheumatism 2007;57(1):
116-24.
115. Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, 
Ostergaard M. Interobserver agreement in ultrasonography of the finger and 
toe joints in rheumatoid arthritis. Arthritis and rheumatism 2003;48(4):955-62.
116. Wakefield RJ, Brown AK, O'Connor PJ, Emery P. Power Doppler 
sonography: improving disease activity assessment in inflammatory 
musculoskeletal disease. Arthritis and rheumatism 2003;48(2):285-8.
117. Wakefield RJ, D'Agostino MA, Iagnocco A, Filippucci E, Backhaus M, 
Scheel AK, et al. The OMERACT Ultrasound Group: status of current activities 
and research directions. The Journal of rheumatology 2007;34(4):848-51.
118. Hammer HB, Bolton-King P, Bakkeheim V, Berg TH, Sundt E, Kongtorp AK, 
et al. Examination of intra and interrater reliability with a new ultrasonographic 
reference atlas for scoring of synovitis in patients with rheumatoid arthritis. 
Annals of the rheumatic diseases 2011;70(11):1995-8.
119. Ejbjerg BJ, Vestergaard A, Jacobsen S, Thomsen HS, Ostergaard M. The 
smallest detectable difference and sensitivity to change of magnetic 
resonance imaging and radiographic scoring of structural joint damage in 
rheumatoid arthritis finger, wrist, and toe joints: a comparison of the 
OMERACT rheumatoid arthritis magnetic resonance imaging score applied to 
different joint combinations and the Sharp/van der Heijde radiographic score. 
Arthritis and rheumatism 2005;52(8):2300-6.
120. Filippucci E, Iagnocco A, Salaffi F, Cerioni A, Valesini G, Grassi W. Power 
Doppler sonography monitoring of synovial perfusion at the wrist joints in 
patients with rheumatoid arthritis treated with adalimumab. Annals of the 
rheumatic diseases 2006;65(11):1433-7.
121. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. 
Presence of significant synovitis in rheumatoid arthritis patients with disease-
modifying antirheumatic drug-induced clinical remission: evidence from an 
imaging study may explain structural progression. Arthritis Rheum 
2006;54(12):3761-73.
122. Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, 
et al. Guidelines for musculoskeletal ultrasound in rheumatology. Annals of 
the rheumatic diseases 2001;60(7):641-9.
123. Albrecht K, Muller-Ladner U, Strunk J. Quantification of the synovial 
perfusion in rheumatoid arthritis using Doppler ultrasonography. Clinical and 
experimental rheumatology 2007;25(4):630-8.
124. Scire CA, Montecucco C, Codullo V, Epis O, Todoerti M, Caporali R. 
Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis 
in clinical remission: power Doppler signal predicts short-term relapse. 
Rheumatology (Oxford, England) 2009;48(9):1092-7.
125. Terslev L, Torp-Pedersen S, Qvistgaard E, Kristoffersen H, Rogind H, 
Danneskiold-Samsoe B, et al. Effects of treatment with etanercept (Enbrel, 
TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. 
Annals of the rheumatic diseases 2003;62(2):178-81.
126. Terslev L, Torp-Pedersen S, Savnik A, von der Recke P, Qvistgaard E, 
Danneskiold-Samsoe B, et al. Doppler ultrasound and magnetic resonance 
imaging of synovial inflammation of the hand in rheumatoid arthritis: a 
comparative study. Arthritis and rheumatism 2003;48(9):2434-41.
277
127. Seymour MW, Kelly S, Beals CR, Malice MP, Bolognese JA, Dardzinski BJ, 
et al. Ultrasound of metacarpophalangeal joints is a sensitive and reliable 
endpoint for drug therapies in rheumatoid arthritis: results of a randomized, 
two-center placebo-controlled study. Arthritis research & therapy 
2012;14(5):R198.
128. Seymour M, Petavy F, Chiesa F, Perry H, Lukey PT, Binks M, et al. 
Ultrasonographic measures of synovitis in an early phase clinical trial: a 
double-blind, randomised, placebo and comparator controlled phase IIa trial 
of GW274150 (a selective inducible nitric oxide synthase inhibitor) in 
rheumatoid arthritis. Clinical and experimental rheumatology 2012;30(2):
254-61.
129. Ellegaard K, Torp-Pedersen S, Terslev L, Danneskiold-Samsoe B, 
Henriksen M, Bliddal H. Ultrasound colour Doppler measurements in a single 
joint as measure of disease activity in patients with rheumatoid arthritis--
assessment of concurrent validity. Rheumatology (Oxford, England) 
2009;48(3):254-7.
130. Koski JM, Saarakkala S, Helle M, Hakulinen U, Heikkinen JO, Hermunen H. 
Power Doppler ultrasonography and synovitis: correlating ultrasound imaging 
with histopathological findings and evaluating the performance of ultrasound 
equipments. Annals of the rheumatic diseases 2006;65(12):1590-5.
131. Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, et 
al. Ultrasonographic and radiographic results from a two-year controlled trial 
of immediate or one-year-delayed addition of infliximab to ongoing 
methotrexate therapy in patients with erosive early rheumatoid arthritis. 
Arthritis and rheumatism 2006;54(1):47-53.
132. Shio K, Homma F, Kanno Y, Yamadera Y, Ohguchi Y, Nishimaki T, et al. 
Doppler sonographic comparative study on usefulness of synovial vascularity 
between knee and metacarpophalangeal joints for evaluation of articular 
inflammation in patients with rheumatoid arthritis treated by infliximab. 
Modern rheumatology / the Japan Rheumatism Association 2006;16(4):220-5.
133. Terslev L, Torp-Pedersen S, Bang N, Koenig MJ, Nielsen MB, Bliddal H. 
Doppler ultrasound findings in healthy wrists and finger joints before and after 
use of two different contrast agents. Annals of the rheumatic diseases 
2005;64(6):824-7.
134. Naredo E, Moller I, Acebes C, Batlle-Gualda E, Brito E, de Agustin JJ, et al. 
Three-dimensional volumetric ultrasonography. Does it improve reliabililty of 
musculoskeletal ultrasound? Clinical and experimental rheumatology 
2010;28(1):79-82.
135. Naredo E, Acebes C, Brito E, de Agustin JJ, de Miguel E, Mayordomo L, et 
al. Three-dimensional Volumetric Ultrasound: A Valid Method for Blinded 
Assessment of Response to Therapy in Rheumatoid Arthritis. The Journal of 
rheumatology 2013;40(3):253-60.
136. Krishnamoorthy VK, Sengupta PP, Gentile F, Khandheria BK. History of 
echocardiography and its future applications in medicine. Critical care 
medicine 2007;35(8 Suppl):S309-13.
137. Filippucci E, Iagnocco A, Meenagh G, Riente L, Delle Sedie A, Bombardieri 
S, et al. Ultrasound imaging for the rheumatologist VII. Ultrasound imaging in 
rheumatoid arthritis. Clin Exp Rheumatol 2007;25(1):5-10.
138. Filippucci E, Iagnocco A, Meenagh G, Riente L, Delle Sedie A, Bombardieri 
S, et al. Ultrasound imaging for the rheumatologist II. Ultrasonography of the 
hand and wrist. Clinical and experimental rheumatology 2006;24(2):118-22.
139. Botar-Jid C, Bolboaca S, Fodor D, Bocsa C, Tamas MM, Micu M, et al. 
Gray scale and power Doppler ultrasonography in evaluation of early 
rheumatoid arthritis. Med Ultrason 2010;12(4):300-5.
140. Ohashi S, Ohnishi I, Matsumoto T, Bessho M, Matsuyama J, Tobita K, et al. 
Measurement of articular cartilage thickness using a three-dimensional image 
reconstructed from B-mode ultrasonography mechanical scans feasibility 
278
study by comparison with MRI-derived data. Ultrasound in medicine & 
biology 2012;38(3):402-11.
141. Delle Sedie A, Riente L, Iagnocco A, Filippucci E, Meenagh G, Grassi W, et 
al. Ultrasound imaging for the rheumatologist X. Ultrasound imaging in 
crystal-related arthropathies. Clinical and experimental rheumatology 
2007;25(4):513-7.
142. Walther M, Harms H, Krenn V, Radke S, Faehndrich TP, Gohlke F. 
Correlation of power Doppler sonography with vascularity of the synovial 
tissue of the knee joint in patients with osteoarthritis and rheumatoid arthritis. 
Arthritis Rheum 2001;44(2):331-8.
143. Schmidt WA, Volker L, Zacher J, Schlafke M, Ruhnke M, Gromnica-Ihle E. 
Colour Doppler ultrasonography to detect pannus in knee joint synovitis. Clin 
Exp Rheumatol 2000;18(4):439-44.
144. Fiocco U, Cozzi L, Rubaltelli L, Rigon C, De Candia A, Tregnaghi A, et al. 
Long-term sonographic follow-up of rheumatoid and psoriatic proliferative 
knee joint synovitis. British journal of rheumatology 1996;35(2):155-63.
145. Krenn V, Morawietz L, Burmester GR, Kinne RW, Mueller-Ladner U, Muller 
B, et al. Synovitis score: discrimination between chronic low-grade and high-
grade synovitis. Histopathology 2006;49(4):358-64.
146. Krenn V, Morawietz L, Haupl T, Neidel J, Petersen I, Konig A. Grading of 
chronic synovitis--a histopathological grading system for molecular and 
diagnostic pathology. Pathol Res Pract 2002;198(5):317-25.
147. Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, et 
al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium 
correlates with change in DAS28 and magnetic resonance imaging synovitis 
scores following initiation of biologic therapy--a single centre, open-label 
study. Arthritis research & therapy 2011;13(1):R7.
148. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et 
al. American College of Rheumatology. Preliminary definition of improvement 
in rheumatoid arthritis. Arthritis and rheumatism 1995;38(6):727-35.
149. Hanson MT, Keiding S, Lauritzen SL, Manthorpe R, Sorensen SF, Wiik A. 
Clinical assessment of disease activity in rheumatoid arthritis. Scand J 
Rheumatol 1979;8(2):101-5.
150. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis 
improvement criteria that include simplified joint counts. Arthritis and 
rheumatism 1998;41(10):1845-50.
151. van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid 
arthritis. Annals of the rheumatic diseases 2000;59 Suppl 1:i28-31.
152. Hameed B, Pilcher J, Heron C, Kiely PD. The relation between composite 
ultrasound measures and the DAS28 score, its components and acute phase 
markers in adult RA. Rheumatology (Oxford, England) 2008;47(4):476-80.
153. Salaffi F, Filippucci E, Carotti M, Naredo E, Meenagh G, Ciapetti A, et al. 
Inter-observer agreement of standard joint counts in early rheumatoid 
arthritis: a comparison with grey scale ultrasonography--a preliminary study. 
Rheumatology (Oxford) 2008;47(1):54-8.
154. Naredo E, Gamero F, Bonilla G, Uson J, Carmona L, Laffon A. 
Ultrasonographic assessment of inflammatory activity in rheumatoid arthritis: 
comparison of extended versus reduced joint evaluation. Clinical and 
experimental rheumatology 2005;23(6):881-4.
155. Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Satoh K, Tamai M, et 
al. The power Doppler ultrasonography score from 24 synovial sites or 6 
simplified synovial sites, including the metacarpophalangeal joints, reflects 
the clinical disease activity and level of serum biomarkers in patients with 
rheumatoid arthritis. Rheumatology (Oxford, England) 2011;50(5):962-5.
156. Szkudlarek M, Klarlund M, Narvestad E, Court-Payen M, Strandberg C, 
Jensen KE, et al. Ultrasonography of the metacarpophalangeal and proximal 
interphalangeal joints in rheumatoid arthritis: a comparison with magnetic 
279
resonance imaging, conventional radiography and clinical examination. 
Arthritis research & therapy 2006;8(2):R52.
157. Kane D, Balint PV, Sturrock RD. Ultrasonography is superior to clinical 
examination in the detection and localization of knee joint effusion in 
rheumatoid arthritis. The Journal of rheumatology 2003;30(5):966-71.
158. Damjanov N, Radunovic G, Prodanovic S, Vukovic V, Milic V, Simic Pasalic 
K, et al. Construct validity and reliability of ultrasound disease activity score in 
assessing joint inflammation in RA: comparison with DAS-28. Rheumatology 
(Oxford, England) 2012;51(1):120-8.
159. Almoallim H, Attar S, Jannoudi N, Al-Nakshabandi N, Eldeek B, Fathaddien 
O, et al. Sensitivity of standardised musculoskeletal examination of the hand 
and wrist joints in detecting arthritis in comparison to ultrasound findings in 
patients attending rheumatology clinics. Clinical rheumatology 2012;31(9):
1309-17.
160. Nakagomi D, Ikeda K, Okubo A, Iwamoto T, Sanayama Y, Takahashi K, et 
al. Ultrasound can improve the accuracy of the 2010 ACR/EULAR 
classification criteria for rheumatoid arthritis to predict methotrexate 
requirement. Arthritis and rheumatism 2013.
161. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Wakefield R, et al. 
Should imaging be a component of rheumatoid arthritis remission criteria? A 
comparison between traditional and modified composite remission scores 
and imaging assessments. Annals of the rheumatic diseases 2011;70(5):
792-8.
162. Wakefield RJ, D'Agostino MA, Naredo E, Buch MH, Iagnocco A, Terslev L, 
et al. After treat-to-target: can a targeted ultrasound initiative improve RA 
outcomes? Ann Rheum Dis 2012;71(6):799-803.
163. Saleem B, Nizam S, Emery P. Can remission be maintained with or without 
further drug therapy in rheumatoid arthritis? Clinical and experimental 
rheumatology 2006;24(6 Suppl 43):S-33-6.
164. Conaghan PG, Ostergaard M, McGonagle D, O'Connor P, Emery P. The 
validity and predictive value of magnetic resonance imaging erosions in 
rheumatoid arthritis: comment on the article by Goldbach-Mansky et al. 
Arthritis Rheum 2004;50(3):1009-11.
165. Freeston JE, Conaghan PG, Dass S, Vital E, Hensor EM, Stewart SP, et al. 
Does extremity-MRI improve erosion detection in severely damaged joints? A 
study of long-standing rheumatoid arthritis using three imaging modalities. 
Annals of the rheumatic diseases 2007;66(11):1538-40.
166. Quinn MA, Green MJ, Conaghan P, Emery P. How do you diagnose 
rheumatoid arthritis early? Best practice & research 2001;15(1):49-66.
167. Ogishima H, Tsuboi H, Umeda N, Horikoshi M, Kondo Y, Sugihara M, et al. 
Analysis of subclinical synovitis detected by ultrasonography and low-field 
magnetic resonance imaging in patients with rheumatoid arthritis. Modern 
rheumatology / the Japan Rheumatism Association 2013.
168. Palosaari K, Vuotila J, Takalo R, Jartti A, Niemela RK, Karjalainen A, et al. 
Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr 
observational MRI and NC scintigraphy study. Rheumatology (Oxford, 
England) 2006;45(12):1542-8.
169. Ohrndorf S, Hensch A, Naumann L, Hermann KG, Scheurig-Munkler C, 
Meier S, et al. Contrast-enhanced ultrasonography is more sensitive than 
grayscale and power Doppler ultrasonography compared to MRI in therapy 
monitoring of rheumatoid arthritis patients. Ultraschall Med 2011;32 Suppl 
2:E38-44.
170. Backhaus M BG, Sandrock D, et al. Prospective two year follow up study 
comparing novel and conventional imaging procedures in patients with 
arthritic finger joints. . Ann Rheum 2002; 61:895-904.
171. Hermann KG, Backhaus M, Schneider U, Labs K, Loreck D, Zuhlsdorf S, et 
al. Rheumatoid arthritis of the shoulder joint: comparison of conventional 
280
radiography, ultrasound, and dynamic contrast-enhanced magnetic 
resonance imaging. Arthritis and rheumatism 2003;48(12):3338-49.
172. Szkudlarek M, Narvestad E, Klarlund M, Court-Payen M, Thomsen HS, 
Ostergaard M. Ultrasonography of the metatarsophalangeal joints in 
rheumatoid arthritis: comparison with magnetic resonance imaging, 
conventional radiography, and clinical examination. Arthritis and rheumatism 
2004;50(7):2103-12.
173. Schmidt WA, Schicke B, Ostendorf B, Scherer A, Krause A, Walther M. 
Low-field MRI versus ultrasound: which is more sensitive in detecting 
inflammation and bone damage in MCP and MTP joints in mild or moderate 
rheumatoid arthritis? Clinical and experimental rheumatology 2013;31(1):91-6.
174. Amin MF, Ismail FM, El Shereef RR. The role of ultrasonography in early 
detection and monitoring of shoulder erosions, and disease activity in 
rheumatoid arthritis patients; comparison with MRI examination. Acad Radiol 
2012;19(6):693-700.
175. Keen HI, Mease PJ, Bingham CO, 3rd, Giles JT, Kaeley G, Conaghan PG. 
Systematic review of MRI, ultrasound, and scintigraphy as outcome measures 
for structural pathology in interventional therapeutic studies of knee arthritis: 
focus on responsiveness. J Rheumatol 2011;38(1):142-54.
176. Grassi W, Filippucci E, Farina A, Cervini C. Sonographic imaging of 
tendons. Arthritis and rheumatism 2000;43(5):969-76.
177. Grassi W, Tittarelli E, Blasetti P, Pirani O, Cervini C. Finger tendon 
involvement in rheumatoid arthritis. Evaluation with high-frequency 
sonography. Arthritis and rheumatism 1995;38(6):786-94.
178. Grassi W, Tittarelli E, Pirani O, Avaltroni D, Cervini C. Ultrasound 
examination of metacarpophalangeal joints in rheumatoid arthritis. Scand J 
Rheumatol 1993;22(5):243-7.
179. Leslie BM. Rheumatoid extensor tendon ruptures. Hand clinics 1989;5(2):
191-202.
180. Fornage BD, Rifkin MD. Ultrasound examination of the hand and foot. 
Radiologic clinics of North America 1988;26(1):109-29.
181. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, 
D'Agostino MA, et al. Musculoskeletal ultrasound including definitions for 
ultrasonographic pathology. The Journal of rheumatology 2005;32(12):
2485-7.
182. Symmons DP, Silman AJ. Aspects of early arthritis. What determines the 
evolution of early undifferentiated arthritis and rheumatoid arthritis? An update 
from the Norfolk Arthritis Register. Arthritis research & therapy 2006;8(4):214.
183. Keen HI, Emery P. How should we manage early rheumatoid arthritis? From 
imaging to intervention. Current opinion in rheumatology 2005;17(3):280-5.
184. Wakefield RJ, Kong KO, Conaghan PG, Brown AK, O'Connor PJ, Emery P. 
The role of ultrasonography and magnetic resonance imaging in early 
rheumatoid arthritis. Clinical and experimental rheumatology 2003;21(5 Suppl 
31):S42-9.
185. Farrant JM, Grainger AJ, O'Connor PJ. Advanced imaging in rheumatoid 
arthritis: part 2: erosions. Skeletal Radiol 2007;36(5):381-9.
186. Funck-Brentano T, Gandjbakhch F, Etchepare F, Jousse-Joulin S, Miquel 
A, Cyteval C, et al. Sonographic erosions and power-Doppler signal predict 
radiographic damage in early arthritis: The ESPOIR ultrasonography 
longitudinal study. Arthritis Care Res (Hoboken) 2012.
187. Wakefield RJ, Gibbon WW, Conaghan PG, O'Connor P, McGonagle D, 
Pease C, et al. The value of sonography in the detection of bone erosions in 
patients with rheumatoid arthritis: a comparison with conventional 
radiography. Arthritis and rheumatism 2000;43(12):2762-70.
188. Freeston JE, Wakefield RJ, Conaghan PG, Hensor EM, Stewart SP, Emery 
P. A diagnostic algorithm for persistence of very early inflammatory arthritis: 
281
the utility of power doppler ultrasound when added to conventional 
assessment tools. Annals of the rheumatic diseases 2009.
189. van de Stadt LA, Bos WH, Meursinge Reynders M, Wieringa H, Turkstra F, 
van der Laken CJ, et al. The value of ultrasonography in predicting arthritis in 
auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis 
research & therapy 2010;12(3):R98.
190. van den Broek M, Lems WF, Allaart CF. BeSt practice: the success of 
early-targeted treatment in rheumatoid arthritis. Clinical and experimental 
rheumatology 2012;30(4 Suppl 73):S35-8.
191. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, 
Breedveld FC, et al. Early versus delayed treatment in patients with recent-
onset rheumatoid arthritis: comparison of two cohorts who received different 
treatment strategies. Am J Med 2001;111(6):446-51.
192. van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld FC. The 
Leiden Early Arthritis Clinic. Clinical and experimental rheumatology 
2003;21(5 Suppl 31):S100-5.
193. Ellegaard K, Christensen R, Torp-Pedersen S, Terslev L, Holm CC, Konig 
MJ, et al. Ultrasound Doppler measurements predict success of treatment 
with anti-TNF-&alpha; drug in patients with rheumatoid arthritis: a prospective 
cohort study. Rheumatology (Oxford, England) 2011;50(3):506-12.
194. Ostergaard M, Szkudlarek M. Ultrasonography: a valid method for 
assessing rheumatoid arthritis? Arthritis and rheumatism 2005;52(3):681-6.
195. Joshua F, Lassere M, Bruyn GA, Szkudlarek M, Naredo E, Schmidt WA, et 
al. Summary findings of a systematic review of the ultrasound assessment of 
synovitis. The Journal of rheumatology 2007;34(4):839-47.
196. Algergawy S, Haliem T, Al-Shaer O. Clinical, laboratory, and ultrasound 
assessment of the knee in juvenile rheumatoid arthritis. Clin Med Insights 
Arthritis Musculoskelet Disord 2011;4:21-7.
197. Backhaus TM, Ohrndorf S, Kellner H, Strunk J, Hartung W, Sattler H, et al. 
The US7 score is sensitive to change in a large cohort of patients with 
rheumatoid arthritis over 12 months of therapy. Annals of the rheumatic 
diseases 2012.
198. Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, et 
al. Comparison of ultrasonographic assessment of synovitis and joint 
vascularity with radiographic evaluation in a randomized, placebo-controlled 
study of infliximab therapy in early rheumatoid arthritis. Arthritis and 
rheumatism 2004;50(4):1107-16.
199. Teh J, Stevens K, Williamson L, Leung J, McNally EG. Power Doppler 
ultrasound of rheumatoid synovitis: quantification of therapeutic response. Br 
J Radiol 2003;76(912):875-9.
200. Qvistgaard E, Rogind H, Torp-Pedersen S, Terslev L, Danneskiold-Samsoe 
B, Bliddal H. Quantitative ultrasonography in rheumatoid arthritis: evaluation 
of inflammation by Doppler technique. Ann Rheum Dis 2001;60(7):690-3.
201. Naredo E, Moller I, Moragues C, de Agustin JJ, Scheel AK, Grassi W, et al. 
Interobserver reliability in musculoskeletal ultrasonography: results from a 
"Teach the Teachers" rheumatologist course. Annals of the rheumatic 
diseases 2006;65(1):14-9.
202. Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen T, 
Ostergaard M. Contrast-enhanced power Doppler ultrasonography of the 
metacarpophalangeal joints in rheumatoid arthritis. European radiology 
2003;13(1):163-8.
203. Qvistgaard E, Torp-Pedersen S, Christensen R, Bliddal H. Reproducibility 
and inter-reader agreement of a scoring system for ultrasound evaluation of 
hip osteoarthritis. Annals of the rheumatic diseases 2006;65(12):1613-9.
204. Wiell C, Szkudlarek M, Hasselquist M, Moller JM, Vestergaard A, 
Norregaard J, et al. Ultrasonography, magnetic resonance imaging, 
radiography, and clinical assessment of inflammatory and destructive 
282
changes in fingers and toes of patients with psoriatic arthritis. Arthritis 
research & therapy 2007;9(6):R119.
205. Naredo E, Rodriguez M, Campos C, Rodriguez-Heredia JM, Medina JA, 
Giner E, et al. Validity, reproducibility, and responsiveness of a twelve-joint 
simplified power doppler ultrasonographic assessment of joint inflammation in 
rheumatoid arthritis. Arthritis and rheumatism 2008;59(4):515-22.
206. Luz KR, Furtado R, Mitraud SV, Porglhof J, Nunes C, Fernandes AR, et al. 
Interobserver reliability in ultrasound assessment of rheumatoid wrist joints. 
Acta Reumatol Port 2011;36(3):245-50.
207. Ohrndorf S, Fischer IU, Kellner H, Strunk J, Hartung W, Reiche B, et al. 
Reliability of the novel 7-joint ultrasound score: results from an inter- and 
intraobserver study performed by rheumatologists. Arthritis Care Res 
(Hoboken) 2012;64(8):1238-43.
208. Strunk J, Strube K, Rumbaur C, Lange U, Muller-Ladner U. Interobserver 
agreement in two- and three-dimensional power Doppler sonographic 
assessment of synovial vascularity during anti-inflammatory treatment in 
patients with rheumatoid arthritis. Ultraschall Med 2007;28(4):409-15.
209. Koski JM, Saarakkala S, Helle M, Hakulinen U, Heikkinen JO, Hermunen H, 
et al. Assessing the intra- and inter-reader reliability of dynamic ultrasound 
images in power Doppler ultrasonography. Annals of the rheumatic diseases 
2006;65(12):1658-60.
210. Scheel AK, Schmidt WA, Hermann KG, Bruyn GA, D'Agostino MA, Grassi 
W, et al. Interobserver reliability of rheumatologists performing 
musculoskeletal ultrasonography: results from a EULAR "Train the trainers" 
course. Annals of the rheumatic diseases 2005;64(7):1043-9.
211. Fink B, Makowiak C, Fuerst M, Berger I, Schafer P, Frommelt L. The value 
of synovial biopsy, joint aspiration and C-reactive protein in the diagnosis of 
late peri-prosthetic infection of total knee replacements. J Bone Joint Surg Br 
2008;90(7):874-8.
212. Munoz-Gomez J, Gomez-Perez R, Sole-Arques M, Llopart-Buisan E. 
Synovial fluid examination for the diagnosis of synovial amyloidosis in patients 
with chronic renal failure undergoing haemodialysis. Annals of the rheumatic 
diseases 1987;46(4):324-6.
213. Lurie DP, Musil G. Knee arthropathy in ochronosis: diagnosis by 
arthroscopy with ultrastructural features. The Journal of rheumatology 
1984;11(1):101-3.
214. Isaacson C, Bothwell TH. Synovial iron deposits in black subjects with iron 
overload. Arch Pathol Lab Med 1981;105(9):487-9.
215. Archer-Harvey JM, Henderson DW, Papadimitriou JM, Rozenbilds MA. 
Pigmented villonodular synovitis associated with psoriatic polyarthropathy: 
and electron microscopic and immunocytochemical study. J Pathol 
1984;144(1):57-68.
216. Saaibi DL, Schumacher HR, Jr. Percutaneous needle biopsy and synovial 
histology. Bailliere's clinical rheumatology 1996;10(3):535-54.
217. Gerlag D, Tak PP. Synovial biopsy. Best Pract Res Clin Rheumatol 
2005;19(3):387-400.
218. Kane D, Veale DJ, FitzGerald O, Reece R. Survey of arthroscopy 
performed by rheumatologists. Rheumatology (Oxford, England) 2002;41(2):
210-5.
219. Baeten D, Van den Bosch F, Elewaut D, Stuer A, Veys EM, De Keyser F. 
Needle arthroscopy of the knee with synovial biopsy sampling: technical 
experience in 150 patients. Clinical rheumatology 1999;18(6):434-41.
220. Collins JJ. Knee-joint arthroscopy--early complications. The Medical journal 
of Australia 1989;150(12):702-3, 06.
221. Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, 
Fearon U, et al. Synovial tissue sublining CD68 expression is a biomarker of 
283
therapeutic response in rheumatoid arthritis clinical trials: consistency across 
centers. The Journal of rheumatology 2009;36(8):1800-2.
222. Koski JM, Helle M. Ultrasound guided synovial biopsy using portal and 
forceps. Ann Rheum Dis 2005;64(6):926-9.
223. van Vugt RM, van Dalen A, Bijlsma JW. Ultrasound guided synovial biopsy 
of the wrist. Scand J Rheumatol 1997;26(3):212-4.
224. Scire CA, Epis O, Codullo V, Humby F, Morbini P, Manzo A, et al. 
Immunohistological assessment of the synovial tissue in small joints in 
rheumatoid arthritis: validation of a minimally invasive ultrasound-guided 
synovial biopsy procedure. Arthritis Res Ther 2007;9(5):R101.
225. Youssef PP, Kraan M, Breedveld F, Bresnihan B, Cassidy N, Cunnane G, et 
al. Quantitative microscopic analysis of inflammation in rheumatoid arthritis 
synovial membrane samples selected at arthroscopy compared with samples 
obtained blindly by needle biopsy. Arthritis and rheumatism 1998;41(4):
663-9.
226. Smeets TJ, Kraan MC, Galjaard S, Youssef PP, Smith MD, Tak PP. Analysis 
of the cell infiltrate and expression of matrix metalloproteinases and 
granzyme B in paired synovial biopsy specimens from the cartilage-pannus 
junction in patients with RA. Ann Rheum Dis 2001;60(6):561-5.
227. Kane D, Jensen LE, Grehan S, Whitehead AS, Bresnihan B, Fitzgerald O. 
Quantitation of metalloproteinase gene expression in rheumatoid and 
psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus 
junction. The Journal of rheumatology 2004;31(7):1274-80.
228. Smith MD, Barg E, Weedon H, Papengelis V, Smeets T, Tak PP, et al. 
Microarchitecture and protective mechanisms in synovial tissue from clinically 
and arthroscopically normal knee joints. Annals of the rheumatic diseases 
2003;62(4):303-7.
229. Smith MD. The normal synovium. Open Rheumatol J 2011;5:100-6.
230. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. 
Vascular permeability factor/endothelial growth factor (VPF/VEGF): 
accumulation and expression in human synovial fluids and rheumatoid 
synovial tissue. J Exp Med 1994;180(1):341-6.
231. van Lent PL, Blom AB, van der Kraan P, Holthuysen AE, Vitters E, van 
Rooijen N, et al. Crucial role of synovial lining macrophages in the promotion 
of transforming growth factor beta-mediated osteophyte formation. Arthritis 
and rheumatism 2004;50(1):103-11.
232. Li P, Sanz I, O'Keefe RJ, Schwarz EM. NF-kappa B regulates VCAM-1 
expression on fibroblast-like synoviocytes. J Immunol 2000;164(11):5990-7.
233. Xu H, Edwards J, Banerji S, Prevo R, Jackson DG, Athanasou NA. 
Distribution of lymphatic vessels in normal and arthritic human synovial 
tissues. Annals of the rheumatic diseases 2003;62(12):1227-9.
234. Singh JA, Arayssi T, Duray P, Schumacher HR. Immunohistochemistry of 
normal human knee synovium: a quantitative study. Annals of the rheumatic 
diseases 2004;63(7):785-90.
235. Smith MD. Immunohistochemistry of normal synovium. Annals of the 
rheumatic diseases 2004;63(11):1532-3; author reply 33.
236. Szekanecz Z, Koch AE. Mechanisms of Disease: angiogenesis in 
inflammatory diseases. Nature clinical practice 2007;3(11):635-43.
237. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor 
antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
238. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, et 
al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167(2):
1072-80.
239. Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni G, et al. 
Systematic microanatomical analysis of CXCL13 and CCL21 in situ 
production and progressive lymphoid organization in rheumatoid synovitis. 
Eur J Immunol 2005;35(5):1347-59.
284
240. Manzo A, Bombardieri M, Humby F, Pitzalis C. Secondary and ectopic 
lymphoid tissue responses in rheumatoid arthritis: from inflammation to 
autoimmunity and tissue damage/remodeling. Immunol Rev 2010;233(1):
267-85.
241. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid 
synovitis. Annals of the New York Academy of Sciences 2003;987:140-9.
242. Weyand CM, Kang YM, Kurtin PJ, Goronzy JJ. The power of the third 
dimension: tissue architecture and autoimmunity in rheumatoid arthritis. 
Current opinion in rheumatology 2003;15(3):259-66.
243. Bugatti S, Manzo A, Bombardieri M, Vitolo B, Humby F, Kelly S, et al. 
Synovial tissue heterogeneity and peripheral blood biomarkers. Current 
rheumatology reports 2011;13(5):440-8.
244. Corsiero E, Bombardieri M, Manzo A, Bugatti S, Uguccioni M, Pitzalis C. 
Role of lymphoid chemokines in the development of functional ectopic 
lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 
2012;145(1-2):62-7.
245. Yanni G, Whelan A, Feighery C, Bresnihan B. Analysis of cell populations in 
rheumatoid arthritis synovial tissues. Seminars in arthritis and rheumatism 
1992;21(6):393-9.
246. Yanni G, Whelan A, Feighery C, Quinlan W, Symons J, Duff G, et al. 
Contrasting levels of in vitro cytokine production by rheumatoid synovial 
tissues demonstrating different patterns of mononuclear cell infiltration. Clin 
Exp Immunol 1993;93(3):387-95.
247. Singh JA, Pando JA, Tomaszewski J, Schumacher HR. Quantitative 
analysis of immunohistologic features of very early rheumatoid synovitis in 
disease modifying antirheumatic drug- and corticosteroid-naive patients. J 
Rheumatol 2004;31(7):1281-5.
248. Baeten D, Houbiers J, Kruithof E, Vandooren B, Van den Bosch F, Boots 
AM, et al. Synovial inflammation does not change in the absence of effective 
treatment: implications for the use of synovial histopathology as biomarker in 
early phase clinical trials in rheumatoid arthritis. Annals of the rheumatic 
diseases 2006;65(8):990-7.
249. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP. Analysis 
of the cell infiltrate and expression of proinflammatory cytokines and matrix 
metalloproteinases in arthroscopic synovial biopsies: comparison with 
synovial samples from patients with end stage, destructive rheumatoid 
arthritis. Annals of the rheumatic diseases 2003;62(7):635-8.
250. Klaasen R, Wijbrandts CA, van Kuijk AW, Pots D, Gerlag DM, Tak PP. 
Synovial synoviolin in relation to response to TNF blockade in patients with 
rheumatoid arthritis and psoriatic arthritis. Annals of the rheumatic diseases 
2012;71(7):1260-1.
251. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, et al. 
Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in 
germinal center of ectopic lymphoid follicles within the synovium of chronic 
arthritis patients. J Immunol 2001;166(1):650-5.
252. Bombardieri M, Barone F, Lucchesi D, Nayar S, van den Berg WB, Proctor 
G, et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine 
dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. 
J Immunol 2012;189(7):3767-76.
253. Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI. 
Blockade of lymphotoxin-beta receptor signaling reduces aspects of 
Sjogren's syndrome in salivary glands of non-obese diabetic mice. Arthritis 
research & therapy 2009;11(1):R24.
254. Astorri E, Bombardieri M, Gabba S, Peakman M, Pozzilli P, Pitzalis C. 
Evolution of ectopic lymphoid neogenesis and in situ autoantibody production 
in autoimmune nonobese diabetic mice: cellular and molecular 
285
characterization of tertiary lymphoid structures in pancreatic islets. J Immunol 
2010;185(6):3359-68.
255. Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, et al. 
Ectopic lymphoid structures support ongoing production of class-switched 
autoantibodies in rheumatoid synovium. PLoS medicine 2009;6(1):e1.
256. Pitzalis C, Kelly S, Humby F. New learnings on the pathophysiology of RA 
from synovial biopsies. Current opinion in rheumatology 2013.
257. Kasperkovitz PV, Timmer TC, Smeets TJ, Verbeet NL, Tak PP, van Baarsen 
LG, et al. Fibroblast-like synoviocytes derived from patients with rheumatoid 
arthritis show the imprint of synovial tissue heterogeneity: evidence of a link 
between an increased myofibroblast-like phenotype and high-inflammation 
synovitis. Arthritis and rheumatism 2005;52(2):430-41.
258. Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, et al. 
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like 
synoviocytes. Arthritis Res Ther 2006;8(6):R171.
259. Tolboom TC, van der Helm-Van Mil AH, Nelissen RG, Breedveld FC, Toes 
RE, Huizinga TW. Invasiveness of fibroblast-like synoviocytes is an individual 
patient characteristic associated with the rate of joint destruction in patients 
with rheumatoid arthritis. Arthritis and rheumatism 2005;52(7):1999-2002.
260. Buckley CD. Why does chronic inflammatory joint disease persist? Clin 
Med 2003;3(4):361-6.
261. Rooney T, Bresnihan B, Andersson U, Gogarty M, Kraan M, Schumacher 
HR, et al. Microscopic measurement of inflammation in synovial tissue: Inter-
observer agreement for manual quantitative, semi-quantitative and 
computerized digital image analysis. Annals of the rheumatic diseases 2007.
262. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, et al. 
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in 
relation to local disease activity. Arthritis and rheumatism 1997;40(2):217-25.
263. Kraan MC, Haringman JJ, Post WJ, Versendaal J, Breedveld FC, Tak PP. 
Immunohistological analysis of synovial tissue for differential diagnosis in 
early arthritis. Rheumatology (Oxford, England) 1999;38(11):1074-80.
264. Pettit AR, Weedon H, Ahern M, Zehntner S, Frazer IH, Slavotinek J, et al. 
Association of clinical, radiological and synovial immunopathological 
responses to anti-rheumatic treatment in rheumatoid arthritis. Rheumatology 
(Oxford) 2001;40(11):1243-55.
265. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud 
PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and 
clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50(12):
3783-91.
266. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten 
D, et al. Synovial tissue macrophages: a sensitive biomarker for response to 
treatment in patients with rheumatoid arthritis. Annals of the rheumatic 
diseases 2005;64(6):834-8.
267. Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag 
DM, et al. The relationship between synovial lymphocyte aggregates and the 
clinical response to infliximab in rheumatoid arthritis: a prospective study. 
Arthritis and rheumatism 2009;60(11):3217-24.
268. Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina 
A, et al. The gene expression profile in the synovium as a predictor of the 
clinical response to infliximab treatment in rheumatoid arthritis. PLoS ONE 
2010;5(6):e11310.
269. Buch MH, Reece RJ, Quinn MA, English A, Cunnane G, Henshaw K, et al. 
The value of synovial cytokine expression in predicting the clinical response 
to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 2008;47(10):
1469-75.
286
270. Kanbe K, Chiba J, Nakamura A. Decrease of CD68 and MMP-3 expression 
in synovium by treatment of adalimumab for rheumatoid arthritis. Int J Rheum 
Dis 2011;14(3):261-6.
271. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, 
et al. Updated consensus statement on the use of rituximab in patients with 
rheumatoid arthritis. Annals of the rheumatic diseases 2011;70(6):909-20.
272. Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and 
efficacy of rituximab in patients with rheumatoid arthritis refractory to disease 
modifying antirheumatic drugs and anti-tumor necrosis factor-alpha 
treatment. The Journal of rheumatology 2005;32(11):2109-15.
273. Cohen SB. Targeting the B cell in rheumatoid arthritis. Best practice & 
research 2010;24(4):553-63.
274. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. 
Synovial tissue response to rituximab: mechanism of action and identification 
of biomarkers of response. Annals of the rheumatic diseases 2008;67(7):
917-25.
275. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. 
Mode of action of abatacept in rheumatoid arthritis patients having failed 
tumour necrosis factor blockade: a histological, gene expression and 
dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 
2009;68(7):1220-7.
276. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: 
'vascular rheumatology'. Arthritis research & therapy 2008;10(5):224.
277. Poole TJ, Finkelstein EB, Cox CM. The role of FGF and VEGF in angioblast 
induction and migration during vascular development. Dev Dyn 2001;220(1):
1-17.
278. Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, et al. 
Angiogenesis factors. Internal medicine (Tokyo, Japan) 2001;40(7):565-72.
279. Magnusson P, Rolny C, Jakobsson L, Wikner C, Wu Y, Hicklin DJ, et al. 
Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in 
fibroblast growth factor receptor-1-deficient vascular stem cell development. 
Journal of cell science 2004;117(Pt 8):1513-23.
280. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. 
Heterozygous embryonic lethality induced by targeted inactivation of the 
VEGF gene. Nature 1996;380(6573):439-42.
281. Burri PH, Djonov V. Intussusceptive angiogenesis--the alternative to 
capillary sprouting. Molecular aspects of medicine 2002;23(6S):S1-27.
282. Risau W, Lemmon V. Changes in the vascular extracellular matrix during 
embryonic vasculogenesis and angiogenesis. Developmental biology 
1988;125(2):441-50.
283. Anderson-Berry A, O'Brien EA, Bleyl SB, Lawson A, Gundersen N, 
Ryssman D, et al. Vasculogenesis drives pulmonary vascular growth in the 
developing chick embryo. Dev Dyn 2005;233(1):145-53.
284. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-
Maguire M, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and 
Tie-2 in blood vessel formation. Nature 1995;376(6535):70-4.
285. Seegar TC, Eller B, Tzvetkova-Robev D, Kolev MV, Henderson SC, Nikolov 
DB, et al. Tie1-Tie2 interactions mediate functional differences between 
angiopoietin ligands. Molecular cell 2010;37(5):643-55.
286. Stahl A, Connor KM, Sapieha P, Chen J, Dennison RJ, Krah NM, et al. The 
mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci 
2010;51(6):2813-26.
287. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in 
cardiovascular disease: a critical appraisal. Circulation 2005;112(12):
1813-24.
288. Amoroso A, Del Porto F, Di Monaco C, Manfredini P, Afeltra A. Vascular 
endothelial growth factor: a key mediator of neoangiogenesis. A review. 
287
European review for medical and pharmacological sciences 1997;1(1-3):
17-25.
289. Szekanecz Z, Szegedi G, Koch AE. Angiogenesis in rheumatoid arthritis: 
pathogenic and clinical significance. J Investig Med 1998;46(2):27-41.
290. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z. Angiogenesis: vascular 
remodeling of the extracellular matrix involves metalloproteinases. Current 
opinion in hematology 2003;10(2):136-41.
291. Mould AW, Tonks ID, Cahill MM, Pettit AR, Thomas R, Hayward NK, et al. 
Vegfb gene knockout mice display reduced pathology and synovial 
angiogenesis in both antigen-induced and collagen-induced models of 
arthritis. Arthritis and rheumatism 2003;48(9):2660-9.
292. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. 
Autocrine VEGF signaling is required for vascular homeostasis. Cell 
2007;130(4):691-703.
293. Hofmann JJ, Luisa Iruela-Arispe M. Notch expression patterns in the retina: 
An eye on receptor-ligand distribution during angiogenesis. Gene Expr 
Patterns 2007;7(4):461-70.
294. Taki A, Abe M, Komaki M, Oku K, Iseki S, Mizutani S, et al. Expression of 
angiogenesis-related factors and inflammatory cytokines in placenta and 
umbilical vessels in pregnancies with preeclampsia and chorioamnionitis/
funisitis. Congenit Anom (Kyoto) 2012;52(2):97-103.
295. Gu JW, Young E, Busby B, Covington J, Johnson JW. Oral administration of 
pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor 
angiogenesis, and growth of breast cancer in female mice. Cancer Biol Ther 
2009;8(6):514-21.
296. Hendriksen EM, Span PN, Schuuring J, Peters JP, Sweep FC, van der 
Kogel AJ, et al. Angiogenesis, hypoxia and VEGF expression during tumour 
growth in a human xenograft tumour model. Microvasc Res 2009;77(2):
96-103.
297. Azizi AA, Haberler C, Czech T, Gupper A, Prayer D, Breitschopf H, et al. 
Vascular-endothelial-growth-factor (VEGF) expression and possible response 
to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part 
sarcoma. Lancet Oncol 2006;7(6):521-3.
298. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, et al. 
Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, 
invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 
2006;26(5A):3579-83.
299. Haigh JJ, Gerber HP, Ferrara N, Wagner EF. Conditional inactivation of 
VEGF-A in areas of collagen2a1 expression results in embryonic lethality in 
the heterozygous state. Development (Cambridge, England) 2000;127(7):
1445-53.
300. Shamloo A, Xu H, Heilshorn S. Mechanisms of vascular endothelial growth 
factor-induced pathfinding by endothelial sprouts in biomaterials. Tissue Eng 
Part A 2012;18(3-4):320-30.
301. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification 
and NH2-terminal amino acid sequence of guinea pig tumor-secreted 
vascular permeability factor. Cancer Res 1990;50(6):1774-8.
302. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-
binding growth factor specific for vascular endothelial cells. Biochem Biophys 
Res Commun 1989;161(2):851-8.
303. Ruggiero D, Dalmasso C, Nutile T, Sorice R, Dionisi L, Aversano M, et al. 
Genetics of VEGF serum variation in human isolated populations of cilento: 
importance of VEGF polymorphisms. PLoS ONE 2011;6(2):e16982.
304. Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA. 
Solution structure of the heparin-binding domain of vascular endothelial 
growth factor. Structure 1998;6(5):637-48.
288
305. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, 
et al. VEGF165b, an inhibitory vascular endothelial growth factor splice 
variant: mechanism of action, in vivo effect on angiogenesis and endogenous 
protein expression. Cancer Res 2004;64(21):7822-35.
306. Kim WU, Kang SS, Yoo SA, Hong KH, Bae DG, Lee MS, et al. Interaction of 
vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid 
synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax 
translocation. J Immunol 2006;177(8):5727-35.
307. Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, 
et al. Vascular endothelial growth factor (VEGF) expression and survival in 
human epithelial ovarian carcinomas. Cancer Lett 1997;121(2):169-75.
308. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, 
et al. Significantly higher levels of vascular endothelial growth factor (VEGF) 
and shorter survival times for patients with primary operable triple-negative 
breast cancer. Ann Oncol 2009;20(10):1639-46.
309. Linderholm B, Tavelin B, Grankvist K, Henriksson R. Does vascular 
endothelial growth factor (VEGF) predict local relapse and survival in 
radiotherapy-treated node-negative breast cancer? Br J Cancer 1999;81(4):
727-32.
310. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. 
Vascular endothelial growth factor is an autocrine survival factor for 
neuropilin-expressing breast carcinoma cells. Cancer Res 2001;61(15):
5736-40.
311. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, et al. Correlation of total 
VEGF mRNA and protein expression with histologic type, tumor angiogenesis, 
patient survival and timing of relapse in non-small-cell lung cancer. Int J 
Cancer 2000;89(6):475-83.
312. Hinton RJ, Serrano M, So S. Differential gene expression in the 
perichondrium and cartilage of the neonatal mouse temporomandibular joint. 
Orthod Craniofac Res 2009;12(3):168-77.
313. Sun Y, Jin K, Childs JT, Xie L, Mao XO, Greenberg DA. Vascular 
endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from 
knockout mice and growth factor administration. Developmental biology 
2006;289(2):329-35.
314. Nag S, Eskandarian MR, Davis J, Eubanks JH. Differential expression of 
vascular endothelial growth factor-A (VEGF-A) and VEGF-B after brain injury. 
J Neuropathol Exp Neurol 2002;61(9):778-88.
315. Yu DH, Wen YM, Sun JD, Wei SL, Xie HP, Pang FH. [Relationship among 
expression of vascular endothelial growth factor-C(VEGF-C), angiogenesis, 
lymphangiogenesis, and lymphatic metastasis in oral cancer]. Ai Zheng 
2002;21(3):319-22.
316. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al. 
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (New 
York, N.Y 1997;276(5317):1423-5.
317. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. 
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory 
neovascularization via macrophage recruitment. J Clin Invest 2004;113(7):
1040-50.
318. Cha HS, Bae EK, Koh JH, Chai JY, Jeon CH, Ahn KS, et al. Tumor necrosis 
factor-alpha induces vascular endothelial growth factor-C expression in 
rheumatoid synoviocytes. The Journal of rheumatology 2007;34(1):16-9.
319. Polzer K, Baeten D, Soleiman A, Distler J, Gerlag DM, Tak PP, et al. 
Tumour necrosis factor blockade increases lymphangiogenesis in murine and 
human arthritic joints. Annals of the rheumatic diseases 2008;67(11):1610-6.
320. Das H, George JC, Joseph M, Das M, Abdulhameed N, Blitz A, et al. Stem 
cell therapy with overexpressed VEGF and PDGF genes improves cardiac 
function in a rat infarct model. PLoS One 2009;4(10):e7325.
289
321. Wang JH, Wu QD, Bouchier-Hayes D, Redmond HP. Hypoxia upregulates 
Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic 
activity in human tumor derived endothelial cells. Cancer 2002;94(10):
2745-55.
322. Li X, Dang X, Sun X. Expression of survivin and VEGF-C in breast cancer 
tissue and its relation to lymphatic metastasis. Eur J Gynaecol Oncol 
2012;33(2):178-82.
323. Li S, Chen X, Wu T, Zhang M, Zhang X, Ji Z. Role of heparin on serum 
VEGF levels and local VEGF contents in reducing the severity of experimental 
severe acute pancreatitis in rats. Scandinavian journal of gastroenterology 
2012;47(2):237-44.
324. Sathasivam S. VEGF and ALS. Neuroscience research 2008;62(2):71-7.
325. Thanigaimani S, Kichenadasse G, Mangoni AA. The emerging role of 
vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons 
from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol 2011;9(3):
358-80.
326. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and 
acidosis independently up-regulate vascular endothelial growth factor 
transcription in brain tumors in vivo. Cancer Res 2001;61(16):6020-4.
327. Szekanecz Z, Besenyei T, Szentpetery A, Koch AE. Angiogenesis and 
vasculogenesis in rheumatoid arthritis. Current opinion in rheumatology 
2010;22(3):299-306.
328. Kurihara T, Kubota Y, Ozawa Y, Takubo K, Noda K, Simon MC, et al. von 
Hippel-Lindau protein regulates transition from the fetal to the adult 
circulatory system in retina. Development (Cambridge, England) 2010;137(9):
1563-71.
329. Abaci HE, Truitt R, Luong E, Drazer G, Gerecht S. Adaptation to oxygen 
deprivation in cultures of human pluripotent stem cells, endothelial progenitor 
cells, and umbilical vein endothelial cells. American journal of physiology 
2010;298(6):C1527-37.
330. Murakami M. Signaling required for blood vessel maintenance: molecular 
basis and pathological manifestations. Int J Vasc Med 2012;2012:293641.
331. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-
induced production of stromal cell-derived factor 1 (CXCL12) and vascular 
endothelial growth factor by synovial fibroblasts. Arthritis and rheumatism 
2002;46(10):2587-97.
332. Larsen H, Muz B, Khong TL, Feldmann M, Paleolog EM. Differential effects 
of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and 
angiogenesis in RA. Arthritis research & therapy 2012;14(4):R180.
333. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 
2004;117:3-32.
334. Kim HR, Park MK, Cho ML, Yoon CH, Lee SH, Park SH, et al. Macrophage 
migration inhibitory factor upregulates angiogenic factors and correlates with 
clinical measures in rheumatoid arthritis. The Journal of rheumatology 
2007;34(5):927-36.
335. Kataru RP, Jung K, Jang C, Yang H, Schwendener RA, Baik JE, et al. 
Critical role of CD11b+ macrophages and VEGF in inflammatory 
lymphangiogenesis, antigen clearance, and inflammation resolution. Blood 
2009;113(22):5650-9.
336. Haigh JJ. Role of VEGF in organogenesis. Organogenesis 2008;4(4):
247-56.
337. Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, et al. VEGF 
receptor 2/-3 heterodimers detected in situ by proximity ligation on 
angiogenic sprouts. The EMBO journal 2010;29(8):1377-88.
338. Nakayama M, Berger P. Coordination of VEGF receptor trafficking and 
signaling by coreceptors. Exp Cell Res 2013.
290
339. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE. VEGF-dependent tumor 
angiogenesis requires inverse and reciprocal regulation of VEGFR1 and 
VEGFR2. Cell death and differentiation 2010;17(3):499-512.
340. Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, et al. Neuropilin-2 
mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. The 
Journal of cell biology 2010;188(1):115-30.
341. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, et 
al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is 
not equivalent to VEGF receptor 3 deletion in mouse embryos. Molecular and 
cellular biology 2008;28(15):4843-50.
342. Makinen T, Norrmen C, Petrova TV. Molecular mechanisms of lymphatic 
vascular development. Cell Mol Life Sci 2007;64(15):1915-29.
343. Koch M, Dettori D, Van Nuffelen A, Souffreau J, Marconcini L, Wallays G, et 
al. VEGF-D deficiency in mice does not affect embryonic or postnatal 
lymphangiogenesis but reduces lymphatic metastasis. J Pathol 2009;219(3):
356-64.
344. Qiu X, Yao S, Zhang S. Advances in the research on lymphangiogenesis in 
carcinoma tissues (Review). Oncol Lett 2010;1(4):579-82.
345. Kawamura H, Li X, Goishi K, van Meeteren LA, Jakobsson L, Cebe-Suarez 
S, et al. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK 
and endothelial cell organization. Blood 2008;112(9):3638-49.
346. Saban MR, Backer JM, Backer MV, Maier J, Fowler B, Davis CA, et al. 
VEGF receptors and neuropilins are expressed in the urothelial and neuronal 
cells in normal mouse urinary bladder and are upregulated in inflammation. 
American journal of physiology 2008;295(1):F60-72.
347. Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR. 
Constitutive expression of angiopoietin-1 and -2 and modulation of their 
expression by inflammatory cytokines in rheumatoid arthritis synovial 
fibroblasts. The Journal of rheumatology 2002;29(2):230-9.
348. Zhang J, Fukuhara S, Sako K, Takenouchi T, Kitani H, Kume T, et al. 
Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular 
quiescence by inducing delta-like 4 expression through AKT-mediated 
activation of beta-catenin. J Biol Chem 2011;286(10):8055-66.
349. Singh H, Hansen TM, Patel N, Brindle NP. The molecular balance between 
receptor tyrosine kinases Tie1 and Tie2 is dynamically controlled by VEGF 
and TNFalpha and regulates angiopoietin signalling. PLoS ONE 
2012;7(1):e29319.
350. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, et al. 
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the 
effects of VEGF inhibition. Cancer Res 2013;73(1):108-18.
351. Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin-
tie signaling pathway. Cold Spring Harb Perspect Med 2012;2(9):a006550.
352. Qu H, Nagy JA, Senger DR, Dvorak HF, Dvorak AM. Ultrastructural 
localization of vascular permeability factor/vascular endothelial growth factor 
(VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar 
organelles of tumor microvascular endothelium. J Histochem Cytochem 
1995;43(4):381-9.
353. Carbajo-Lozoya J, Lutz S, Feng Y, Kroll J, Hammes HP, Wieland T. 
Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of 
type 1 and type 2 receptor stimulation in the microvascular endothelium. 
Cellular signalling 2012;24(6):1261-9.
354. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. 
Organogenesis 2008;4(4):241-6.
355. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, 
and molecular control of edema formation. Lymphatic research and biology 
2008;6(3-4):123-37.
291
356. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in 
regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 
2006;312(5):549-60.
357. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in 
angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21(2):
154-65.
358. Fagiani E, Lorentz P, Kopfstein L, Christofori G. Angiopoietin-1 and -2 exert 
antagonistic functions in tumor angiogenesis, yet both induce 
lymphangiogenesis. Cancer Res 2011;71(17):5717-27.
359. Onimaru M, Yonemitsu Y, Fujii T, Tanii M, Nakano T, Nakagawa K, et al. 
VEGF-C regulates lymphangiogenesis and capillary stability by regulation of 
PDGF-B. Am J Physiol Heart Circ Physiol 2009;297(5):H1685-96.
360. Szekanecz Z, Besenyei T, Paragh G, Koch AE. New insights in synovial 
angiogenesis. Joint Bone Spine 2010;77(1):13-9.
361. Jung SY, Choi JH, Kwon SM, Masuda H, Asahara T, Lee YM. Decursin 
inhibits vasculogenesis in early tumor progression by suppression of 
endothelial progenitor cell differentiation and function. J Cell Biochem 
2012;113(5):1478-87.
362. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling 
pathways: therapeutic perspective. Clin Cancer Res 2006;12(17):5018-22.
363. Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold 
Spring Harb Perspect Med 2013;3(1):a006569.
364. Pratheeshkumar P, Kuttan G. Nomilin inhibits tumor-specific angiogenesis 
by downregulating VEGF, NO and proinflammatory cytokine profile and also 
by inhibiting the activation of MMP-2 and MMP-9. Eur J Pharmacol 
2011;668(3):450-8.
365. Taylor PC. Serum vascular markers and vascular imaging in assessment of 
rheumatoid arthritis disease activity and response to therapy. Rheumatology 
(Oxford, England) 2005;44(6):721-8.
366. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski 
J, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and 
vascular endothelial growth factor (VEGF) in patients with distinct variants of 
rheumatoid synovitis. Annals of the rheumatic diseases 2002;61(9):804-9.
367. Volin MV. Soluble adhesion molecules in the pathogenesis of rheumatoid 
arthritis. Curr Pharm Des 2005;11(5):633-53.
368. Haskard DO. Cell adhesion molecules in rheumatoid arthritis. Current 
opinion in rheumatology 1995;7(3):229-34.
369. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, et 
al. Reduction of chemokine levels and leukocyte traffic to joints by tumor 
necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis 
and rheumatism 2000;43(1):38-47.
370. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, et al. VEGF-B is 
dispensable for blood vessel growth but critical for their survival, and VEGF-B 
targeting inhibits pathological angiogenesis. Proceedings of the National 
Academy of Sciences of the United States of America 2009;106(15):6152-7.
371. Etherington PJ, Winlove P, Taylor P, Paleolog E, Miotla JM. VEGF release is 
associated with reduced oxygen tensions in experimental inflammatory 
arthritis. Clinical and experimental rheumatology 2002;20(6):799-805.
372. Lund-Olesen K, . Oxygen tension in synovial fluids. Arthritis and 
rheumatism 1970;13:769-76.
373. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. 
Current opinion in rheumatology 2005;17(3):293-8.
374. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et 
al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial 
growth factor production in rheumatoid arthritis. Arthritis and rheumatism 
2003;48(6):1521-9.
292
375. Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ, et al. 
Synoviocyte-derived CXCL12 is displayed on endothelium and induces 
angiogenesis in rheumatoid arthritis. J Immunol 2003;170(4):2147-52.
376. Cho ML, Ju JH, Kim HR, Oh HJ, Kang CM, Jhun JY, et al. Toll-like receptor 
2 ligand mediates the upregulation of angiogenic factor, vascular endothelial 
growth factor and interleukin-8/CXCL8 in human rheumatoid synovial 
fibroblasts. Immunol Lett 2007;108(2):121-8.
377. Ji RC. Macrophages are important mediators of either tumor- or 
inflammation-induced lymphangiogenesis. Cell Mol Life Sci 2012;69(6):
897-914.
378. Swenson C, Sward L, Karlsson J. Cryotherapy in sports medicine. Scand J 
Med Sci Sports 1996;6(4):193-200.
379. Bleakley CM, Costello JT. Do thermal agents affect range of movement and 
mechanical properties in soft tissues? A systematic review. Archives of 
physical medicine and rehabilitation 2013;94(1):149-63.
380. Holm B, Husted H, Kehlet H, Bandholm T. Effect of knee joint icing on knee 
extension strength and knee pain early after total knee arthroplasty: a 
randomized cross-over study. Clinical rehabilitation 2012;26(8):716-23.
381. Albrecht K, Albert C, Lange U, Muller-Ladner U, Strunk J. Different effects 
of local cryogel and cold air physical therapy in wrist rheumatoid arthritis 
visualised by power Doppler ultrasound. Annals of the rheumatic diseases 
2009;68(7):1234-5.
382. Knobloch K, Grasemann R, Jagodzinski M, Richter M, Zeichen J, Krettek 
C. Changes of Achilles midportion tendon microcirculation after repetitive 
simultaneous cryotherapy and compression using a Cryo/Cuff. The American 
journal of sports medicine 2006;34(12):1953-9.
383. Beste KW, Essiger H. [Ultrasound-Doppler analysis of arterial blood flow 
before and after cryotherapy]. Zeitschrift fur Rheumatologie 1984;43(2):66-74.
384. Semerano L, Gutierrez M, Falgarone G, Filippucci E, Guillot X, Boissier MC, 
et al. Diurnal variation of power Doppler in metacarpophalangeal joints of 
patients with rheumatoid arthritis: a preliminary study. Annals of the rheumatic 
diseases 2011;70(9):1699-700.
385. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should 
improvement in rheumatoid arthritis clinical trials be defined as fifty percent or 
seventy percent improvement in core set measures, rather than twenty 
percent? Arthritis and rheumatism 1998;41(9):1564-70.
386. Taylor PC. VEGF and imaging of vessels in rheumatoid arthritis. Arthritis 
research 2002;4 Suppl 3:S99-107.
387. Mitchell KL, Pisetsky DS. Early rheumatoid arthritis. Current opinion in 
rheumatology 2007;19(3):278-83.
388. Iagnocco A, Perella C, Naredo E, Meenagh G, Ceccarelli F, Tripodo E, et 
al. Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over 
one year by ultrasonography. Clinical rheumatology 2008;27(4):491-6.
389. Felson DT. Choosing a core set of disease activity measures for 
rheumatoid arthritis clinical trials. The Journal of rheumatology 1993;20(3):
531-4.
390. Anderson JJ, Bolognese JA, Felson DT. Comparison of rheumatoid arthritis 
clinical trial outcome measures: a simulation study. Arthritis and rheumatism 
2003;48(11):3031-8.
391. Bresnihan B, Baeten D, Firestein GS, Fitzgerald OM, Gerlag DM, 
Haringman JJ, et al. Synovial tissue analysis in clinical trials. The Journal of 
rheumatology 2005;32(12):2481-4.
392. Tak PP. Analyzing synovial tissue samples. What can we learn about early 
rheumatoid arthritis, the heterogeneity of the disease, and the effects of 
treatment? J Rheumatol Suppl 2005;72:25-6.
393. Arayssi TK, Schumacher HR, Jr. Evaluation of a modified needle for small 
joint biopsies. J Rheumatol 1998;25(5):876-8.
293
394. Bresnihan B, Tak PP. Synovial tissue analysis in rheumatoid arthritis. 
Baillieres Best Pract Res Clin Rheumatol 1999;13(4):645-59.
395. van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, et 
al. A multicentre, randomised, double blind, placebo controlled phase II 
study of subcutaneous interferon beta-1a in the treatment of patients with 
active rheumatoid arthritis. Ann Rheum Dis 2005;64(1):64-9.
396. Naredo E, Moller I, Cruz A, Carmona L, Garrido J. Power Doppler 
ultrasonographic monitoring of response to anti-tumor necrosis factor therapy 
in patients with rheumatoid arthritis. Arthritis and rheumatism 2008;58(8):
2248-56.
397. Mal F, Meyrier A, Callard P, Kleinknecht D, Altmann JJ, Beaugrand M. The 
diagnostic yield of transjugular renal biopsy. Experience in 200 cases. Kidney 
Int 1992;41(2):445-9.
398. Bilbao JI, Idoate F, Joly MA, Vazquez C, Sangro B, Larrea JA, et al. Renal 
biopsy with forceps through the femoral vein. J Vasc Interv Radiol 1995;6(4):
641-5.
399. Sam R, Leehey DJ, Picken MM, Borge MA, Yetter EM, Ing TS, et al. 
Transjugular renal biopsy in patients with liver disease. Am J Kidney Dis 
2001;37(6):1144-51.
400. Abbott KC, Musio FM, Chung EM, Lomis NN, Lane JD, Yuan CM. 
Transjugular renal biopsy in high-risk patients: an American case series. BMC 
Nephrol 2002;3:5.
401. Rychlik I, Petrtyl J, Tesar V, Stejskalova A, Zabka J, Bruha R. Transjugular 
renal biopsy. Our experience with 67 cases. Kidney Blood Press Res 
2001;24(3):207-12.
402. McAfee JH, Keeffe EB, Lee RG, Rosch J. Transjugular liver biopsy. 
Hepatology 1992;15(4):726-32.
403. Rasband WS. ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/. 1997-2008.
404. Hammer HB, Kvien TK. Comparisons of 7- to 78-joint ultrasonography 
scores: all different joint combinations show equal response to adalimumab 
treatment in patients with rheumatoid arthritis. Arthritis research & therapy 
2011;13(3):R78.
405. Backhaus M, Ohrndorf S, Kellner H, Strunk J, Backhaus TM, Hartung W, et 
al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic 
practice: a pilot project. Arthritis and rheumatism 2009;61(9):1194-201.
294
